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Abstract   
Background   
Diabetic Foot ulceration has devastating complications. These include amputations resulting in 
poor quality of life, and serious infections including osteomyelitis and life threatening sepsis. 
Diabetic wounds can be protracted, take significant time to heal, and they can recur after they 
have healed. They can be very costly and consume healthcare resources. These consequences 
have serious public health and clinical implications. Debridement is often used as a standard of 
care in efforts to help avert these consequences. It is used to remove nonviable or necrotic tissue 
such as nonviable tissue in order to facilitate the wound healing process and help prevent these 
disabling outcomes. What is/are the most effective method(s) of debridement remains unclear? 
This systematic review of the literature on debridement of diabetic foot ulcers synthesizes all 
experimental evidence in an effort to help answer this important question. 
Foot ulceration affects 15% of diabetics at some point in their lives. The prevalence of diabetic 
foot ulcers is 4.6% in the UK, 8.3% in the US, and includes 7% of the world’s population. The 
non-healing wound increases the risk of amputations, complicating infections, healthcare costs, 
and reduces quality of life. Debridement is regarded as an effective intervention to accelerate 
ulcer healing and to decrease the risk of serious complications. 
Current published literature is unclear on which specific method of debridement interventions 
have the optimal effect on these important public health and clinical implications including: 
amputation rates, complicating infection rates, quality of life, cost of care) and clinical 
implications (wound healing rates, wound recurrence rates, and time to complete healing. 
Analyzing moderators or prognostic risk factors can facilitate the development of population-
specific guidelines or recommendations on the effects of debridement. This can promote better 
understanding of which groups may benefit from debridement based on prognostic factors. This 
understanding could increase adherence to the common practices used in diabetic wound care 
including debridement, provided the evidence supports its efficacy.   
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Objectives   
The current systematic review and meta-analysis was conducted in order to obtain overall effect 
sizes of all debridement interventions on the following outcomes (Amputation frequency, 
Complicating wound infection rates such as Methicillin Resistant Staphylococcus Aureus 
(MRSA), Quality of life, Proportion of ulcers healing, Proportion of ulcer recurrence, Cost, and 
Time to complete healing). The goal was to evaluate the variability and consistency of these 
effects across the current literature on this topic. Any significant variability across the current 
literature was investigated using moderator analysis based on study-specific and sample-specific 
characteristics.   
Does the use of any form of debridement in diabetic foot ulcers demonstrate benefit over any 
other form of debridement including standard gauze dressings with respect to amputation 
frequency, complicating infection rates, quality of life, cost, proportion of ulcers healed, 
recurrence rates, and time to healing? Are any prognostic or other moderating factors predictive 
of benefit in some populations or groups? This study summarizes and synthesizes the evidence in 
a comprehensive qualitative systematic review and quantitative systematic review/meta-analysis 
of all randomized control trials (RCT’s) on this research question.  
Methods 
A comprehensive literature search was conducted to retrieve articles that met the following 
inclusion criteria. 
Inclusion/Exclusion Criteria 
The following inclusion/exclusion criteria were utilized: 
a) Individual studies, Systematic reviews (SR’s) and/or meta-analyses (MA’s) that included 
randomized controlled trials (RCT’s) on debridement of diabetic foot ulcers. Comparison 
of any method of debridement (i.e. the removal of nonviable tissue from the wound, by 
either mechanical or non-mechanical debridement) with control or an alternative method 
of debridement were included The search included any form of debridement but did not 
include studies on Negative Pressure Wound Therapy (NPWT). NPWT includes 
mechanical debridement but has other functions. 
b) Adult Type 1, or Type 2 diabetics with ischemic, neuropathic, or neuro-ischemic diabetic 
foot ulcers.  The wounds were not limited in severity or in grading system utilized 
including Wagner Wound Grade, and the Texas Classification systems. 
c) There were no other limitations based on age, gender, country, healthcare setting, or 
language. 
d) RCT’s, and Systematic reviews/Meta-analyses that included other wound types i.e. 
venous stasis ulcers, arterial insufficiency ulcers in non-diabetics, pressure ulcers, and 
atypical ulcers were excluded. 
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e) Studies that were nonrandomized (observational studies) were excluded. Systematic 
Reviews/Meta-analyses that were limited to nonrandomized studies were excluded. All 
systematic reviews were retrieved along with RCT’s for purposes of comparison and 
contrasting them with the results of this review. 
Search methods   
The search included: The Cochrane Wounds Group Specialized Register; The Cochrane Central 
Register of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE, PubMed, 
EMBASE, EBSCO, CINAHL, and Web of Science. 
Selection criteria   
Randomized controlled trials (RCTs) evaluating any method of debridement used in diabetic foot 
ulcers. There was no restriction on articles/trials based on language or publication status. 
Data collection and analysis   
Data extraction and assessment of study quality were undertaken by two independent reviewers 
and referred to a methods expert and content expert when there was disagreement. When 
necessary, if disagreements were not resolved they were referred to the Wounds Group to resolve 
any remaining discordance between reviewers. 
The primary outcomes of interest included: 1) Amputation rates, 2) Complicating wound 
infection rates, and 3) Quality of life.  
The secondary outcomes of interest included: 4) Proportion of participants with ulcers 
completely healed, 5) Time to complete healing, 6) Proportion of ulcers recurring after healing, 
and 7) Cost of treatment. 
These outcomes have direct bearing on clinical and public health implications including 
morbidity and mortality. These consequences cause significant hardships for individuals with 
wounds. A major amputation (above or below knee) is considered by experts to be a predictor of 
increased 5-year mortality. 
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Results 
Descriptive Statistics 
Sample sizes 
This review included an analysis of thirty studies with a total of 2654 participants. All 30 studies 
reported total sample size for each of the included studies. The mean sample size for the included 
studies was 152 (SD = 119) participants. The included studies ranged from sample sizes of 18 to 
619 participants.  
Range of follow-up and study period duration 
The range of follow up was 10 days to 24 weeks for the included studies. The study period or 
duration ranged from 1992 – 2012 for the included studies.  
Participant characteristics (age, gender, ethnicity) 
The mean ages for the samples in the included studies ranged from 52.1 years through 69.3 
years. A total of 23 studies reported mean age, 1 study reported a median age of 59.5 years 
(Roberts 2001), while 6 other studies did not report age. The mean age for the sample of studies 
was 59.01 (SD = 4.31) years. 
Gender was reported in 21/30 (70%) of studies. The number of male participants ranged from 12 
to 240, while the number of female participants ranged from 1 to 88 for the reported studies. 
Ethnicity was reported in 5/30 (16.7%) studies. 
Socioeconomic status was reported in 1/30 (3.3%) study. 
Geographic location and healthcare setting 
A majority of the studies were conducted in the US or Europe 21/30 (70%) and published in 
English 28/30 (93%). The study settings included outpatient or specialized clinics 17/30 (56.7%), 
hospital settings 8/30 (26.7%), and both inpatient-hospital and outpatient settings 2/30 (6.7%), 
and was unclear in 5/30 (16.7%) studies. 
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Wound severity 
Thirteen studies reported on wound severity, which included wounds up to Wagner grade 4, and 
wounds up to Texas classification Grade 3. The size of the wound was reported in 20/30 (67%) 
studies. Depth of wound was specified in 5/30 (16.7%) studies. A total of 14/30 (70%) studies 
reported on wound duration which ranged from 0 – 60 weeks. 
Clinical prognostic factors 
8/30 (26.7%) studies reported on hemoglobin a1c which ranged from 7.25% – 9.25%. 14/30 
(70%) studies reported on duration of diabetes which ranged from 13 to 21 years. The proportion 
of baseline peripheral arterial insufficiency was reported in 9/30 (30%) studies. BMI was 
reported in 5/30 (16.7%) studies. 
Table 1 Descriptive summaries of the 30 included studies used in this systematic review and 
meta-analysis. 
Table 1 of Descriptive Statistics 
Total number of studies 30 
Total number of participants 2564 
Sample size range 18 to 619 
Average sample size per 
study 
152 
Total Range of follow up 10 days to 24 weeks 
Total Study period or 
duration 
1992 - 2012 
Studies reporting age 24/30 (70%) 
Mean age (range) 52.1 – 69.3 years 
Total number of studies 
reporting gender 
21/30 (70%) 
Range of number of males 12 to 240 
Range of number of females 1 to 88 
Number of studies reporting 
ethnicity 
5/30 (16.7%) 
Number of studies reporting 
socioeconomic status 
1/30 (3.3%) 
Geographic setting Europe and US (70%) 
Publication Language English 93% 
Healthcare setting Hospital 8/30 (26.7%) 
Outpatient 17/30 (56.7%) 
Both 2/30 (6.7%) 
Studies reporting wound size 
(area) 
20/30 (67%) 
Studies reporting wound 
duration 
14/30 (70%) 
Studies reporting 
Hemoglobin a1c (Hgba1c) 
8/30 (26.7%) 
Hgba1c (range) 7.25% - 9.25% 
Studies reporting on duration 
of diabetes 
14/30 (70%) 
Duration of diabetes (range) 13 to 21 years 
Studies reporting baseline 
peripheral arterial 
insufficiency 
9/30 (30%) 
Studies reporting BMI 5/30 (16.7%) 
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Intervention comparisons 
Nineteen combinations of debridements or debridement with the control condition were made. 
This included 12 forms of debridement: 1) sharp, 2) larva, 3) low frequency ultrasound, 4) 
jet/irrigation lavage, 5) wet to dry gauze, 6) hydrogel, 7) foam, 8) silver based foam dressing, 9) 
fibrous-hydrocolloid, 10) alginates, 11) honey/jam, and 12) collagenase. The debridements were 
either compared to each other, or to a gauze/control condition. The control condition included 
moistened gauze that usually was moistened with saline but could have included an antiseptic 
(e.g. iodine). The intervention arms were paired with a “standard therapy” (adjunctive wound 
care measures). 
These comparisons included debridement interventions against standard gauze therapy 
(moistened/saline gauze which may be categorized as a form of autolytic debridement) which 
was frequently used as a control condition in the included studies OR one form of debridement 
compared to another form of debridement. 
There were significant effects of debridement for some of the outcomes of interest reported in 
single studies that utilized distinct debridement combination. These combinations could not be 
pooled in the meta-analysis portion of this systematic review since each of the distinct 
debridement combinations was only available in one study. These findings are summarized 
below with respect to the outcomes of interest. 
Comparison 1 (Piaggesi 1998) – Sharp surgical debridement demonstrated a statistically 
significant reduction in quality of life score by 2.2 as compared with nonsurgical management -
2.20 (95% CI -3.16 to -1.24), (Heterogeneity: Tau2 = 0.00, χ2 = 0.11, I2=0%). Sharp surgical 
debridement demonstrated a statistically significant increase in time to complete healing by 82 
days as compared with nonsurgical management 81.68 (95% CI 41.07 to 122.29). 
Comparison 2 (Goretti 2008) – Superoxide solution demonstrated a significant beneficial effect 
as compared with standard local treatment using povidone iodine dressing. There was a decrease 
in time to complete healing by 6 days compared with standard local treatment with povidone 
iodine -6.00 (95% CI -6.94 to -5.06). 
Comparison 5 (Whalley 2001) – Hydrogel purilon as compared with hydrogel intrasite reported a 
difference of 35% versus 19% in proportion of ulcers healing. It was unclear whether this was 
significant beneficial effect as there was not enough information reported to make that 
determination (e.g. no reported counts of events/nonevents). 
Comparison 8 (Lalau 2002) – Calcium alginate demonstrated a significant increase in time to 
complete healing by 2.8 days as compared with gauze 2.80 (95% CI 1.46 to 4.14). 
Comparison 12 (Jeffcoate 2009) – Iodine impregnated fiber dressing demonstrated a 45% 
increase in the number of infections as compared with gauze dressing 1.45 (95% CI 1.13 to 
1.86). 
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Comparison 15 (EhsanUrRehman 2013) – Honey soaked gauze as compared with iodine saline 
dressing demonstrated a cost difference of 334 Jordanian Dinars in mean difference (MD -
334.00, 95% CI -373.99 to -294.01).  
Comparison 16 (Hammouri 2004) – Honey/saline dressing demonstrated a statistically 
significant decrease in treatment cost as compared with iodine peroxide saline – 334.00 (95% CI 
– 373.99 to – 294.01). 
Eight other distinct comparisons that were described in single studies could not be pooled, as 
there were no other similar intervention comparisons in at least one other study. These studies 
included: Comparison 3 (Amini 2013) Low frequency ultrasound compared with sharp 
debridement, Comparison 4 (Markevich 2000) Larvae compared with hydrogel, Comparison 7 
(Clever 1995) Polyurethane gel as compared with polyurethane foam, Comparison 9 (Apelqvist 
1990) Hydrocolloid as compared with adhesive Zinc, Comparison 11 (Roberts 2001) Foam 
dressing as compared with saline nonadherent gauze dressing, Comparison 14 (Foster 1994) 
Hydrocellular polyurethane as compared with Calcium alginate,  Comparison 17 (Rhaiem 1998)  
Sugar Jam with Hydrogen peroxide and topical antibiotic as compared with hydrogen peroxide 
and topical antibiotic, and Comparison 18 (Belcaro 2010) Silver (standard cleaning and 
compression management methods) dressing group as compared with (standard cleaning and 
compression management methods without silver ointment). These comparisons either did not 
report or did not demonstrate any significant difference in treatment effects for this systematic 
review’s prespecified outcomes of interest. 
Four of the 19 distinct comparisons did include 2 or more studies. These 4/19 comparisons were 
pooled in meta-analyses for the pre-specified outcomes of interest if reported. This included 
comparisons 6, 10, 13, and 19. 
Pooled data in four separate comparisons including: Comparison 6 Hydrogel compared with 
gauze (3 studies pooled including: (D'Hemecourt 1998; Jensen 1998; Vandeputte 1997), 
Comparison 10 Foam dressing compared with Wet to Dry (2 studies pooled including: 
(Blackman 1994; Mazzone 1993), Comparison 13 Hydrofiber compared with gauze (2 studies 
pooled including: (Jeffcoate 2009; Piaggesi 2001), and Comparison 19 - Any debridement 
compared with gauze (10 studies pooled including: (Jeffcoate 2009; Jensen 1998; Piaggesi 2001; 
Piaggesi 1998; Vandeputte 1997; Lalau 2002; D'Hemecourt 1998; Donaghue 1998; Goretti 2008; 
Roberts 2001) found no significant beneficial difference, except for the proportion of ulcers 
completely healed in Comparison 19 - Any debridement as compared with gauze, and 
Comparison 6 – Hydrogel as compared with gauze.  
Comparison 6 - Hydrogel demonstrated a significant beneficial effect as compared with saline 
gauze. There was a 71% increase in the number of ulcers healed as compared with good wound 
care 1.71 (95% CI 1.16 to 2.52), (Heterogeneity: Tau2 = 0.00, χ2 = 0.95, I2=0%). 
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Comparison 19 - Any debridement demonstrated a 17% increase in the number of ulcers healed 
as compared with saline gauze 1.17 (95% CI 1.00 to 1.36), (Heterogeneity: χ2 = 13.89, I2 = 28%). 
However, when the two studies available only as abstracts were removed in a subgroup analysis 
a weaker and nonsignificant beneficial difference was found. 1.12 (95% CI 0.95 to 1.32), 
(Heterogeneity: χ2 = 2.23, I2 = 55.1%). 
There was no significant study heterogeneity that was explained with any of univariate models 
that were analyzed, except gender. The effects demonstrated low to moderate heterogeneity for 
the specified outcomes used in this systematic review. Moderators that were analyzed included 
age, peripheral arterial disease, duration of diabetes, gender, data collection year, and study 
follow-up duration. All moderators were scrutinized for the recommended number of studies per 
covariate for each of the prespecified outcomes of interest. There were 6 moderators that 
satisfied these requirements for the intervention comparison Any debridement as compared with 
gauze. This analysis was only possible for two of the outcomes of interest this included 
proportion of infections, and proportion of ulcers healed. There was no significant association or 
effect using the moderators for either of these two outcomes of interest. A Meta-regression was 
performed and none of the candidate moderators yielded results any different from the null 
hypothesis with the exception of the moderator “gender”. This coincides with data that support a 
gender differential favoring males in the development of wounds in diabetics and amputations 
having a higher sex predilection among male diabetics. However, the effect was nonsignificant 
prior to the use of gender as a moderating variable. 
Publication bias was assessed and based on the combination of funnel plot and statistical tests 
(Beggs, Eggers). No significant publication bias was observed despite the fact that 13/30 studies 
were supported financially by industry. 
The GRADE approach was utilized to construct summary of findings tables in order to 
summarize our conclusions using a structured standardized evidence grading format. This 
yielded very low to low evidence of efficacy. 
Conclusion   
Currently there exists weak research evidence to suggest that debridement in one form is more 
effective in diabetic foot ulcers than other competing forms of debridement or standard gauze for 
the outcomes of interest in this review. Many of the randomized studies included in this review 
used small sample sizes that may have been underpowered with too few events/nonevents to 
make meaningful conclusions. This is evidenced by studies of varying sizes yielding too few 
events in the intervention arms making it challenging to detect true effects. The included studies 
often demonstrated significant risk of bias that contributed to the low quality evidence. The 
studies were variable in the inclusion/exclusion criteria reported.  
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The findings of researchers could be better supported by following standardized reporting 
guidelines such as the CONSORT statement. The existing body of literature complicates efforts 
to synthesize the evidence in systematic reviews. Stakeholders, including patients, physicians, 
public health professionals, and policy makers, may consider individualized decision making 
such as indications/contraindications, allergies, tolerability, response, and cost as alternatives 
pending more definitive standardized RCT’s on this research question. The range of insufficient 
information in reporting and variation in methods used are summarized in this systematic review. 
Investigators interested in this research question may benefit from the findings reported in this 
systematic review as an aide in guiding the design of future randomized studies.
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Chapter 1 
Background 
Diabetic Foot ulceration has devastating complications. These include amputations resulting in 
poor quality of life, and serious infections including osteomyelitis and life threatening sepsis. 
Diabetic wounds can be protracted, take significant time to heal and they can recur after they 
have healed. They can be very costly and consume healthcare resources. These consequences 
have serious public health and clinical implications. Debridement is often used as a standard of 
care in efforts to help avert these consequences. It is used to remove nonviable or necrotic tissue 
in order to facilitate the wound healing process and help prevent these disabling outcomes. What 
is/are the most effective method(s) of debridement remains unclear? This systematic review of 
the literature on debridement of diabetic foot ulcers synthesizes all experimental evidence in an 
effort to help answer this important question. 
Global Data Reports 
In 2009 the International Working Group on the Diabetic Foot (IWGDF) began its efforts to 
produce consensus guidelines on the diabetic foot. In 2011 the IWGDF estimated that worldwide 
approximately 366 million people have diabetes, which includes 7.0% of the world’s population. 
80% of these people live in developing countries. The IWGDF 2012 estimated that by the year 
2030 there will be 552 million individuals globally who are afflicted with Diabetes (Type 1 and 
Type 2) or approximately 8% of the adult population. Younger people are developing DM at an 
alarming rate. Annually approximately 1 million people undergo a limb amputation, or 1 
amputation occurs every 30 seconds. The majority of amputations are preceded by a foot ulcer.  
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The most important risk factors involved in the development of these ulcers include peripheral 
neuropathy, foot deformities, relatively minor foot trauma, and peripheral arterial disease (PAD). 
Once the ulcer appears, infection and peripheral arterial disease are considered major causes 
leading to amputation. The burden of amputations in the developing world is greater than it is in 
the developed world. The working group estimated that approximately one quarter of wounds 
will not heal, and 28% may progress to the point where they require amputation (Bakker 2012; 
IWGDF 2012; Ragnarson 2000). 
There is a significant psychosocial impact in that people with foot ulcers and amputations often 
have comorbid depression and a reduced quality of life (Cosgrove 2012; Kumari 2004). There is 
an increase in “social isolation”. Stress can have immunocompromising effects (Nakata 2012). 
Risk of amputation is increased in people living alone, and those who lack the social support of 
family and friends. Timely healing was found to be important in improving quality of life. The 
working group has stated that investing in diabetic foot care guidelines is one of the most cost-
effective forms of health-care expenditure (IWGDF 2012). 
These global data by the IWGDF is contrasted below with country-specific data using US and 
UK data. This is done in order to better compare global health data on this question with health 
data from two industrialized countries in Europe and North America. This contrast is to help the 
reader better appreciate the context of global heath data from the developing world against 
country-specific health data from selected representative countries in the industrialized world. 
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US Data Reports 
In the United States the diabetes epidemic includes 25.8 million children and adults, or 8.3% of 
the U.S. population, approximating 1 in 12 people.  A total of 18.8 million people are diagnosed, 
7.0 million people are undiagnosed. There are approximately 79 million people living with pre-
diabetes. This includes over 104.8 million individuals with some stage of diabetes, or 
approximately 1/3 of the U.S population. These data correspond with the rising rates of obesity, 
hypertension, and the increasing age of the US population. There were 1.9 million incident cases 
of diabetes diagnosed in people aged 20 years and older in 2010. The disease burden varies 
among race and ethnicity including 7.1% of non-Hispanic whites, 8.4% of Asian Americans, 
12.6% of non-Hispanic blacks, and 11.8% of Hispanics. The annual death toll includes 231,404 
deaths exceeding HIV/AIDS, and Breast Cancer combined. The diabetes epidemic is the number 
1 cause of blindness or 4.8% of 30 million people. It is the leading cause of kidney failure 
accounting for 44% of new cases or 202,290 people per year, and as in the UK is the leading 
cause of amputations in the United States (ADA 2011; USAHQR 2012; USCDC 2012; Ramsey 
1999). 
Surgical amputations in the United States have reached staggering levels among diabetics 
including 65,700 (60% of nontraumatic amputations in 2006). The prevalence of diabetic foot 
ulcers is estimated to be up to 8% of the diabetic population. Approximately 15% of diabetics are 
expected to develop a wound in their lifetime.  
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Based on pathophysiology irrespective of diabetes status 82% of amputations are due to vascular 
disease (includes diabetics), 22% due to trauma, 4% due to congenital causes, and 4% due to 
tumors. Approximately 1.6 million people are living with amputations in the U.S. and 
approximately 113,000 lower limb amputations are performed each year from all causes in the 
US (ADA 2011; USAHQR 2012; USCDC 2012). 
Among diabetics approximately 75 percent of all amputations occur in people over the age of 65. 
Amputation rates are higher in males than they are in females, 12% versus 10.8% respectively. 
African-Americans with diabetes have a 1.5 to 2.5 time’s greater rate of amputation than their 
Caucasian counterparts with diabetes (Ashry 1998). Poor circulation including microarterial 
occlusive disease is the main cause of amputation and accounts for over half of all amputations 
that occur among diabetics (ADA 2011; USAHQR 2012; USCDC 2012). Major amputations 
(above knee, or below knee) are a marker for increased mortality. It is estimated that 5-year 
mortality may be increased as high as 61% - 74% after a major amputation (Robbins 2008; 
Tentolouris 2004). 
UK Data Reports 
Approximately 4.6 % of the UK population or 2.9 million people are estimated to have diabetes, 
which is increased from 2% of the population almost a decade earlier. 10% of diabetics have 
Type 1 diabetes and 90% have Type 2 diabetes. Foot ulceration is thought to affect 15% of 
people with diabetes at some time in their lives. In the UK people with diabetes are 15 times 
more likely to undergo lower limb amputations than people without diabetes. In the UK 70 % of 
people die within 5 years of having an amputation due to diabetes. Diabetes accounts for one-
half of all limb amputations in the UK (DiabetesUKorg 2013).  
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These data are not significantly changed from those previously reported in 1997 and 2009. 
(SIGN 1997; SIGN 2009; Spencer 2000). 
The World Health organization reports that 9.2% of males and 7.6% of females have raised 
blood glucose in the UK based on 2008 data estimates. 67.7% of males and 60.8% of females are 
overweight or obese. 65.6% of males and 65.7% of females have raised cholesterol while 46.4% 
and 40.8% had raised blood pressure in 2008. These risk factors are collectively referred to as 
“metabolic syndrome” and are driving the rising trend in diabetes, diabetic foot ulcers and the 
associated complications including amputations (WHO 2011; Calman 1998). 
Estimated Costs 
Global Cost Estimates 
The International working group on the Diabetic Foot (IWGDF) has issued a report on the cost 
of Diabetic foot ulcers and amputations. Foot related problems may use 12-15% of healthcare 
resources for diabetes in the developed world, whereas in developing countries this may be as 
high as 40% (Bakker 2012; IWGDF 2012) see Table 2 below. 
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Table 2  IWGDF 2012 (Reproduced here with permission from the IWGDF) 
Table of Costs of Treating Foot Ulcers and Amputations 
Reference Country Number 
of 
Patients 
Costs 
(year of 
costing) 
USD 2005 
equivalent 
Comments 
Ulcers not requiring amputation 
Apelqvist et al, 
1994 
Sweden 197 Sweden 
197 SEK 
51,000 
(1990) 
8,654 All ulcer types; total 
Harrington, et 
al, 2000 
USA 400,000 USA 
400,000 
USD 
3,999-6 
(1996) 
4,982-
7,821 
Inpatient and 
outpatient costs 
Holzer et al, 
1998 
USA 1846 c USD 
1,929 
(1992) 
2,695 Inpatient and 
outpatient costs, those 
>64 yr. excluded 
Metha et al, 
1999 
USA 5149 USA 
5149 
USD 
900-2,600 
(1995) 
1,150-
3,322 
Private insurance 
charges; mean age 51 
yr. 
Ragnarson 
Tennvall et al, 
2000 
Sweden 88 Sweden 
88 SEK 
136,600 
(1997) 
18,719 Deep foot infection; 
total direct costs 
Ramsey et al, 
1999 
USA 514 d USD 
27,987 
(1995) 
35,758 Including 2 yr. after 
diagnosis 
Van Acker et al 
2000 
Belgium 120 Belgium 
120 USD 
5,227 
(1993) 
7,039 Inpatient and 
outpatient costs 
Costs of lower extremity amputations 
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Apelqvist et al 
1994 
Sweden 27 Sweden 
27 SEK 
258,000 
(1990) 
43,778 All ulcer types; minor 
LEA; total direct 
costs 
Apelqvist et al 
1994 
Sweden 50 Sweden 
50 SEK 
390,000 
(1990) 
66,176 All ulcer types; major 
LEA; total direct 
Costs 
Ashry et al 1998 USA 5062 USA 
5062 
USD 
27,930 
(1991) 
39,891 Hospital charges 
Only 
Holzer et al, 
1998 
USA 504 c USD 
15,792 
(1992) 
22,062 Gangrene/amputation, 
those >64 yr. 
excluded 
van Houtum et 
al, 1995 
Netherlands 1575 e NLG 
28,433 
(1992) 
19,052 Hospital costs only 
Panayiotopoulos 
et al, 1997 
UK 20 UK 20 
GBP 
15,500 
(1994-95) 
33,587 Inpatient and 
prostheses costs 
(46% diabetics) 
Ragnarson 
Tennvall 
et al, 2000 
Sweden 77 Sweden 
77 SEK 
261,000 
(1997) 
35,767 Deep infection; 
minor LEA; total 
direct costs 
Ragnarson 
Tennvall 
et al, 2000 
Sweden 19 Sweden 
19 SEK 
234,500 
(1997) 
32,136 Deep infection; major 
LEA; total direct 
costs 
Van Acker et al, 
2000 
Belgium 7 Belgium 
7 USD 
18,515 
(1993) 
24,933 Inpatient and 
outpatient costs; 
minor LEA 
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US Cost Estimates 
The estimated total cost of diabetes in the United States in 2007 was $218 billion, exceeding 1/5 
of a trillion dollars. This includes direct and indirect costs. The peak age-range for amputations is 
between 41 and 70 years. This is a time period of prime working age and productivity for adults. 
This poses a significant health challenge to our workforce since amputations can result in 
permanent impairment often qualifying an individual for disability benefits resulting in lost 
wages, and productivity (Holtzer 1998). This poses a significant stress on the family unit. 
Van Acker et al, 
2000 
Belgium 9 Belgium 
9 USD 
41,984 
(1993) 
56,538 Inpatient and 
outpatient costs; 
major LEA 
Footnotes 
For comparison of the results, costs were first adjusted for inflation to 2005 prices with the 
consumer price index f and then converted to USD with the appropriate currency exchange 
rate for 2005. 
NA = not applicable.  
LEA = Lower Extremity Amputation.  
Minor = amputation below the ankle; 
Major = amputation above the ankle. 
a Based on data from observational studies 
b Based on data from databases and other secondary sources 
c Number of episodes 
d Includes 80 amputations 
e Number of hospitalizations 
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It imposes an economic burden upon society at large in providing for impaired and disabled 
individuals. The rate of amputations is rising and these factors are directly contributing to this 
alarming trend (ADA 2011; USAHQR 2012; USCDC 2012).  
US Government estimates for the 2007 GDP portion allocated for direct healthcare costs was 
$2.2 trillion or 16% of the GDP (NCHS 2010).  Chronic diseases, including heart disease, stroke, 
cancer, and diabetes, cause 7 out of 10 deaths and are responsible for 75% of the $2 trillion spent 
on health care (CDC 2009). In comparison the direct and indirect costs for Diabetes in 2007 
approximate 10% of 2.2 trillion dollars. Up to 15% of costs for DM in the developed world is 
estimated to be allocated for foot related problems, approximately 33 billion dollars in the US 
(IWGDF 2012; Harrington 2000). 
UK Cost Estimates 
The UK National Health Service (NHS) spends an estimated £10 billion per year on diabetes or 
10% of the National Health Service budget.  Total direct and indirect costs for diabetes in the UK 
is £23.7 billion per year (DiabetesUKorg 2013). In the previous protocol from 2001 it was 
estimated that £12.4 million was spent on amputations per year. A report published in March of 
2012 by the British National Health Service (NHS) - Diabetes estimates that £650 million ( £1 in 
£150 in the NHS total expenditures) is spent on foot ulcers or amputations each year (NHS 2012; 
King's Fund 1996). 
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Description of the condition   
Etiology of Diabetic Foot Ulcers 
The diabetic foot ulcer is considered multifactorial in its etiology. 
Wound progression 
Wound repair and closure helps re-establish hemostasis, preserving the barrier function of the 
skin in order to prevent infection, and maintaining the overall protective role of the skin. An 
ulcer is the result of a break in the dermal barrier, with subsequent erosion of underlying 
subcutaneous tissue. In severe cases, the breach may be extended to muscle and bone. The 
progression to ulceration may be attributed to an impaired arterial supply, neuropathy, musculo-
skeletal deformities, or a combination of these factors (Bauer 2000). If the process of wound 
healing is impaired and the wound progresses then the risks of infection, amputation, morbidity 
and mortality increase (Sheffield 2004). 
Wound development and progression are a major risk factor for amputation and follow what is 
considered a predictable course among experts in the field. Wounds healing progresses through 
the following phases: 1) Hemostasis/Coagulation phase, 2) Inflammatory phase 3) Proliferative 
phase, 4) Maturation/Remodeling phase (Baronski 2008; Myers 2008; Sheffield 2004). 
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Problems with wound healing may impede wound progression and are considered multifactorial 
in diabetics. These prognostic problems may include some or all of the following: vascular 
insufficiency/peripheral arterial disease, peripheral neuropathy (sensory, motor, and autonomic), 
immunosuppression, critical colonization/infection. These prognostic problems may be more 
common in the presence of nonviable tissue (contributing to an increased risk of infection and 
delayed wound healing), smoking (contributory to the risk of vascular insufficiency, and 
inflammatory burden), and poor nutritional status (inadequate protein and nutrients required for 
wound healing). It is believed that these combined problems contribute to the wound stagnating 
within the inflammatory phase of the healing process. Typically, the development of a wound 
involves a relatively minor soft-tissue injury or insult possibly compounded by these other 
factors. The trauma can be the result of friction, mechanical shearing forces, direct pressure, or 
penetrating tissue injury including sharp or blunt trauma (Baronski 2008; Myers 2008; Sheffield 
2004). 
These factors are believed to have a major role in the pathogenesis of diabetic foot ulcerations 
leading to wound progression and the associated complications including serious infection and 
amputation (Davies 1989). 
Vascular Insufficiency 
Disease of blood vessels are a major cause of complications in diabetes and affects all types of 
vessels (Faris 1991a). The Framingham study reported that more than 50% of men and women 
with diabetes had absent foot pulses (Abbott 1990).  
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Peripheral vascular disease (PVD) tends to occur at a younger age in people with diabetes and is 
believed to involve smaller blood vessels and capillaries further away from the heart. Reports 
from US, UK and Finland (Pecoraro 1990; Reiber 1999; Siitonen 1993) have concur that PVD is 
a major contributory factor in the pathogenesis of foot ulceration and subsequent major 
amputations (Boulton 2000). 
Impaired blood flow can occur at both the microvascular and macrovascular arterial circulation 
levels in diabetics and can compound the problem of delayed wound healing by leading to 
inadequate tissue oxygenation. Microcirculation involvement includes the occlusion of small 
blood vessels and capillaries, whereas macrovascular insufficiency is defined as the occlusion of 
medium and large sized blood vessels. Hemodynamically significant macrovascular arterial 
insufficiency is considered an advanced stage of peripheral arterial disease (PAD). This may 
warrant surgical revascularization procedures (Panayiotopoulos 1997). These vascular occlusions 
and the resulting wound hypoxia poses a major risk factor in the development of non-healing 
problem wounds (IWGDF 2012; Neuman 2008; Sheffield 2004). A host of considerations are 
believed to compound vascular insufficiency which restricts the delivery of oxygen and nutrients 
required for adequate wound healing, immune function, and can increase susceptibility of co-
infections. Considerations may include nutritional status, cardiovascular insufficiency, hydration 
status, psychosocial factors, smoking and alcohol history, patient compliance, socioeconomic 
status, availability of ancillary treatment modalities, proficiency and expertise of the healthcare 
provider involved in the wound care, the type of wound and the presence of wound occurrence 
from combined wound mechanisms, the age of the patient, and possibly the type of debridement 
method provided to the patient for removal of nonviable tissue from the wound bed and 
periwound (Bakker 2012; Edwards 2011; IWGDF 2012; Smith 2002; Sheffield 2004). 
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Neuropathy (Sensory, Motor, Autonomic) 
Impairment of nerve function is an important and frequent complication of diabetes. All types of 
nerve fibers can be affected including motor, sensory and autonomic nerve fibers and their 
associated functions. Impaired nerve function in the foot is common in people with diabetes 
although the person themselves may be unaware of its presence. Neuropathy remains one of the 
major factors leading to the development of foot lesions in people with diabetes (Le Quesne 
1991). 
This is a frequent occurrence among diabetics. Approximately 60-70% of diabetics have 
neurologic disease, most often a peripheral neuropathy involving the lower extremities (ADA 
2011; USAHQR 2012; USCDC 2012). This microvascular disease component is believed to 
cause occlusion within the vasonervorum which provides the blood supply to the nerves. This is 
may be due to the direct cytotoxic effect of the hyperglycemia. This form of microvascular 
occlusive disease contributes to the development of peripheral neuropathy. Since diabetic 
neuropathy involves motor, sensory and autonomic nerve fibers the pathologic deficits may 
include the deformed, insensate, and dry cracking foot. 
a) Sensory neuropathy 
Damage to the nerves carrying signals from the foot renders the foot insensitive to temperature, 
vibration, pressure, and pain. This is referred to as sensory neuropathy. The loss of sensation 
means that small injuries often go undetected. 
 
14 
 
b) Motor neuropathy 
Denervation of muscles has direct effects on the function of the foot. The small muscles of the 
foot, the extensor digitorum brevis, lumbrical and interosseous muscles are commonly affected. 
Paralysis of these small muscles results in the metatarsophalangeal joints becoming hyper-
extended and the interphalangeal joints becoming flexed. The joints initially remain mobile, but 
later degenerative changes occur and the joints become fixed (Le Quesne 1991). The 
consequence of such muscle wastage is a foot shape that increases foot pressures over bony 
prominences where wounds most commonly occur in diabetics. 
c) Autonomic neuropathy 
Autonomic neuropathy is thought to contribute to the pathogenesis of ulceration, neuropathic 
edema, and Charcot arthropathy (Le Quesne 1991). Impairment of sweating is suggested to 
contribute, through dehydration, to the formation of hyperkeratotic plaques and fissures in the 
skin. If this callus (increased glycation of keratin) becomes too thick, it presses on the soft tissues 
underneath contributing to ulceration (Edmonds 2000a). Callus is defined as a buildup of 
keratinized skin, in reaction to persistent pressure (Cutting 1999), and can itself exert pressure on 
the soft tissues of the foot. 
The dry cracking foot is a function of the anhidrosis that can develop due to the autonomic 
neuropathic changes. Impaired temperature regulation from the autonomic neuropathy may 
contributes to these local effects (IWGDF 2012). 
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Immunosuppression/Critical Colonization/Infection 
Diabetes is considered an immune-compromising condition. It has been observed that white 
blood cells may behave atypically in a hyperglycemic (high glucose) environment. They 
demonstrate dysfunctional behavior and do not marginate, migrate, or secrete the cytokines 
sufficiently that are required in order to combat infection. This can increase the risk of critical 
colonization and infection. Critical colonization is defined as a concentration of bacteria at least 
100,000 organisms per gram of tissue. The immunosuppressive state that may occur in Diabetes 
in the presence of an open wound can lead to critical colonization and infection which are 
complicating factors that can increase the risk of non-healing chronic wound (IWGDF 2012; 
Sheffield 2004). 
The chronicity of this condition may increase the risk of Methicillin Resistant Staphylococcus 
Aureus (MRSA), which is among the cultured organisms found in chronic wounds and a major 
public health concern. Infections that have reached the deeper bony level of tissue involvement 
may become especially problematic making them refractory to treatment. The patient can be at 
risk for life threatening sepsis from a wound as an infectious source (IWGDF 2012; Sheffield 
2004). This may warrant urgent amputation to remove the source of life threatening sepsis. 
Pathway to Ulceration 
Despite the presence of the predisposing factors noted above, an uninjured foot may not develop 
serious problems. Physical trauma is an inciting event e.g. a puncture wound, localized pressure, 
repeated mechanical trauma, heat or chemical injury (Faris 1991b).  
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When there is sensory impairment, a small lesion may progress because it may go unrecognized 
and the source of injury not alleviated. Lack of sensation allows the damage to progress to 
ulceration. Impairment of the blood supply may result in delayed healing. Complicating infection 
may contribute as an additional risk factor by increasing the amount of damaged tissue (Faris 
1991b). 
Chronic wounds may continue to progress beyond full thickness (limited to the epidermis and 
dermis). This progression can extend further involving deeper tissues including the hypodermis, 
muscle, tendon, and bone. Progression of vascular compromise and infection may lead to tissue 
ischemia, non-viable tissue, and gangrene. This pathway ultimately may lead to limb amputation. 
Deep seated wound infections such as chronic osteomyelitis and significant bone destruction can 
become considerations in the decision to amputate limbs (ADA 2011; Bakker 2012; Edwards 
2011; Smith 2002; USAHQR 2012; USCDC 2012). 
Common Grading systems used to classify the severity of diabetic wounds 
The Wagner grading system and the Texas classifications are internationally utilized grading 
systems. These grading systems were compared and the results concluded that increasing stage, 
regardless of the grade, is associated with increased risk of amputation and a delay in ulcer 
healing time. The University of Texas system's inclusion of stage suggested it was a superior 
predictor of outcome (Oyibo 2001) See Table 3; Table 4 below. 
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Table 3 Wagner Wound Grade Classification System 
Grade 
0 1 2 3 4 5 
 
No ulcer in a 
high risk foot 
Wound 
involving full 
skin thickness 
Wound 
extending to 
ligament and 
muscle 
Wound with 
cellulitis or 
abscess 
Localized 
gangrene 
Extensive 
gangrene 
involving 
the whole 
foot 
 
Table 4 University of Texas Wound Classification System 
 Grade 
Stage 0 
Pre or Post 
ulcerative lesion 
completely 
epithelialized 
1 
Superficial wound 
not involving 
tendon, muscle, or 
bone 
2 
Wound 
penetrating to 
tendon or capsule 
3 
Wound 
penetrating to 
bone or joint 
 
A 
No Infection, or 
Ischemia 
0A 1A 2A 
 
3A 
B 
Infection but no 
ischemia 
0B 1B 2B 3B 
C 
Ischemia but no 
infection 
0C 1C 2C 3C 
D 
Infection and 
ischemia are 
present 
0D 1D 2D 3D 
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Description of the intervention   
Debridement as the Wound Care Intervention of Interest 
Currently debridement is considered a central component of conventional treatment in wound 
care (the removal of non-viable or necrotic “dead” tissue from the wound). This component of 
wound care is used to remove non-viable tissue which may pose a risk of colonization and 
infection. Nonviable tissue may impede wound healing by obstructing cellular migration across 
the wound. It is believed to impede the normal development of the wound bed and prevent 
granulation tissue formation (Baronski 2008; Sheffield 2004; Strohal 2013).  
Debridement is considered to be a means of enabling the clinician to better gauge the size of the 
wound. Debridement may facilitate drainage from the wound. Removal of nonviable tissue may 
reduce the risk of infection and facilitate cellular migration of cells in the wound healing process. 
It is believed that an accurate wound culture should be obtained post-debridement and following 
saline irrigation of the wound itself (Sheffield 2004; Strohal 2013). 
Treatment is focused on closing the wounds within the first 4-6 weeks of their development. 
Wounds that decrease their surface area by 20 – 40 % within the first 4 weeks are considered to 
have a higher likelihood of closing by experts (Baronski 2008; Sheffield 2004). Desirable goals 
include reducing the time to complete healing, accelerate healing rates, and reducing the rates of 
recurrence of wounds. If the wound is closed in a timely manner the risks of complicating 
infections, and amputation may be prevented thus improving the patient’s overall quality of life. 
The following are considered alternate methods of wound debridement: 
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Mechanical Debridement – This method uses mechanical energy such as surgical debridement, 
high pressure saline irrigation, whirlpool, wet to dry saline dressings, ultrasound, or jet lavage. 
The nonselective nature of these forms of debridement can remove granulation tissue that is 
produced during the proliferative phase of wound healing Table 5. 
i) Sharp Surgical Debridement – This may be performed either in the inpatient or 
outpatient settings. It may be done in the operating room suite if an extensive 
debridement is required in lieu of an outpatient “office” surgical procedure when the 
debridement is less extensive and superficial. Ultimately the decision on what setting 
in which to perform the debridement is based both upon the patient’s comfort level 
and how extensive a debridement procedure is required. Expert opinion in sharp 
surgical debridement has generally dictated that all the nonviable and necrotic tissue 
should be removed and debrided down to bleeding tissue, in effect creating a new 
acute wound. This repeats the phases of wound healing from the beginning. This is 
often not possible without injuring healthy tissue in the process of attempting to 
remove nonviable (dead) tissue. This dissection process can be time-intensive and is 
considered semi or non-selective. The injury of healthy tissue results from the 
delicate task of separating viable from nonviable tissue using standard sharp 
dissection instruments i.e. scalpels and curettes.  
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Gross dissection using instruments classified as blunt are not capable of ultra-
selective microdissection even in the hands of the most skilled health professionals. 
Microdissection may only be possible with the use of biosurgery or maggot 
debridement therapy described later. This may be problematic in that every “new” 
injury increases the risk for a complicating superinfection (Bakker 2012; Edwards 
2011; Smith 2002; Strohal 2013). 
 
ii) Wet to Dry Mechanical Debridement removes non-viable tissue by allowing gauze 
saturated with saline and applied to a wound to dry. The gauze then become adherent 
to the wound during the drying phase. The gauze is then removed, which can non-
selectively pull away both non-viable tissues along with viable granulation tissue 
(Sheffield 2004; Strohal 2013). 
 
iii) Aqueous high pressure lavage/irrigation involves a jet-stream of saline that 
mechanically removes nonviable tissue. This is considered a non-selective form of 
debridement and is capable of removing granulation tissue. This theoretically may 
pose a risk to the healthcare provider performing the debridement. The mist created 
by the high pressure irrigation may expose the provider to contamination (Sheffield 
2004; Strohal 2013). Whirlpool also involves a form of high pressure hydro-
irrigation except the entire limb or patient is immersed in a whirlpool bath during 
irrigation. Cross contamination is possible using this method as other wounds and 
body surfaces may be immersed in the same water. This is also considered a non-
selective form of debridement (Sheffield 2004; Strohal 2013). 
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iv) Ultrasound Debridement utilizes sound energy to mechanically debride wounds. This 
is usually carried out through contact or noncontact low frequency ultrasound energy. 
 
v) Biosurgery or Maggot Debridement Therapy (MDT) - This has been an area of 
interest for over 400 years and provides a complex system of wound care. Maggots 
are larva of flies such as Lucilia Sericata that consume nonviable tissue selectively. 
This is typically done in the U.S. with another form of larva, the blow fly maggot 
variety (Phoenicia Sericata larvae). Medicinal maggots are believed to carry out this 
biosurgical debridement of nonviable tissue selectively as compared with blunt 
dissection using sharp surgical instruments. This may reduce the risk of secondary or 
superinfection. The species of flies used are cultured for this purpose and provide a 
source of enzymatic debridement. The maggots are capable of consuming bacteria 
and are believed to produce antimicrobial secretions. This has been demonstrated in 
mechanistic in vitro studies (Margolin 2010). Maggot debridement therapy may have 
antimicrobial properties including those from hospital acquired resistant organisms 
such as MRSA. They may secrete substances that stimulate wound healing (Margolin 
2010). 
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Non-Mechanical Debridement 
i) Enzymatic Debridement – This involves the use of exogenous enzyme products that 
digest the non-viable tissue as opposed to exclusively relying on endogenously 
produced wound enzymes such as matrix metalloproteinases that provide autolytic 
debridement. 
ii) Autolytic Debridement – This approach involves keeping the wound moist which 
may facilitate the endogenous enzymes produced by the wound itself in order to auto-
digest or “self-digest” nonviable tissue. The use of agents such as hydrogel facilitates 
moist wound healing and allows endogenous locally produced enzymes to digest the 
non-viable tissues. Many topical agents that are applied directly to skin facilitate 
autolytic debridement such as topical antimicrobials even though they are also used to 
treat local wound infections. The ability of a variety of topical agents to maintain a 
moist wound environment permits concurrent autolytic debridement irrespective of 
the other functions of the topical agent used. Other dressings that facilitate autolytic 
debridement include: Alginates, Hydrocolloids, Foam, Film, and Honey. Moist saline 
gauze is commonly used and has served as a control or standard form of debridement 
in studies (Sheffield 2004; Strohal 2013). See Table 5 for a comparison of methods of 
debridement. 
The evidence to support these various forms of debridement and their impact on such important 
indicators as amputation frequency, complicating wound infection frequency, cost, quality of 
life, and wound healing rates, recurrence, and time to complete healing will be scrutinized in this 
review. 
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Standard Wound Care Prevention and Treatment 
The treatment of diabetic foot ulcer generally involves a multidisciplinary team approach and 
includes comprehensive advanced wound care. This team may be comprised of a primary care 
physician, wound care physician, a wound care nurse, a nutritionist, orthotics consultant, 
physical therapist, and a hyperbaracist. This comprehensive advanced wound care approach 
provided by a multi-disciplinary team may include the following interventions: (Baronski 2008; 
Sheffield 2004). 
i) Off-loading: Weight bearing redistribution is the considered the most important consideration 
for wound healing of the diabetic foot ulcer. This provides support by redistribution of weight 
bearing away from the wound and relocates it to the adjacent surfaces of the affected foot or leg 
through the use of orthotics. Alternatively, complete offloading can be achieved by using 
wheelchairs, walkers, crutches, or other wheeled mobile devices to remove all weight bearing 
entirely (non-weight bearing) from the affected wound (Sheffield 2004). 
ii) Physical Therapy: The use of offloading equipment may require special instruction routinely 
provided by a physical therapy department. This may require instruction in the proper use of 
crutches, wheelchair, or other ancillary mobile non-weight bearing equipment.  
The patient may require rehabilitation due to long periods of immobility in order to regain 
function and strength in order to maintain function and support the use of offloading devices. 
iii) Medical Optimization of Comorbidities including Diabetes: The patient may require 
optimization of current treatment for diabetes and other conditions that if left untreated or poorly 
controlled may impede wound healing. 
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iv) Nutritional Consultation Services and Supplementation: These services have been utilized 
to address nutritional deficiency states that may impede wound healing. Laboratory markers such 
as Total Lymphocyte Count, pre-Albumin, Albumin, and Total Protein along with clinical 
parameters have been used to help direct the proper nutritional interventions. 
v) Infection Eradication: If the wound is critically colonized or infected then this may impair 
wound healing and antimicrobial therapy is often prescribed. Treatment can be directed locally 
or systemically depending on the extent of the infection. 
vi) Medical and Surgical Vascular interventions: Hemodynamically significant macrovascular 
insufficiency can compound microarterial insufficiency and may require vascular surgical 
evaluation. Therapy may involve more extensive medical treatment or it may require surgical re-
vascularization. Surgical revascularization could include angioplasty, stenting, atherectomy, or 
surgical bypass grafting. 
vii) Hyperbaric Oxygen Therapy: Periwound tissue hypoxia can be measured using 
transcutaneous oximetry. If tissue hypoxia is found to be reversible with normobaric or 
hyperbaric oxygen challenge; then adjuvant hyperbaric oxygen therapy has been considered 
adjuvant therapy in healing problem wounds in diabetics. This testing may suggest 
microvascular insufficiency. Hyperbaric oxygen therapy may increase tissue oxygen tensions up 
to fifteen times normal. Angiogenesis and vasculogenesis are believed to be stimulated by the 
use of hyperbaric oxygen therapy, which may enhance the blood supply around the wound. Pro-
inflammatory intracellular adhesion molecules are down regulated providing an anti-
inflammatory effect (Thom 1989). Edema may be decreased by the use of hyperbaric oxygen 
therapy through peripheral vasoconstriction without a negative effect on tissue oxygenation. 
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Oxygen diffusion is increased up to a factor of 4 in the affected tissues (Fife 2007). 
Antimicrobial tissue penetration and leukocyte function is believed to be enhanced by the use of 
hyperbaric oxygen therapy. Susceptible organisms such as anaerobic or facultative anaerobic 
organisms that do not tolerate high oxygen environments may be inhibited by the use of 
hyperbaric oxygen therapy. An increase in stem cell production, differentiation, and presence in 
the wound bed has been demonstrated (Thom 2005). Hyperbaric oxygen therapy may be 
especially useful in those diabetics that have had wound care for greater than 4 weeks with poor 
or no response to treatment (Sheffield 2004; UHMS 2008). 
Mechanism of the Intervention 
Debridement - Current practice 
Debridement involves the removal of devitalized, contaminated or foreign material from within 
or adjacent to a wound, until surrounding viable tissue is exposed. It is widely practiced in 
diabetic foot care (Dorland's 1998). Debridement is regarded by many as an effective 
intervention to speed up ulcer healing. Sharp debridement of an ulcer, including the removal of 
callus (which may surround or “roof over” an ulceration) and all devitalized tissue may facilitate 
wound healing, though direct evidence of this is lacking.  
Once an ulcer has developed the aim is to heal it in as short a time period as possible and prevent 
recurrence. Margolis conducted a meta-analysis of the control group healing of 10 treatment 
trials in people with diabetic neuropathic foot ulcers and estimated that 24% heal within 12 
weeks and 31% by 20 weeks with good wound care (Margolis 1999).  
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High quality management of the diabetic foot often requires multidisciplinary input and good 
communication between primary and tertiary care providers (Young 2000). 
Edmonds (Edmonds 2000b) suggests six aspects of "control" to be addressed when caring for 
people with diabetes, particularly in relation to foot health: 
 mechanical control; 
 wound control; 
 microbiological control; 
 vascular control; 
 metabolic control; 
 educational control. 
Debridement (see Table 5 Methods of debridement) is recommended by the SIGN diabetic foot 
guidelines (SIGN 1997) alongside antibiotic therapy for infection and pressure relief as a 
treatment for patients who have developed ulceration or gangrene with risk of amputation. The 
Royal College of General Practitioners' Guidelines (RCGP 2000) also recommend debridement 
as a treatment of the ulcerated foot alongside local wound management and appropriate 
dressings. Neither of the guidelines recommend a specific method of debridement. 
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Edmonds gave the following rationale for debridement of neuropathic ulcers which included 
(Edmonds 2000b): 
 enables the true dimensions of the ulcer to be perceived 
 allows drainage of exudate and removal of dead tissue, both render infection less likely 
 enables a deep swab to be taken for culture 
 encourages healing. 
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Figure 1 Serial images depicting measurements of wound progress over the course of 
sequential combined forms of debridement lasting 12 weeks including sharp, enzymatic, 
and autolytic. 
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The diabetic foot ulcer has serious consequences to the individual patient, their families, the 
healthcare system, and to society as a whole. The patients who undergo amputations, serious 
infections along with the associated impairment and disability results in financial hardship and 
lost productivity. The patient faces a reduced quality of life along and an increase in 5-year 
mortality. 
These outcomes may be averted if efforts are made to accelerate successful wound healing. 
Wound care is considered by many to be a multidisciplinary team approach. The standard of care 
in wound care includes debridement. There are numerous methods of debridement and it is 
unclear which method(s) is/are effective.
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Chapter 2 Literature Search for Prior Systematic Reviews 
with a Similar Research Question 
Introduction/Background 
Systematic Reviews and Meta-analyses are important tools in Evidence Based Medicine and 
Healthcare. These tools provide researchers with an exhaustive, objective, and transparent 
scientific approach using duplicate efforts in synthesizing the evidence around a specific research 
question. They provide researchers with the means of determining what the best available 
evidence concludes. The systematic review itself is a scientific investigation that is 
comprehensive, transparent, promotes duplication of effort, and facilitates replication (Cooper 
2009; Higgins 2008). 
This may include a qualitative systematic review, and when possible a quantitative systematic 
review. The qualitative systematic review exhaustively pools together and collectively 
summarizes all the available evidence retrieved and extracted on a specific research question. It 
does so by using objective search methods, a data extraction tool, and an objective risk of bias 
evaluation tool to assess and judge the quality of the evidence (Cooper 2009; Higgins 2008). 
The researchers can determine if a quantitative systematic review (meta-analysis) is warranted 
based on the results of the qualitative systematic review. The meta-analysis is a quantitative 
synthesis or combination of the evidence from the sample of studies that are included in the 
review. The quantitative systematic review may pool together these raw data originally used in 
the included studies. Alternatively, and more commonly the summary statistics from each of the 
included separate studies are pooled together. This will include the various effect estimates 
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which may have been measured on different scales. If the scales differ the researchers can 
transform the different effect estimates into a common scale effect estimate. The effect estimates 
could include mean differences, odds ratios, relative risk ratios, standardized mean differences, 
or correlation coefficients (Cooper 2009; Higgins 2008). 
Pre-requisite to any planned systematic review requires an exhaustive search of the literature 
systematically for other systematic reviews (SR’s) that may have been conducted on a similar 
research question. 
The retrieval of prior systematic reviews that evaluated competing debridement interventions to 
treat diabetic foot ulcers for comparative effectiveness is an essential component of this current 
review. The goal is to help determine what is/are the most effective form(s) of debridement in 
treating non-healing wounds in diabetics. The prior systematic reviews may have afforded 
researcher’s new information on reducing the risk of amputations and associated mortality, 
reducing complicating wound infections, improving quality of life, accelerating healing rates, 
and reducing costs. 
Contrasting our systematic review against other similar reviews is essential to determine if our 
systematic review is to add additional knowledge to the body of literature on this important 
research question. 
Objectives 
This review included the literature search and retrieval of all other systematic reviews on this 
research question using similar inclusion and exclusion criteria. These other systematic reviews 
could then be compared and contrasted with this review.  
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Methods 
Inclusion/Exclusion Criteria 
The inclusion/exclusion criteria that were utilized to retrieve all prior systematic reviews on the 
same research question included the following: 
a) Systematic reviews (SR’s) and/or meta-analyses (MA’s) that included randomized 
controlled trials (RCT’s) on debridement of diabetic foot ulcers. The search included any 
form of debridement but did not include SR’s on Negative Pressure Wound Therapy 
(NPWT). NPWT includes debridement as one of its numerous functions but this form of 
therapy has been studied in a separate Cochrane review. 
b) Adult Type 1, or Type 2 diabetics with ischemic, neuropathic, or neuroischemic diabetic 
foot ulcers.  The wounds were not limited in severity or in grading system utilized 
including Wagner Wound Grade, and Texas Classification. 
c) There were no other limitations based on age, gender, country, healthcare setting, or 
language. 
d) RCT’s that included other wound types i.e. venous stasis ulcers, arterial insufficiency 
ulcers in non-diabetics, pressure ulcers, and atypical ulcers were excluded. 
e) Systematic reviews that were limited to nonrandomized trials or that focused exclusively 
on other wound types were excluded. 
Database searched 
Data sources were searched and collected accordingly per the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement Reporting guidelines. 
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The searches utilized the following databases and dates: Ovid Medline (1996 – 2013 March 
Week 4), PubMed (1940’s – Present), Ovid Embase (1996 – 2013 week 13), Embase via Scopus 
(1960 – Present), EBSCO CINAHL (1981 to Present), Web of Science (1974 – Present), The 
Cochrane Library, Cochrane Wounds Group Specialized Register (4/15/2015). The detailed 
search methods utilized are included under Search Strategies (Appendix 1). 
Data Extraction 
Two independent reviewers reviewed the search results and independently extracted all 
systematic reviews that met the pre-determined inclusion criteria. These data from the SR’s were 
extracted from the SR’s along with the respective authors conclusions for comparison with this 
review using the same data extraction tool (Appendix 2) used for our review of randomized 
controlled trials (RCT’s) for our systematic review. However, the SR’s were not pooled and no 
meta-analysis was conducted on the retrieved SR’s. The data extraction was used to facilitate a 
qualitative review of the SR’s for contrast purposes with this systematic review. The retrieved 
bibliographies were hand searched to locate additional RCT’s for this SR. 
These data extracted from systematic reviews included:  
a) Author/year which served as a study ID. 
b) Number of studies included in the systematic review. 
c) Study types including randomized, non-randomized and the number of studies for each 
designation. 
d) Total number of participants included. 
e) Follow up period 
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f) Study period 
g) Wound severity or grade 
h) Debridement intervention type(s). 
i) Outcomes included in the systematic reviews. 
j) Identification as a Cochrane review or not. 
k) The SR’s authors concluding statements regarding the outcome effects and their findings 
along with the strength of the evidence were extracted verbatim and are listed in 
quotations. 
These are summarized in Table 3a below in the results section. 
Results 
The search retrieved 10 related systematic reviews. Four of the studies retrieved combined both 
randomized and nonrandomized studies. This practice is discouraged as randomized studies and 
nonrandomized studies should generally be combined with similarly designed studies in separate 
systematic reviews i.e. randomized studies alone and nonrandomized studies alone. The 
reasoning behind this approach is that non-randomized studies are generally considered to be at 
higher risk of demonstrating biased exaggerated effect estimates than randomized studies. 
Despite this concern the findings in the four systematic reviews that included non-randomized 
studies are came to comparable conclusions with other systematic reviews that were limited to 
randomized studies. See table 3a below. 
35 
 
The number of systematic reviews that used similar inclusion/exclusion criteria as this review 
(i.e. Type 1 or 2 Diabetic participants with foot ulcers, randomized studies, and any debridement 
method) are listed in the following table: 
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Table 6 Comparison of systematic reviews preceding this current systematic review 
# 
 
[Revie
w] 
[# 
Studies 
included] 
[Study 
Type(s)] 
[Total 
sample 
size] 
Follow 
up period 
Study 
perio
d 
Type 
of 
wound 
[Partici
pant 
Type] 
[Interventio
n Type] 
Outcomes 
Coc
hran
e 
Revi
ew 
[Conclusion
s] 
 
 
1 
Edwar
ds 
2011 
6 (3/6 
pooled) 
6 
Randomi
zed 
488 
 
 
 
10 days 
to 24 
weeks 
 
 
 
1995 
to 
2001 
 
 
DFU 
Diabetic
s (1,2) 
4 
comparisons 
Hydrogel v 
gauze 
(pooled) 
Larva 
Surgical 
debridement 
4 
Ulcers 
healed 
Time to 
Complete 
Healing 
Recurrence 
Adverse 
Events 
Yes 
Low 
evidence  
 
2 
Mason 
1999 
10 total 
(4 on 
debridem
ent not 
pooled) 
8 
Randomi
zed 
2 
Nonrand
omized 
202 
 
 
4 weeks 
to 2 
months 
 
 
Uncle
ar 
 
DFU 
Diabetic
s 
(2) 
Film 
Alginate 
Ulcers 
healed 
Mean time 
to healing 
No 
Low 
evidence 
"evidence 
base for 
treating 
infections 
and dressing 
wounds is 
poor" 
Summarized 
studies 
 
 
3 
Game 
2012 
5 
4 
Randomi
zed (not 
pooled), 
149 
30 
ischemic 
 
 
 
 
100 
DFU Diabetic
s (1,2), 
Ischemi
c, 
Venous 
Sharp 
Debridemen
t, Aquacel, 
Larva, 
Hydrotherap
y 
Ulcers 
healed, 
Time to 
Healing, 
No 
Low 
evidence 
"scientific 
evidence to 
confirm the 
benefit of 
sharp 
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1 
Nonrand
omized 
12 weeks 
– 6 
months 
1998 
- 
2007 
30 
Ischem
ic 
19 
venous 
Infection, 
Amputation 
debridement 
was not 
strong", 
"weak 
evidence to 
support the 
use of 
hydrogels", 
"no benefit 
in larva and 
hydrotherap
y" 
 
 
 
4 
Hinchl
iffe 
2008 
10 
6 
Randomi
zed (not 
pooled)  
4 
Nonrand
omized 
575 
 
 
 
 
 
 
5 weeks 
to 20 
weeks 
 
 
 
 
 
 
1989 
to 
1998 
 
 
 
 
 
DFU 
Diabetic
s (1,2) 
Hydrogel, 
Alginates, 
Carboxymet
hylcellulose, 
Polymeric 
semipermea
ble 
membranes 
Ulcers 
healed, 
Healing 
time, 
No 
Low 
evidence 
"evidence to 
underpin the 
use of sharp 
debridement 
and 
debriding 
agents is not 
strong, 
evidence is, 
urgently 
needed to 
substantiate 
role of 
larvae, 
topical 
antiseptics 
and all 
dressing 
products. No 
data were 
available to 
support 
the current 
widespread 
use of 
silver-
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containing 
dressings 
 
 
5 
Dumv
ille 
2015 
6 (2/6 
studies 
pooled 
for 
alginate 
v 
BWCD, 
and 2 
pooled 
for 
Alginate 
v foam) 
6 
Randomi
zed 
375 
 
 
 
4 weeks 
to 8 
weeks 
 
 
 
1992 
- 
2004 
 
 
 
DFU Diabetic
s (1,2) 
Alginate v. 
BWCD 
Alginate v. 
Foam 
Silver 
fibrous-
hydrocolloid 
dressing v 
alginate 
(3) Ulcers 
healed, 
HRQoL, 
Adverse 
Events 
Yes 
Low 
Evidence 
"no research 
evidence to 
suggest that 
alginate 
wound 
dressings are 
more 
effective in 
healing 
diabetic foot 
ulcers than 
other types 
of dressing" 
 
 
6 
Dumv
ille 
2011 
6 
6 
Randomi
zed 
4 pooled 
157 
 
 
 
 8 weeks 
– 24 
weeks 
 
 
 
1993 
- 
2001 
 
 
 
DFU 
Diabetic
s (1,2) 
Foam(vs)B
WCD 
Foam(vs)Al
ginate 
Foam(vs)Hy
drocolloid 
(4) Ulcers 
healed 
Adverse 
events 
Yes 
Low 
evidence "no 
research 
evidence to 
suggest that 
foam wound 
dressings are 
more 
effective in 
healing 
diabetic foot 
ulcers than 
other types 
of dressing". 
 
 
7 
Dumv
ille 
2013 
Hydro
colloi
d 
5 (2/5 
studies 
pooled) 
6 
Randomi
zed 
535 
 
 
 
 
 
 
 
 
 
DFU 
Diabetic
s (1,2) 
Fibrous-
Hydrocolloi
d 
[Hydrofiber]
(vs)Basic 
Wound 
Contact 
Ulcers 
healed 
HRQoL 
Adverse 
Events 
Yes 
Moderate 
evidence 
"no research 
evidence 
that any type 
of 
hydrocolloid 
wound 
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8 weeks 
to 24 
weeks 
1995 
- 
2007 
Dressings 
(BWCD) 
Foam 
Alginate 
 
dressing is 
more 
effective in 
healing 
diabetic foot 
ulcers than 
other 
dressings" 
 
 
8 
Dumv
ille 
2013 
Hydro
gel 
5 studies 
(3/5 
pooled) 
5 
Randomi
zed 
446 
 
 
10 days - 
20 weeks 
 
 
1997 
- 
2001 
 
 
DFU 
Diabetic
s 
(1,2) 
Hydrogel(vs
)BWCD 
Larva 
PDGF 
Purilon/intra
site hydrogel 
Ulcers 
healed 
Yes 
“moderate 
evidence for 
efficacy 
hydrogel v. 
BWCD 
uncertain 
due to risk 
of bias. 
Other 
comparisons
, low 
evidence’ 
 
 
 
9 
Voigh
t 2011 
8 (5 
studies 
pooled) 
8 
Randomi
zed (2 
pooled) 
1 study 
discernab
le on 
DFU 
others 
mixed 
wound 
etiology 
178 
 
 
 
 
2 weeks 
 
 
 
 
2006 
 
 
 
Subgro
ups of 
Venou
s 
Ulcers 
and 
DFU 
outco
mes 
Diabetic
s 
Low 
frequency 
Ultrasound(
vs)Sharp 
Complete 
healing, 
Wound size 
reduction 
No 
"no 
difference 
demonstrate
d in 
complete 
healing 
between 
LFHICU 
and sharps 
debridement 
in patients 
with diabetic 
foot ulcers, 
quality of 
the evidence 
as 
it relates to 
biases was 
poor" 
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undisc
erned 
 
 
 
 
 
 
1
0 
Tian 
2013 
4 
1 
Randomi
zed 
3Nonran
domized 
356 
 
 
 
 
 
10 days 
 
 
 
 
 
1998 
 
 
 
 
 
 
DFU 
Diabetic
s 
MDT(vs) 
Hydrogel 
MDT(vs) 
Conventiona
l 
MDT(vs) 
Sharp 
MDT(vs) 
SWC 
*Complete 
healing, 
Time to 
Healing, 
Amputation, 
Incidence of 
Infection 
No 
"no evidence 
between 
healing rates 
for MDT vs 
standard 
treatment. 
MDT 
resulted in 
greater 
proportion 
of patients 
to 
achieve 
complete 
healing vs 
control 
group. MDT 
more 
effective 
than 
standard 
treatment 
decreasing 
time to 
healing, rate 
of 
amputation 
for DFUs; 
however, no 
evidence 
that MDT 
reduces 
infection vs 
standard 
care." 
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These systematic reviews included a range of 4 to 10 studies. Six of the systematic reviews were 
restricted to randomized studies, whereas 4 systematic reviews included randomized and non-
randomized studies. The publication years ranged from 1999 – 2013. The number of participants 
ranged from 149 - 575 participants. The number of comparisons ranged from 1 - 4 methods of 
debridement in the studies retrieved for the 10 systematic reviews SR’s listed in table 3a above. 
The types of debridement included sharp, autolytic (hydrogel, foam, alginates, hydrocolloids, 
semipermeable polymeric membranes, silver-containing), larva or maggot debridement, and 
hydrotherapy. Four of these systematic reviews were Cochrane reviews.  
Two out of 10 studies included venous ulcers in addition to diabetic foot ulcers, and one of these 
two studies also included ischemic ulcers. The outcome measures of interest included the 
following: amputation frequency, infections rates, complete healing rates, time to complete 
healing, wound size reduction, health related quality of life (HRQoL), wound recurrence, and 
adverse events. The majority of systematic reviews ranged in their findings on the quality of the 
evidence from Low evidence to no evidence that forms of non-autolytic debridement studied 
were beneficial. Two studies suggested moderate evidence to low evidence that forms of 
autolytic debridement were beneficial. 
Conclusion 
The study’s findings were relatively consistent in that they reported weak or poor evidence to 
conclude that one form of debridement was superior to either an alternate form of debridement; 
or the control condition or standard treatment. The form of debridement used as control was 
autolytic debridement specifically using moistened gauze with either saline or an antiseptic such 
as iodine.  
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Iodine is frequently used to clean wounds as part of adjunctive measures of wound preparation 
prior to and post-debridement. Many of the conclusions reported in these reviews regarding the 
direction of future trials included the need for larger sample sizes, and standardized reporting 
among authors. The findings in these systematic reviews were relatively consistent in that they 
found weak evidence that any debridement or debridement dressing type was more effective than 
other dressings in healing diabetic foot ulcers. 
Patients, healthcare providers, policy makers, and all other stakeholders are strongly cautioned in 
altering clinical practice on the basis of findings derived from small trials of unclear or high risk 
of bias including nonrandomized studies.  
Stakeholders are cautioned on extrapolation of findings to other wound types, though diabetic 
wounds are considered among the most recalcitrant of wounds. Therefore, findings related to 
these resistant wound types may be applicable to researchers studying more resistant wound 
types. The findings in reviewing the literature for systematic reviews that were conducted on a 
similar research question support the need to design and conduct a comprehensive exhaustive 
systematic review that strictly utilizes all of our best available evidence i.e. randomized 
controlled trials. The systematic review of experimental evidence should retrieve the maximum 
number of comparisons that were made between debridement types in order to help delineate 
how these interventions compare to each another. This will assist all stakeholders in making 
important clinical, public health and policy decisions regarding debridement interventions.
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Chapter 3 Systematic Review Objectives   
Study Aims 
Study Aim 1. Perform a comprehensive and worldwide systematic review of the literature on all 
forms of debridement as a treatment for diabetic foot ulcers. 
Study Aim 2. Assessment of the evidence of the effectiveness of all commonly used forms of 
debridement as a treatment for diabetic foot ulcers, and the quantitative evidence assessment of 
the possible variability or heterogeneity among the comparisons. 
Study Aim 3. Meta-regression and subgroup analysis for possible characteristics that may be 
moderating the variability of the effectiveness of debridement as a treatment across populations, 
settings, and study characteristics. 
Research Questions and Research Hypotheses 
Study Aim 1. Perform a comprehensive and worldwide systematic review of the literature on all 
forms of debridement as a treatment for diabetic foot ulcers. 
Research Question 1. How many experimental studies have been published on the topic of 
debridement of diabetic foot ulcers? 
Research Hypothesis 1a (RH1a): There exists a sufficient number of experimental studies on the 
topic of debridement of diabetic foot ulcers to enable the researcher to conduct a meta-analysis.  
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Research Question 2. Has all the literature on this topic been published or is there a 
substantial body of literature that remains unpublished? 
RH2a: There exists a substantial body of literature on the topic of debridement of diabetic foot 
ulcers that remains unpublished and is eligible for inclusion in the meta-analysis. 
Research Question 3. For the studies that exist are they of sufficient quality with relatively low 
risk of bias that makes them eligible for inclusion in our analysis? 
RH3a: There exist both published and unpublished experimental studies that meet the eligibility 
criteria for inclusion in a meta-analysis that are of sufficient quality and relatively low risk of 
bias. 
Study Aim 2. Assessment of the evidence of the effectiveness of all commonly used forms of 
debridement as a treatment for diabetic foot ulcers, and the quantitative evidence assessment of 
the possible variability or heterogeneity among the comparisons. 
Research Question 4. Does any form of debridement and standard wound care as compared to 
autolytic debridement and standard wound care: 
i)    Reduce the time to complete healing of diabetic foot ulcers? 
RH4a: There will be a difference in time to complete healing of diabetic foot ulcers using 
debridement in any form as compared to standard wound care and autolytic debridement, with 
significant variability in the distribution of the effects. 
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ii)   Improve healing rates of diabetic foot wounds? 
RH4b: The healing rates of diabetic foot ulcers using debridement in any form will be different 
as compared to standard wound care and autolytic debridement with significant variability in the 
distribution of the effects. 
iii)  Decrease recurrence rates of diabetic foot wounds? 
RH4c: There is a difference in the frequency of recurrent diabetic foot ulcers using debridement 
in any form with standard wound care as compared to autolytic debridement and standard wound 
care, with significant variability in the distribution of the effects. 
iv) Decrease the frequency of amputations that may result from diabetic foot wounds? 
RH4d: There is a difference in the frequency of amputations associated with diabetic foot ulcers 
using debridement in any form as compared to autolytic debridement with standard wound care, 
with significant variability in the distribution of the effects. 
v)   Decrease the frequency of Methicillin Resistant Staphylococcus Aureus (MRSA) or other 
wound infections that may complicate diabetic foot wounds? 
RH4e: There is a difference in the frequency of MRSA or other wound infections in diabetic foot 
ulcers using debridement in any form against autolytic debridement with standard wound care. 
 
 
46 
 
vi) Reduce healthcare costs for diabetic foot wounds? 
RH4f: There is a difference in the healthcare costs associated in treating diabetic foot ulcers 
using debridement in any form as compared to using autolytic debridement with standard wound 
care. 
vii) Improve the quality of life for those with diabetic foot wounds? 
RH4g: There is a difference in quality of life indicators in treating diabetic foot ulcers using 
debridement in any form as compared to autolytic debridement with standard wound care. 
Research Question 5.  Which specific method(s) of debridement is/are most effective at 
achieving the desirable outcomes listed? Do the specific method(s) of debridement: 
i)    Differ in the time to complete healing of diabetic foot ulcers? 
RH5a: The time to complete healing of diabetic foot ulcers is dependent on the method of 
debridement used. 
ii)   Improve healing rates of diabetic foot wounds? 
RH5b: The healing rates of diabetic foot ulcers are dependent on the method of debridement 
used. 
iii)  Decrease recurrence rates of diabetic foot wounds? 
RH5c: The frequency of recurrent diabetic foot ulcers is dependent on the method of 
debridement used. 
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iv) Decrease the frequency of amputations that may result from diabetic foot wounds? 
RH5d: The frequency of amputations associated with diabetic foot ulcers is dependent on the 
method of debridement used. 
v)   Decrease the frequency of Methicillin Resistant Staphylococcus Aureus (MRSA) or other 
wound infections that may complicate diabetic foot wounds? 
RH5e: The frequency of MRSA or other wound infections is dependent on the method of 
debridement used. 
vi) Reduce healthcare costs for diabetic foot wounds? 
RH5f: The healthcare costs associated with treating diabetic foot ulcers is dependent on the 
method of debridement used. 
vii) Improve the quality of life for those with diabetic foot wounds? 
RH5g: The Quality of life indices among those with diabetic foot ulcers is dependent on the 
method of debridement used. 
Study Aim 3. Meta-regression and subgroup analysis for possible characteristics that may be 
moderating the variability of the effectiveness of debridement as a treatment across populations, 
settings, and study characteristics. 
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Research Question 5.  Do there exist any prognostic or other moderating factors that are 
population specific, disease specific, or study specific characteristics that explain the 
variability of the effect sizes for the various forms of debridement? 
RH5a: There exist moderating factors responsible for the variability of the effect sizes among the 
debridement interventions compared.
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Chapter 4 
Methods   
In accordance with our primary aim, Study Aim 1, this method sections describes in detail the 
methods used to perform a comprehensive and worldwide systematic review of the literature on 
all forms of debridement as a treatment for diabetic foot ulcers. The search was designed to 
capture all randomized controlled trials and all systematic reviews pertaining to our research 
question. Data sources were collected accordingly per the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement Reporting guidelines Moher 
2009. 
Inclusion/Exclusion Criteria   
Types of studies   
All Randomized controlled trials (RCTs), either published or unpublished were included, which 
compare the effectiveness of two or more methods of debridement in the treatment of diabetic 
foot ulcers. There will be no restriction in the search or in the studies included for analysis based 
on language, or country of origin.  
Non-randomized studies were excluded. This exclusion includes prospective cohort studies, case 
controlled studies, cross sectional studies, data archival analysis, Case series/Case studies. 
Mechanistic in vitro or animal studies were also rejected. 
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Types of participants   
Studies with samples of participants that have Type 1 or 2 diabetes, with an active foot ulcer or 
wounds of neuropathic, neuro-ischemic, or ischemic etiology were included. The review was 
limited to participants >/= 18 years of age. There were no other limitations based on age, gender, 
country, healthcare setting, or language. The wounds are not limited in severity or in grading 
system utilized including Wagner Wound Grade, and Texas Classification. 
Studies that included non-diabetics were excluded. Studies that included venous stasis wounds, 
nondiabetic arterial insufficiency wounds, pressure ulcers, or atypical wounds were excluded. 
Types of interventions   
Comparison of any method of debridement (i.e. the removal of necrotic tissue from the wound, 
by either mechanical or non-mechanical debridement) with no debridement, control, or an 
alternative method of debridement were included Table 5. 
These debridement methods included: autolytic debridement (including moistened saline gauze, 
or antiseptic treated gauze as a control condition), sharp surgical debridement, enzymatic 
debridement, biosurgery (or Maggot Debridement Therapy, MDT), mechanical debridement 
(including wet to dry, and ultrasound debridement). The search included any form of 
debridement but did not include SR’s on Negative Pressure Wound Therapy (NPWT). NPWT 
includes debridement a one of its functions but this form of therapy has other mechanisms and 
has been studied in a separate Cochrane review Dumville 2013b. 
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The ancillary and adjunctive services that are provided as part of routine standard of care 
discussed were coded to control for them as possible modifying factors favoring the intervention 
or control effect. It was anticipated that both the control group and debridement intervention 
groups would have received these other adjunctive services. However, the researchers coded 
accordingly to ensure there was no evidence of differential standards of care in favor of 
treatment or control. 
The term “autolytic debridement” is a process that occurs, naturally, in all wounds. Autolytic 
debridement is however enhanced with the application of certain “autolytic debridement agents”, 
hence using autolytic debridement as a control is based on the naturally occurring phenomenon 
in all wounds such as proteolytic enzymes e.g. Matrix - Metalloproteinases that are released from 
the wound for “self-digestion” or debridement of the wound.  We have restricted the “control 
condition” specifically to using autolytic debridement with saline moist gauze, and or antiseptic 
agents such as betadine, or chlorhexidine. Autolytic debridement agents (e.g. hydrogel) that 
facilitate moist wound healing other than “saline moistened gauze and antiseptic agents” (control 
condition) were compared as experimental interventions against alternate forms of autolytic 
debridement, or other forms of debridement (mechanical). These alternate forms of autolytic 
debridement were often compared to the “control group” defined here as gauze, saline moistened 
gauze, or antiseptic dressings in the included studies. Wet to dry saline moistened gauze was 
designated as a form of mechanical debridement and not autolytic debridement. Using saline 
moistened gauze and antiseptic cleaning solutions has been widely used for an extensive period 
as a form of default wound dressing. This warranted the use of this type of autolytic debridement 
with gauze, saline moistened gauze, and/or antiseptic solutions as a control condition in this 
systematic review (Strohal 2013). 
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Types of outcome measures   
Included studies were searched for any of the following outcome measures reported. 
1. Amputation frequency – The frequency of amputations, and type major (above or below knee) 
or minor (digital, ray, transmetatarsal, forefoot) 
2. MRSA or other complicating wound infection frequency – These may include the frequency 
of MRSA or other wound complicating infections such as osteomyelitis, cellulitis, or Clostridia 
infection and gas gangrene. 
3. Quality of Life (QOL) – This may include subjective ordinal scales such as an SF-36 
questionnaire or some other established alternative quality of life metric. 
4. Healing rates -The rate of reduction in wound size expressed in either absolute or relative 
terms. 
5. Time to complete healing or the proportion of people whose ulcers heal completely at a fixed 
point in time. 
6. Recurrence rates - The proportion of ulcers recurring among participants in or near the same 
location as the previously healed ulcer. 
7. Cost of care – This could have been presented as cost per wound treated or based on a 
reference cost of treatment and is conducted in cost effectiveness analysis (CEA). Cost was not 
standardized across included studies that reported on this outcome. Currency and cost of 
treatment was also anticipated to vary across countries. 
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Primary outcomes   
The primary outcomes of interest that were considered to be most relevant included 1-3: These 
outcomes have direct bearing on clinical and public health implications. 
Secondary outcomes   
The secondary outcomes of interest were considered to have indirect but important bearing on 
the primary outcomes and included 4 – 7. 
Search methods for identification of studies   
Three separate searches were conducted between March of 2103 and March of 2015, see 
Appendix 1. They included two separate searches by the trials search coordinator at the 
Cochrane Review Group - wounds in March of 2013 and in March of 2015. A separate 
institutional search in collaboration with the University of Connecticut medical research librarian 
was also conducted in April of 2014. 
Six computer databases were searched, as were other relevant sources. The specialized trials 
register of the Cochrane Review Group - Wounds was searched for Randomized Controlled 
Trials (RCT) on debridement of diabetic foot ulcers without any country, language, or year 
restriction that are available to date. The register is compiled by searching bibliographic 
databases such as MEDLINE, CINAHL, EMBASE, Cochrane Controlled Trials Register, Web 
of Science, CINAHL, World Health Organization, Conference Proceedings and Abstracts 
relevant to wound care including International Working Group on the Diabetic Foot, the 
54 
 
European Wound Management Association, the American Professional Wound Care 
Association, and the European Tissue Repair Society (Booth 2006; Cooper 2009; DeLuca 2008; 
Warren 2011). Searches were limited to humans and to experimental studies.  
The search strategy incorporated the type of participants including adult (>/= 18 years of age) 
type 1 and type 2 diabetics with Diabetic or lower extremity non-healing ulcerations/wounds. 
The intervention is any treatment classified as a form of debridement. 
This systematic review was restricted to include all randomized controlled trials and all existing 
systematic reviews related to the research question (Lefebvre 2011). 
Hand searching included conference proceedings and journals not indexed in electronic 
databases. Citations within systematic reviews and the bibliographies of included studies were 
scrutinized to identify additional studies. 
Manufacturers and distributors of debridement products were contacted for details of 
unpublished and ongoing trials. Experts in the field of diabetic foot management were also 
contacted for details of unpublished and ongoing trials. The search was not limited by language 
or publication status. 
Upon completion of our search the studies that were accepted and met the two independent 
reviewers’ shared inclusion/exclusion criteria were retrieved along with studies for which the 
reviewers were not able to determine eligibility based solely on the title and abstracts alone. 
These studies were retrieved and the full text article was scrutinized further if not excluded 
earlier based on title and/or abstract. 
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Electronic searches   
A comprehensive literature search was conducted. The literature searches were conducted 
separately with the assistance of the trials search coordinator at the Cochrane Review Group – 
Wounds, and with the assistance of the University of Connecticut Medical Health Sciences 
Librarian. The search terms included medical subject headings and other search terms that are 
directly related to the aims of this study. Detailed search strategies and search terms used for this 
review are illustrated in Appendix 1. 
For this review we searched the following electronic databases to find reports of relevant RCTs: 
 The Cochrane Wounds Group Specialized Register (4/15/2015); 
 The Cochrane Central Register of Controlled Trials (CENTRAL) (1898 to present); 
 Ovid MEDLINE (1996 to March Week 4 2013); 
 Ovid MEDLINE (In-Process & Other Non-Indexed Citations, (1946 to Present, 2013 to 
April 14 2015); 
 Ovid EMBASE (1974 to 2015, June 16 1996 to 2013 Week 13, 2013 to April 14 2015); 
 EBSCO CINAHL (1981 - present, 2013 to April 15 2015) 
 EMBASE via Scopus (1960 to present) 
 Web of Science (1974 to present) 
Searching other resources   
We searched the bibliographies of all included studies and all existing systematic reviews related 
to the research question. 
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Selection of studies   
Studies were selected independently for inclusion based on the consensus of two independent 
reviewers. An independent subject/content area expert, and an independent methods expert were 
available for technical support and to resolve any discordance between the two primary 
reviewers.  
Any disagreements were initially resolved through discussion between the two primary 
reviewers and then if unresolved referred to the respective independent experts. Any 
disagreements that still remained were referred for arbitration to the Cochrane Review Groups – 
Wounds. However, no disagreements were referred to the review group, as they were all 
resolved internally. Any studies that required full article retrieval and were subsequently rejected 
were included in the excluded studies section with the reason for rejection See Characteristics of 
Excluded studies section. These steps are in accordance with efforts to maximize the 
transparency and redundancy in the process (Cooper 2009; Higgins 2008). 
Data collection and analysis   
A coding system using a data extraction form was developed and pilot tested for use with all the 
variables selected for coding. See Appendix 2 for the full version of the data extraction form 
used in this analysis. The coding data extraction form created included study-specific 
characteristics, quality-specific characteristics, participant-specific characteristics, and 
intervention-specific characteristics. The breadth of the coding form comprises summary 
statistical fields, prognostic predictor variables, outcome variables, study design and quality 
indicators including risk of bias indicators, and demographic information.  
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The program Microsoft Access was used to create an electronic data entry form/program based 
on the data extraction form in Appendix 2. This was to facilitate data entry, and reduce data entry 
errors that can occur by inputting data directly into a data grid by the two independent reviewers. 
The variables were extracted and transferred onto an Excel spreadsheet independently by each 
reviewer using the (reliability pre-tested) data extraction tool (Cooper 2009; Higgins 2008). The 
extraction of these characteristics were dependent upon reporting status in the respective studies 
selected. Many of the pre-specified variables were either not reported or were not uniformly 
reported in the studies. 
Variables that represented study-specific characteristics were grouped together including for 
example publication year, and data collection year. The estimated year of data collection (earliest 
date for data collection or manuscript submission/publication were used. If the study was 
unpublished and/or the date unknown, then the length of follow-up and/or year of manuscript 
was used as an estimate for data collection year. Other study-specific characteristics included 
language, and the source, or type of publication (abstract, conference proceeding, journal article, 
book, unpublished manuscript, thesis/dissertation) were extracted. 
The variables included in the coding form represented sample characteristics, e.g. age (mean and 
standard deviation), gender (percentage of males and females in the sample), region (country or 
city where the study was conducted), hospital or outpatient settings (specialized center, or private 
office settings), and racial/ethnic composition (the proportion of minorities in each of the 
respective samples). Ethnicity was coded as a moderator for the higher risk of amputations that 
has been observed in minority groups, and for lower socioeconomic status. Socioeconomic status 
was included as a surrogate for healthcare literacy, and access to healthcare. 
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Covariates or modifiers that are suspected of influencing wound healing and represent clinically 
prognostic risk factors were extracted. Separate from the nonclinical sample characteristic 
moderators described above, clinically relevant modifiers were included such as peripheral 
vascular disease status (percentage of the sample), periwound tissue oxygen levels (mean and 
standard deviation), diabetes disease severity indicators such as hgba1c (mean and standard 
deviation), diabetes duration (percentage of the sample), Body Mass Index (BMI, mean and 
standard deviation), hypertension status (percentage of the sample), and immunosuppression 
status (percentage of the sample). Immunosuppression was coded and included percentage of the 
sample that were HIV positive or receiving Immunosuppressive medication, if reported in the 
study. 
Study characteristics included quality-specific indicators (following the Cochrane Risk of Bias 
table format) was collected from the individual studies selected for the review, and were coded 
for analysis. Specific quality indicators included: random sequence generation, allocation 
concealment, blinding (specific to participants, personnel delivering interventions, and outcome 
assessors), incomplete outcome data, and selective reporting, and other bias (e.g. industry 
support). 
Data extraction and management   
Data extraction 
A comprehensive data extraction tool or coding form was created to acquire relevant data based 
on the prevailing standards in wound care. The data extraction form had a total of 237 possible 
variables. These variables represented outcome variables of interest and moderators.  
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Efforts were made to help facilitate and minimize the risk of incorrect data entry between the two 
independent authors and an electronic data entry form was created using the Microsoft Access 
program. 
After retrieval of the included studies data were extracted in duplicate by two separate 
independent reviewers. 
The data extraction tool that was created was reliability tested between the 2 reviewers and 
utilized all of the included studies. The reliability testing of the data extraction coding form was 
conducted after data extraction and prior to the data analysis phase of this systematic review. All 
of the variable results were used except for the outcome variables. The data extraction was 
evaluated and expected to demonstrate a kappa statistic that reflected at minimum a 0.74 or 
greater agreement prior to its use on studies selected for inclusion (Higgins 2008). Any 
discrepancies between the two reviewers were reconciled until all entries were finalized and 
identical. The data extraction form served as the sole data extraction tool for each of the studies 
selected. Any disagreements in extracted content were fully resolved by discussion and if 
unresolved would be referred to the content and methods expert, and if still unresolved, to the 
Cochrane Review Group Wounds for arbitration (Cooper 2009; Higgins 2008). 
Collectively the 30 individual studies selected did contain every outcome effect of interest. The 
Meta-analysis portion of the analysis was conducted on similar studies based on shared outcome 
effects as all studies did not necessarily report on all of the outcomes of interest. The way that 
missing data were handled in the studies (i.e. Bayesian methods, imputation methods, last 
observation carried forward) was reported in the systematic review.  
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Intention-to-treat analysis was evaluated further by the reviewers in order to determine if the 
specific method used and classified by the authors as intention-to-treat was reported in the 
methods section of each study (Harel 2012).  
Reliability testing 
Reliability testing was conducted on all of the modifying factors for the 30 included studies as 
these represented the majority of the 235 variables in the data extraction coding form. 
The dichotomous variables were compared between the two researchers using cross tabulations. 
Percent agreement and kappa statistics were calculated. The kappa statistics representing each of 
the categorical variables were averaged, and the mean kappa was 0.33, which is representative of 
poor agreement between coders for the data extraction coding form. 
The continuous variables were compared between the two researchers using correlation matrices. 
Pearson's correlations were obtained for each of the respective continuous variables and then 
they were subsequently averaged. The mean Pearson's correlation was 0.75 which is 
representative of good agreement between the researchers. This contrasted significantly with the 
kappa for the categorical data. 
This difference likely reflected the inherent subjectivity in many of the dichotomous variables 
that included quality assessment judgments, whereas the continuous variables represented more 
objective variables e.g. hemoglobin a1c. Another possibility may have been a differences in 
background knowledge between the two researchers.  
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The third source of discordant data extraction may have been that the data extraction tool 
included some questions with ambiguous meaning to the reviewers. The data extraction coding 
form was then edited for future updates of the present systematic review with the intent of 
reducing discordant responses between reviewers.  
Regardless of the source of discordant data extraction all disagreements were reconciled in a 
series of meetings. A general reliability calculator was used for the reliability process (Huedo-
Medina 2013). The general reliability calculator is a program that utilizes an excel spreadsheet 
with predesigned formula to permit data entry in either a Pearson correlation matrix for 
continuous variables or a cross tabulation for categorical variables. The program helps generate 
the Pearson correlations and chi square values for all variables compared. It then can be used to 
calculate reliability between two reviewers using a data extraction coding form. 
Assessment of risk of bias in included studies   
The assessment of the risk of bias for each of the studies included in the systematic review relied 
on the Cochrane Collaboration’s Risk of Bias table format. The risk of bias tables included the 
following indicators the this systematic review (Higgins 2008; Hulley 2007): 
i)                  Allocation sequence generation (randomization status and method of randomization 
                     reported) 
ii)                 Allocation of concealment (concealment of the order of random allocation from the 
                     investigators assigning individuals to treatment groups reported) (EBN 2001) 
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iii)                Blinding (blinding status of participants, investigators, and outcome assessors 
                     reported) (EBN 2001) 
iv)                Incomplete outcome data addressed (reporting of missing data along with 
                    procedures used to address missing data) 
v)                 Free of selective reporting (selective reporting of outcomes pre-specified in the 
                    protocol or the methods) 
vi)                Free of other bias (other potential threats to validity related to the specific study 
                    design used, early stopping of study, baseline imbalance between the comparison 
                    groups i.e. high suspicion of confounding/effect modification) 
These risk of bias considerations were extracted accordingly into the data coding form (Higgins 
2008). 
Funnel plot assessment of reporting bias was conducted on the individual studies included in the 
review. A minimum of 10 studies is recommended for assessment of publication bias. The funnel 
plot graphs standard error against the effect size. The positive/negative study classification can 
then be graphically compared for smaller and larger studies. If the studies fall in a symmetric 
pattern around the null value than the likelihood of publication bias is lessened. If the funnel plot 
is asymmetric favoring positive effect sizes this suggests publication bias.  
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Beggs and Eggers statistical tests were also utilized to evaluate for reporting bias. These test are 
explained further below (Cooper 2009; Higgins 2008). 
Measures of treatment effect   
The effect measures included dichotomous events/nonevents data which were used to generate 
Relative risks (RR) for proportion of sample with amputation, proportion of sample with 
infections, proportion of sample with wound recurrence, and proportion of sample with wound 
completely healed. Difference in means (MD) or standardized mean difference (SMD) were used 
for continuous data such as time to complete healing, cost, quality of life index. Mean difference 
was favored for purposes of reporting in this systematic review provided the scale and 
measurement were comparable. This was used because mean difference is inherently better 
understood by the reader than is standardized mean difference. 
Dichotomous events/nonevents data used to calculate the effect estimate risk ratio (RR): 
1) Proportion with amputations 
2) Proportion with complicating infections 
3) Proportion with ulcers completely healed 
4) Proportion with ulcer recurrence 
Continuous data (MD), (SMD) 
5) Quality of Life Index 
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6) Time to complete healing 
7) Treatment cost 
Statistical Analysis 
Effect size (ES) estimates for the association of each independent variable with each of the 
outcomes were extracted accordingly using an effect size extraction program (Huedo-Medina 
2013). The trials varied in the effect measures reported. The Effect size calculator utilizes an 
excel spreadsheet with included formulas that converts effect sizes into different forms 
interchangeably. 
Proportion of participants with amputations, infections, complete ulcer healing, and ulcer 
recurrence were reported for each of the included studies from events and nonevents for both the 
intervention and control groups.  The results were extracted from dichotomous events/nonevents 
data into the respective proportions and these effects were transformed into Relative Risk ratios 
(RR). Risk difference (RD). Numbers Needed to Treat for an additional Beneficial outcome 
(NNTB), and Numbers Needed to Treat for an additional Harmful outcome (NNTH) were then 
subsequently calculated (Morris 2002).  
Time to complete healing, and cost of care were reported as continuous effect sizes measures 
using mean differences (MD) along their respective standard deviations (SD) for both the 
intervention and control groups. 
Quality of life was reported using subjective questionnaire scales on a continuous or ordinal 
scale. These scales were not necessarily standardized across studies using similar or identical 
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debridement interventions. Therefore, the effect sizes were converted to mean differences if a 
similar scale was used, or to a standardized mean differences (d) if the scales differed.  
These procedures were used in order to make it possible to compare the effects of the 
intervention regardless of the outcome metric used. These conversions or transformations were 
contingent upon the same intervention being used in at least two studies. 
The standardized mean difference is defined as the difference between the treatment and control 
groups divided by the pooled standard deviation for two-groups design, or the difference 
between two d for pre-post group design, one for the experimental and another for the control 
group. The pre-post design d (Cohen’s d) is defined as the  posttest and baseline difference of 
sample means divided by the baseline standard deviation (Becker 1988; Hedges 1981; McGrath 
2006). 
In the absence of means and standard deviations, other statistical information (e.g., F-values, p-
values) could be used as surrogates for effect estimates, these statistics were also extracted. 
Although using test statistics and p-values is less ideal than using the direct effect size estimates 
(Huedo-Medina 2006; Huedo-Medina 2013; Sanchez 2003; Hedges 1985). Effect sizes for the 
same outcomes may be reported differently in different studies. Therefore, transformation of the 
outcome effect sizes into the same effect estimate in order to standardize them for comparison 
purposes was required. This was utilized in the meta-analysis by transforming the statistical 
information reported into a uniform effect size estimate for analysis, e.g. RR, OR, MD, 
standardized mean difference, d, using HLSM-Meta software version 0.9 (Huedo-Medina 2006; 
Huedo-Medina 2013). 
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Unit of analysis issues   
The unit of analysis reported was based on a single outcome response per individual. There were 
studies that reported simultaneous treatment of wounds on multiple sites for each individual; the 
authors of the studies generally based the outcome assessments on the most severe of these 
wounds.  
Few studies reported multiple time points or observations for the same outcome (e.g. repeated 
measurements, recurring events). The studies all reported post design (final observations). The 
limited studies that did report multiple time points, were reported in this study as post design 
(e.g. final observations number with amputations by the end of the study) for both the 
intervention and control groups. In the studies where initial measurements or observations were 
reported these were summarized for the reader in tabular format along with wound severity based 
on classification and/or wound duration at baseline. 
The follow up periods and the length of the study are reported, and summarized between studies 
for the reader.  This review prioritized sustained or long term outcome or last reported outcome 
responses for debridement interventions, as these were considered the optimal long-term 
indicators of outcome success or failure. 
Study treatment of missing data   
The individual included studies were not expected to contain every outcome effect of interest for 
this review. The pooled date for the meta-analyses utilized similar studies based on shared 
outcome effects and interventions. The respective included studies sharing similar intervention 
comparisons and outcomes were then grouped and analyzed together.  
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When these data were extracted the method used to address missing data was scrutinized and 
reported accordingly, e.g. Intention to treat analysis, last observation carried forward, Bayesian 
methods, or imputation. The method of missing data treatment was scrutinized for each of the 
respective included studies and if reported the method was subsequently reported in this 
systematic review (Harel 2012). 
If studies with continuous outcome measures reported effect sizes but did not report the 
associated standard deviations; then the respective continuous study outcome was not analyzed 
in the meta-analysis phase of this review. In studies reporting dichotomous outcomes, if the 
actual number of events/nonevents were not reported or could not be extracted or calculated from 
a respective study; then the outcome was not included in the meta-analysis phase of this review. 
Assessment of reporting biases   
Publication bias and other reporting biases were addressed using funnel plots, statistical tests and 
through the use of Cochrane risk of bias tables. The authors acknowledge that asymmetric funnel 
plots are not necessarily caused by publication bias (and that publication bias does not 
necessarily cause asymmetry in a funnel plot). For example, the other reasons that may bias the 
results toward exaggerated positive findings in smaller studies might include differences in 
methodological quality, heterogeneity in the intervention effects in certain higher risk groups, 
and random error. 
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Cochrane risk of bias tables were used to assess each study for sequence generation, allocation 
concealment, blinding (including 3 categories participant, personnel delivering interventions, 
outcome assessor), reporting biases, and other biases including funding sources, unpublished 
abstracts. 
Funnel plot assessment of publication bias was conducted on the studies included in the review. 
This was based on standard assessment that includes sample size and positive/negative effect 
size magnitude and direction. Asymmetries of effect sizes suggest reporting biases as they may 
be found associated with a propensity to report positive studies disproportionately as compared 
to negative studies (Cooper 2009; Higgins 2008). 
Alternatively, tests were used for publication bias including Beggs technique uses a 
nonparametric rank correlation test to detect publication bias in meta-analyses (Begg 1994). The 
test is an adjusted rank correlation test which is considered a statistical analogue of the funnel 
plot. The test generates a Kendall’s tau between the standardized effect size and the variances (or 
standard errors) of these effects. Tau is interpreted analogous to a correlation. A value of zero 
indicating no relationship between effect size and precision (variance or standard error). Values 
in either direction away from “0” indicates an association.  
The test is considered powerful and useful for large meta-analyses that include at least 75 studies 
or greater, but moderate power for meta-analyses with at least 25 - 75 included studies. The test 
is not ideal for small studies. Bias cannot be ruled out if the test result is non-significant. The test 
is considered complementary to the funnel plot (Begg 1994).  
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An alternative graphical test is available called Egger’s technique which detects bias in meta- 
analyses (Egger 1997). Funnel plots can plot effect estimates against standard error in order to 
detect bias in meta-analyses. Egger uses a “simple” test of asymmetry of funnel plots in order to 
attempt to predict discordance of results among meta-analyses when they are compared to large 
trials. The degree of funnel plot asymmetry is assessed. This is based on imprecision of the 
intercept obtained through regression analysis for standard normal. Egger uses the effect sizes 
and precision, which differs from Beggs which uses ranks.  
The Egger test uses the standard normal deviate (effect size divided by its standard error) and 
this is regressed upon precision (inverse of the standard error). The intercept in this regression 
corresponds to the slope in a weighted regression of the effect size on the standard error. By 
demonstrating that it is no different from 0 suggests that there is no asymmetry in the funnel plot 
(Egger 1997). 
The trim and fill method was another alternative method considered. This method removes the 
most extreme small study studies from positive side of the funnel plot to evaluate what the effect 
estimate would be without them. This approach can add symmetrically mirror image extreme 
small studies to the negative side of the funnel plot to determine how that impacts the overall 
effect estimate. (Duval 2000). 
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Data synthesis   
This systematic review included a meta-analysis using a random effects model. A random effects 
model was considered appropriate in this analysis since it is difficult to assume that an 
intervention has a singular fixed effect in complex biological organisms using healthcare 
interventions (Cooper 2009; Higgins 2008; Schmidt 2009). Treatment effects are expected to 
vary widely due to the wide variation in practices that constitute standards of care among the 
healthcare community. This is in addition to individual patient’s biological variability. 
A random effects model approach was considered because it provided a more conservative 
estimate of outcome effects when considering the variation in healthcare interventions. The more 
conservative larger confidence interval is likely more reflective of the broader range of treatment 
effects in healthcare interventions. There exists significant variability between individual 
subjects in their responses to interventions. There are variables that are not accounted for, since 
some mechanisms responsible for the effects of treatment in an individual remain poorly 
understood. These unknown prognostic factors are irrespective of efforts to use modeling to 
account for known modifying characteristics that may interact with the intervention or confound 
the intervention and effect. There may be hyper-responders that may be suggested by outliers. 
There is large biological complexity, making it is reasonable to infer that there likely exist 
numerous treatment effects among the population rather than a single fixed effect. Therefore, our 
analysis accounted for both conditional, and random variability (Cooper 2009; Higgins 2008, 
Borenstein 2009). 
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Sensitivity analysis   
Efforts were made to determine whether the decisions made during the review process were 
robust, such as the inclusion/exclusion of particular studies from the meta-analyses with missing 
or insufficient data such as abstracts. 
Studies that were restricted to unpublished abstracts (Goretti 2008; Roberts 2001) were removed 
and a meta-analysis was then conducted separately in order to determine if the summary effect 
estimates were robust despite the exclusion of these two studies. This was considered appropriate 
since abstracts did not include the degree of information available in full study articles. Risk of 
bias assessments are difficult in light of the limited information provided by abstracts alone. Data 
were extracted from these abstracts for use in the systematic review.  
However, it was important to determine if pooled effect size estimate were disproportionately 
influenced by the inclusion of these two abstracts.  
The decision to use a random effects model for this systematic review was pre-specified. The 
effect estimates using a random effects model were compared to the effect estimates using a 
fixed effects model to determine if the findings were robust despite the model type used in the 
analysis.
72 
 
Chapter 5 
Results   
Description of included studies   
Upon retrieval of all full text studies a total of thirty studies met the Inclusion/Exclusion criteria 
for this systematic review Figure 2; see Characteristics of included studies section. The studies 
were qualitatively and comprehensively summarized, see the Characteristics of included studies 
section of this systematic review. The accompanying risk of bias tables assessed the risk of bias 
in each of the 30 studies Figure 3; Figure 4. Collectively the included studies comprised a total of 
2539 participants Table 7; Figure 5. 
Inclusion / exclusion criteria for the individual included studies 
See Inclusion and exclusion criteria for the individual included studies in the Additional Tables 
section of this review Table 8. The list of inclusion/exclusion criteria in Table 8 represent the 
criteria the authors of the individual studies used, and do not represent the inclusion/exclusion 
criteria used in this review. There was significant variability in the inclusion and exclusion 
criteria between studies Table 8. 
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Study Characteristics for the 30 included studies 
Study duration and follow up period 
The study period ranged from 1992 - 2012 for the 30 included studies Figure 6. The follow up 
period for the included studies ranged from 10 days to 24 weeks see Characteristics of included 
studies. 
Study Settings for the individual included studies 
The study settings were primarily outpatient or specialized clinic settings (17 studies). However, 
8 of the studies were reported in hospital settings, 2 studies included both inpatient-hospital and 
outpatient settings, and the setting was unclear in 5 studies. 
The studies were conducted in the following countries (included in brackets () is the number of 
studies conducted in that respective country): Belgium (2), Brazil (1), Canada (1), Denmark (), 
France (1), Germany (2), Iran (1), Italy (5), Jordan (1 study), Malaysia (2), Pakistan (1), Saudi 
Arabia (1 study), Slovenia (1), Sweden (1), Switzerland (1), Tunisia (1), Turkey (1), UK (5), and 
US (7), Europe (2), Unclear (1) Table 7. Four of the studies were conducted in more than one 
country and the adjacent study numbers are reflective of this. 
Sample sizes for the individual included studies 
The included studies ranged from sample sizes of 18 to 619 participants. Table 9; Figure 5. All 
30 included studies reported total sample size. The mean sample size for the included studies was 
85 (SD = 119) participants.  
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Study Participants in the included studies 
See “Study year, sample sizes and study setting for included studies table” in the Additional 
Tables Section Table 7. 
a) Age 
The mean ages for the included studies ranged from 52.1 through 69.3 years Figure 7. A total of 
23 studies reported on age. The mean age for the reported sample of studies was 59.01 (SD = 
4.31) years. 
b) Gender 
In the majority of studies most participants were men with two studies reporting one or no 
female participants Figure 8; Figure 9. A total of studies 21/30 studies reported gender 
composition, 9 studies did not report gender Table 9. The number of males ranged from 12 to 
240. The total mean number of males was 49 (SD = 53) for the reported studies. The number of 
females ranged from 1 to 88 for the reported studies. The total mean number of females was 26 
(SD = 22) for the reported studies. 
c) Ethnicity 
Ethnicity was reported in 4/30 studies. Four studies out of thirty reported on ethnicity including 
(Shukrimi 2008, Tallis 2013, Singh 2006, and Dhemecourt 1998). 
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Study participants 
d) Other participant data 
BMI was reported in 5/30 studies. Socioeconomic status was reported in 1 study. 
Wound specific characteristics for the included studies grading, surface area, and depth 
Grading of the ulcer (severity) was used in 13 studies and included the use of the Wagner wound 
grading system and the University of Texas classification systems. The wounds were classified 
up to Wagner grade 4 or Texas classification grade 3. A total of 17 studies did not specify the 
wound classification and referred to the wounds as diabetic foot ulcers with partial or full 
thickness wounds. The initial size of the wound was specified in 20 out of the 30 studies using 
wound surface area. This was reported for both the intervention and control groups for each of 
these studies reporting. Depth of the wound was specified in 5 out of 30 studies. Table 10; 
Figure10: Figure 11. 
Wound duration at baseline for the included studies 
Fourteen out of 30 studies reported on wound duration. Wound duration ranged from 1 week to 
15.8 (SD = 10.7) years Figure 12; Figure 13. 
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Prognostic risk factors for the included studies 
a) Mean Hemoglobin a1c, and duration of diabetes status at baseline for the included 
studies 
The studies that reported on comorbidities that may impact wound healing included the 
following information: 8/30 studies reported on mean hemoglobin a1c, mean hgba1c ranged 
from 7.25% to 9.25% Figure 14. 14/30 studies reported on mean duration of diabetes which 
ranged from 13 (SD= 10.6) years to 20.5 (SD = 13.5) years Table 11 Figure 15. 
b) Peripheral arterial disease (PAD) status at baseline for the included studies 
The proportion of the sample with baseline arterial insufficiency was reported in 9 studies Table 
11, Figure 16. 
c) Infection status at baseline for the included studies 
The infection status at study onset was reported in 11 studies Table 11, Figure 17  
d) Offloading status at baseline for the included studies 
Offloading status was reported in 9 studies Table 11, Figure 18.  
e) Immunosuppression status at baseline for the included studies 
Immunosuppression status was reported in 1 study Table 11, Figure 19.  
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f) Nutritional status at baseline for the included studies 
Two of the studies included nutritional status indicator at baseline using albumin Table 11, 
Figure 20.  
g) Smoking status at baseline for the included studies 
The proportion of smokers at baseline was reported in 5 studies Table 11, Figure 21. 
h) Venous insufficiency status at baseline for the included studies 
The proportion of the sample with baseline venous insufficiency was not reported Table 11. 
i) Industry support was reported in 13/30 of the included studies Figure 22. 
Results of the search   
The three separate searches collectively retrieved a total of 3553 citations. 
To these were added 160 citations retrieved through a hand search of the bibliographies of 
systematic reviews related to the research question that were among the full text studies 
retrieved. A hand search of the bibliographies of all 30 included studies along with 10 systematic 
reviews retrieved on a similar research question was conducted. 
After duplicates were removed a total of 2625 citations remained. A total of 2513 citations were 
excluded based on title and abstract using the pre-specified eligibility criteria. 112 full text 
studies were retrieved for further review. 
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Upon scrutinizing 112 full-text articles, 82 of these studies did not meet the inclusion/exclusion 
criteria and were rejected, reasons for rejection are included in this systematic review, see 
Characteristics of excluded studies section of this review. A total of 30 studies met the pre-
specified inclusion/exclusion criteria for this systematic review. 
See Study selection Prisma flow diagram in Figure 2. 
Excluded studies   
A total of 82 studies were excluded from this review. The main reasons cited for exclusion 
included: see Characteristics of excluded studies 
1) The study was not randomized - 30 studies 
2) The intervention was not classifiable as a recognized form of debridement - 30 studies 
3) Other debridement intervention(s) besides the comparison interventions were applied to both 
treatment arms - 12 studies 
4) Other reasons were reported for the remaining - 10 studies 
Risk of bias in included studies   
The risk of bias in included studies was appraised in 6 separate areas including random sequence 
generation, allocation concealment, blinding, incomplete outcome data, selective outcome 
reporting, and other potential sources of bias. 
All of the included studies reported random sequence generation. However in most studies the 
method of randomization was unspecified with the exception of five studies (Amini 2013; 
Bowling 2011; Jeffcoate 2009; Munter 2006; Tallis 2013).  
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The method of sequence generation included simple randomization in (Amini 2013), and 
computer random sequence generation in the other four studies. See Risk of Bias Figure 3 and 
Figure 4. 
Allocation concealment was assessed as a form of selection bias. Most of the included studies 
did not report whether allocation concealment was utilized with the exception of 5 studies; 
(Bowling 2011, Jeffcoate 2009, Jude 2007a, Munter 2006, and Tallis 2013). See Risk of Bias 
Figure 3 and Figure 4. 
Blinding was assessed as a form of performance bias and detection bias. The blinding of 
outcome assessors was reported in 7 studies (Ali 2013, Goretti 2008, Jeffcoate 2009, Lalau 2002, 
Piaggesi 2001, Shukrimi 2008, Singh 2006). Three studies (Apelqvist1990, D'Hemecourt 1998, 
Piaggesi 1998) reported double blinding including outcome assessors and the delivery of the 
intervention. However double blinding was not uniformly and clearly defined. Blinding was 
either not conducted or unclear in the remaining studies. This may have been attributable to the 
nature of the interventions (e.g. surgical debridement, mechanical jet irrigation). See Risk of Bias 
Figure 3 and Figure 4. 
Incomplete outcome data were assessed as a form of attrition bias. Most of the studies did not 
report on the status of incomplete outcome data. One study (Belcaro 2010) reported that there 
were no drop outs in the study. Another study (Whalley 2001) reported withdrawals but reasons 
for withdrawals was unclear and method of addressing withdrawals was not specified.  
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Eight studies (Markevich 2000, Mazzone 1993, Ogce 2007, Piaggesi 1998, Rhaiem 1998, 
Roberts 2001, Shukrimi 2008, and Singh 2006), did not report whether there were any 
participant withdrawals nor was the method of addressing missing data specified. Eight studies 
(Blackman 1994, Clever 1995, Foster 1994, Hammouri 2004, Jensen 1998, Lalau 2002, Piaggesi 
2001, and Vandeputte 1997), reported participant withdrawals or drop outs and cited reasons 
however the methods of addressing missing data were not specified. 
Two studies (D'Hemecourt 1998; Donaghue 1998) reported that an intention to treat analysis was 
conducted but did not specify the method that was used. Three studies (Jeffcoate 2009, Munter 
2006, Tallis 2013), reported using an intention to treat analysis and specified that the method 
used was last observation carried forward. 
Selective outcome reporting was assessed as a form of reporting bias. No pre-study protocols 
were available for any of the studies. Therefore, an assessment of selective reporting was based 
on discordance between pre-specified outcomes reported in the methods section not appearing in 
the results sections of the studies. Approximately 14 out of 30 studies were at low risk for 
selective reporting. Approximately 11 out of 30 studies were at high risk for selective reporting 
based on discordance between outcomes reported in the methods and results sections of the 
study. 
17 out of the 30 studies were at high risk for other potential sources of bias. In the other 13 
studies it was unclear whether other potential sources of bias were likely, since insufficient 
information was available to make this determination. Important sources of confounding were 
not addressed in the results section to determine if they were balanced in both treatment arms, 
especially since many of the studies included small sample sizes. 
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Randomization has a higher likelihood of balancing unknown or uncontrolled confounders in 
both treatment arms the greater the sample size. Characteristics of included studies; Szklo 2007,  
The studies had a broad range of follow up periods with some being as brief as 10 days and 
others being as long as 24 weeks Characteristics of included studies.  
13 of the 30 studies received private source of financial support, 2/30 reported not receiving any 
financial support, and in 15 other studies the source of financial support could not be determined 
or was not reported Table 12; Figure 22. 
Effects of interventions   
Twenty-two out of the 30 included studies collectively represent 19 separate comparisons that 
reported on a minimum of 1 of the 7 pre-specified outcomes of interest for this review.  
These 19 comparisons included one study each in comparisons 1 – 5, 7, 8, 9, 11, 12, 14, 15, 16, 
17, and 18; three studies in comparison 6; two studies in comparisons 10 and 13; and 10 studies 
in comparison 19 Table 13.  
The comparisons include effect sizes for each of the interventions per outcome of interest that 
were reported and include the results of the meta-analyses carried out on 4 comparisons 
including: comparison 6 (3 studies), 10 (2 studies), 13 (2 studies), and 19 (10 studies). The 
effects of the interventions are described under each of the primary outcomes of interest 
(proportion of participants with amputations, proportion of participants with complicating 
infections, and quality of life), and secondary outcomes of interest (proportion of ulcers healed, 
time to complete healing, proportion of ulcers recurring after healing, and cost of treatment). 
82 
 
8 out of the 30 studies, despite meeting our inclusion criteria for the review, did not report on any 
of the pre-specified outcomes of interest. These included the following studies Ali 2013; Baker 
1993; Bowling 2011; Munter 2006; Ogce 2007; Shukrimi 2008; Singh 2006; Tallis 2013. 
The studies are reported in the Characteristics of Included Studies section of this systematic 
review as they did meet our inclusion criteria but are not reported in this effects of interventions 
section since they did not include the outcomes of interest. These 8 studies were not pooled in 
any of the meta-analyses for this reason. The pre-specified outcomes of interest were not used as 
eligibility criteria as this would have restricted the number of studies captured in the search 
phase of this systematic review. They are summarized and included in the Characteristics of 
Included Studies section to prevent the introduction of biased reporting into this systematic 
review. 
Comparison 1: Surgical debridement compared with conventional non-surgical 
management (1 trial, 42 participants) 
This comparison included 1 trial (Piaggesi 1998) with 42 participants. The follow up period was 
24 weeks. The study period was 1995. There was significant risk of bias as many of the risk of 
bias considerations were unclear or high risk Figure 3; Figure 4. 
Types of interventions 
The surgical debridement group underwent surgical excision, eventual debridement or removal 
of bone segments underlying the lesion and surgical closure. The conventional management 
group received saline moistened gauze after an initial surgical debridement. Pressure relief was 
provided to both groups along with regular dressings. Table 5; Table 13. 
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Initial wound stage 
The mean baseline maximum wound size depth was 1.58 (SD = 2.2) cm2 in the sharp 
debridement group and 1.98 (SD = 1.07) cm2 in the conventional non-surgical management 
group Table 10. 
Participant characteristics 
The study comprised a total of 42 participants. The mean age for the study was 64.39 (SD = 
11.67) years. The number of males and females was not reported Table 9. The study setting 
included outpatients in Italy Table 7. Baseline data were collected for the type and duration of 
diabetes, the age of patients, and their HBA1c Table 11. 
Primary outcomes 
Proportion of participants with amputations 
The proportion of individuals with amputations was lower in the surgical debridement group 
0/22 as compared with the conventional non-surgical management group 1/24. (RR 0.36, 95% CI 
0.02 to 8.46; participants = 46; studies = 1) Analysis Table 1.1. No statistically significant 
difference was found. 
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Proportion of participants with complicating infections 
The proportion of participants with complicating infections was lower (64% risk reduction) in 
the surgical debridement group 1/24 (5%) than the convention non-surgical treatment group 3/24 
(13%) (RR 0.36, 95% CI 0.04 to 3.24; participants = 46; studies = 1) Analysis Table 1.2 No 
statistically significant difference. 
Quality of life 
No data were reported although Piaggesi 1998 reported that patients reported a higher degree of 
satisfaction with surgical debridement as well as lower discomfort but did not report how this 
outcome was measured and whether a valid scale had been used. (MD -2.20, 95% CI -3.16 to -
1.24; participants = 46; studies = 1) Analysis Table 1.3 
Secondary outcomes 
Proportion of ulcers completely healed  
Conservative care healed 19/24 (79%) ulcers, compared with 21/22 (95%) of ulcers treated by 
surgical debridement. The number of ulcers healed was 15% greater in the surgical debridement 
group than in the conservative non-surgical treatment group. (RR 1.15, 95% CI 0.90 to 1.47; 
participants = 46; studies = 1) (No statistically significant difference was found) Analysis Table 
1.4. 
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Time to complete healing 
The ulcers treated with conservative methods took longer to heal on average; 129 (+/- 87 days) 
compared with the surgically treated group whose healing time was 47 (+/- 39 days). It was 
unclear in the trial whether the figures in parentheses were ranges, standard errors or standard 
deviations as this was unspecified.  
The mean difference in healing was approximately 82 days shorter in the sharp surgical 
treatment group as compared with the conventional non-surgical treatment group (MD 81.68, 
95% CI 41.07 to 122.29; participants = 46; studies = 1) (statistically significant difference was 
observed). Analysis Table 1.5. 
Proportion of ulcers recurring after healing 
In the non-surgical treatment group, 8/24 (33%) ulcers recurred within six months, compared 
with 3/22 (14%) in the surgical debridement group; There was a 59% reduction in ulcer 
recurrence favoring the sharp surgical debridement group. (RR 0.41, 95% CI 0.12 to 1.35; 
participants = 46; studies = 1) (No statistically significant difference) Analysis Table 1.6. 
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No data were reported for the pre-specified outcome cost of treatment. 
 
Comparison 2: Superoxide solution compared with standard local treatment 
with povidone iodine (1 trial, 40 participants) 
This included 1 trial Goretti 2008 with 40 participants. The study was available in unpublished 
abstract form only. The range of follow up was 24 weeks. The study comparison period was not 
reported. There was significant risk of bias since the study information was limited to an 
unpublished abstract and much of the risk of bias considerations were unclear Figure 3; Figure 4. 
 
Analysis Table 1.1 – 1.6 Sharp Surgical Debridement compared to nonsurgical 
management 
 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect 
Estimate 
1.1 Number of 
amputations 
reported 
1 46 Risk Ratio (M-
H, Random, 
95% CI) 
0.36 [0.02, 
8.46] 
1.2 Number of 
Infections reported 
1 46 Risk Ratio (M-
H, Random, 
95% CI) 
0.36 [0.04, 
3.24] 
1.3 Quality of life / 
Limitations 
1 46 Mean 
Difference (IV, 
Random, 95% 
CI) 
-2.20 [-3.16, -
1.24] 
1.4 Number of 
ulcers completely 
healed 
1 46 Risk Ratio (M-
H, Random, 
95% CI) 
1.15 [0.90, 
1.47] 
1.5 Time to 
complete healing 
(days) 
1 46 Mean 
Difference (IV, 
Random, 95% 
CI) 
81.68 [41.07, 
122.29] 
1.6 Recurrence rates 1 46 Risk Ratio (M-
H, Random, 
95% CI) 
0.41 [0.12, 
1.35] 
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Types of Interventions 
The interventions in these studies included superoxide solution as compared with standard local 
treatment with povidone iodine. Standard local treatment was not defined in the study Table 5; 
Table 13. 
Initial Wound Stage 
The mean wound size in the study was reported as greater than 5 cm2. The mean wound depth, 
wound staging, and mean duration of ulcers in the study was not reported Table 10. 
Participant Characteristics 
The studies comprised a total of 40 participants. The mean ages for the study was not reported. 
The number of males and females included were not reported Table 9. The study setting included 
hospitalized patients and was conducted in Italy Table 3. 
Goretti 2008 
Primary Outcomes 
No data were reported for any of the primary outcomes of interest. 
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Secondary Outcomes 
Proportion of participants with ulcers completely healed 
Proportion of participants with ulcers healed was higher 17/20 (85%) in the superoxide solution 
group than the standard local treatment with iodine group 11/20 (55%). There was a 55% 
increase in ulcer healing favoring the superoxide solution group as compared to the standard 
local treatment with iodine group (RR 1.55, 95% CI 1.00 to 2.39; participants = 40; studies = 1) 
Analysis 2.1. No statistically significant difference was observed. 
Time to complete healing 
Time to complete healing was reported to be 6 days shorter (MD -6.00, 95% CI -6.94 to -5.06; 
participants = 40; studies = 1) Analysis 2.2 in the superoxide solution group 10.5 (SD = 1.3 days) 
than the standard local treatment with iodine group 16.5 (SD = 1.7days). A statistically 
significant difference. 
No data were reported for the secondary outcomes proportion of ulcers recurring after healing, 
and cost of treatment. 
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Analysis Table 2.1 – 2.2 Superoxide solution dressing and 
standard local treatment as compared with standard local 
treatment with povidone iodine dressing 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
2.1 Number of 
ulcers completely 
healed 
1 40 Risk Ratio (M-H, 
Random, 95% CI) 
1.55 [1.00, 2.39] 
2.2 Time to 
complete healing 
(days) 
1 40 Mean Difference 
(IV, Random, 
95% CI) 
-6.00 [-6.94, -
5.06] 
 
Comparison 3: Low frequency ultrasound compared with sharp debridement (1 
trial, 40 participants) 
This comparison included 1 trial Amini 2013 with 40 participants. The range of follow up was 6 
months or until complete wound healing. The study comparison period was March 2009 to May 
2010. There was significant risk of bias since much of the risk of bias characteristics were not 
reported. Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included low frequency ultrasound debridement as compared 
with standard local sharp debridement Table 5; Table 13. 
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Initial Wound Stage 
The mean wound size in the study was reported to be 6.8 (SD = 6) cm2 in the ultrasound group 
and 9.9 (SD = 7.6) cm2 in the sharp debridement group. The mean wound depth was not 
reported. The wound stage in the study was Wagner Grade 3. The mean duration of ulcers in the 
study was 15.6 (SD=16.8) weeks in the low frequency ultrasound group and 17.6 (SD = 18.8) 
weeks in the sharp debridement group Table 10. 
Participant Characteristics 
The studies comprised a total of 40 participants. The mean age for the study was not 55.2 (SD = 
9.4) years. The study included 24 males and 16 females Table 9. The study setting was a diabetic 
foot ulcer clinic in Iran Table 3. 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was 9% higher (RR 1.09, 95% CI 
0.64 to 1.86; participants = 40; studies = 1) Analysis 3.1 in the low frequency ultrasound 
debridement group 12/20 (60%) as compared with the sharp debridement group 11/20 (55%). No 
statistically significant difference. 
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Time to complete healing (days) 
The mean time to complete healing was 19.6 days shorter (MD -19.60, 95% CI -69.96 to 30.76; 
participants = 40; studies = 1) Analysis 3.2 in the low frequency ultrasound debridement group 
61.6 (SD = 84 days) than in the sharp debridement group 81.2 (SD = 78.4). No statistically 
significant difference. 
No data were reported for the secondary outcomes proportion of participants with ulcers 
recurring, or cost of treatment. 
Analysis Table 3.1 – 3.2 Low frequency ultrasound 
debridement compared with sharp debridement 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect 
Estimate 
3.1 Number of ulcers 
completely healed 
1 40 Risk Ratio (M-H, 
Random, 95% 
CI) 
1.09 [0.64, 1.86] 
3.2 Time to complete 
healing (days) 
1 40 Mean Difference 
(IV, Random, 
95% CI) 
-19.60 [-69.96, 
30.76] 
Comparison 4: Larvae compared with hydrogel (1 trial, 140 participants) 
This comparison included 1 study Markevich 2000 and a total of 140 participants. The range of 
follow up was 10 days. The study period was not reported. The study was available in abstract 
form. The abstract reports follow up was 10 days whilst the trial was reported to be 30 months in 
duration. Attempts to contact the authors have been unsuccessful. 
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Types of Interventions 
The interventions in these studies included maggot debridement therapy as compared with 
hydrogel Table 5; Table 13. 
Initial Wound Stage 
The baseline wound characteristics were reported as comparable between both groups but were 
not otherwise specified. The mean wound depth was not reported. The average ulcer duration at 
baseline was 15.8 (SD = 10.7) years. The wound grade or stage was not reported. The mean 
duration of ulcers in the study was not reported Table 10. 
Participant Characteristics 
The studies comprised a total of 140 participants. The mean age for the study was not 53.6 (SD = 
15.4) years. The number of males and females were not reported Table 9. The study setting was 
conducted in Europe Table 3. 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
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Secondary Outcomes 
Proportion of ulcers completely healed 
In the larvae group 5/70 (7%) patients achieved complete healing, compared with 2/70 (3%) 
patients from the hydrogel group. There was a 150% greater healing rate in the larvae group as 
compared with the hydrogel group (RR 2.50, 95% CI 0.50 to 12.46; participants = 140; studies = 
1) (no statistically significant difference) Analysis 4.1. 
No were reported for the secondary outcomes time to complete healing, proportion of 
participants with ulcers recurring after healing, and cost of treatment. 
 
Analysis Table 4.1 Larvae compared with Hydrogel 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
4.1 Number of 
ulcers completely 
healed 
1 140 Risk Ratio (M-H, 
Random, 95% CI) 
2.50 [0.50, 12.46] 
 
Comparison 5: Hydrogel purilon gel compared with hydrogel intrasite (1 trial, 74 
patients) 
This comparison included 1 trial Whalley 2001 and a total of 74 participants (Whalley 2001). 
The range of follow up was until ulcer healing or a maximum of 10 weeks. The study period was 
not reported and it was published in abstract form only. Attempts to contact the authors have 
been unsuccessful. 
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Types of Interventions 
The interventions in these studies included hydrogel purilon gel as compared with hydrogel 
intrasite Table 5; Table 13. 
Initial Wound Stage 
The baseline wound size in surface area was 2.5 (SD = 3.2) cm2 in the purilon hydrogel group 
and 2.4 (SD = 2.9) cm2 in the intrasite hydrogel group. The mean wound depth was not reported. 
Wounds with wound grade 1 - 2 were included. The average ulcer duration at baseline was not 
reported. The mean duration of ulcers in the study was not reported Table 10. 
Participant Characteristics 
The studies comprised a total of 74 participants. The mean age for the study was not reported. 
The number of males and females was not reported Table 9. The study specific setting 
(outpatient or inpatient was unreported. The study was conducted in Europe. Table 3. 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
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Secondary outcomes 
Proportion of ulcers completely healed 
66 people were evaluated for this outcome and in the first hydrogel group (Purilon) 35% 
achieved complete healing compared with 19% in the second hydrogel group (Intrasite) Analysis 
5.1 . The numbers of people in each group were not reported in the abstract, therefore no further 
analysis was possible. 
No data were reported for the secondary outcomes time to complete healing (days), proportion of 
participants with ulcers recurring after healing, and cost of treatment. 
Analysis Table 5.1 Hydrogel purilon compared with 
hydrogel intrasite 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
5.1 Number of 
ulcers completely 
healed 
1 74 Other data No numeric data 
 
Comparison 6: Hydrogel compared with gauze/good wound care (3 trials, 232 
participants) 
D'Hemecourt 1998; Jensen 1998; Vandeputte 1997 
Trial 1: Hydrogel compared with wet to moist saline gauze (31 participants) 
This comparison included 1 study (Jensen 1998) and a total of 31 participants. The range of 
follow up was 20 weeks. The study period was not reported. 
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Types of Interventions 
The interventions in these studies included hydrogel as compared with wet to moist saline gauze 
Table 5; Table 13. 
Initial Wound Stage 
The study included all ulcers of at least 1 cm2 mean wound surface area. The mean wound depth 
was not reported. The study included Wagner grade 2 wounds. The ulcer duration at baseline 
was not reported. The mean duration of ulcers was 32 weeks in the hydrogel group and 12 weeks 
in the wet to moist saline gauze group Table 10. Good wound care and other ancillary care is 
defined in the characteristics of included studies tables for each of the respective studies. 
Participant Characteristics 
The studies comprised a total of 31 participants. The mean age for the study was not reported. 
The number of males and females in the study was not reported Table 9. The hospital/outpatient 
study setting was unclear, and the study was conducted in Europe Table 3. 
Primary outcomes 
Proportion of participants with amputations 
0/14 or 0% amputations were reported in the hydrogel group as compared with 1/17 or 5.9% in 
the wet to moist saline group. There was a 60% reduction in amputations favoring the hydrogel 
group as compared with the control group (RR 0.40, 95% CI 0.02 to 9.12; participants = 31; 
studies = 1) No statistically significant difference was demonstrated. 
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Proportion of participants with complicating infections 
2/14 or 14.3% of complicating wound infections were reported in the hydrogel group as 
compared with 1/17 or 5.9% in the wet to moist saline group. There was a 143% increase in 
complicating infections in the hydrogel group as compared with control (RR 2.43, 95% CI 0.24 
to 24.07; participants = 31; studies = 1); No statistically significant difference was observed. 
No data were reported for the primary outcome quality of life. 
Secondary outcomes 
Proportion of ulcers completely healed 
In the hydrogel group 11/14 (79%) of patients healed completely compared with 6/17 (46%) in 
the control group. There was a 123% increase in ulcers healed in the hydrogel group as 
compared with the control group (RR 2.23, 95% CI 1.11 to 4.48; participants = 98; studies = 3). 
There was a statistically significant difference demonstrated. 
Time to complete healing 
Those ulcers treated with the hydrogel were reported as achieving healing in an average of 10 
weeks, with the control group healing in an average of 12 weeks (no statistically significant 
difference was observed). 
No data were reported for the secondary outcome proportion of participants with ulcers recurring 
after healing. 
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Cost of treatment 
Insufficient reporting prevented the determination of whether the difference in cost between 
hydrogel ($7/day) as compared with the control condition ($12/day) was statistically significant. 
Trial 2: Hydrogel (NaCMC aqueous based gel) compared with good wound care alone (172 
participants) 
This comparison included 1 study (D'Hemecourt 1998) and a total of 172 participants. The range 
of follow up was 20 weeks. The study period was not reported. In this trial the intention-to-treat 
population consisted of 172 patients. 
Types of Interventions 
The interventions in these studies included NaCMC aqueous based gel as compared with good 
wound care alone Table 5; Table 13. 
Initial Wound Stage 
The study included ulcers with a mean baseline wound surface area and depth of 3.5 (SD = 3.53) 
cm2, 0.4 (SD = 0.52) cm in the aqueous based gel group as compared with 3.2 (SD = 2.75) cm2, 
0.4 (SD = 0.20) cm in the control group respectively. The study included Wagner grade 3 to 4 
wounds. The mean duration of ulcers at baseline was 42 +/- 42 weeks and 52.8 (SD = 60.92) 
weeks in the aqueous based gel and control group respectively Table 10. 
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Participant Characteristics 
The studies comprised a total of 172 participants. The mean age for the study was 58.3 (SD = 
12.13) years. There were 127 males and 45 females in the study Table 9. The study setting was 
unclear and was conducted in the USA Table 3. 
Primary outcomes 
Proportion of participants with complicating infections 
21/70 or 30% of participants in the aqueous based gel group developed complicating wound 
infections as compared with 19/68 or 28% in the control group. There was a 7% increase in the 
proportion of participants with complicating wound infections in the aqueous based gel group as 
compared with the control group (RR 1.07, 95% CI 0.64 to 1.81); no statistically significant 
difference was observed. 
No data were reported for the primary outcomes proportion of participants with amputations, 
quality of life. 
In the control group 10/68 (15%) of patients reported an increase in pain compared with 11/70 
(16%) in the hydrogel group, RR 1.07 (95% CI 0.49 to 2.35) (no statistically significant 
difference). It is not clear in the reporting of the trial how pain was measured or whether a valid 
scale was used. 
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Secondary outcomes 
Proportion of ulcers completely healed 
Within a 20-week study period 15/68 (22%) of patients healed with good wound care alone 
(daily dressing changes; sharp debridement of ulcer; systemic control of any present infection; 
off-loading of pressure) compared with 25/70 (36%) of patients healed with hydrogel. There was 
a 62% increase in proportion of healed participants as compared with the good wound care alone 
group, RR 1.62 (95% CI 0.94 to 2.80) (no statistically significant difference). 
No data were reported for the secondary outcomes time to complete healing, proportion of 
participants with ulcers recurring after healing, cost of treatment 
Trial 3: "Immunomodulating" hydrogel compared with dry gauze (29 participants) 
This comparison included 1 study (Vandeputte 1997) and a total of 29 participants. The range of 
follow up was 12 weeks. The study period was not reported. 
Types of Interventions 
The interventions in these studies included hydrogel as compared with dry gauze; Table 5; Table 
13. 
Initial Wound Stage 
The baseline wound size, depth, wound stage, and duration of ulcer was not reported for this 
study Table 10. 
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Participant Characteristics 
The studies comprised a total of 29 participants. The mean age for the study was 63.95 +/- 14.5 
years. There were 13 males and 16 females in the study Table 9. The study was conducted in the 
outpatient setting in Belgium Table 3. 
Primary outcomes 
Proportion of participants with amputations 
1/14 or 7.1% of amputations were reported in the hydrogel group as compared with 5/15 or 
33.3% in the gauze group. There was a 79% reduction in amputations favoring the hydrogel 
group as compared with the gauze group (RR 0.21, 95% CI 0.03 to 1.61; participants = 29; 
studies = 1). No statistically significant difference was observed. 
Proportion of participants with complicating infections 
1/15 or 7% of complicating wound infections were reported in the hydrogel group as compared 
with 7/14 or 50% in the gauze group. There was an 87% reduction in complicating wound 
infections in the hydrogel group as compared with control (RR 0.13, 95% CI 0.02 to 0.95; 
participants = 29; studies = 1); there was a statistically significant difference. It was not reported 
that the study was stopped early. 
No data were reported for the primary outcome quality of life. 
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Secondary outcomes 
Proportion of ulcers completely healed 
7/15 (47%) of ulcers were completely healed in the hydrogel group as compared with 5/14 (36%) 
in the gauze group. This was a 31% increase in proportion of participants with ulcers completely 
healed; RR 1.31, 95% CI 0.54 to 3.17). No statistically significant difference. 
No data were reported for the secondary outcomes time to complete healing, proportion of 
participants with ulcers recurring after healing, and cost of treatment. 
Summary: Hydrogel compared with gauze/good wound care alone 
The three trials (D'Hemecourt 1998; Jensen 1998; Vandeputte 1997) comparing hydrogel with 
either gauze dressing or good wound care (dressing not specified) were considered sufficiently 
similar to pool, using a random effects model. They included a combined total of 232 
participants. The follow up ranged from 12 - 20 weeks. The study period was not reported in the 
3 studies. There was unclear to high risk of bias as many of the risk of bias considerations 
utilized in this review were either unclear or high Figure 3; Figure 4. 
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Proportion of participants with amputations 
The two studies that reported number of amputations were pooled these included Jensen 1998 
and Vandeputte 1997. Pooling these two studies yielded a relative risk for amputation of 0.26 
(95% CI 0.05 to 1.40; participants = 60; studies = 2; in the presence of heterogeneity, p = 0.74, I2 
= 0%) Analysis 6.1. No statistically significant difference. This translates to 74% reduction in 
proportion of amputations for the hydrogel group as compared to gauze and a number needed to 
treat of 8 (95% CI 3 [NNTB], 12 [NNTH]): that is to prevent one additional patient with diabetic 
foot ulcer from having an amputation, eight patients must be treated with hydrogel instead of 
gauze or standard care (treatment time varied from 12 to 20 weeks). No statistical significant 
difference was observed Figure 23. 
Proportion of participants with complicating infections 
All 3 studies reported on proportion of infections, and on the proportion of ulcers completely 
healed. 
Pooling the three trials yielded a relative risk for infections with hydrogel of 0.74, (95% CI 0.18 
to 2.99; participants = 198; studies = 3; in the presence of heterogeneity, p = 0.09, I2 = 59%) 
Analysis 6.2. This translates to a 26% reduction in proportion of infections for the hydrogel 
group as compared to gauze, and a number needed to treat of 12 (95% CI 3 [NNTB], 6 [NNTH]): 
that is to prevent one additional patient with diabetic foot ulcer from having an infection, twelve 
patients must be treated with hydrogel instead of gauze or standard care (treatment time varied 
from 12 to 20 weeks). No statistically significant difference was observed Figure 24. 
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Proportion of participants with ulcers healed 
The proportion of ulcers healed yielded a relative risk of 1.71, 95% CI 1.16 to 2.52; participants 
= 198; studies = 3; in the absence of significant heterogeneity, p = 0.62, I2 = 0%) Analysis 6.3. 
This translates to a 71% increase in the proportion of ulcers healed in the hydrogel group as 
compared to gauze group, and a number needed to treat of 12 (95% CI 50 [NNTB] to 3 
[NNTB]): that is to heal one additional patient with diabetic foot ulcer, twelve patients must be 
treated with hydrogel instead of gauze or standard care (treatment time varied from 12 to 20 
weeks). No statistically significant difference was observed Figure 25. 
Quality of life index, proportion of participants with recurrent ulcers, time to complete healing, 
and cost of treatment were either not reported at all or not reported in at least two or more 
studies. 
Analysis Table 6.1 – 6.3 Hydrogel compared with gauze or 
good wound care (gwc) 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
6.1 Number of 
amputations 
reported 
2 60 Risk Ratio (M-H, 
Random, 95% CI) 
0.26 [0.05, 1.40] 
6.2 Number of 
Infections reported 
3 198 Risk Ratio (M-H, 
Random, 95% CI) 
0.74 [0.18, 2.99] 
6.3 Number of 
ulcers completely 
healed 
3 198 Risk Ratio (M-H, 
Random, 95% CI) 
1.71 [1.16, 2.52] 
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Comparison 7 Polyurethane gel dressing compared with polyurethane foam 
dressing (1 trial, 40 participants) 
This included 1 trial Clever 1995 with 40 participants. The study was available in unpublished 
abstract form only. The range of follow included healing occurrence or a maximum of 16 weeks. 
The study comparison period was not reported. There was significant risk of bias since many of 
the risk of bias considerations were either unclear or high risk Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included Hydroactive polyurethane gel dressing (Cutinova 
Hydro) and standard therapy as compared with Hydrophilic polyurethane foam dressing 
(Allevyn) and standard therapy. Standard therapy was defined as offloading, infection control 
with antibiotics, wound cleansing with ringer’s solution, and "debridement" with removal of 
callus if needed. The separate form of debridement was not defined Table 5; Table 13. 
Initial Wound Stage 
The initial mean wound surface area in the study was reported to be 2.05 (SD = 3.14) cm2 in the 
polyurethane gel dressing group and 2.08 (SD = 2.72) cm2 in the polyurethane foam dressing 
group. The initial mean depth of wound, or wound stage was not reported for either the 
intervention or comparison groups. The initial mean duration of ulcers in the study was 162.37 
(SD = 325.55) days in the polyurethane gel dressing group and 165 (SD = 318.68) days in the 
polyurethane foam dressing group Table 10. 
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Participant Characteristics 
The studies comprised a total of 40 participants. The mean age for the study was 56 (SD = 13.13) 
years. There were 32 males and 8 females. The study setting included outpatients, and the study 
was conducted in Germany. 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of patients with ulcers completely healed was lower in the Polyurethane gel 
dressing group 14/20 (70%) as compared with the polyurethane foam dressing group 16/20 
(80%) (RR 0.88, 95% CI 0.61 to 1.26; participants = 40; studies = 1) Analysis 7.1 No 
statistically significant difference was observed. 
Time to complete healing (days) 
The time to complete healing was on average 4.76 days shorter in the Polyurethane gel dressing 
group as compared with the polyurethane foam dressing group (MD -4.76, 95% CI -16.93 to 
7.41; participants = 40; studies = 1) Analysis 7.2. No statistically significant difference was 
observed. 
No data were reported for the secondary outcomes proportion of participants with ulcers 
recurring after healing, cost of treatment. 
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Analysis Table 7.1 -7.2 Polyurethane gel dressing 
compared with polyurethane foam dressing 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect 
Estimate 
7.1 Number of ulcers 
completely healed 
1 40 Risk Ratio (M-H, 
Random, 95% 
CI) 
0.88 [0.61, 1.26] 
7.2 Time to complete 
healing (days) 
1 40 Mean Difference 
(IV, Random, 
95% CI) 
-4.76 [-16.93, 
7.41] 
Comparison 8 Alginate dressing compared with gauze (2 Trials, 152 
participants) 
Trial 1: Calcium alginate as compared with Vaseline gauze (1 trial, 77 participants) 
This comparison included 1 trial Lalau 2002 with 77 participants. The range of follow up was 4 
weeks this was reduced from the planned 6 week follow up period due to 13 withdrawals. The 
study comparison period was not reported. There was significant risk of bias since many of the 
risk of bias considerations were either unclear or high risk. See Figure 3; Figure4. 
Types of Interventions 
The interventions in these studies included the calcium alginate dressing group as compared with 
Vaseline gauze. The study reported that no other treatments were permitted, except unrestricted 
saline solution and mechanical debridement was authorized "as needed" Table 5; Table 13. 
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Initial Wound Stage 
The initial mean wound surface area was reported as 8.0 (SD = 10.5) cm2 in the calcium alginate 
dressing group and 8.8 (SD = 16.0) cm2 in the Vaseline gauze dressing group. The initial mean 
wound depth and wound staging were not reported. The mean duration of ulcers was 19.6 (SD = 
31.2) weeks in the Calcium alginate group, and 36.4 (SD = 52.4) weeks in the Vaseline gauze 
group Table 10. 
Participant Characteristics 
The studies comprised a total of 77 participants. The mean age reported was 62.2 (SD = 11.75) 
years. There were 45 males and 32 females in the study. Table 9 The study was conducted at 13 
outpatient settings "throughout" France. Table 3 
Primary Outcomes 
Proportion of participants with complicating infections 
1/39 (2.6%) complicating wound infections were reported in the calcium alginate group as 
compared with 3/38 (7.9%) in the Vaseline gauze group. There was a 68% reduction in 
complicating wound infections in the calcium alginate group as compared with the Vaseline 
gauze group (RR 0.32, 95% CI 0.04 to 2.99; participants = 77; studies = 1) Analysis 8.1. No 
statistically significant difference was observed. 
No data were reported for the primary outcomes proportion of participants with amputations, and 
quality of life. 
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Secondary Outcomes 
No data were reported for any of the secondary outcomes. 
Trial 2: Collagen alginate as compared with moist gauze (1 trial, 75 participants) 
This comparison included 1 trial Donaghue 1998 with 75 participants. The follow up period was 
until the wound healed or a maximum of 8 weeks. The study comparison period was not 
reported. There was significant risk of bias since many of the risk of bias considerations were 
either unclear or high risk. See Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included the collagen alginate dressing group as compared 
with moist gauze Table 5; Table 13. The study reported that in all participant’s weight-bearing 
limitations for offloading were employed using self-adhesive felted foam with a window at the 
wound site, and "healing" sandals. 
Initial Wound Stage 
The initial mean wound surface area was reported as 2.6 (SD = 0.50) cm2 in the collagen alginate 
dressing group and 2.99 (SD = 0.62) cm2 in the moist gauze group. The initial mean wound depth 
was 0.4 (SD = 0.52) cm in the collagen alginate group, and 0.4 (SD = 0.20) cm in the moist 
gauze group. The wound staging reported as Wagner grade 1 to 3. The mean duration of ulcers 
was 20.86 (SD = 10.43) weeks in the collagen alginate group, and 32.14 (SD = 14.86) weeks in 
the Vaseline gauze group Table 10. 
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Participant Characteristics 
The studies comprised a total of 75 participants. The mean age reported was 59.5 years (no SD 
reported). There were 54 males and 21 females in the study. Table 9 The study was conducted at 
outpatient settings in the US. Table 3 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of patients with ulcers completely healed were greater in the collagen alginate 
dressing group 24/50 (48%) as compared with the Vaseline gauze dressing group 9/25 (36%). 
There was a 33% increase in the proportion of ulcers healed in the collagen alginate group as 
compared with Vaseline gauze group (RR 1.33, 95% CI 0.73 to 2.42; participants = 75; studies = 
1) Analysis 8.2 No statistically significant difference was observed. 
Time to complete healing (days) 
The time to complete healing was on average 2.80 days shorter in the calcium alginate dressing 
group as compared with the Vaseline gauze dressing group. (MD 2.80, 95% CI 1.46 to 4.14; 
participants = 75; studies = 1) Analysis 8.3. There was a statistically significant difference 
observed. 
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No data were reported for the secondary outcomes proportion of participants with ulcers 
recurring after healing, and cost of treatment. 
Analysis Table 8.1 – 8.3 Calcium alginate compared with 
moist gauze 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
8.1 Number of 
Infections reported 
1 77 Risk Ratio (M-H, 
Random, 95% CI) 
0.32 [0.04, 2.99] 
8.2 Number of 
ulcers completely 
healed 
1 75 Risk Ratio (M-H, 
Random, 95% CI) 
1.33 [0.73, 2.42] 
8.3 Time to 
complete healing 
(days) 
1 75 Mean Difference 
(IV, Random, 
95% CI) 
2.80 [1.46, 4.14] 
 
Comparison 9 Hydrocolloid dressing compared with adhesive Zinc tape dressing 
(1 trial, 44 participants) 
This included 1 trial Apelqvist 1990 with 44 participants. The follow up period was 5 weeks. The 
study comparison period was not reported. There was significant risk of bias since many of the 
risk of bias considerations were unclear. Figure 3: Figure 4. 
Types of Interventions 
The interventions in these studies included hydrocolloid dressing as compared with Zinc 
adhesive tape dressing (Allevyn). All patient received pressure relief offloading. All ulcers were 
cleaned with sterile saline Table 5; Table 13. 
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Initial Wound Stage 
The initial mean wound surface area in the study was reported to be 2.2 cm2 in the hydrocolloid 
dressing group and 2.2 cm2 in the Zinc adhesive tape dressing group. The initial mean depth of 
wound, initial wound stage, and mean duration of ulcers were not reported in the study for either 
intervention arm Table 10. 
Participant Characteristics 
The studies comprised a total of 40 participants. The mean age for the study was 63 (SD = 36) 
years. There were 26 males and 20 females. Table 9 The study setting included outpatients, and 
the study was conducted in Sweden Table 3. 
Primary Outcomes 
Proportion of participants with complicating infections 
There were a greater number of complicating infections 1/22 (4.5%) in the hydrocolloid dressing 
group as compared with 0/22 (0%) of the Zinc adhesive tape dressing group. (RR 3.00, 95% CI 
0.13 to 69.87; participants = 44; studies = 1) No statistically significant difference was observed. 
No data were reported for the primary outcomes proportion of participants with amputations, and 
quality of life. 
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Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of patients with ulcers completely healed was lower in the Hydrocolloid dressing 
group 5/22 (22.3%) as compared with the Zinc adhesive tape dressing group 9/22 (40.9%). There 
was a 44% reduction in ulcers healed in the hydrocolloid dressing group as compared with the 
Zinc adhesive tape dressing group (RR 0.56, 95% CI 0.22 to 1.39; participants = 44; studies = 1) 
Analysis 9.2 No statistically significant difference was observed. 
Time to complete healing (days) 
No data were reported for the secondary outcomes proportion of participants with ulcers 
recurring after healing, and cost of treatment. 
Analysis Table 9.1 – 9.2 Hydrocolloid dressing compared 
with adhesive Zinc tape dressing 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect 
Estimate 
9.1 Number of 
Infections reported 
1 44 Risk Ratio (M-H, 
Random, 95% 
CI) 
3.00 [0.13, 
69.87] 
9.2 Number of ulcers 
completely healed 
1 44 Risk Ratio (M-H, 
Random, 95% 
CI) 
0.56 [0.22, 1.39] 
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Comparison 10 Foam dressing compared with Wet to dry gauze dressing (2 
trials, 37 participants) 
Trial 1: Polymeric membrane foam dressing as compared with Wet to dry saline gauze (18 
participants) 
This comparison included 1 trial Blackman 1994 with 18 participants. The follow up period was 
6 months or until the ulcer healed. The study comparison period was not reported. There was 
significant risk of bias since many of the risk of bias considerations were either unclear or high 
risk Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included a Polymeric membrane foam dressing group as 
compared with a Wet to dry saline gauze group. All the participants were "encouraged" to obtain 
orthotic foot wear Table 5; Table 13. 
Initial Wound Stage 
The initial mean wound surface area was reported as 2.67 (SD = 1.20) cm2 in the calcium 
alginate dressing group and 1.81 (SD = 0.75) cm2 in the wet to dry gauze dressing group. The 
initial mean wound depth was not reported. Wagner grade 1 and 2 wounds were included. The 
mean duration of ulcers was 25 (SD = 7) weeks in the Polymeric membrane group, and 28 (SD = 
6) weeks in the Wet to dry saline group Table 10. 
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Participant Characteristics 
The studies comprised a total of 18 participants. The mean age reported was 55.9 (SD = 13.6) 
years. There were 17 males and 1 female in the study Table 9. The inpatient/outpatient study 
setting was unclear, and the study was conducted in the US Table 3. 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was higher in the Polymeric 
membrane dressing group 8/11 (73%) as compared with the Wet to dry saline dressing group 0/7 
(0%). There was an increased risk of healing in the Polymeric membrane dressing group as 
compared with 0/7 (0%) in the Wet to dry saline dressing group (RR 11.33, 95% CI 0.76 to 
170.03; participants = 37; studies = 1). 
No data were reported for the secondary outcomes time to complete healing (days), proportion of 
participants with ulcers recurring after healing, and cost of treatment. 
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Trial 2: Polymeric foam membrane dressing as compared with Wet to dry saline gauze 
mesh (19 participants) 
This comparison included 1 trial Mazzone 1993 with 19 participants. The follow up period was 8 
weeks. The study comparison period was not reported. There was significant risk of bias as many 
of the risk of bias considerations were either unclear or high risk Figure 3; Figure 4. The study 
was only available as a published abstract. 
Types of Interventions 
The interventions in these studies included Polymeric foam membrane as compared with Wet to 
dry saline gauze mesh. No other treatments were reported Table 5; Table 13. 
Initial Wound Stage 
The initial mean wound surface area, initial mean wound depth, wound staging, and mean 
duration of ulcers was not reported Table 10. 
Participant Characteristics 
The studies comprised a total of 19 participants. Age, and gender composition were not reported 
Table 9. The study was conducted in an outpatient setting in the US Table 3. 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
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Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of patients with ulcers completely healed was greater in the Polymeric foam 
membrane group 7/11 (48%) as compared with the Wet to dry saline gauze mesh dressing group 
2/8 (36%). There was a 155% increase in the proportion of ulcers healed in the Polymeric foam 
membrane group as compared with Wet to dry saline gauze mesh dressing group (RR 2.55, 95% 
CI 0.71 to 9.16; participants = 19; studies = 1) No statistically significant difference was 
observed. 
No data were reported for the secondary outcomes time to complete healing (days), proportion of 
participants with ulcers recurring after healing, cost of treatment 
Summary: Foam compared with gauze/good wound care alone 
The two trials (Blackman 1994; Mazzone 1993) comparing Foam dressing with Wet to dry gauze 
dressing were considered sufficiently similar to pool, using a random effects model. They 
included a combined total of 37 participants. The follow up period ranged from 8 - 24 weeks. 
The study comparison period was not reported in the 2 studies. There was unclear to high risk of 
bias as many of the risk of bias considerations were either unclear or high Figure 3: Figure 4. 
Types of Interventions 
The interventions in these studies included Foam dressing as compared with Wet to dry gauze 
Table 5; Table 13. 
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Initial Wound Stage 
The initial mean wound surface area was reported in Blackman 1994, but not in Mazzone 1993. 
The mean wound depth was not reported in either study. The wound staging included in the 
studies were classified as Wagner grade 1 - 2 in the Blackman 1994 but not reported in Mazzone 
1993. The mean duration of ulcers was 25 (SD = 7) weeks in the Blackman 1994 study and not 
reported in Mazzone 1993; Table 10. 
Participant Characteristics 
The studies comprised a total of 37 participants. The mean ages for the studies were 55.9 (SD = 
13.6) years in Blackman 1994 and was not reported in Mazzone 1993. There were a total of 17 
males and 1 female in Blackman 1994, while gender was not reported in Mazzone 1993; Table 4. 
The study setting was unclear in Blackman 1994 and was conducted in an outpatient setting in 
Mazzone 1993. Both studies were conducted in the US Table 3. 
Proportion of participants with ulcers healed 
The proportion of ulcers healed yielded a relative risk of (RR 3.56, 95% CI 0.93 to 13.66; 
participants = 37; studies = 2); in the absence of significant heterogeneity, p = 0.28, I2 = 13%); 
Analysis 10.1; No statistically significant difference was observed. This translates to a 256% 
increase in the proportion of ulcers healed in the foam membrane group as compared with the 
Wet to dry gauze group, and a number needed to treat of 2 (95% CI 2 [NNTB] to 5 [NNTB]): 
that is to heal one additional patient with a diabetic foot ulcer, two patients must be treated with 
foam dressing instead of Wet to dry gauze (treatment time varied from 8 to 24 weeks). No 
statistically significant difference was observed. 
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Proportion of participants with amputations, Proportion of participants with complicating 
infections, Quality of life index, Proportion of participants with recurrent ulcers, Time to 
complete healing, and Cost of treatment were either not reported at all or were not reported in 
both studies and therefore could not be pooled for a meta-analysis Figure 26. 
Analysis Table 10.1 Foam dressing compared with Wet to 
Dry Saline 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
10.1 Number of 
ulcers completely 
healed 
2 37 Risk Ratio (M-H, 
Random, 95% CI) 
3.56 [0.93, 13.66] 
Comparison 11 Foam dressing compared with saline nonadherent gauze dressing 
(1 trial, 30 participants) 
Roberts 2001 
This comparison included 1 trial with 30 participants. The follow up period was 13 weeks. The 
study comparison period was not reported. There was significant risk of bias since many of the 
risk of bias considerations were either unclear or high Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included Foam dressing as compared with saline nonadherent 
Gauze dressing. All patient received "standard podiatric care" which was not defined Table 5; 
Table 13. 
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Initial Wound Stage 
The initial median wound surface area in the study was reported to be 1.1 cm2 in the Foam 
dressing group and 1.45 cm2 in the saline nonadherent Gauze dressing group. The initial depth of 
wound, wound stage were not reported in the study for either treatment arm. The mean duration 
of ulcers for the sample was 15.2 weeks. Table 10 
Participant Characteristics 
The studies comprised a total of 30 participants. The median age for the study was 59.5 years. 
There were 23 males and 7 females Table 9. The study setting included hospitalized patients, and 
the study was conducted in UK Table 3. 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was higher in the foam dressing 
group 6/14 (43%) as compared with the saline nonadherent gauze dressing group 4/16 (25%) 
(RR 1.71, 95% CI 0.60 to 4.86; participants = 30; studies = 1). There was a 71% increase in the 
proportion of participants with ulcers completely healed in the foam dressing group than in the 
nonadherent gauze dressing group. No statistically significant difference was observed. 
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No data were reported for the secondary outcomes time to complete healing (days), proportion of 
participants with ulcers recurring, and cost of treatment. 
Analysis Table 11.1 Foam dressing compared with saline 
gauze dressing 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
11.1 Number of 
ulcers completely 
healed 
1 30 Risk Ratio (M-H, 
Random, 95% CI) 
1.71 [0.60, 4.86] 
Comparison 12 Iodine impregnated fiber dressing compared with gauze dressing 
(1 trial, 214 participants) 
This comparison included 1 trial Jeffcoate 2009 with 214 participants. The follow up period was 
24 weeks. The study comparison period was June 2003 to March 2007. There was some risk of 
bias however many of the risk of bias considerations were low. Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included Iodine impregnated fiber dressing as compared with 
gauze dressing. All patient received ulcer management including regular use of debridement, and 
"recommended" fiberglass or polyester boot for offloading. It was not clear whether another 
alternate form of debridement was used or whether the study relied on the debridement effect of 
the dressing itself Table 5; Table 13. 
Initial Wound Stage 
The wound surface area included in the study ranged between 0.25 - 2.25 cm2. It was further 
subdivided into 3 additional ranges that included 0.25 - 1 cm2, 1.01 - 0.25 cm2, and 2.5 - 25cm2. 
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The number of participants in each subgroup was 48, 36, and 24 for the Inadine group; and 50, 
34, and 22 for the gauze group, respectively. The initial depth of wound, wound stage, and 
wound duration were not reported in the study for either of the treatment arms Table 10. 
Participant Characteristics 
The study comprised a total of 214 participants. The mean age for the study participants was 
reported was 59.6 (SD = 12.6) years. There were 159 males and 54 females Table 9. The study 
setting included multidisciplinary outpatient centers, and the study was conducted in the UK 
Table 3. 
Primary Outcomes 
Proportion of participants with amputations 
The proportion of participants with amputations was lower in the Inadine dressing group 1/108 
(1%) as compared with the gauze dressing group 2/106 (2%). There was a 51% reduction in 
amputations observed in the Inadine group as compared to control. (RR 0.49, 95% CI 0.05 to 
5.33; participants = 214; studies = 1); No statistically significant difference was observed. 
Proportion of participants with complicating infections 
The proportion of participants with complicating infections was higher in the Inadine dressing 
group 71/108 (66%) as compared with the gauze dressing group 48/106 (45%). There was a 45% 
increase in complicating infection observed in the Inadine group as compared to control. (RR 
1.45, 95% CI 1.13 to 1.86; participants = 214; studies = 1); a statistically significant difference 
was observed. 
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Quality of Life 
The Quality of life Index was higher in the Inadine dressing group 0.3838 +/- 0.1085 as 
compared with the gauze dressing group 0.3939 +/- 0.1093. There was a - 0.01 Quality of life 
mean difference reduction in the Inadine group as compared to control. (MD -0.01, 95% CI -0.04 
to 0.02; participants = 214; studies = 1); No statistically significant difference was observed. 
Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was higher in the Inadine dressing 
group 48/108 (44%) as compared with the gauze dressing group 41/106 (39%). There was a 15% 
increase in the proportion of participants with ulcers completely healed in the Inadine dressing 
group as compared with the gauze-dressing group. (RR 1.15, 95% CI 0.84 to 1.58; participants = 
214; studies = 1); No statistically significant difference was observed. 
Time to complete healing (days) 
The time to complete healing was lower in the Inadine dressing group as compared with the 
gauze dressing group. There was reduction of 2.9 days in time to complete healing in the Inadine 
dressing group 127.8 (SD = 54.2) days as compared with the gauze dressing group 130.7 (SD = 
52.4) days; (MD -2.90, 95% CI -17.18 to 11.38; participants = 214; studies = 1); No statistically 
significant difference was observed. 
 
124 
 
The proportion of participants with ulcers recurring after healing 
The proportion of participants with ulcers recurring after healing was higher in the Inadine 
dressing group 7/108 (6.5%) as compared with the gauze dressing group 3/106 (3%). There was 
a 129% increase in the proportion of participants with ulcers completely healed in the Inadine 
dressing group as compared with the gauze dressing group; (RR 2.29, 95% CI 0.61 to 8.62; 
participants = 214; studies = 1); No statistically significant difference was observed. 
Cost of treatment 
The cost of treatment was higher in the Inadine dressing group 183.60 (SD = 286.47) British 
Pounds as compared with the gauze dressing group 141.18 (SD = 171.31) British Pounds. The 
mean difference in cost of treatment was 42.42 British Pounds greater in the Inadine dressing 
group as compared with the gauze dressing group; (MD 42.42, 95% CI -20.69 to 105.53; 
participants = 214; studies = 1). 
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Comparison 13 Hydrofiber compared with gauze dressing (2 trials, 229 
participants) 
Jeffcoate 2009; Piaggesi 2001 
Trial 1: Hydrofiber dressing as compared with gauze dressing (209 participants) 
This comparison included 1 study Jeffcoate 2009 and a total of 209 participants. The follow up 
period was 24 weeks. The study comparison period was June 2003 to March 2007.  
Analysis Table 12.1 – 12.7 Iodine impregnated fiber 
dressing compared with gauze dressing 
 
Outcome or 
Subgroup 
Studies Participants 
Statistical 
Method 
Effect Estimate 
12.1 Number of 
amputations reported 
1 214 Risk Ratio (M-H, 
Random, 95% 
CI) 
0.49 [0.05, 5.33] 
12.2 Number of 
Infections reported 
1 214 Risk Ratio (M-H, 
Random, 95% 
CI) 
1.45 [1.13, 1.86] 
12.3 Quality of life 1 214 Std. Mean 
Difference (IV, 
Random, 95% 
CI) 
-0.09 [-0.36, 
0.18] 
12.4 Number of 
ulcers completely 
healed 
1 214 Risk Ratio (M-H, 
Random, 95% 
CI) 
1.15 [0.84, 1.58] 
12.5 Time to 
complete healing 
(days) 
1 214 Mean Difference 
(IV, Random, 
95% CI) 
-2.90 [-17.18, 
11.38] 
12.6 Recurrence rates 1 214 Risk Ratio (M-H, 
Random, 95% 
CI) 
2.29 [0.61, 8.62] 
12.7 Treatment cost 1 214 Mean Difference 
(IV, Random, 
95% CI) 
42.42 [-20.69, 
105.53] 
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There was some risk of bias however many of the risk of bias considerations were low risk for 
bias Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included hydrofiber dressing as compared with gauze dressing. 
All patient received ulcer management including regular use of debridement, and 
"recommended" fiberglass or polyester boot for offloading. It was not clear whether another 
alternate form of debridement was used or whether the study relied on the debridement effect of 
the dressing itself Table 5; Table 13. 
Initial Wound Stage 
The wound surface area included in the study ranged between 0.25 - 2.25 cm2. It was further 
subdivided into 3 additional ranges that included 0.25 - 1 cm2, 1.01 - 0.25 cm2, and 2.5 - 25cm2. 
The number of participants in each subgroup was 53, 34, and 16 for the hydrofiber group; and 
50, 34, and 22 for the gauze group, respectively. The initial depth of wound, wound stage, and 
wound duration were not reported in the study for either of the treatment arms Table 10. 
Participant Characteristics 
The study comprised a total of 209 participants. The mean age for the study participants was 
reported was 59.6 +/- 12.6 years. There were 159 males and 49 females Table 9. The study 
setting included multidisciplinary outpatient centers, and the study was conducted in the UK 
Table 3. 
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Types of Outcomes 
Primary Outcomes 
Proportion of participants with amputations 
The proportion of participants with amputations was higher in the Hydrofiber dressing group 
4/103 (4%) as compared with the gauze dressing group 2/106 (2%). There was a 106% increase 
in the proportion of participants with amputations observed in the Hydrofiber group as compared 
to control. (RR 2.06, 95% CI 0.39 to 10.99; participants = 209; studies = 1); No statistically 
significant difference was observed. 
Proportion of participants with complicating infections 
The proportion of participants with complicating infections was higher in the Hydrofiber 
dressing group 54/103 (52%) as compared with the gauze dressing group 48/106 (45%). There 
was a 16% increase in proportion of participants with complicating infections observed in the 
Hydrofiber group as compared to the control group. (RR 1.16, 95% CI 0.88 to 1.53; participants 
= 209; studies = 1); No statistically significant difference was observed. 
Quality of Life 
The Quality of life Index was higher in the Hydrofiber dressing group 0.3822 (SD = 0.1085) as 
compared with the gauze dressing group 0.3939 (SD = 0.1093). There was a - 0.10 Quality of 
life mean difference reduction in the Hydrofiber group as compared to control. (MD -0.10, 95% 
CI -0.38 to 0.17; participants = 209; studies = 1); No statistically significant difference was 
observed. 
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Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was higher in the Hydrofiber 
dressing group 46/103 (45%) as compared with the gauze dressing group 41/106 (39%). There 
was a 15% increase in the proportion of participants with ulcers completely healed in the 
Hydrofiber dressing group as compared with the gauze-dressing group. (RR 1.15, 95% CI 0.84 to 
1.59; participants = 209; studies = 1); No statistically significant difference was observed. 
Time to complete healing (days) 
The time to complete healing was lower in the Hydrofiber dressing group 125.8 (SD = 55.9) days 
as compared with the gauze dressing group 130.7 (SD = 52.4) days. There was a mean reduction 
of 4.9 days in time to complete healing in the Hydrofiber dressing group as compared with the 
gauze dressing group; (MD -4.90, 95% CI -19.60 to 9.80; (participants = 209; studies = 1); No 
statistically significant difference was observed. 
The proportion of participants with ulcers recurring after healing 
The proportion of participants with ulcers recurring after healing was higher in the Hydrofiber 
dressing group 3/103 (3%) as compared with the gauze dressing group 3/106 (3%). There was a 
small 3% increase in the proportion of participants with ulcers completely healed in the 
Hydrofiber dressing group as compared with the gauze dressing group; (RR 1.03, 95% CI 0.21 to 
4.98; participants = 209; studies = 1); No statistically significant difference was observed. 
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Cost of treatment 
The cost of treatment was higher in the Hydrofiber dressing group 191.33 (SD = 219.63 British 
Pounds as compared with the gauze dressing group 141.18 (SD = 171.31). The mean difference 
in cost of treatment was 50.15 British pounds greater in the Hydrofiber dressing group as 
compared with the gauze dressing group; (MD 50.15, 95% CI -3.35 to 103.65; participants = 
209; studies = 1), no statistically significant difference was observed. 
Trial 2: Hydrofiber dressing as compared with gauze dressing (20 participants) 
Piaggesi 2001 
This comparison included 1 study Piaggesi 2001 and a total of 20 participants. The follow up 
period was 8 weeks. The study period was 1998. There was significant risk of bias as many of 
the risk of bias considerations were unclear or high risk for bias Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included hydrofiber dressing as compared with gauze dressing. 
All patient received for post-operative shoes for pressure relief and were trained to walk on 
crutches until there was satisfactory healing Table 5; Table 13. 
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Initial Wound Stage 
The initial mean wound volume included in the study was 19.2 (SD = 6.4) cm3 in the Hydrofiber 
dressing group and 22.6 (SD = 8.4) cm3 in the gauze-dressing group. The initial mean wound 
depth was 2.9 (SD = 1.1) cm in the Hydrofiber dressing group and 2.3 (SD = 1.4) cm in the 
Saline moistened dressing group. The wound stage, and wound duration were not reported in the 
study for either of the treatment arms. Table 10 
Participant Characteristics 
The study comprised a total of 20 participants. The median age for the study participants was 
reported was 59.5. Gender composition was not reported. Table 9 The study setting included 
outpatients, and the study was conducted in the Italy. Table 3 
Types of Outcomes 
Primary Outcomes 
Proportion of participants with amputations 
The proportion of participants with amputations was lower in the hydrofiber dressing group 0/10 
(0%) as compared with the gauze dressing group 1/10 (10%). There was a decrease in the 
proportion of participants with amputations observed in the hydrofiber group as compared to 
control. (RR 0.33, 95% CI 0.02 to 7.32; participants = 20; studies = 1); No statistically 
significant difference was observed. 
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Proportion of participants with complicating infections 
The proportion of participants with complicating infections was higher in the Hydrofiber 
dressing group 1/10 (10%) as compared with the Saline moistened gauze dressing group 3/10 
(30%). There was a 67% decrease in the proportion of participants with complicating infections 
observed in the hydrofiber group as compared to the gauze group. (RR 0.33, 95% CI 0.04 to 
2.69; participants = 20; studies = 1); No statistically significant difference was observed. 
No data were reported for the primary outcome quality of life. 
Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was higher in the hydrofiber 
dressing group 10/10 (100%) as compared with the saline nonadherent gauze dressing group 
9/10 (90%). There was an 11% increase in the proportion of participants with ulcers completely 
healed in the Hydrofiber dressing group as compared with the gauze dressing group. (RR 1.11, 
95% CI 0.85 to 1.44; participants = 20; studies = 1); No statistically significant difference was 
observed. 
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Time to complete healing (days) 
The time to complete healing was less in the Hydrofiber dressing group 127 (SD = 46) days as 
compared with the gauze dressing group 234 (SD = 61) days. There was a mean reduction of 107 
days in time to complete healing in the Hydrofiber dressing group as compared with the gauze 
dressing group; (MD -107.00, 95% CI -154.35 to -59.65; (participants = 20; studies = 1); 
Statistically significant difference was observed. 
No data were reported for the secondary outcomes proportion of participants with ulcers 
recurring after healing, or cost of treatment. 
Summary: Hydrofiber compared with saline moistened gauze 
The two trials (Jeffcoate 2009; Piaggesi 2001) comparing hydrofiber with saline moistened 
gauze dressing were considered sufficiently similar to pool, using a random effects model. They 
included a combined total of 229 participants. The follow up ranged from 12 - 24 weeks. The 
study comparison period was 1998, and June 2003 - March 2007. There was significant risk of 
bias as many of the risk of bias characteristics were either unclear (unreported) or high risk of 
bias Figure 3; Figure 4. 
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Proportion of participants with amputations 
The two studies on the number of amputations and were pooled. Pooling these two studies 
yielded a relative risk for amputation of (RR 1.34, 95% CI 0.29 to 6.10; participants = 229; 
studies = 2); in the absence of significant heterogeneity, p = 0.31, I2 = 3%) Analysis 13.1. No 
statistically significant difference. This translates to 34% increase in the proportion of 
participants with amputations for the hydrofiber dressing group as compared to saline moistened 
gauze dressing group; and a number needed to treat [NNTB] of 100 (95% CI 25 [NNTB], 15 
[NNTH]): that is to prevent one additional patient with diabetic foot ulcer from having an 
amputation, 100 patients must be treated with hydrofiber instead of saline moistened gauze. No 
statistically significant difference was observed Figure 27. 
Proportion of participants with complicating infections 
Both studies reported on proportion participants with complicating infections. 
Pooling the two trials yielded a relative risk for infections with hydrofiber of 0.96, (95% CI 0.40 
to 2.31; participants = 229; studies = 2); in the absence of significant heterogeneity, p = 0.24, I2 = 
27%); Analysis 13.2. This translates to 4% reduction in the proportion participants with 
complicating infections for the hydrofiber dressing group as compared to saline moistened gauze 
dressing group, and a number needed to treat [NNTB] of 50 (95% CI 4 [NNTB] to 5 [NNTH]): 
that is to prevent one additional patient with diabetic foot ulcer from developing an infection, 
fifty patients must be treated with hydrofiber instead of gauze (treatment time varied from 8 to 
24 weeks). Though no statistically significant difference was observed Figure 28. 
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Proportion of participants with ulcers healed 
The proportion participants with ulcers healed yielded a relative risk of (RR 1.13, 95% CI 0.92 to 
1.38; participants = 229; studies = 2); in the absence of significant heterogeneity, p = 0.79, I2 = 
0%). This translates to a 13% increase in the proportion of ulcers healed in the hydrofiber 
dressing group as compared to saline moistened gauze group, and a number needed to treat of 15 
(95% CI 6 [NNTB], 20 [NNTH): (Analysis 13.4) that is to heal one additional patient with 
diabetic foot ulcer, fifteen patients must be treated with hydrofiber instead of saline moistened 
gauze (treatment time varied from 8 to 24 weeks). No statistically significant difference was 
observed Figure 29. 
Time to complete healing 
The Time to complete healing yielded a mean difference of 53.37 days less in the hydrofiber 
dressing group as compared to the saline moistened dressing group (MD -53.37, 95% CI -153.29 
to 46.56; participants = 229; studies = 2); (Analysis 13.5) in the presence of significant 
heterogeneity, p < 0.0001, I2 = 94%) (treatment time varied from 8 to 24 weeks). No statistically 
significant difference was observed Figure 30. 
The primary outcome quality of life index, and the secondary outcomes proportion of 
participants with recurrent ulcers, and cost of treatment were not reported in one or both studies. 
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Analysis Table 13.1 – 13.7 Hydrofiber compared with 
gauze dressing 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
13.1 Number of 
amputations 
reported 
2 229 Risk Ratio (M-H, 
Random, 95% CI) 
1.34 [0.29, 6.10] 
13.2 Number of 
Infections reported 
2 229 Risk Ratio (M-H, 
Random, 95% CI) 
0.96 [0.40, 2.31] 
13.3 Quality of life 1 209 Std. Mean 
Difference (IV, 
Random, 95% CI) 
-0.10 [-0.38, 0.17] 
13.4 Number of 
ulcers completely 
healed 
2 229 Risk Difference 
(M-H, Random, 
95% CI) 
0.07 [-0.05, 0.19] 
13.5 Time to 
complete healing 
(days) 
2 229 Mean Difference 
(IV, Random, 
95% CI) 
-53.37 [-153.29, 
46.56] 
13.6 Recurrence 
rates 
1 209 Risk Ratio (M-H, 
Random, 95% CI) 
1.03 [0.21, 4.98] 
13.7 Treatment 
cost 
1 209 Std. Mean 
Difference (IV, 
Random, 95% CI) 
0.25 [-0.02, 0.53] 
Comparison 14: Hydrocellular polyurethane foam compared with Calcium 
Alginate (1 trial, 30 participants) 
This comparison included 1 trial (Foster 1994) with 30 participants. The follow up period was 8 
weeks or the ulcer healing whichever came first. The study comparison period was not reported. 
There was significant risk of bias since many of the risk of bias considerations were either 
unclear or high Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included Hydrocellular foam dressing group as compared with 
Calcium alginate dressing group. Patients were prescribed "appropriate antibiotic cover" for 
prevention and control of infection Table 5; Table 13. 
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Initial Wound Stage 
The initial median wound surface area in the study was reported to be 0.88 cm2 in the 
Hydrocellular foam dressing group and 0.79 cm2 in the Calcium alginate dressing group. The 
initial depth of wound was not specified other than 12, and 13 without units for either respective 
groups respectively. The wound stage was not reported in the study for either treatment arm. The 
mean duration of ulcers for the sample was 15.3 weeks in the Foam dressing group and 24.3 
weeks in the Calcium alginate group. Table 10 
Participant Characteristics 
The study comprised a total of 30 participants. The median age for the study was 65.5 years. 
There were 20 males and 10 females. Table 9 The study setting included outpatients, and the 
study was conducted in UK. Table 3 
Primary Outcomes 
No data were reported for any the primary outcomes. 
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Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was greater in the Hydrocellular 
polyurethane foam group 9/15 (60%) as compared with the calcium alginate group 8/15 (53%). 
(RR 1.13, 95% CI 0.60 to 2.11; participants = 30; studies = 1) Analysis 14.1. There was a 13% 
increase in the proportion of participants with ulcers completely healed in the Foam dressing 
group as compared with the Calcium alginate dressing group. No statistically significant 
difference was observed. 
No data were reported for the secondary outcomes time to complete healing (days), proportion of 
participants with ulcers recurring after healing, cost of treatment. 
Analysis Table 14.1 Hydrocellular polyurethane foam 
compared with calcium alginate 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect 
Estimate 
14.1 Number of ulcers 
completely healed 
1 30 Risk Ratio (M-
H, Random, 95% 
CI) 
1.13 [0.60, 2.11] 
Comparison 15 Honey soaked dressing compared with povidone iodine saline 
dressing (1 trial, 60 participants) 
This comparison included 1 trial EhsanUrRehman 2013 with 60 participants. The follow up 
period was 2 weeks. The study comparison period was from July to December 2012. There was 
significant risk of bias since many of the risk of bias considerations were either unclear or high. 
Figure 3; Figure 4. 
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Types of Interventions 
The interventions in these studies included Honey soaked dressing group as compared with 
povidone iodine saline dressing group. Patient's in both groups had their wounds washed with 
copious normal saline Table 5; Table 13. 
Initial Wound Stage 
The initial wound surface area, and initial wound depth in the study was not reported. The wound 
stage was reported as Wagner grade 1 - 2. The mean duration of ulcers was not reported. Table 
10 
Participant Characteristics 
The study comprised a total of 30 participants. The median age for the study was 55.3 (SD = 
3.89) years. There were 35 males and 25 females. Table 9 The study setting included 
hospitalized patients, and the study was conducted in Pakistan. Table 3 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
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Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was greater in the honey soaked 
dressing group 24/30 (80%) as compared with the povidone iodine saline dressing group 22/30 
(73%). There was a 9% increase in proportion of participants with ulcers completely healed in 
the honey soaked dressing group as compared with the povidone iodine saline dressing group 
(RR 1.09, 95% CI 0.82 to 1.44; participants = 60; studies = 1) Analysis 15.1. No statistically 
significant difference was observed. 
No data were reported for the secondary outcomes time to complete healing (days), proportion of 
participants with ulcers recurring after healing, and cost of treatment. 
Analysis Table 15.1 Honey soaked dressing compared with 
povidone iodine saline dressing 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
15.1 Number of 
ulcers completely 
healed 
1 60 Risk Ratio (M-H, 
Random, 95% CI) 
1.09 [0.82, 1.44] 
Comparison 16 Honey/Normal saline dressing compared with povidone iodine 
saline dressing (1 trial, 200 participants) 
This comparison included 1 trial Hammouri 2004 with 200 participants. The follow up period 
was not pre-specified. The study comparison period was from 1996 to 2001. There was 
significant risk of bias since many of the risk of bias considerations were either unclear or high. 
Figure 3; Figure 4. 
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Types of Interventions 
The interventions in these studies included Honey/saline dressing group as compared with 
povidone iodine/saline dressing group. All patients were debrided in advance in both treatment 
arms and washed with normal saline Table 5; Table 13. 
Initial Wound Stage 
The initial wound surface area, initial wound depth, wound stage, and mean duration of ulcers 
was not reported. Table 10 
Participant Characteristics 
The study comprised a total of 200 participants. The mean age for the study was 58 years. There 
were 112 males and 88 females. Table 9 The study setting included hospitalized patients, and the 
study was conducted in 4 district hospitals in Jordan. Table 3 
Primary Outcomes 
Proportion of participants with amputations 
The proportion of participants with amputations were less in the honey/normal saline dressing 
group 10/100 (10%) as compared with the povidone iodine saline dressing group 20/100 (20%). 
There was a 50% decrease in the proportion of participants with amputations in the 
honey/normal saline dressing group as compared with the povidone iodine saline dressing group 
(RR 0.50, 95% CI 0.25 to 1.01; participants = 200; studies = 1); Analysis 16.1. No statistically 
significant difference was observed. 
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No data were reported for the primary outcomes proportion of participants with complicating 
infections, and quality of life. 
Secondary Outcomes 
Cost of treatment 
The cost of treatment was on average 334.00 Jordanian Dinar's less in the honey/normal saline 
dressing group as compared with the povidone peroxide/saline dressing group (MD -334.00, 
95% CI -373.99 to -294.01; participants = 200; studies = 1) Analysis 16.2. Whether this was total 
cost or cost per treatment was not specified. 
No data were reported for the secondary outcomes proportion of participants with ulcers 
completely healed, time to complete healing (days), and proportion of participants with ulcers 
recurring after healing. 
Analysis Table 16.1 – 16.2 Honey/normal saline dressing 
compared with povidone peroxide saline dressing 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect 
Estimate 
16.1 Number of 
amputations reported 
1 200 Risk Ratio (M-
H, Random, 
95% CI) 
0.50 [0.25, 1.01] 
16.2 Treatment cost 1 200 Mean Difference 
(IV, Random, 
95% CI) 
-334.00 [-
373.99, -294.01] 
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Comparison 17 Sugar jam (with hydrogen peroxide and topical antibiotic) 
compared with (hydrogen peroxide and topical antibiotic) (1 trial, 80 
participants) 
This comparison included 1 trial Rhaiem 1998 with 80 participants. The follow up period was 
not pre-specified. The study comparison period was from 1992 to 1995. There was significant 
risk of bias since many of the risk of bias considerations were either unclear or high. Figure 3; 
Figure 4. 
Types of Interventions 
The interventions in these studies included Honey/saline dressing group as compared with 
povidone iodine/saline dressing group Table 5; Table 13. 
Initial Wound Stage 
The initial wound surface area, initial wound depth, wound stage, and mean duration of ulcers 
was not reported Table 10. 
Participant Characteristics 
The study comprised a total of 80 participants. The mean age for the study was 56 (SD = 32) 
years. There were 59 males and 21 females Table 9. The study setting included hospitalized 
patients, and the study was conducted in Tunisia Table 3. 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
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Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was higher in the Sugar jam (with 
hydrogen peroxide and topical antibiotic) 19/40 (47.5%) as compared with the (hydrogen 
peroxide and topical antibiotic) 16/40 (40%). There was a 19% increase in the proportion of 
participants with ulcers completely healed in the Sugar jam (with hydrogen peroxide and topical 
antibiotic) as compared with the (hydrogen peroxide and topical antibiotic) (RR 1.19, 95% CI 
0.72 to 1.96; participants = 80; studies = 1); Analysis 17.1. No statistically significant difference 
was observed. 
No data were reported for the secondary outcomes, time to complete healing (days), proportion 
of participants with ulcers recurring after healing, and cost of treatment. 
Analysis Table 17.1 Sugar jam (hydrogen peroxide and 
topical antibiotic) dressing compared with (hydrogen 
peroxide and topical antibiotic) 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect Estimate 
17.1 Number of 
ulcers completely 
healed 
1 80 Risk Ratio (M-H, 
Random, 95% CI) 
1.19 [0.72, 1.96] 
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Comparison 18 Silver (standard cleaning and compression management 
methods) dressing group as compared with control group (standard cleaning and 
compression management methods without silver ointment) (1 trial, 66 
participants) 
Belcaro 2010 
This comparison included 1 trial with 66 participants. The follow up period was 4 weeks. The 
study comparison period was not reported. There was significant risk of bias since many of the 
risk of bias considerations were either unclear or high. Figure 3; Figure 4. 
Types of Interventions 
The interventions in these studies included Silver (standard cleaning and compression 
management methods) dressing group as compared with control group (standard cleaning and 
compression management methods without silver ointment) Table 5; Table 13. 
Initial Wound Stage 
The initial mean wound surface area was 2.22 (SD = 0.24) cm2 in the Silver (standard cleaning 
and compression management methods) dressing group, and 2.18 (SD = 1.66) cm2 in the control 
group. The initial wound depth, wound stage, and mean duration of ulcers was not reported. 
Table 10 
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Participant Characteristics 
The study comprised a total of 80 participants. The mean age for the study was 55.9 (SD = 3.8) 
years. There were 29 males and 37 females Table 9. The study setting included hospitalized 
patients, and the study was conducted in Tunisia Table 3. 
Primary Outcomes 
No data were reported for any of the primary outcomes. 
Secondary Outcomes 
Proportion of participants with ulcers completely healed 
The proportion of participants with ulcers completely healed was higher in the Silver dressing 
group 13/34 (38%) as compared with the control group 5/32 (16%). There was a 145% increase 
in the proportion of participants with ulcers completely healed in the Silver dressing group as 
compared with the control group (RR 2.45, 95% CI 0.98 to 6.09; participants = 66; studies = 1); 
Analysis 18.1. No statistically significant difference was observed. 
No data were reported for the secondary outcomes time to complete healing (days), proportion of 
participants with ulcers recurring after healing, and cost of treatment. 
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Analysis 18.1 Silver dressing compared with control group 
(standard cleaning and compression management methods 
without silver ointment) 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect 
Estimate 
18.1 Number of 
ulcers completely 
healed 
1 66 Risk Ratio (M-H, 
Random, 95% 
CI) 
2.45 [0.98, 6.09] 
Comparison 19 Debridement (Any form of debridement against gauze or saline 
gauze) (10 trials, 807 participants) 
Jeffcoate 2009; Jensen 1998; Piaggesi 2001; Piaggesi 1998; Vandeputte 1997; Lalau 2002; 
D'Hemecourt 1998; Donaghue 1998; Goretti 2008; Roberts 2001 
Summary: Any form of debridement as compared with gauze 
The 10 trials (D'Hemecourt 1998; Donaghue 1998; Goretti 2008; Jeffcoate 2009; Jensen 1998; 
Lalau 2002; Piaggesi 1998; Piaggesi 2001; Roberts 2001; Vandeputte 1997) comparing any form 
of debridement with gauze dressing were considered sufficiently similar to pool, using a random 
effects model. They included a combined total of 807 subjects. The follow up period ranged 
from 4 - 24 weeks. The study comparison period ranged from 1995 to March 2007, however the 
study period was not reported for 8/10 studies. There was significant risk of bias as many of the 
risk of bias characteristics were either unclear (unreported) or at high risk of bias. Figure 3; 
Figure 4. 
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Types of Interventions 
The interventions in these studies included: Any (All) forms of debridement as compared with 
gauze or saline gauze. Gauze was the most frequently used method of control or "alternative" 
treatment arm. This was often paired with some form of standard treatment to both arms that 
when specified ranged from pressure relief/offloading, antiseptic or saline skin cleansing, 
secondary dressings, or infection control with antibiotics. Some of the studies used an alternate 
separate form of debridement that was not uniformly clearly defined in all studies. There were no 
details in the studies as to the extent this was done other than references to "as needed", "as 
required", or "regularly". If a study specified that a separate identical form of debridement was 
used on both intervention arms throughout the study it was excluded, as this would confound any 
debridement effect from the intervention and control groups Table 5; Table 13. 
Initial Wound Stage 
The initial wound size in the studies ranged from 0.21 cm2 to 25 cm2. The only study that did not 
report wound size was Vandeputte 1997. The wound depth ranged from 0.4 cm to 2.9 cm. Four 
studies in this comparison reported wound depth Table 10. The wound staging included in the 
studies were classified as Wagner grade 1 - 4. Four studies reported Wound stage in this 
comparison. The duration of ulcers in this comparison ranged from 5.9 weeks to 42 (SD = 42) 
weeks. There were 7 studies that reported duration of ulcers Table 10. 
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Participant Characteristics 
The studies comprised a total of 807 participants Table 3. The mean ages for the studies ranged 
from to 58.3 (SD = 12.13) years to 64.39 (SD = 11.67) years Table 9. There were a total of at 
least 502 males in the studies that actually reported gender in this total sample Table 9. The 
studies were conducted in a variety of settings including outpatient and inpatient (hospitalized) 
patients Table 3. The studies were conducted in the following countries: Belgium, France, Italy, 
UK, and the US Table 3. The risk of bias in the included studies was significant as most of the 
risk of bias characteristics used in this review were unclear or high for the studies used in this 
comparison Figure 3, Figure 4. 
Types of Outcomes 
Primary Outcomes 
Proportion of participants with amputations 
Five studies reporting on the number of amputations were pooled. There were fewer amputations 
using ANY form of debridement 6/272 as compared with gauze 10/171. Pooling these studies 
yielded a relative risk for amputation of (RR 0.48, 95% CI 0.17 to 1.37; participants = 443; 
studies = 5; I2 = 0%); in the absence of significant heterogeneity, p = 0.75, I2 = 0%) Analysis 
19.1. This translates to 52 % reduction in the proportion of participants with amputations in the 
Any debridement group as compared to gauze dressing group; and a number needed to treat for 
benefit [NNTB] of 50 (95% CI 15 [NNTB], 34 [NNTH]): that is to prevent one additional patient 
with diabetic foot ulcer from having an amputation, 50 patients must be treated with Any form of 
debridement instead of gauze. No statistically significant difference was determined Figure 31. 
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Proportion of participants with complicating infections 
The seven studies reporting on the number of infections were pooled. There were more 
infections using ANY form of debridement 152/381 as compared with gauze 84/278. Pooling 
these studies yielded a relative risk for amputation of (RR 1.07, 95% CI 0.76 to 1.52; participants 
= 659; studies = 7); in the absence of significant heterogeneity, p = 0.15, I2 = 35%) Analysis 
19.2; Figure 32. 
This translates to 7% increase in the proportion of participants with infections in the Any 
debridement group as compared to the gauze dressing group; and a number needed to treat 
[NNTH] of 50 (95% CI 9 [NNTB], 12 [NNTH]): that is to prevent one additional patient with 
diabetic foot ulcer from having an infection, 50 patients must be treated with Any form of 
debridement instead of gauze. No statistically significant difference was determined Figure 32. 
Secondary Outcomes 
Proportion of participants with ulcers healed 
The ten studies reporting on the number of patients with ulcers completely healed were pooled. 
There were more ulcers healed using ANY form of debridement 213/462 as compared with 
gauze 134/336. Pooling these studies yielded a relative risk for amputation of (RR 1.22, 95% CI 
1.04 to 1.44; participants = 798; studies = 10); in the absence of significant heterogeneity, p = 
0.18, I2 = 28%) Analysis 19.3.  
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This translates to 22% increase in the proportion of participants with infections in the Any 
debridement group as compared to the gauze dressing group; and a number needed to treat 
[NNTB] of 10 (95% CI 5 to 100 [NNTB]): that is to heal one additional patient with diabetic foot 
ulcer, 10 patients must be treated with Any form of debridement instead of gauze. Statistically 
significant difference was determined Figure 33. 
Proportion of participants with ulcers healed - Subgroup analysis excluding the two abstracts 
A subgroup analysis was performed excluding two studies that were only available as abstracts 
including: Goretti 2008; Roberts 2001. 
The eight studies reporting on the number of patients with ulcers completely healed were pooled. 
There were more ulcers healed using ANY form of debridement 190/428 as compared with 
gauze 119/300. Pooling these studies yielded a relative risk for amputation of (RR 1.18, 95% CI 
0.99 to 1.41; participants = 728; studies = 8); in the absence of significant heterogeneity, p = 
0.14, I2 = 35%) Analysis 19.3.  
This translates to an 18% increase in the proportion of participants with infections in the Any 
debridement group as compared to the gauze dressing group; and a number needed to treat to 
benefit [NNTB] of 12 (95% CI 6 [NNTB], 50 [NNTH]): that is to heal one additional patient 
with diabetic foot ulcer, 12 patients must be treated with Any form of debridement instead of 
gauze. No statistically significant difference was determined when excluding the two studies 
available as abstracts only. 
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Quality of Life Index 
One study with 3 arms reported on this outcome. The mean difference was 0.01 points lower in 
the Any debridement group (using either Hydrofiber or Iodine impregnated fiber dressing) as 
compared with the gauze dressing group (MD -0.01, 95% CI -0.04 to 0.01; participants = 317; 
studies = 1); in the absence of significant heterogeneity, p < 0.95, I2 = 0%; Analysis 19.4. No 
statistically significant difference was demonstrated Figure 34. 
Time to complete healing 
Four studies reported on this outcome. Time to complete healing yielded a mean difference of -
27.88 days less time to achieve healing in the Any debridement dressing group as compared to 
the gauze dressing group (MD -27.88, 95% CI -52.53 to -3.23; participants = 458; studies = 4); 
in the presence of significant heterogeneity, p < 0.0001, I2 = 90%); Analysis 19.5. No 
statistically significant difference was observed Figure 35. 
Proportion of participants with recurrent ulcers 
Two studies reporting on the proportion of patients with recurrent ulcers were pooled. There 
were less recurrent ulcers using ANY form of debridement group 13/232 as compared with 
gauze dressing group 11/125. Pooling these studies yielded a relative risk for recurrent ulcers of 
(RR 0.81, 95% CI 0.25 to 2.58; participants = 357; studies = 3); in the absence of significant 
heterogeneity, p = 0.18, I2 = 39%); Analysis 19.6 .  
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This translates to 19% reduction in the proportion of participants with recurrent ulcers in the Any 
debridement group as compared to the gauze dressing group; and a number needed to treat 
[NNTB] of 100 (95% CI 10 [NNTB], 13 [NNTH]): that is to prevent one additional patient with 
diabetic foot ulcer from developing a recurrent ulcer, 100 patients must be treated with Any form 
of debridement instead of gauze. No statistically significant difference was demonstrated Figure 
36. 
Cost of treatment was either not reported at all or not reported in at least 2 out of the 10 studies 
used in this comparison. 
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Analysis Table 19.1 – 19.6 Any debridement compared 
with saline gauze control 
Outcome or 
Subgroup 
Studies Participants Statistical 
Method 
Effect 
Estimate 
19.1 Number of 
amputations reported 
5 443 Risk Ratio (M-H, 
Random, 95% 
CI) 
0.48 [0.17, 1.37] 
  19.1.1 Any 
debridement 
compared with saline 
gauze 
5 443 Risk Ratio (M-H, 
Random, 95% 
CI) 
0.48 [0.17, 1.37] 
19.2 Number of 
Infections reported 
7 659 Risk Ratio (M-H, 
Random, 95% 
CI) 
1.07 [0.76, 1.52] 
  19.2.1 Any 
debridement 
compared with saline 
gauze 
7 659 Risk Ratio (M-H, 
Random, 95% 
CI) 
1.07 [0.76, 1.52] 
19.3 Number of 
ulcers completely 
healed 
10 798 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.17 [1.00, 1.36] 
  19.3.1 Any 
Debridement vs 
Saline Gauze 
8 728 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.12 [0.95, 1.32] 
  19.3.2 SA w/o 
Abstracts 
2 70 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.59 [1.04, 2.42] 
19.4 Quality of life 1 317 Mean Difference 
(IV, Random, 
95% CI) 
-0.01 [-0.04, 
0.01] 
19.5 Time to 
complete healing 
(days) 
4 458 Mean Difference 
(IV, Random, 
95% CI) 
-27.88 [-52.53, -
3.23] 
19.6 Recurrence rates 2 357 Risk Ratio (M-H, 
Random, 95% 
CI) 
0.81 [0.25, 2.58] 
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Summary of Results, Overall Effect sizes, and Heterogeneity 
Table 14 below summarizes the overall results, effect sizes discussed in this section, along with 
heterogeneity that were reported for all meta-analyses done in this review. 
Table 14 Summary of Results, Overall Effect Sizes, and Heterogeneity 
             RR (95% CI) **MD (95% CI) Heterogeneity of Outcome Effects Summary 
Statisticsb 
Intervention 
comparison 
Outcome k Fixed-Effects Random-Effects τ2 χ2 I2 (%) p-value 
Hydrogel vs. 
Gauze 
Proportion of 
Amputations 
2 0.26 (0.05, 1.37) 0.26 (0.05, 1.40) 0.00 0.11 0 0.74 
 Proportion of 
Infections 
3 0.87 (0.54, 1.40) 0.74 (0.18, 2.99) 0.91 4.89 59 0.09 
 Proportion of 
Ulcers Healing 
3 1.68 (1.14, 2.49) 1.71 (1.16, 2.52) 0.00 0.95 0 0.62 
Foam vs. Wet to 
Dry 
Proportion of 
Ulcers Healing          
2 studies 
2 4.35 (1.33, 14.29) 3.56 (0.93, 13.66) 0.18 1.15 13 0.28 
Hydrofiber vs. 
Gauze 
Proportion of 
Amputations 2 
studies 
2 1.31 (0.33, 5.16) 1.34 (0.29, 6.10) 0.05 1.03 3 0.31 
 Proportion of 
Infections      2 
studies 
2 1.11 (0.84, 1.46) 0.96 (0.40, 2.31) 0.21 1.37 27 0.24 
 Proportion of 
Ulcers Healing          
2 studies 
2 0.06 (0.06, 0.19) 0.07 (0.05, 0.19) 0.00 0.09 0 0.76 
 Mean Time to 
Complete Healing          
2 studies 
2 **-13.87 (-27.91, 0.16) **-53.37 (-153.29, 
46.56) 
4892.23 16.29 94 < 0.0001 
Any debridement 
vs. Gauze 
Proportion of 
Amputations 5 
studies (n=6) 
5 0.49 (0.19, 1.27) 0.48 (0.17, 1.37) 0.00 2.67 0 0.75 
 Proportion of 
Infections      7 
studies (n=8) 
7 1.10 (0.89, 1.36) 1.07 (0.76, 1.52) 0.07 10.82 35 0.15 
 Quality of Life                
1 study (n=2) 
1 -0.01 (-0.04, 0.01) -0.01 (-0.04, 0.01) 0.00 0.00 0 0.95 
 Proportion of 
Ulcers Healing        
10 studies (n=11) 
3 1.17 (1.00, 1.36)        
 
1.22 (1.04, 1.44) 
 
0.02 13.89 28 0.18 
 Proportion of 
Ulcers Healing       
(two studies 
available only as 
abstracts) 
10 1.12 (0.95, 1.32)]  1.18 (0.99, 1.41) 0.02 12.26 35 0.14 
 Proportion of Ulcer 
Recurrence   2 
studies (n=3) 
2 0.77 (0.34, 1.71) 0.81 (0.25, 2.58) 0.42 3.29 39 0.19 
 Mean Time to 
Complete Healing          
4 studies (n=5) 
4 2.54 (1.20, 3.87) -27.88 (-52.53, -3.23) 614.40 39.33 90 < 0.00001 
Note: 
** indicates a significant effect; k represents the number of studies for each outcome included in the analysis; Q represents Cochran’s Q indicating 
significance of heterogeneity; I2 represents the magnitude of heterogeneity; p-value represents the significance of heterogeneity. 
b) Relative risk (RR) was the effect estimate for proportion of amputations, proportion of infections, and proportion of ulcers healed, and proportion of 
recurrence. Mean difference (MD) was the effect estimate for the outcomes Quality of life, and Time to complete healing.  
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Sensitivity Analysis 
A sensitivity analysis was conducted by removing the two studies that were only available as 
abstracts (Goretti 2008; Roberts 2001). This was performed in order to determine if the results 
were robust despite their exclusion from the analysis. Prior to removing the studies there was a 
statistically significant increase in proportion of ulcers healed using a random effects model. 
When the studies were removed there was no statistically significant difference in the proportion 
of ulcers healed. The fixed effects model demonstrated no statistically significant benefit 
irrespective of whether the abstracts were included or not. 
Table 14 contrasts the fixed effects versus random effects model estimates. The findings were 
generally robust despite model used. The exception was in the comparisons Wet to Dry 
debridement versus Foam dressing for the outcome proportion of ulcers healed where the fixed 
effects model demonstrated a statistically significant increase in proportion of ulcers healed 
whereas the random effects model did not demonstrate a statistically significant difference. The 
Any debridement as compared with the control condition demonstrated the mean Time to 
complete healing to be longer in the intervention group using the fixed effects model but shorter 
in duration using the random effects model. 
 
 
 
 
156 
 
Publication bias investigation 
The studies used in this comparison of any debridement against gauze for the outcome 
proportion of ulcers healed. These 10 studies were plotted in a funnel plot to investigate 
publication bias. The funnel plot suggested slight asymmetry favoring disproportionately 
positive studies to the right side of the graph including the smaller studies which suggests 
publication bias Figure 37.  
This analysis included the Beggs and Eggers tests which did not detect any significant 
asymmetries using these statistical tests Table 15. 13/30 (43%) studies retrieved in this review 
received funding through private sources though despite this fact few significant associations 
were found further suggesting a lack of publication bias Figure 22.
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Chapter 6 Meta-regression Analysis 
Introduction 
Moderator analysis is an important part of any comprehensive SR and meta-analysis. It is 
utilized in a manner similar to the way regression analysis is conducted in an individual study. 
Moderators or covariates may result in effect modification, or interact with the intervention of 
interest. This may include confounding, magnifying or diminishing the interventions effect.  
Efforts were made to understand any unexplained heterogeneity. This systematic review and 
meta-analysis demonstrated relatively low heterogeneity as evidenced by the statistical tests 
reported in Table 14.  
The tests for homogeneity including τ2, χ2, and I2 demonstrated large and significant 
heterogeneity in one outcome (mean time to complete healing) for the interventions Hydrofiber 
and “Any debridement”, both as compared with gauze.  Moderate heterogeneity though not 
statistically significant was suggested in the outcome proportion of infections for the intervention 
Hydrogel as compared with gauze. The outcomes proportion of infections, proportion of ulcers 
healed, and proportion of ulcer recurrence, demonstrated moderate heterogeneity for the 
intervention “Any debridement” as compared with gauze, though these were not found to be 
statistically significant. If the degree of heterogeneity reached significance based on our 
statistical test results; then efforts were made to explain it. Therefore, this meta-regression 
analysis was conducted on prognostic variables or moderators with the goal of explaining any 
significant heterogeneity between the studies.  
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This portion of the analysis was limited. The optimal number of covariates is 10 studies per 
moderator/covariate for each of the outcomes of interest. This is a similar threshold used in 
multivariate regression analysis. Therefore, this analysis was limited to Comparison 19 where the 
number of studies per covariate included 10 studies. 
The moderators that were used for analysis included the sample and risk specific characteristics 
age, peripheral arterial disease, duration of diabetes, proportion of females. These prognostic 
factors are suspected of having an association with wound healing. The study specific 
characteristics data collection year, and study duration follow up were also investigated.  
There were two outcomes that satisfied the minimal studies per covariate requirement these 
included proportion of infections and proportion of ulcers healed. The outcome included 10 
studies though not all studies reported on every moderator of interest. See Tables 7, 9, 10, and 11 
for the 30 respective studies which include information on which of the studies reported on the 
moderators of interest for this review. 
Methods 
Assessment of heterogeneity 
Design heterogeneity was discussed and summarized in the Characteristics of Included studies 
tables. Methods for identifying statistical heterogeneity included visual graphical analysis of 
Forest plots, the use of the Q-statistic, tau-squared, χ2 test, and the I2 test statistic). 
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Assessment of heterogeneity included using visual assessment of the Forest Plots generated 
whenever 2 or more studies were available for analysis to meet the study objectives. Evaluation 
for heterogeneity included the use of the Q-test, τ2, and the I2 test statistics.  
These statistical techniques were utilized to both detect the presence and magnitude of 
heterogeneity, respectively (Higgins 2002; Higgins 2003; Higgins 2008). The homogeneity 
statistic, Q, determines whether each set of the weighted mean effect sizes (d+s) shared a 
common effect size, a significant Q indicates a lack of homogeneity and an inference of 
heterogeneity of the effect sizes between studies (Higgins 2002; Higgins 2003; Higgins 2008).  
To assess the extent or magnitude to which studies’ outcomes were consistent, the I2 index and 
its corresponding 95% confidence intervals (CIs) were calculated; I2 varies between 0 
(homogeneous) and 100% (non-homogeneous/heterogeneous). If the CI around I2 includes zero, 
the set of effect sizes (ES’s) is considered homogeneous. The I2 has been demonstrated as a 
statistic used to complement the Q-test statistic, but is not used in lieu of it (Huedo-Medina 
2006). 
In order to address residual unexplained heterogeneity that is not a function of a single outlier 
effect or exaggerated idiosyncratic effects among outlying responders, the study reports were 
reviewed. This was done to determine whether the authors of the studies described how they 
addressed these outliers, and their explanations for any outlier effects. The effects of outliers 
were either not reported or the threshold for defining outliers were not standardized across 
studies. This information would be helpful at the individual study level since the respective 
authors have access to these raw data. 
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This systematic review relied on the summary statistics which poses greater challenges in 
determining the reasons for within study variance. The unit of analysis or observation in this 
systematic review is the study not the individual which compounds this challenge. 
This systematic review used clinical, methodological, and statistical heterogeneity to help decide 
whether to conduct a meta-regression analysis. We relied on visual graphical methods by 
analyzing the Forest plots, the Q statistic, tau-squared (τ2), χ2 statistic, and the I2 statistic. Tau-
squared (τ2) is defined as the between-studies variance or the variance of the effect size 
parameter across the population of studies. The risk of bias tables and the characteristic of 
included studies tables served as the basis for methodological considerations (Borenstein 2009, 
Higgins 2008, Cooper 2009).  
Meta-regression was performed on moderators/covariates in order to explain any remaining 
variability between studies for the 7 outcomes of interest.  The approach to variability present in 
the primary and secondary outcomes and for the comparison interventions was standardized for 
all moderators. This was conditional on a sufficient number of studies to permit this type of 
analysis.  
Meta-regression and moderator analysis was limited since there were too few comparisons with 
sufficient studies for the recommended 10 studies per moderator ratio. This restricted the 
analysis to 2 of the 19 pairwise comparisons that were made. The 19 comparisons grouped 
studies accordingly based on the same intervention against an alternate control/comparison 
intervention. Comparison 19 grouped “any’ form of debridement intervention against the same 
control group (see effects of interventions section). 
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Besides varying in the type of debridement comparisons the studies varied in some 
characteristics including design-specific, and sample-specific characteristics. 
There were sample-specific factors that were considered to influence wound healing. These are 
considered higher risk and include severity of diabetes, age, peripheral arterial disease and 
offloading, among others that were previously discussed. These moderators are considered high 
priority and clinically significant based on content expert opinion. There were also study-specific 
factors including the duration of the intervention that might influence these clinical and public 
health outcomes that warrant further study. However, many of the covariates of interest that were 
originally sought in this systematic review were not reported adequately to allow for a 
comprehensive meta-regression analysis. 
This segment of the analysis includes modeling each of the moderators specified above in order 
to determine if there is any effect on the between study variance irrespective of the lack of 
significant heterogeneity. This will facilitate hypothesis generation and provide insight into 
future areas for research. 
The analysis included a series of models that utilize one covariate per model. The use of more 
than one moderator in a model is precluded by the limitation in the information reported in the 
studies and the finite number of studies available for more detailed meta-regression analysis. The 
moderators are analyzed for purposes of hypothesis generation as well as to determine whether 
they help explain heterogeneity. This approach was scrutinized to avoid over-reliance on 
allowing the availability of data to drive the meta-regression analysis. Therefore, the Meta-
regression analysis proceeds with an effort to limit any broad conclusions on moderator effect 
under these circumstances as a result of the limited information reported. 
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The multivariate approach was not possible for all the reasons discussed. Weighted mean effect 
size by the inverse of the variance of each study was calculated across all studies under the 
random effects assumptions for the Meta-regression analysis. The random effects model assumes 
that these data are coming from different populations and accounts for both within and between-
study variance.  The random effects assumption is arguably more consistent with biological and 
clinical variability in complex health systems. The fixed effects model assumes that all effect 
sizes are from the same population and accounts strictly for within study variance.  To test for 
heterogeneity, Cochran’s Q and I2 were calculated.  The Q test evaluates for the significance of 
heterogeneity. I2 calculates the magnitude of heterogeneity with a range from 0%-100%.   
In order to assess whether the moderators explain the heterogeneity of the effect sizes, moderator 
analysis using weighted mixed-effects models with maximum likelihood estimation of the 
random effects weights was performed.  
This systematic review tested each variable for study where sufficiently reported information 
was available and if clinically warranted based on known risk factors.  Moderator analysis was 
conducted by using CMA (CMA 2005). 
Results 
The Meta analyses portion of the systematic review reported previously was conducted on 
comparisons 6, 10, 13, and 19. Of these 4 comparisons conducted, comparison 19 was the sole 
comparison out of the four where an adequate number of studies were available for meta-
regression analysis on moderators (Analysis 19). The moderator analysis for Comparison 19 
included 9 – 10 studies per covariate for two outcomes. 
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The two outcomes included the proportion of complicating Infections (Analysis 19.2), and the 
proportion of ulcers healed (Analysis 19.3). The meta analyses for these two respective outcomes 
involved the comparison “any debridement” against the pre-specified control condition. Please 
refer to Tables 16 – 31 concurrently. 
Age 
A model was generated in order to determine what effect if any does the moderating variable age 
have on the outcome variables of interest including number of Infection, number of ulcers 
healed. 
There was no significant association or effect using age as a moderator for either outcomes of 
interest including number of infections and number of ulcers healed. (Binfection = - 0.2131, p < 
0.0651; Bulcerhealed = -0.0130, p < 0.6873 for number of infections, and ulcers healed 
respectively).  Therefore, the coefficient or slope of the effect of the moderator age on the 
outcomes interest is no different from 0.  
The comparison of the new model with the null model for Tau2, I2, Q, and R2 suggest no 
significant effect on heterogeneity by including the moderator age. These results are presented in 
Table 16 and Table 17 respectively with associated scatterplots (See also summary tables 28, 39, 
and 30 below). Each circle on the scatterplot represents the point estimate of the effect for that 
study. The size or area of that circle represents the weighting for that respective study in the 
scatterplot. 
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Peripheral Arterial Disease (PAD) 
A model was generated in order to determine what effect if any does the moderating variable 
PAD have on the outcome variables of interest including number of Infection, number of ulcers 
healed, and the effect of heterogeneity.  There was no significant association or effect using PAD 
as a moderator for either outcomes of interest including number of infections and number of 
ulcers healed. (Binfection = 3.3706, p = 0.3023; Bulcerhealed = -0.4095, p = 0.6191 for number of 
infections, and ulcers healed respectively).  Therefore, the coefficient or slope of the effect of the 
moderator PAD on the outcomes interest is no different from 0. The comparison of the new 
model with the null model for Tau2, I2, Q, and R2 suggest no significant effect on heterogeneity 
by including the moderator PAD. These results are presented in Table 18 and Table 19 
respectively with associated scatterplots (See also summary tables 28, 29, and 30 below).  
Duration of Diabetes 
A model was generated in order to determine what effect if any does the moderating variable 
Duration of Diabetes have on the outcome variables of interest including number of Infection, 
number of ulcers healed, and the effect of heterogeneity.  There was no significant association or 
effect using duration of diabetes as a moderator for either outcomes of interest including number 
of infections and number of ulcers healed. (Binfection = - 0.1528, p = 0.5460; Bulcerhealed = 0.0419, p 
= 0.5625 for number of infections, and ulcers healed respectively).  Therefore, the coefficient or 
slope of the effect of the moderator diabetes duration on the outcomes interest is no different 
from 0. The comparison of the new model with the null model for Tau2, I2, Q, and R2 suggest no 
significant effect on heterogeneity by including the moderator duration of diabetes.  
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These results are presented in Table 20 and Table 21 respectively with associated scatterplots. 
The moderator analysis displayed in Table 28 demonstrates no statistically significant effect on 
the outcomes proportion of infections or proportion of ulcers healed for all but one of the 
moderators. This analysis was conducted for the intervention any debridement as compared with 
saline gauze and the proportion of females demonstrates a statistically significant reduction in 
the proportion of infections (See also summary tables 28, 29, and 30 below). 
Proportion of Females 
A model was generated in order to determine what effect if any does the moderating variable 
Proportion of females have on the outcome variables of interest including number of Infection, 
number of ulcers healed, and the effect of heterogeneity.  There was a statistically significant 
effect on the proportion of infections. No significant association or effect using proportion of 
females as a moderator for number of ulcers healed was found. (Binfection = - 6.1651, p = 0.0264; 
Bulcerhealed = 0.2486, p = 0.8683 for number of infections, and ulcers healed respectively).  
Therefore, the coefficient or slope of the effect of the moderator proportion of females on the 
outcomes interest is different from 0. The comparison of the new model with the null model for 
Tau2, I2, Q, and R2 suggest a significant effect on heterogeneity by including the moderator 
proportion of females. These results are presented in Table 22 and Table 23 respectively with the 
associated scatterplots (See also summary tables 28, 29, and 30 below). 
Data collection year 
A model was generated in order to determine what effect if any does the moderating variable 
Data Collection Year have on the outcome variables of interest including number of Infection, 
number of ulcers healed, and the effect of heterogeneity. 
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There was no significant association or effect using data collection year as a moderator for either 
outcomes of interest including number of infections and number of ulcers healed. (Binfection = 
0.0246, p = 0.3890; Bulcerhealed = 0.0013, p = 0.9274 for number of infections, and ulcers healed 
respectively).  Therefore, the coefficient or slope of the effect of the moderator data collection 
year on the outcomes of interest is no different from 0. The comparison of the new model with 
the null model for Tau2, I2, Q, and R2 suggest no significant effect on heterogeneity by including 
the moderator data collection year. These results are presented in Table 24 and Table 25 
respectively with associated scatterplots (See also summary tables 28, 29, and 30 below). 
Study duration follow up 
A model was generated in order to determine what effect if any does the moderating variable 
Study duration follow up have on the outcome variables of interest including number of 
Infection, number of ulcers healed, and the effect of heterogeneity.  There was no significant 
association or effect using study duration of follow up as a moderator for either outcomes of 
interest including number of infections and number of ulcers healed. (Binfection = 0.0482, p = 
0.1857; Bulcerhealed = 0.0048, p = 0.6043 for number of infections, and ulcers healed respectively).  
Therefore, the coefficient or slope of the effect of the moderator follow up period on the 
outcomes interest is no different from 0. The comparison of the new model with the null model 
for Tau2, I2, Q, and R2 suggest no significant effect on heterogeneity by including the moderator 
follow up period. These results are presented in Table 26 and Table 27 respectively with 
associated scatterplots (See also summary Tables 28, 29, and 30 below). 
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Table 28 Moderators of effect size magnitude for the “Any debridement vs. gauzea” 
comparison. 
Outcome(s) Moderator(s)Characteristic(s)/Level(s) RR (95% 
CI) 
Kb Coefficient p-value 
 Participant-specific demographic 
characteristics 
 
Proportion of 
infections 
Age 1.07 (0.76, 
1.52) 
7 -0.2132 0.0651 
 Risk-specific characteristics  
Proportion of 
infections 
PADc 1.07 (0.76, 
1.52) 
7 3.3706 0.3023 
Proportion of 
infections 
Duration of diabetes (yrs.) 1.07 (0.76, 
1.52) 
7 -0.1528 0.5460 
Proportion of 
infections 
Proportion of females 1.07 (0.76, 
1.52) 
7 -6.1651 0.0264 
 Study-specific characteristics  
Proportion of 
infections 
Data collection year 1.07 (0.76, 
1.52) 
7 0.0246 0.3890 
Proportion of 
infections 
Duration of follow up 1.07 (0.76, 
1.52) 
7 0.0482 0.1857 
Proportion of 
Ulcers healed 
Age 1.17 (1.00, 
1.36) 
10 -0.0130 0.6873 
Proportion of 
Ulcers healed 
PAD(c) 1.17 (1.00, 
1.36) 
10 -0.4095 0.6191 
Proportion of 
Ulcers healed 
Duration of diabetes (yrs.) 1.17 (1.00, 
1.36) 
10 0.0419 0.5626 
Proportion of 
Ulcers healed 
Proportion of females 1.17 (1.00, 
1.36) 
10 0.2486 0.8683 
 Study-specific characteristics  
Proportion of 
Ulcers healed 
Data collection year 1.17 (1.00, 
1.36) 
10 0.0013 0.9247 
Proportion of 
Ulcers healed 
Duration of follow up 1.17 (1.00, 
1.36) 
10 0.0048 0.6043 
a. Each moderator listed is evaluated individually without controlling for the other listed moderators. Effect sizes 
are based on random effects assumptions for the comparison and respective outcome listed in two columns. In this 
analysis there was 1 comparison (“any debridement” as compared with gauze) and 2 outcomes (proportion of 
infections, and Proportion of ulcers healed) that approximated a sufficient (number of studies): moderator ratio in 
order to facilitate moderator analysis. 
b. k = number of studies 
c. PAD = proportion with initial baseline peripheral arterial disease. 
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Table 29 Non-Significant Moderators 
Non-Significant Moderators 
All the following moderators assessed were non-significant. 
Age 
PAD (Peripheral arterial disease) 
Duration of diabetes 
Data collection year 
Duration of follow up 
 
Table 30 Moderators that were Unable to be analyzed due to lack of Reported Information 
Out of the 235 coded variables on our data extraction form, 138 of these were non-effect size related 
variables. These were reviewed as candidate variables for regression analysis and most were unable to 
be analyzed due to the lack of reported information on the outcomes of interest for this systematic 
review. See Data extraction form Appendix 2. 
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Chapter 7 
Discussion   
Summary of main results   
This systematic review included a comprehensive, exhaustive, and transparent search of the 
literature accordingly using established standards. This systematic review retrieved, identified, 
extracted, synthesized, and appraised all available evidence from randomized controlled studies 
on the debridement of diabetic foot ulcers. The evidence included direct and indirect 
fundamental clinical and public health outcomes on established and widely used forms of 
debridement in the treatment of diabetic foot ulcers. A total of 19 comparisons were made in the 
30 studies included in this review. This included variable reporting on all 7 pre-specified 
outcomes of interest that have both clinical and public health implications. The comparisons 
were based on data from the individual studies that were extracted in order to conduct both a 
qualitative and quantitative systematic review (meta-analysis). There were a total of four 
comparisons where evidence was pooled into meta-analyses for the pre-specified outcomes to 
help answer our research question. 
There was no statistically significant beneficial difference in amputation frequency, or infection 
frequency in any of the comparisons that were analyzed with meta-analyses Table 14, for the 
studies that reported on these outcomes. 
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Quality of life was reported in 3 studies (Piaggesi 1998; D'Hemecourt 1998; Jeffcoate 2009) and 
there was no significant difference found between the debridement and the control/comparison 
condition (Jeffcoate 2009) utilized the (SF-36) questionnaire. 
In the studies that reported on ulcers healed, no evidence of any difference in ulcer healing was 
found between the specific forms of debridement when compared to each other except between 
hydrogel as compared with gauze/good wound care. There was evidence of an increase in ulcers 
healed in the comparison any form of debridement as compared with gauze dressing though this 
was not statistically significant. However when the two studies (Goretti 2008; Roberts 2001) that 
were available only as abstracts were excluded in a sensitivity analysis there was less significant 
difference in complete healing found, see Table14. 
There was no evidence of any difference in time to complete healing for diabetic foot ulcers 
healed except in 3 analyses, the superoxide solution as compared with standard local treatment 
with povidone iodine which was 6 days shorter (Goretti 2008). The time to complete healing was 
2.8 days longer in the alginate dressing group as compared with the gauze (Donaghue 1998). The 
Any debridement versus saline gauze group demonstrated a significant reduction of 
approximately 28 days in healing time using the random effects model whereas there was a 2.5-
day increase in healing time using the fixed effects model, see Table 14.  
The random effects model was pre-specified for this systematic review. However, the fixed 
effects model was used for purposes of sensitivity analysis. The findings were relatively robust 
irrespective of model used with one exception where the fixed effect model demonstrated a 
significant beneficial effect on the proportion of ulcers healed in the Foam as compared to the 
Wet to dry intervention; whose benefit was not significant under the random effects model.  
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The other exception was in the Any debridement group as compared with gauze that found a 
significant beneficial effect in proportion of ulcers healed using the random effects model but not 
the fixed effects model. When the two studies available exclusively as abstracts were removed 
both models failed to demonstrate a beneficial difference for the outcome proportion of ulcers 
healed. See Table 14, Analysis Tables 1.1 through 19.6, Results section. 
The meta-analysis using foam as compared with wet to dry debridement demonstrated no 
beneficial effect in the random effects model though a significant beneficial difference was 
found in fixed effects model for the outcome proportion of ulcers healed. 
In the studies that reported recurrence rates there was no significant beneficial difference 
between the competing forms of debridement or between any debridement and gauze dressing. 
Cost of treatment was reported in 3 studies (Jensen 1998; Jeffcoate 2009; Hammouri 2004) the 
Iodine impregnated fiber dressing group, the Hydrofiber group, and the honey normal saline 
dressing group as compared with the gauze dressing group. No statistically significant difference 
was found. The hydrogel group as compared with the gauze dressing group suggested a reduced 
daily cost for hydrogel however this was not found to be statistically significant (Jensen 1998). 
The studies retrieved in this review included trials that used relatively smaller sample sizes 
which may have been statistically underpowered. This would create difficulty in detecting small 
treatment effects. 
A Meta-regression analysis found that none of the candidate moderators demonstrated a 
beneficial effect on the respective outcomes of interest. The coefficients were not significantly 
different from the null value with one exception, the proportion of females.  
172 
 
This correlates with the coherent understanding that an observed gender predilection favors 
males in the development of wounds and amputations. There was no significant study 
heterogeneity that was explained with any of univariate models that were performed. (See Tables 
16 – 30). 
This finding may be a function of the variability in reporting that limited the moderator analysis 
through meta-regression to a small sub sample of studies retrieved in this systematic review. The 
effects of these moderators on the outcomes of interest may be better delineated as the 
standardization of reporting across studies improves. This would increase sample size for meta-
regression analysis and improve detection of significant effect interactions. 
Overall completeness and applicability of evidence   
The clinical and public health indicators included seven pre-specified outcomes of interest that 
were defined in the methods section of this review. Quality of life and cost of treatment were not 
well defined. For example, an acceptable robust standardized quality of life measure such as SF-
36 or a similarly acceptable measurement tool was universally under-utilized in the included 
studies.  
Quality of life and treatment cost are fundamental considerations in comparing the various 
debridement methods. Standardized reporting should include quality of life and economic data. 
The other five outcomes of interest were variably reported between studies including outcomes 
with very serious public health and clinical implications such as amputation and infection. 
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Applicability of the evidence is dependent on the four primary outcomes (amputations, 
complicating infections, quality of life, and cost) being universally reported as they have direct 
public health and clinical implications.  
Indirect evidence that is applicable to the primary outcomes of interest are provided by the 3 pre-
specified secondary outcomes (recurrence rates, complete healing, and time to complete healing) 
as they have clinical and public health bearing (SVD 1990). 
The pre-specified outcomes were variably reported throughout the 30 included studies making 
meaningful and comprehensive synthesis and analysis challenging. 
Quality of the evidence   
All 30 studies included in this review were classifiable as unclear or high risk of bias for many of 
the risk of bias characteristics utilized in this systematic review Characteristics of included 
studies; Figure 3, Figure 4. Though randomization was reported throughout most of the included 
studies did not report the method of randomization utilized. Allocation concealment was unclear 
in greater than 75% of studies. Due to the nature of the interventions blinding may not have been 
possible in the participants and the personnel delivering the intervention. Blinding of outcome 
assessors was unclear or high risk in approximately 70% of studies. Incomplete outcome data 
reporting was unclear or high risk in over 75% of the included studies. Selective reporting of 
outcomes was unclear or high risk in 50% of the included studies. Other bias was either unclear 
or high risk in the included studies. 
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The studies did not follow established reporting practice conduct such as the CONSORT 
guidelines (CONSORT). Major considerations consistent with these guidelines include 
appropriate random sequence generation and allocation concealment. The 30 studies reported 
randomization, though most studies did not report the specific method of randomization that was 
used i.e. computer generated, coin toss, except in 5/30 studies (Amini 2013; Bowling 2011; 
Jeffcoate 2009; Munter 2006; Tallis 2013) . Allocation concealment was universally unreported 
except in 5/30 studies (Bowling 2011, Jeffcoate 2009, Jude 2007a, Munter 2006, and Tallis 
2013). 
Blinding was often either absent or incomplete. This could have been a function of the nature of 
applying the specific debridement intervention. For example, in some cases it would be 
challenging for the investigator delivering the intervention to be blinded from the intervention 
they were using e.g. sharp/surgical debridement. It is difficult to blind the patient from the 
debridement method used e.g. sharp debridement or maggot debridement therapy. The studies 
that did report blinding/masking did not clearly define what was meant by "double-blinding" 
(Devereaux 2002). It was unclear whether the principal investigator, and/or the participants, 
and/or the outcome assessor were blinded.  
The studies that did report blinding of the outcome assessor included the following 8 studies (Ali 
2013; Apelqvist1990; D'Hemecourt 1998; Jeffcoate 2009; Lalau 2002; Piaggesi 2001; Shukrimi 
2008; Singh 2006). 
All study authors should report on these quality considerations. Study authors should anticipate 
that their respective study might be considered for inclusion in systematic reviews.  
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The Consort guidelines were meant to standardize reporting guidelines for study authors in order 
to help better define and reduce the variability in what is reported in the medical and public 
health literature. Universal standardized reporting guidelines would make it less difficult for 
authors synthesizing the evidence in systematic reviews and meta-analyses. 
Methods of addressing incomplete outcome data were not clearly reported in most of the studies. 
Intention to treat analysis (ITT) was not reported in the majority of studies. The 4 studies that 
reported an ITT analysis used last observation carried forward (D'Hemecourt 1998; Jeffcoate 
2009; Munter 2006; Tallis 2013).  
Other methods of Intention to Treat Analysis (ITT)such as Bayesian methods and imputation 
(imputing values for missing data) were not utilized. Fundamentally better efforts should be 
made before and during the conduct of the study to prevent or limit the amount of missing data to 
the maximum degree possible. This is the most ideal approach and lessens the reliance of 
researchers on the use of ITT methods to make up for missing data. ITT methods are not 
universally standardized and the specific methods used are variable. However irrespective of ITT 
method utilized, the reporting of method used should still be mandatory. 
Selective reporting of outcomes was difficult to determine as all studies did not provide a pre-
study protocol. Efforts were made to determine whether all of the outcomes defined and reported 
in the methods sections were subsequently reported in the results sections of the included studies. 
This was conducted as an alternative surrogate method of detecting selective reporting by the 
authors. Many of the studies were characterized as unclear or high risk of bias with respect to 
selective reporting of outcomes.  
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Authors should specify every outcome of interest in the methods section and these should be 
summarily reported in the results. Any deviation from this approach should be clearly explained. 
All studies were characterized as high risk or unclear risk of bias (See Characteristics of Included 
Studies Table Section and Risk of Bias Table section for individual studies), Figure 1 – 2. This 
was in part due to the variability of inclusion/exclusion criteria, and patient/study specific 
characteristics which were under-reported by the investigators of the included studies e.g. disease 
severity, variable methods of measurement e.g. variable methods of determining the presence of 
arterial insufficiency Table 7 - 11. The majority of studies were industry supported 13/30 Table 
12. Publication bias was suggested graphically in the funnel plot. However other statistical tests 
for publication bias including Beggs, and Eggers test did not demonstrate significant evidence of 
publication bias. Publication bias assessment was limited to the Any debridement as compared 
with the control condition for the outcome number of ulcers healed. This was the only condition 
that met the recommended 10 studies threshold for publication bias testing. 
Potential biases in the review process   
This systematic review made efforts to include studies that were not published in English 
language journals. These studies were translated using Google Translate, and the reviewers relied 
on outside translators only when needed information was not translated by Google translate. 
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Efforts were made to contact authors of the studies that were only available as abstracts but were 
unsuccessful. We conducted a sensitivity analysis with and without the studies that were only 
available as abstracts in order to determine what the impact that would have on the effect 
estimates if they were excluded. This resulted in a smaller effect size and nonsignificance when 
the two abstracts were not included as reported above. 
The potential for bias in translating the studies that were screened and included is possible. 
Though this risk is likely to be limited in this review given the negative findings in the translated 
studies are concordant with other similar findings that have been published. 
Many of the studies paired both intervention treatment arms with sharp debridement on an as 
needed basis, even if sharp debridement was not one of the primary treatment arms. These 
studies were included unless they specified regular use sharp debridement in both intervention 
treatment arms, as this would have made it impossible to determine the inherent efficacy of the 
primary alternate forms of debridement used in the respective study. This could have introduced 
bias in that “as needed periodic” use of an alternative form of debridement conducted in both 
treatment arms could still have confounded the effect of the primary debridement methods of 
interest or debridement against control. 
Studies with short-term follow-up periods were compared alongside studies that included longer 
follow up periods e.g. 10 days to 24 weeks. Length of study was not used as inclusion/exclusion 
criteria to prevent missing pertinent studies as a result of relying on narrower and more 
restrictive search criteria. 
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An additional study on Ultrasound debridement is currently underway and based on its 
description would meet eligibility criteria for inclusion in future updates of this review. 
Three studies are presently designated as “studies awaiting classification”. Three studies in a 
previous review that were awaiting classification were assessed for inclusion during the course 
of this review and have been designated to the excluded studies section. 
The designation “studies awaiting classification” indicates that a study is unclassifiable until 
further information is made available that can clarify whether or not it meets the 
inclusion/exclusion criteria. It cannot be classified as included, or excluded until there is 
sufficient additional information. 
Agreements and disagreements with other studies or 
reviews   
The objectives in this review included the search and retrieval of all other systematic reviews 
focusing on the same research question utilizing similar eligibility criteria. These other 
systematic reviews could then be compared and contrasted with this review. The search retrieved 
10 related systematic reviews that were compared with our findings, see Table 31 below. The 
first row represents collective ranges and summary data of the 10 systematic reviews that were 
retrieved. The first row is a condensed summary form of Table 6, see Table 6 for further details 
on each of the other 10 respective systematic reviews. The systematic reviews that included 
nonrandomized studies in addition to RCT’s made comparable conclusions to reviews restricted 
to randomized studies. 
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This summary table of the 10 systematic reviews retrieved that shared similar eligibility criteria 
(i.e. Type 1 or 2 Diabetic participants with foot ulcers, randomized studies, and any debridement 
method) are contrasted with the findings in this systematic review below:
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Table 31 Comparison of systematic reviews preceding this current systematic review 
#  [Review] [# Studies 
included] 
[Study 
Type(s)] 
[Total 
sample 
size] 
Follow 
up period 
Study 
period 
Type of 
wound 
[Participant 
Type] 
[Intervention 
Type] 
Outcomes SR/MA 
methodology 
Evidence 
Grading 
 
[Conclusions]  
10 SR’s 4 – 10 
 
4 – 8 
RCT’s 
2 – 4 
Pooled 
 
149 - 575 10 days 
to 24 
weeks 
1989 - 
2007 
DFU 
Ischemic 
Venous 
Diabetic 
Nondiabetic 
1.Alginates 
2.Foam 
3.Film 
4.Hydrogel 
5.Hydrocolloid 
6.Hydrotherapy 
7.Larva 
8.Sharp 
9.LFU 
 
 
1.Amputation 
2.Infection 
3.HRQoL 
4.Ulcer 
healing 
5.Time to 
complete 
healing 
6.Recurrence 
7.Adverse 
events 
 
5 
CR/GRADE 
 
AND 
 
5 Other SR 
No Meta-
Regression 
“No evidence 
Insufficient 
evidence 
 
Low evidence   
 
Moderate Evidence 
for Hydrogel 
uncertain 
 
Moderate for 
Hydrocolloid but 
not strong 
evidence” 
 
1 SR 30 30 RCT’s 
(10 pooled) 
2539 10 days 
to 24 
weeks 
1992 - 
2012 
DFU Diabetic Alginates 
Foam 
Film 
Hydrogel 
Hydrocolloid 
Hydrotherapy 
Larva 
Silver dressing 
Sharp 
LFU 
19 comparisons 
1.Amputations 
2.Infection 
3.HRQoL 
4.Ulcer 
healing 
5.Time to 
complete 
healing 
6. Recurrence 
7.Cost 
SR/MA 
 
AND 
 
Meta-
regression 
 
AND 
 
GRADE 
approach 
Very low to low 
evidence. 
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The 10 systematic reviews retrieved in the search phase of this systematic review included Type 
1 and Type two diabetics with one review restricted to Type 2 diabetics (Mason 1999). The 
studies all included participants with diabetic foot ulcers with 2/10 systematic reviews including 
venous and ischemic wound types (Game 2012, Voight 2011). These reviews reported their 
results under the different wound types separately. The reviews included a range of 4 - 10 
studies. The studies all included randomized studies with 3/10 systematic including 
nonrandomized studies (Mason 1999; Game 2012; Hinchliffe 2008). If the systematic reviews 
included nonrandomized studies the comparison with this systematic review was restricted to the 
summary findings of the included randomized studies. The number of participants ranged from 
149 - 575 participants. The follow up period in the retrieved systematic reviews ranged from 10 
days to 24 weeks. The study period for the studies included in the systematic reviews ranged 
from 1989 – 2007. The number of comparisons ranged from 1 - 9 methods of debridement 
including: Alginates, Foam, Film, Hydrogel, Hydrocolloid, Hydrotherapy, Larva, Sharp, and 
Low frequency ultrasound.  
The outcomes reported in the retrieved systematic reviews included amputations, infections, 
quality of life, ulcer healing, time to complete healing, recurrence. Frequently amputation, and 
infection were reported as an adverse effect. It was unclear whether this was attributed to the 
debridement intervention in these reviews or in the studies themselves as amputation and 
infection are an inherent risk in the non-healing wound irrespective of method of debridement 
used. This systematic review did not attribute these outcomes to either the intervention or to the 
wound as this would be difficult to discern. This systematic review treated infection and 
amputation not necessarily as adverse outcomes to the intervention as outcomes inherent in 
chronic wounds that could also be averted through debridement interventions. 
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Five out of the 10 systematic reviews utilized a standardized approach to summarizing their 
findings. These were all Cochrane reviews and the method used was the Grade approach (Grade 
Working Group 2010). The 10 systematic reviews pooled a range of 2 – 6 of their included 
studies in their respective analyses. The systematic reviews findings were collectively consistent 
in concluding no, low, to weak evidence that one form of debridement was superior to another 
alternate form of debridement or superior to the control or standard condition. One systematic 
review reported moderate evidence of efficacy for hydrogel as compared with basic wound 
contact dressing, although this was uncertain due to risk of bias considerations (Dumville 2013). 
None of the 10 systematic reviews utilized Meta-regression or conducted any type of moderator 
analysis. 
In contrast this review retrieved a total of 30 studies. 10 of these studies were pooled. This 
review included a total of 2539 participants, a follow up period of 10 days to 24 weeks, and a 
study period from 1992 – 2012. The studies included were exclusively RCT’s. The wound type 
focus was exclusively diabetic foot ulcers in type 1 and type 2 diabetics. The methods of 
debridement included: Alginates, Foam, Film, Hydrogel, Hydrocolloid, Hydrotherapy, Larva, 
Silver dressing, Sharp, low frequency ultrasound. There were a total of 19 debridement 
comparison types reported. The outcomes of interest in this review included: amputations, 
infections, quality of life, ulcer healing, time to complete healing, recurrence, and cost. This 
review included a qualitative systematic review, meta-analyses, and meta regression. 
Summarizing of this reviews findings were based on the Grade approach (Grade Working Group 
2010). 
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Many of the conclusions reached in our review regarding the direction of future trials were 
similar to these preceding reviews with respect to the need for larger sample sizes, and 
standardized reporting.  
The findings in this review are consistent with other similar systematic reviews that found low 
evidence that any dressing type was more effective than others in healing diabetic foot ulcers. 
There was low evidence for Hydrogel, and for Any debridement as compared with gauze but this 
was unclear due to risk of bias. The geographic scope of the 30 studies in this review includes: 
70% Europe/North America, 27% from Asia, with 1 study 3% not reporting international setting 
see pie chart below. 
 
 
70
27
3
International Study Settings (%)
Europe/US Asia Unclear
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Chapter 8 Conclusion   
Implications for practice   
Based on a comprehensive systematic review of all the currently available evidence, any 
debridement method (i.e. any and all forms of the debridement types described) used as an 
intervention in the treatment of diabetic foot ulcers do not appear to increase the healing rates of 
diabetic foot ulcers compared with any other form of debridement or standard practice. Most of 
the included studies evaluated debridement interventions on participants who appeared to have a 
wide variation in foot ulcers including size and duration. However, disease severity and co-
morbidities may not have been balanced between both intervention groups. This may have been 
more apparent in smaller studies despite the use of randomization to balance for confounding. 
Grade assessments were made on the 4 Meta-analyses comparisons and the utilized in this data 
synthesis. These included the Hydrogel compared with gauze/good wound care Summary of 
findings Table 32, Foam dressing compared with wet to dry saline dressings Summary of 
findings Table 33 Hydrofiber compared with gauze dressing Summary of findings Table 34, and 
Any debridement compared with gauze dressing Summary of findings Table 35. 
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The grading of the evidence is either High quality: Further research is very unlikely to change 
our confidence in the estimate of effect, Moderate quality: Further research is likely to have an 
important impact on our confidence in the estimate of effect and may change the estimate, Low 
quality: Further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate, and Very low quality: We are very 
uncertain about the estimate. The use of the GRADE approach (Grade Working Group 2010) to 
evaluate the evidence includes the following considerations: the quality of evidence includes all 
of the following: 
1) Risk of bias/study limitations, 2) Directness, 3) Consistency of results, 4) Precision, 5) 
Publication bias, 6) Magnitude of the effect, 7) Dose-response gradient, and 8) 
Influence of residual plausible confounding. 
 The quality of the evidence is low to very low for these comparisons using the Grade approach. 
There was one outcome that was given a moderate evidence rating regarding the quality of life 
indicator for any debridement compared with gauze. This comparison included two arms of the 
same study (Jeffcoate 2009). The control condition was divided in half to avoid double counting 
the participants. The reduction in quality of life index was modestly lower in the intervention 
group for Any debridement compared with gauze Summary of findings Table 35. 
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The evidence was found to be weak based on several considerations that are utilized in the 
GRADE approach (Grade Working Group 2010): 
1) Downgraded as substantial risk of bias characteristics were either unclear or high. 
2) Downgraded due to the 95% confidence interval (or alternative estimate of precision) 
around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable 
benefit or appreciable harm. (GRADE suggests that the threshold for "appreciable 
benefit" or "appreciable harm" that should be considered for downgrading is a relative 
risk reduction (RRR) or relative risk increase (RRI) greater than 25%.) 
3) Downgraded due to total (cumulative) sample size being lower than the calculated 
optimal information size (OIS) and/or total population size is less than 400 (a threshold 
rule-of-thumb value; using the usual α and β, and an effect size of less than 0.2 SD, 
representing a small effect).  
4) 95% confidence interval includes no effect and the upper or lower confidence limit 
crosses the minimal important difference (MID), either for benefit of harm.  
5) Downgraded due to widely differing estimates of the treatment effect (i.e. heterogeneity 
or variability in results) across studies suggest true differences in underlying treatment 
effect. 
These findings collectively do not support the endorsement of any single form of debridement 
over any other form of debridement. Nor do the findings support the use of ANY form of 
debridement over the frequently used control comparison gauze. This systematic review may be 
considered a non-inferiority study. 
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The confidence intervals for the point estimates have been large, frequently including thresholds 
that would include equivalence and the threshold of inferiority making this a reasonable 
conclusion. 
Practitioners may therefore elect to consider other characteristics such as individualization of 
therapy, tolerability, indications/contraindications, cost, when choosing between the alternative 
methods of debridement. Alterations in practice habits with respect to the wide choices of 
debridement types available to clinicians may be based on clinical experience, biological 
plausibility, mechanistic and animal data, individual patient characteristics, tolerability. Relying 
on information from individual nonrandomized human studies which are available may have 
more biased effect estimates as a function of their design. These challenges should be 
appreciated along with the consideration that uncertainty exists around this treatment decision 
due to the quality of data used to inform clinical decision making. 
Implications for research   
Currently inadequate evidence exists to conclude that there is any difference, advantage or 
benefit between the various competing forms of debridement or against standard care. 
It is of critical importance that future studies include better standardized reporting of outcomes 
including quality of life and cost-effectiveness analyses. There needs to be less variability and 
more uniform reporting of specific outcomes that clearly have direct implications on clinical 
decision making and critical public health implications including amputation frequency, 
infection frequency, and quality of life. 
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Future research clearly needs to be optimized to be of greater value to all stakeholders including 
patients, physicians, allied health providers, public health professionals, and policy makers. 
There exist numerous choices of debridement available and the design of future studies should be 
guided by findings reached in this systematic review to help meet the needs of all stakeholders. 
The comprehensive set of outcomes utilized in this systematic review include important direct 
and indirect clinical and public health indicators e.g. diabetics account for most of the 
amputations and this can be directly extrapolated to mortality risk. 
It is important to view the ulcer or wound as a determinant or risk factor for these adverse 
outcomes, rather than viewing the ulcer or wound strictly as a disease state. Future research 
studies should qualify what constitutes standard care, and address patient lifestyle issues. The 
standard of care in diabetic foot ulcers includes offloading, nutritional services, infection 
eradication, smoking status and cessation, and addressing arterial insufficiency. The status of 
these other interventions should be universally reported in future studies. 
Studies should be conducted in accordance with standardized uniform good practice guidelines 
in the design, conduct, and reporting of randomized controlled trials. This would afford 
researchers the opportunity to design and conduct better quality systematic reviews of the 
evidence. The synthesis could potentially be more comprehensive and include both qualitative 
and quantitative components in the systematic review for all comparisons. This will undoubtedly 
aid in the decision making about the competing forms of debridement. 
 
189 
 
The costs associated with complicating amputations, infections, premature mortality, quality of 
life and mortality transcends monetary costs. These complications are rising and 
disproportionately burden the individual, healthcare resources, society, the family unit, the 
workplace, the employer, along with government and private services for the disabled. The 
obesity epidemic, diabetes incidence rates, and non-healing wounds qualify as an imminent and 
growing pandemic with serious public health and clinical implications. Methods of prevention 
and intervention including debridement require further investigation to determine efficacy.   
Systematic reviews that are undertaken area useful tool in Evidence based Medicine. They 
require summarizing and pooling studies of high quality in order to make broader inference and 
can identify knowledge gaps. This will not only summarize and make broader inference on the 
state of current evidence but help direct future research efforts as this systematic review has 
highlighted. 
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Differences between protocol and review   
This systematic review was a significant expansion and revision on the subject of Debridement 
of Diabetic Foot Ulcers. The creation of a new protocol was necessary in order to make the 
expansion and revision transparent and reduce the risk of bias in this review. The review 
expanded the outcomes from 4 to 7 including amputation risk, infection frequency risk, and cost. 
These were added in addition to the 4 other variables.  One of the 3 searches conducted included 
a comprehensive search without any date restrictions. The other two searches relied on finite 
search dates from the dates of the last review on this research question.
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Characteristics of included studies/Risk of 
bias summaries  
Characteristics of included studies 
 
1. Ali 2013  Methods Randomized Clinical Trial 
Texas classification used. 
 
 Participants A) 35 (25M10F, age <50 yrs. = 10, 
age > 50 yrs. = 25, 7 smoking, 10 
Hgba1c </= 7) 
B) 35 (23M/12F, age < 50yrs = 12, 
age > 50 yrs. = 23, 8 smoking, 9 
Hgba1c </= 7) 
No statistical difference in 
demographics between both groups 
nor in initial glycemic or 
cholesterol control. 
 Interventions A) Cutimed Sorbact 
B) Standard Dressing (Saline 
cleansed povidone soaked gauze 
dressing) 
 Outcomes No outcomes were reported that 
were targeted in this review. 
 Notes Outcomes reported in this study 
include comparison of foot 
inspection pre and post intervention 
(i.e. edema, pulse, temperature, skin 
color). Other outcomes included 
comparison of wound granulation 
and grade pre and post intervention, 
and wound changes and pain pre 
and post intervention (i.e. wound 
size, wound depth, and exudates). 
Reported that edema, impaired 
pulse, cold extremities, and 
abnormal skin color demonstrated 
better improvements in the study 
group. 
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Improvements in granulation tissue 
and wound grade were reported in 
the study group. 
Reported that the study group 
patients had higher wound grades 
than control at study onset. 
These findings were found to be 
statistically significant differences. 
Wound size but not depth improved 
in the study group and was found to 
be statistically significant. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Study Reports randomization of 
subjects but does not specifically 
identify the method of sequence 
generation. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding (performance bias and 
detection bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not Reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Low risk The study reports blind assessment 
of the outcomes was done by 
trained nurses not involved in the 
study. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported 
Selective outcome reporting 
(reporting bias) 
Low risk Unclear if a protocol was prepared 
for this study. The outcomes 
discussed in the methods section 
were reported in the results. The 
point estimates reported in this 
study included dichotomous 
nominal cutoff values in lieu of 
mean point estimates it is unclear if 
the cutoffs assigned were arbitrary. 
Other Bias Unclear risk The study text reports that 60 
patients were enrolled in the study 
however the tables suggest that 70 
were enrolled in the study. 
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2. Amini 2013   
 
Methods Randomized Clinical Trial 
6 months’ duration or until 
complete wound healing 
Weekly wound evaluations 
(photo documentation) 
Plain x-rays and bone scan to 
exclude osteomyelitis  
 Participants 40 patients from a diabetic foot 
ulcer clinic 
Hgba1c = 8.9 +/- 2.3 
#patients, gender, mean age +/-SD, 
diabetes duration, smoker, BMI, 
PVD 
A) 20, 14M/6F, 55.3 +/- 9.5 yrs., 
14.4 +/- 8.2 yrs., 0.05, 27.9, 0.60 
B) 20, 10M/10F, 55 +/- 9.6 yrs., 
15.2 +/- 6.2 yrs., 0.10, 28.7, 0.40 
Reported that the only statistically 
significant difference was more 
heart disease in the ultrasound 
group. 
 Interventions A) Low frequency (20-60kHz) 
ultrasound assisted wound therapy 
+ standard wound care 
B) Standard wound care alone ( 
All wounds reported to be initially 
surgically debrided and thereafter 
as needed. 
Daily dressing changes 
All patients received offloading and 
antibiotics. 
 Outcomes 1) Proportion Healed 
A) 0.60 
B) 0.55 
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Not statistically significant 
difference 
2) Complete healing Time 
A) 61.6 +/- 84 days 
B) 81.2 +/- 78.4 days 
 Notes Other outcomes reported included: 
Mean wound size reduction at 6 
months 
A) 0.879 +/- 0.338 
B) 0.824 +/- 0.33 
No statistically significant 
difference 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk RCT reported. Specific method of 
sequence generation reported as 
simple randomization. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding (performance bias and 
detection bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not Reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported 
Selective outcome reporting 
(reporting bias) 
Low risk Preselected outcomes in the 
methods section were reported in 
the results section. No pre-specified 
protocol was reported. 
Other Bias Unclear risk Sharp debridement reportedly 
performed initially and as needed. 
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3. Apelqvist 1990   Methods -Open randomized controlled 
study 
5-week study 
Blinded evaluation 
Weekly evaluation included 
color photos and evaluation 
by combined foot care team 
(diabetologist, orthopedist, 
orthotist, podiatrist, and a 
nurse) 
Study reports foot wear 
corrected when necessary. 
Intervention stopped for 
surgical debridement, 
hospitalization, 
noncompliance, increase in 
size or necrosis of the ulcer 
by 50%, and reaction to 
dressing. 
 Participants 44 outpatients 26M/18F, mean age 
63 yrs. (23-86), Hgba1c = 8.2 mean 
duration of diabetes = 20 yrs. (2 - 
54), 
A) 22, 8.4 +/- 1.4, 22 +/- 15, 
B) 22, 8.0 +/- 2.1, 19 +/- 12, 
 Interventions A) Hydrocolloid 
B) Adhesive Zinc Oxide tape 
Ulcers cleaned with sterile saline. 
Dressing changes daily for 1st week 
then every 3 days afterwards where 
wound and surrounding area 
inspected and assessed. 
 Outcomes 1) Proportion healed 
A) 5/22 = 0.227 
B) 9/22 = 0.409 
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2) Proportion of Infections 
A) 1/22 = 0.045 
B) 0/22 = 0 
Not statistically significant 
difference 
2) Complete healing Time 
A) 61.6 +/- 84 days 
B) 81.2 +/- 78.4 days 
 Notes Changes in necrotic ulcer 
area were also reported. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Randomized study reported. 
Method of sequence generation not 
specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding (performance bias and 
detection bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not Reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Low risk Blinded evaluation was reported. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported 
Selective outcome reporting 
(reporting bias) 
Low risk Prespecified protocol not reported. 
Prespecified outcomes in the 
methods section reported in the 
results. 
Other Bias Unclear risk Study financially supported by 
industry. 
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4. Baker 1993   Methods RCT - Pilot Study 
Duration - 12 weeks 
Limited - Abstract available 
only 
 Participants 19 with neuropathic foot ulcers, 
number of participants in each 
intervention group not reported. 
Age, sex, grade or duration of 
wounds, severity of peripheral 
arterial disease, presence of 
infection and diabetes disease 
severity not reported. 
 Interventions A) Allevyn Hydrocellular dressing 
B) Sorbsan Calcium-Alginate 
dressings 
 Outcomes 1) Proportion of ulcers healed 
90% vs 44% at 12 weeks 
2) Median time to healing 28 
days vs. 84 days 
 Notes Allevyn Hydrocellular 
reported as significantly more 
absorbent (p= 0.001) and less 
adherent or easier to remove 
(p=0.011) than the alginate 
dressing. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Randomization was reported. 
Specific method of sequence 
generation was unspecified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding (performance bias and 
detection bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not Reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported 
Selective outcome reporting 
(reporting bias) 
Unclear risk No protocol reported or clearly pre-
specified outcomes in methodology. 
Only abstract available. 
Other Bias High risk Other significant covariates and 
differences between intervention 
groups not reported. 
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5. Belcaro 2010 Methods Open-label registry 
randomized pilot study. 4 
weeks 
Categorized: venous ulcers 
and diabetic ulcers 
 Participants 148 patients 
A) 34 patients, 16M/18F, Mean 
Age 56.5 +/- 4.4 years 
B) 32 patients, 13M/19F Mean Age 
55.3 +/- 3.2 years 
 Interventions A) Multivalent silver oxide Ag4O4 
ointment + elastic compression 
B) Control group (standard cleaning 
and elastic compression 
management methods without 
silver ointment) 
 Outcomes Complete closure of the 
ulceration 
A) 39% 
b) 16% 
(p </=0.05). 
 Notes Notes The study also 
reported the following 
outcomes of noninvasive 
vascular investigations to 
exclude major vascular 
problems that could result in 
decreased perfusion. These 
include Skin PO2 and Skin 
flux. 
perimalleolar Skin (P02) 
(Oxygenation in the skin of 
the affected limb) 
Baseline at 4 weeks 
A) 43 mmHg 53 mmHg 
(increase of 23.3%) 
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B) 44 mmHg 48mmHg 
(increase of 9.1 %) 
(p </= 0.05) 
Laser Doppler flowmetry 
perimalleolar Skin flux (RF) 
Baseline at 4 weeks 
A) 3.22 flux units 2.36 flux 
units (decrease of -26.7%) 
B) 3.21 flux units 3.01 flux 
units (decrease of -6.2%) 
(p </= 0.05) 
Total surface area reduction 
of the ulcer 
A) -89.0% 
B) -23.9% 
(p </= 0.05) 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk The study reports that the patients 
were randomly assigned however 
method of sequence generation was 
not specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding (performance bias and 
detection bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not Reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported. 
Incomplete outcome data (attrition 
bias) 
Low risk The study reported no dropouts. 
Selective outcome reporting 
(reporting bias) 
High risk No protocol was available for this 
study and the outcomes were not all 
clearly pre-specified in the methods 
section of the study. 
Other Bias Unclear risk The study does not compare the 
intervention groups on other risk 
factors that could influence 
outcomes. No further detail was 
232 
 
provided on how balanced both 
intervention groups were. 
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6. Blackman 1994 Methods RCT 
Surface area tracings of 
wound margins. 
Foot ulcer measurements 
every 3 weeks for a follow up 
period of 24 weeks. 
Cross-over design after two 
months to group A 
Subjects encouraged to obtain 
orthotic footwear 
Subjects followed until ulcer 
healed, or until 6 months had 
elapsed. 
 Participants 18 subjects Type 1 and 2 DM 
#, gender, mean age, Hgba1c, 
A) 11, 11M/0F, 59 +/- 5yrs, 8.4 +/- 
0.9 
B) 7, 6M/1F, 51 +/- 4yrs, 9.5 +/- 
1.1 
No statistical significant difference 
 Interventions A) Polymeric dressing 
B) Wet to dry saline dressing 
Dressing changes at minimum once 
daily or when saturated. 
4 wounds surgically debrided in 
group A and 3 in group B prior to 
start. 
 Outcomes 1) Proportion healed 
A) 0.73 OR 0.27 
B) 0  
(p </=0.05). 
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 Notes Other outcomes reported 
included: 
Ulcer size reduction 
A) 35 +/- 16% 
B) 105 +/- 28% -> 35 +/- 
11% (post-crossover, p < 
0.02, 5 subjects were crossed 
over from conventional 
treatment to polymeric 
membrane after two months 
of treatment) 
Statistically significant 
difference (p < 0.03) 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Reported that subjects were 
randomly assigned. Method of 
sequence generation not specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding (performance bias and 
detection bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not Reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported. 
Incomplete outcome data (attrition 
bias) 
High risk 2 patients from each group 
progressed to Wagner grade 3 and 
were not included in the study. 
Selective outcome reporting 
(reporting bias) 
Low risk Prespecified protocol not reported. 
Prespecified outcomes in the 
methods section were reported in 
the results. 
Other Bias High risk 2 patients in underwent 
debridement in their referring 
physician’s office during the study. 
No patient obtained new orthotic 
footwear. The study was industry 
supported. 
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7. Bowling 2011 Methods Prospective randomized, 
controlled, double blind, pilot 
study. 
Weekly treatments for 4 
weeks. 
Semi-quantitative wound 
tissue cultures post-
debridement at baseline and 
week 4. 
Maximum wound size Length 
X Width 
 Participants 20 patients 
#, Gender M/F, Type 1/2, Duration 
of diabetes, Hgba1c % 
A) 10, 6/4, 3/7, 21.2 +/- 9.0 yrs., 
9.3 +/- 1.7, 
B) 10, 6/4, 2/8, 17.5 +/- 7.2 yrs., 8.1 
+/- 1.9, 
 Interventions A) Jet lavage debridement with 
superoxide aqueous solution + 
hydrogel 
B) Jet lavage debridement with 
saline solution + hydrogel 
All dressing changes every 3-4 
days, specified treating physician 
Superoxide solution or saline 
applied at every dressing change. 
 Outcomes The study qualitatively 
reports no adverse effects 
were recorded. The study did 
not report that 15% of the 
study ulcers were healed. The 
study reported no statistically 
significant results between 
the two treatments (p>0.05). 
No further information was 
specified on the outcomes of 
interest for this review. 
 Notes Wound bio-burden (bacterial 
load) was reported on an 
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ordinal scale as scatted (0/+), 
light (+), medium (++), heavy 
(+++) 
Reduction in bacterial load at 
week 4 
A) 1.6 +/- 1.3 -> 1.1 +/- 1.2 
B) 1.7 +/- 1.4 -> 1.2 +/- 1.2 
No statistically significant 
difference (p = 0.9) 
The study reports trend 
toward a 75% reduction in 
necrotic tissue in the study 
group (p>0.05) 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Randomized controlled pilot study. 
Method of sequence generation 
reported as computer-generated 
block randomization scheme. 
Allocation concealment (selection 
bias) 
Low risk Reported that medical centers were 
provided with sealed randomization 
envelopes for conducting the 
treatment assignment. 
Blinding participants Unclear risk The authors report that this was a 
double blind study, however it is 
not specified which combination of 
participants, personnel delivering 
the intervention, or outcome 
assessors was blinded. 
Blinding personnel delivering 
intervention 
Unclear risk The authors report that this was a 
double blind study, however it is 
not specified which combination of 
participants, personnel delivering 
the intervention, or outcome 
assessors was blinded. 
Blinding outcome assessors Unclear risk Not reported. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported 
Selective outcome reporting 
(reporting bias) 
High risk No pre-specified protocol was 
reported. The outcomes pre-
specified in the methods section 
were reported in the outcomes. 
However full numeration for both 
groups was not reported in the 
results. 
Other Bias Unclear risk Offloading status was not reported. 
Notes   
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8. Clever 1995 Methods Open, randomized, controlled 
study 
comparing two polyurethane 
dressings 
40 patients 
Objective clinical evaluation: 
ulcer tracings, photographs 
and date of healing. 
At end of treatment, both the 
investigator and patient 
evaluated the wound care 
product subjectively. 
 Participants A) 20 patients, 15M/5F, age 58.85 
+/- 11.64 years 
B) 20 patients, 17M/3F, age 53.15 
+/- 14.62 years No statistically 
significant difference was reported 
in gender or age. 
Sample age range 18 - 80 
Pure neuropathic superficial 
diabetic ulcer of 1-5 cm in 
diameter. 
No clinical or radiological signs of 
osteomyelitis or tendon 
involvement. 
Study reports no statistically 
significant differences between 
intervention groups in terms of 
ankle-brachial pressure index, 
threshold of vibration, average 
duration of ulcer before entering 
study, and number of recent 
recurrences. 
Number of Smokers (9 vs 4, p < 
0.01) was statistically significant. 
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 Interventions A) Hydroactive polyurethane gel 
dressing Cutinova Hydro + 
standard therapy* 
B) Hydrophilic polyurethane foam 
dressing Allevyn + standard 
therapy* 
"Dressing changes reportedly 
performed as often as required, but 
at least once a week." 
*Standard therapy included: 
(i) pressure relief comprising a half-
shoe or so-called "heel sandal" 
therapeutic footwear with 
cushioned insoles and crutches as 
required to meet individual needs. 
(ii) infection control with systemic 
antibiotics if required, 
(iii) wound cleansing with Ringer's 
solution, and 
(iv) debridement with removal of 
callus if needed 
 Outcomes Time to Healing 
A) 25.19 ± 23.52 days 
B) 20.43 ± 14.74 days (p > 
0.2) 
Proportion healed 
A) 14/20 = 0.70 
B) 16/20 = 0.80 
Excluding dropouts, 88% of 
the patients were healed in an 
average of 23 days, 50% 
within 16 days. 
 Notes Dressing changes by patient’s 
in-between the weekly 
assessments: 
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A) 2.23 ± 2.19 times 
B) 2.37 ± 2.18 times, No 
statistically significant 
difference (p > 0.2) 
The study reported 
"subjective product 
evaluation" including ease of 
showering with dressing (p > 
0.1), absorption capacity (p > 
0.1), handling and suitability 
(lack of side-effects or skin 
problems) (p > 0.2), and all 
were found to not be 
statistically significant. No 
details on the subjective 
evaluation was specified. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Randomization reported but method 
of sequence generation not 
specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported. 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported. 
Incomplete outcome data (attrition 
bias) 
High risk 2 patients in group A and 4 patients 
in group B were reported to not 
have completed the study. It is 
unclear how the missing data were 
addressed. 
Selective outcome reporting 
(reporting bias) 
High risk The study broadly reported 
outcomes in the methods section 
but did not specify all outcomes 
that were reported in the results. No 
protocol specified. 
Other Bias High risk Unclear if both groups were 
adequately balanced for 
confounders or other risk factors 
including disease severity. 
Prospective wound healing study 
was possible due to financial 
support from manufacturer. 
Notes   
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9. D'Hemecourt 1998 Methods RCT Multi-centered (10 
sites); Evaluator-blind 
Study period was not 
reported. Follow up period 
was 140 days. 
 Participants 172 patients 
A) 68 
B) 70 
C) 34 
45 women/127 men; 19 years or 
older; Type 1 / Type 2 diabetes. At 
least one full thickness Stage 3 or 
Stage 4 chronic diabetic ulcer of the 
lower extremity. 
Wound size (area and depth) 
measured at baseline. 
 Interventions A) Good wound care* 
B) Good wound care & NaCMC 
hydrogel 
C) Good wound care & 
Becaplermin 
Off-loading of pressure and 
systemic control of infection for all 
wounds. 
*'Good wound care' was defined by 
the study authors as follows: "this 
regimen consisted of daily dressing 
changes, sharp debridement of the 
ulcer when deemed necessary by 
the investigator, systemic control of 
infection if present, and off-loading 
of pressure". 
 Outcomes 1. Proportion with complete 
wound healing at 20 weeks 
A) 15 / 68 (22%) 
B) 25 / 70 (36%) 
2. Time to complete healing 
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A) 141 days * 
B) 98 days * 
3. Proportion with Infection 
A) 0.28 
B) 0.30 
 Notes Largest trial with regard to 
patient numbers 
* It is unclear if these are 
mean or median times to 
healing. 
Two other indicators reported 
in the study included: 
Pain reported as adverse 
event 
A) 10 / 68 (15%) 
B) 11 / 70 (16%) 
Wound related adverse events 
A) 25 / 68 (37%) 
B) 19 / 70 (27%) 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk The method of sequence generation 
procedure was not specified: 
"patients were randomly assigned 
in a 2:2:1 ratio to one of three 
treatment groups". 
Allocation concealment (selection 
bias) 
Unclear risk Not reported. 
Blinding participants Unclear risk Statement by authors from 
published study: "both the NaCMC 
gel and Becaplermin gel treatment 
groups were conducted in double-
blind fashion; the group receiving 
good wound care alone was blinded 
to the investigator by a third party". 
Blinding personnel delivering 
intervention 
Unclear risk Blinding of personnel delivering the 
intervention: yes - control group; 
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unclear - intervention groups (see 
statement from authors above). 
Blinding outcome assessors Low risk Blinding of outcomes assessor: yes. 
Study described as "evaluator-
blind". 
Incomplete outcome data (attrition 
bias) 
Low risk Intention-to-treat analysis was 
conducted. However, the specific 
Intention to treat analytic method 
was not reported. 
Selective outcome reporting 
(reporting bias) 
Low risk Four parameters pre-specified as 
outcomes, all of which were 
reported 
Other Bias High risk Baseline differences in group size 
and ulcer characteristics (mean 
area, depth, and duration): 
Good wound care (n=68): n=65 at 
stage III; 3.5 cm2; 67cm; 24 weeks. 
NaCMC gel (n=70): n=70 at stage 
III; 3.2 cm2; 69 cm; 24 weeks. 
Becaplermin gel (n=34): n=32 at 
stage III; 2.4 cm2; 33cm; 11 weeks. 
The group receiving Becaplermin 
gel were not comparable with the 
two other groups. 
'Good wound care' included "sharp 
debridement of the ulcer when 
deemed necessary by the 
investigator". No other data 
reported on diabetes disease 
severity or other risk factors. 
Notes   
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10. Donaghue 1998   Methods 75 patients enrolled in an 
open-label design with 
random assignment to two 
groups in 2:1 ratio. 
Wagner classification used. 
Offloading prescribed to all 
patients with self-adhesive 
felted foam and window at 
wound site, and use of 
healing sandals. 
Seen weekly until target ulcer 
healed or maximum of 8 
weeks. 
Exit interview to determine 
satisfaction level. 
 Participants # Gender Age (range) Duration of 
DM(range) Weight Creatinine 
Albumin Proportion 
M/F yrs. (yrs.) (lbs.) (mg/dl) 
(gms/dl) Retinopathy 
A) 50, 33/17, 59 (30-81), 19 (4-47), 
195 +/- 45, 1.2 +/- 0.6, 3.72 +/- 
0.07 0.56 
B) 25, 21/4, 60 (33-79), 17 (2-25), 
214 +/- 49, 1.14 +/- 0.06, 3.79 +/- 
0.11 0.76 
No statistically significant 
difference in any of these baseline 
participant characteristics was 
reported in the study. 
 Interventions A) Collagen Alginate 
B) Saline gauze 
Patients or caregivers given 
instructions to change as often as 
required. 
 Outcomes 1) Proportion healed 
A) 24/50 = 0.48 
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B) 9/25 = 0.36 
No statistically significant 
difference (p=0.3933) 
2) Mean time to complete 
healing 
A) 43.4 +/- 2.8 days 
B) 40.6 +/- 2.8 days 
The study authors reported 
that there were no differences 
in the number or severity of 
adverse effects (p=0.453) No 
other information was 
provided. 
 Notes The study also reported: 
Baseline values: 
Additional outcome included: 
Mean percent reduction of the 
wound area at the end of the 
study was reported as: 
A) 80.6 +/- 6% 
B) 61.1 +/- 26% 
No statistically significant 
difference (p=0.4692) 
The study reported wound 
size reduction rate in a 
multivariate analysis to be 
statistically significant in 
favor of Collagen alginate 
over saline gauze (p=0.049). 
No other information was 
provided. 
Subgroup analysis was 
reported for wounds of less 
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than 6 month’s duration and 
the authors report a faster 
healing rate for Collagen 
alginate over saline gauze but 
the result was not statistically 
significant. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Random assignment to treatment 
groups was reported but method of 
sequence generation was not 
specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported. 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported. 
Blinding outcome assessors Unclear risk Not reported. 
Incomplete outcome data (attrition 
bias) 
Unclear risk 75 patients enrolled, 61 completed 
study, 14 withdrawals (6 patients in 
group A and 8 in group B did not 
complete the study, 5 withdrew no 
reason reported, 3 patients missed > 
2 visits, and 6 patients experienced 
adverse events). The authors report 
that all 75 patients enrolled were 
included in the intention to treat 
analysis. The method used in the 
intention to treat analysis to address 
the 14 withdrawals was 
unspecified. 
Selective outcome reporting 
(reporting bias) 
High risk No protocol was specified in the 
report. The outcomes reported in 
the results section were not 
explicitly prespecified outcomes in 
the methods section. 
Other Bias Unclear risk The study reported adverse effects 
were not statistically significant 
between both groups. Specific 
information on adverse effects was 
not reported. 
Notes   
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11. EhsanUrRehman 2013 Methods 60 subjects randomly 
assigned to two groups. 
non-probability purposive 
sampling 
Wound measurements were 
done on day 15. 
Wagner grade I & II ulcers. 
Length, width and maximum 
perpendicular depth of ulcer 
were measured and multiplied 
post-surgical debridement 
 Participants Not reported. 
 Interventions A) Honey soaked dressing 
B) Povidone-iodine/normal saline 
dressing 
Daily dressing changes 
All wounds washed with saline 
prior to 
Surgical debridement at the time of 
presentation. 
 Outcomes 1) Proportion healed 
A) 24/50 = 0.48 
B) 9/25 = 0.36 
No statistically significant 
difference (p=0.3933) 
2) Mean time to complete 
healing 
A) 43.4 +/- 2.8 days 
B) 40.6 +/- 2.8 days 
The study authors reported 
that there were no differences 
in the number or severity of 
adverse effects (p=0.453) No 
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other information was 
provided, Proportion healed 
A) 0.867 
B) 0.733 
 Notes Other outcomes reported 
include: 
% decrease in wound size 
A) 80.81 +/- 17.27% 
B) 54.63 +/- 3.42% 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Subjects reported randomly 
assorted into two groups. Method of 
sequence generation not specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported. 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported. 
Blinding outcome assessors Unclear risk Not reported. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported 
Selective outcome reporting 
(reporting bias) 
High risk The study reports swab and culture 
would be carried out in the methods 
section but infection not reported in 
the results. Other outcomes 
reported in the results section were 
not pre-specified in the methods 
section. 
Other Bias High risk Prespecified outcomes not reported 
in methods section. Comorbidities 
used as exclusion criteria reported 
in methods section but not 
specified. No patient baseline 
characteristics reported unclear 
whether both groups balanced for 
confounding. Non-probability 
purposive sampling which could 
produce sampling bias. 
Notes   
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12. Foster 1994 Methods RCT, Stratified according to 
neuropathic or ischemic 
diabetic foot ulcers 
Study length 8 weeks or until 
the ulcer. 
Weekly clinic assessments of 
wounds and dressings, and 
where ulcers were debrided. 
 Participants 30 Patients 
A) 15 patients, 12M/3F, mean age 
61, DMT1 = 6 
B) 15 patients 8M/7F, mean age 70, 
DMT1 = 4 
 Interventions A) Hydrocellular polyurethane 
foam dressing Allevyn 
B) Calcium sodium alginate 
dressing changes 
All wounds washed with saline 
prior to 
Surgical debridement at the time of 
presentation. 
 Outcomes Proportion Healed 
A) 9/15 = 0.60 
B) 8/15 = 0.533 
No statistically significant 
difference in time to healing 
between both intervention 
groups. 
 Notes Study reported that some 
evidence ulcer more likely to 
heal if IDDM as opposed to 
NIDDM (p=0.07). 
Also smaller ulcers or ulcers 
of neuropathic origin more 
likely to heal. 
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A statistically significant 
difference was reported 
favoring Polyurethane foam 
dressings over Calcium 
alginate dressings in 1) time 
taken for application (2.1 +/- 
0.6 minutes vs 3.2 +/- 1.0 
minutes), and in subjective 
ordinal scales including ease 
of application (p<0.001), 
absorbency (p<0.01), patient 
comfort (p<0.01), non-
adherence (p<0.01), and ease 
of removal (0.001). % 
decrease in wound size 
A) 80.81 +/- 17.27% 
B) 54.63 +/- 3.42% 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Study reports randomization but 
method of sequence generation is 
unspecified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported. 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported. 
Blinding outcome assessors Unclear risk Not reported. 
Incomplete outcome data (attrition 
bias) 
High risk 4 patients from the alginate group 
withdrew due to: 
severe pain (1); plugged lesion 
prevented free drainage of exudate 
(3) with one becoming infected. 
Unclear how incomplete outcome 
data were addressed. 
Selective outcome reporting 
(reporting bias) 
High risk Study pre-specified a number of 
"ideal" parameters in the 
introduction including infection 
however these were not all were 
reported in the results section. No 
parameters were pre-specified in 
the methods section. 
Other Bias High risk The study reported stratification 
was conducted in order to ensure 
that a more equitable number of 
individuals with neuropathic, 
ischemic ulcers, traumatic wounds 
in each intervention group. 
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However, no mention was made on 
whether other risk factors such as 
diabetes disease severity was 
balanced in both intervention 
groups. Duration of ulcer was 
longer in the calcium alginate group 
(170 days vs 107 days). 
Notes   
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13. Goretti 2008 Methods RCT; Randomized into two 
groups. 
 Participants A) 20 
B) 20 
Wounds > 5 cm2, ABI >/= 0.9 and 
two arteries in the ankle palpable by 
pulse or Doppler. 
Age, gender, diabetes type, duration 
of diabetes, proportion of wounds 
infected, or other data not provided. 
 Interventions A) Super-oxidized solution (SOS) 
treatment 
B) Standard local treatment with 
povidone iodine 
Frequency or number of times 
intervention used was not reported. 
The study abstract mentions that the 
patients received metabolic control, 
systemic antibiotics, and offloading 
as necessary, but no further detail 
was provided. 
 Outcomes 1. Proportion Healed 
A) 0.85 
B) 0.53 
(p<0.01, statistically 
significant difference) 
2. Healing Time 
A) 10.5 +/- 1.3 weeks 
B) 16.5 +/- 1.7 weeks 
(p<0.01, statistically 
significant difference) 
The study reports weekly 
visits to record lesions 
clinical signs of infection, 
microbiological sampling, 
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eventual new debridement 
procedures, and adverse 
events. No further detail is 
available. 
 Notes Other outcomes that were 
reported include: 
Sterilization of lesions (ST) 
A) 5.5 +/- 2.1 weeks 
B) 16.2 +/- 6.6 weeks 
(p<0.01, statistically 
significant difference) 
Number of Debridement 
procedures (ND) 
A) 3/20 
B) 9/20 
(p<0.01, statistically 
significant difference) 
Adverse Events (NA) 
A) 4 
B) 9 
No other information 
provided other than a 
statement that no differences 
were observed in (NA) 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Published abstract only. 
Randomization reported but the 
method of sequence generation 
used was not specified 
Allocation concealment (selection 
bias) 
Unclear risk Published abstract only. Not 
reported. 
Blinding participants Unclear risk Published abstract only. Not 
reported. 
Blinding personnel delivering 
intervention 
Unclear risk Published abstract only. Not 
reported. 
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Blinding outcome assessors Unclear risk Published abstract only. The study 
reports weekly visits to "blindly" 
record lesions clinical signs of 
infection, microbiological 
sampling, eventual new 
debridement procedures, and 
adverse events. Unclear if other 
outcomes were blinded. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Published abstract only. Not 
reported. 
Selective outcome reporting 
(reporting bias) 
Low risk Published abstract only. Results 
were available for all outcomes 
reported in the methods section 
however unclear if protocol was 
written ahead of the study. 
Other Bias Unclear risk Published abstract only. Other 
sources of bias not discernible. 
Notes   
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14. Hammouri 2004 Methods 203 patients allocated 
randomly to two groups, 3 
excluded. 
 Participants 200 patients, 112M/88F, Mean age 
= 58 
A) 100 58M/42F, (24-100), 
B) 100 54M/46F, (22-100) 
 Interventions A) Honey/Normal Saline, washed 
with normal saline post-
debridement 
B) Povidone Iodine/H2O2 (3:1) 
washed with same solution post-
debridement 
All dressings applied 3 times daily 
then declined as treatment 
progresses in both groups. 
 Outcomes 1) Time to healing 
A) Median 21 days, (7-70 
days), SD = 15.97 
B) Median 32 days, (7-90 
days), SD = 20.89 
Statistically significant 
difference (p<0.001) 
2) Treatment Cost 
A) 282 +/- 66.33 Jordan 
Dinar, 
B) 616 +/- 192.97 Jordan 
Dinar, 
Statistically significant 
difference (p<0.001) 
3) Proportion amputations 
A) 0.10 
B) 0.20 
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Statistically significant 
difference (p<0.05) 
 Notes Other outcomes reported: 
Hospital stay 
A) Median 23 days (7-42 
days), SD = 8.26 
B) Median 13 days (7-56 
days), SD = 14.54 
Statistically significant 
difference (p<0.001) 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk The authors report random 
allocation. Method of sequence 
generation is not specified in the 
report. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported 
Incomplete outcome data (attrition 
bias) 
Unclear risk The authors report that 3 patients 
were excluded from the analysis 
that died from other medical illness. 
Selective outcome reporting 
(reporting bias) 
High risk No protocol is reported. The study 
authors report healing, hospital 
stay, and cost as the respective 
outcomes of interest in the methods 
section. These were reported in the 
results section. The study reported 
amputation proportion, bioburden 
reduction which were not explicitly 
pre-specified in the methods 
section. 
Other Bias High risk The study authors did not report 
exclusion criteria and reported only 
diabetic foot ulcers as inclusion 
criteria. Baseline characteristics of 
the ulcers in each group were not 
reported. Disease severity 
indicators including Hgba1c, 
duration of diabetes were not 
reported. Grade of diabetic foot 
ulcers not reported. Debridement 
under anesthesia is reported but 
study authors do not specify 
whether this was an initial 
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debridement only or if 
debridements were conducted 
throughout the course of the study. 
Notes   
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15. Jeffcoate 2009 Methods A multicenter, prospective, 
observer-blinded, parallel 
group, randomized controlled 
trial. 
Research nurse monitored 
every two weeks. 
Primary endpoint number of 
ulcers healing in each group 
within 24 weeks. 
Ulcers monitored by nurses 
every two weeks. Blinded 
wound assessments made at 
baseline, 12 weeks, 24 weeks, 
4 weeks after healing, and 12 
weeks after the 24-week 
assessment. 
Healing defined as complete 
epithelialization with no 
drainage for 4 weeks and 
confirmed by a blinded 
assessor. If an ulcer was 
assessed as healed at any 
point the authors stated that 
ulcer was reassessed at 2 and 
4 weeks after healing. If the 
ulcer recurred within 4 weeks 
or at any point up to 24 
weeks, the patient was re-
entered into the study using 
the allocated dressing. 
The study reported on ulcer-
related endpoints, patient-
related endpoints, and process 
related endpoints. 
A health economics 
evaluation which included the 
direct costs associated with 
dressings used and patient 
travel costs was reported. The 
quality of life assessment 
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included SF-36 questionnaire, 
a visual analogue scale for 
pain, and the CWIS (Cardiff 
wound impact schedule). 
 Participants # Gender M/F Age (yrs.) DM Type 
1/2 DM duration (yrs.) 
Total 317, 240/76, 59.6 +/- 12.6, 
240/76, 15.7 +/- 10.8 
A) 103, 81/22, 59.5 +/- 11.5, 22/81, 
16.0 +/- 11.4 
B) 108, 81/27, 58.8 +/- 13.2, 25/83, 
15.3 +/- 9.8 
C) 106, 78/27, 61.9 +/- 12.8, 78/27, 
15.8 +/- 11.4 
 Interventions A) Hydrofiber dressing Aquacel 
B) Iodine impregnated gauze 
C) Non-adherent viscous filament 
gauze 
Other care reported to include: 
regular use of debridement, 
offloading, 
The study reports dressings were 
changed daily, on alternate days, 
and 3X/week depending on the 
need by the patient or caregiver 
who received training, or by the 
nurse. If patient changed the 
dressing, then nursing oversight 
was conducted every two weeks. 
The study reported that off-loading 
was variable, and 42% of 
participants were issued the 
preferred casting device, two 
centers issued no casting devices, 
one center issued 1. 
 Outcomes 1) Proportion of ulcers healed 
A) 46/103 = 0.447 
B) 48/108 = 0.444 
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C) 41/106 = 0.387 
No statistically significant 
difference (p=0.38) 
2) Proportion of ulcers 
recurring 
A) 3/103 = 0.029 
B) 7/108 = 0.065 
C) 3/106 = 0.028 
3) Time to healing 
A) 125.8 +/- 55.9 days 
B) 127.8 +/- 54.2 days 
C) 130.7 +/- 52.4 days 
No statistically significant 
difference (p=0.80) 
4) Proportion amputated 
A) 4/103 = 0.039 
B) 1/108 = 0.009 
C) 2/106 = 0.019 
Statistical significance not 
reported. 
5) Proportion infected 
A) 54/103 = 0.524 
B) 71/108 = 0.657 
C) 48/106 = 0.453 
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Statistical significance not 
reported 
6) Treatment cost 
A) 194.03 
B) 184.17 
C) 141.1 
Statistical significance not 
reported 
7) Quality of life index 
A) 0.382 
B) 0.384 
C) 0.394 
No statistically significant 
difference (p=NS) 
 Notes Other outcomes reported: 
Hospital stay 
A) Median 23 days (7-42 
days), SD = 8.26 
B) Median 13 days (7-56 
days), SD = 14.54 
Statistically significant 
difference (p<0.001) 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Randomization was reported to be 
stratified by center, size, using 
block size of nine design. 
Randomization was also stratified 
across the whole population by 
ulcer area in three groups. The 
study reports that randomization 
lists were created using statistical 
software. 
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Allocation concealment (selection 
bias) 
Low risk The randomization lists and records 
of the allocation details were 
reported to be held at a central 
location and each recruiting center 
telephoned. 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Low risk The study reports that the clinician 
in charge of care and assessing for 
healing was blinded to the 
randomization group. 
Incomplete outcome data (attrition 
bias) 
Low risk The authors reported that 88 
participants (27.8%) out of the 317 
enrolled were withdrawn. The 
reasons for withdrawal were 
reported as: 
Adverse event = 35 
Protocol violation = 24 
Loss to follow up = 7 
Consent withdrawal = 16 
Death = 5 
Other = 1 
Intention to treat analysis was 
carried out using last observation 
carried forward. 
Selective outcome reporting 
(reporting bias) 
Low risk No protocol was available or 
referred to in the study. The 
outcomes reported in the results 
were pre-specified in the methods 
section. 
Other Bias High risk The study reported 88 withdrawals 
out of 317 participants, last 
observation carried forward was 
utilized as intention to treat. This 
may have biased the results in 
either direction. 
Notes   
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16. Jensen 1998 Methods RCT; Randomized into 2 
groups. 
Study period was not 
reported. Follow up period 
was 20 weeks. 
 Participants 31 patients 
A) 14 
B) 17 
No description of age, sex, type of 
diabetes, or disease severity was 
reported. 
Wound area measured at baseline. 
Average duration of ulceration 
A) 8.9 months 
B) 3 months 
 Interventions A) Carrasyn hydrogel wound 
dressing (CHWD) cleansed with 
ULTRAKLENZ wound cleanser. 
B) Wet-to-moist saline gauze 
cleansed with ULTRAKLENZ 
wound cleanser. 
Adjunctive wound care included all 
patients who initially received sharp 
debridement to remove all non-
viable (dead) tissue and all patients 
received custom made healing 
sandals for pressure redistribution. 
Dressings changes were conducted 
daily. Saline moist gauze 
remoistened as needed. Patients 
evaluated weekly using wound 
tracings and computer planimetry. 
 Outcomes 1. Proportion with complete 
wound healing at 16 weeks 
(Defined as 100% wound re-
epithelialization) 
A) 11/13 84.6% 
B) 6/13 46.1% P=0.05 
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2. Time to complete healing 
A) 10.3 weeks * 
B) 11.69 weeks * 
3. Proportion with amputation 
A) 0/14 = 0 
B) 1/17 = 0.059 
4. Proportion with Infection 
A) 2/14 = 0.143 
B) 1/17 = 0.059 
 
5. Cost 
A) 7.01 - ($/day) 
B) 12.28 - ($/day) 
 Notes * It is unclear if these are 
mean or median times to 
healing. 13/14 patients 
completed the study in the 
Hydrogel group whereas 
13/17 completed the study in 
the control group. 
Other outcomes that were 
reported in this study 
included: 
Complications 
A) 2/14 (14%) 
B) 4/17 (24%) 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Randomization was reported but 
method of sequence generation not 
specified. 
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Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported 
Incomplete outcome data (attrition 
bias) 
High risk 5 patients dropped out (n=1 in 
Group A; n=4 in Group B): no 
intention-to-treat analysis or other 
method of handling missing data 
were specified. 
Selective outcome reporting 
(reporting bias) 
Unclear risk No protocol available. No 
parameters clearly pre-specified as 
outcomes in the methods section. 
Other Bias High risk No Group A and Group B data 
reported on ulcer size, depth, on 
entry to trial other than ulcer with 
minimum of 1cm diameter; and 
Wagner grade II thickness. 
However, the trial report suggests 
that Group A had average ulcer 
duration of 8.9 months compared 
with 3 months for group B. 
Study supported by an educational 
grant from Carrington Laboratories, 
Inc. (the manufacturers of 
Carrasyn). 
Notes   
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17. Lalau 2002 Methods Open - label multicenter 
randomized controlled trial. 
Study reported 13 centers 
throughout France 
participated. 
Number of wound dressings 
and adverse events recorded 
weekly. Follow up visits 
scheduled at weeks 1, 2, 4, 6 
to monitor healing efficacy 
and safety. 
Planimetric evaluation used 
for surface area. 
The study reported a 6-week 
treatment period, though 
efficacy analysis was reduced 
to 4 weeks due to premature 
cessation of treatment in 13 
patients. Reported that there 
was no revision to efficacy 
criteria. 
The study reported that 
conservative management 
was carried out using 
pressure relieving methods. 
 Participants 77 patients enrolled, 13 withdrawn 
#, Gender, Age, BMI, DM type, 
Diabetes duration, Hgba1c, # 
revascularizations, TcPO2, 
A) 39, 22M/17F, 60.8 +/- 10.7 yrs., 
27.6 +/- 5.11, 15/24, 19.2 +/- 11.8 
yrs., 7.6 +/- 2.0, 13, 44.6 +/- 12.3 
B) 38, 23M/25F, 63.5 +/- 12.8 yrs., 
27.3 +/- 5.52, 16/22, 16.9 +/- 8.9 
yrs., 7.9 +/- 1.5, 4, 42.6 +/- 10.3 
No statistically significant 
difference in participants except for 
# revascularizations. 
 Interventions A) Calcium Alginate 
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B) Vaseline Gauze 
The study reported daily dressing 
changes initially until thoroughly 
debrided, then once granulation 
occurred, every 2 - 3 days 
depending on exudate amount as 
determined by nurses. The authors 
reported no other local treatments 
except unrestricted saline. 
The study reported that mechanical 
debridement was authorized as 
necessary. 
 Outcomes Proportion of infections 
A) 1/39 = 0.026 
B) 3/38 = 0.079 
 Notes Proportion of patients with 
granulation tissue > 75% of 
wound area, and a 40% 
decrease in wound surface 
area. Secondary outcomes 
included: pain on dressing 
changes, cumulative number 
of dressing changes, and 
number of adverse events. All 
were reported not to be 
statistically significant except 
for pain and cumulative 
number of dressing changes 
in favor of calcium alginate. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Randomization of participants was 
reported. The method of random 
sequence generation was not 
specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Low risk The study reported that an 
independent investigator, blind to 
the allocated treatment, was 
assigned to analyze wound surface 
areas. Analysis reportedly 
performed two times for each 
patient, and a third as warranted. 
267 
 
Incomplete outcome data (attrition 
bias) 
Unclear risk 77 patients enrolled, and 64 
completed the study for the full 6 
weeks. 13 withdrawals - 1 consent 
withdrawal, and 4 adverse events in 
the Calcium Alginate group, 1 
ineffective treatment, 1 
aggravation, and 6 adverse events 
in the Vaseline group. The study 
reports that due to the loss of data 
as a result of the 13 withdrawals the 
study was shortened to efficacy 
analysis at 4 weeks. 
Selective outcome reporting 
(reporting bias) 
Low risk No protocol was reported in the 
study. Outcomes pre-specified in 
the methods section were reported 
in the results section. 
Other Bias High risk The revascularizations were 
reportedly higher in the Calcium 
Alginate group. Sub group analysis 
on acute versus chronic lesions was 
also reported but demonstrated no 
statistically significant difference. 
Most of the lesions were chronic 
and reportedly may have been more 
refractory to treatment. 
Notes   
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18. Markevich 2000 Methods RCT; Multi-centered; 
Double-blind 
Study period not reported, 
follow up period was 10 days 
 Participants 140 patients, 
A) 70 
B) 70 
Average Age: 53.6 +/- 15.4 years. 
Average duration of Diabetes: 15.8 
+/- 10.7 years 
No description of sex, type of 
diabetes, disease severity, infection 
status, offloading status, or wound 
grade, other than qualitative 
statement that depth and volume 
were comparable at baseline 
between both groups. 
 Interventions A) Larval therapy (green bottle fly - 
Lucilia sericata 6-10 larva per 1 
cm2 of wound surface area) 
removed after 72 hours 
B) Hydrogel (no data on frequency 
of dressing change) 
 Outcomes Complete healing (no data as 
to time this took) 
A) 5/70 (7.1%) 
B) 2/70 (2.8%) 
(no report of whether this was 
a statistically significant 
difference was mentioned) 
 Notes A) Average Surface area of 
wound 14.9 cm2 
B) Average Surface area of 
wound 15.14 cm2  
(no statistically significant 
difference) 
269 
 
Qualitatively reported in 
abstract that surface area, 
depth and volume, 
surrounding skin, tissue 
quality, exudate, odor, and 
glucose levels were 
comparable at baseline but no 
numerical data were 
provided. 
Assessments reported every 3 
days during first 10 days. 
At 10 days granulation tissue 
covering 50% of wound was 
higher in larval therapy (60% 
vs 34.3%; p<0.001 
statistically significant 
difference) 
Proportion of patients with 
greater than 50% reduction in 
wound area was higher in the 
larval group than in the 
hydrogel group (51.1% vs 
27.1% p<0.05, statistically 
significant difference) 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Published abstract only - 
Randomization reported but method 
of sequence generation not 
reported. 
Allocation concealment (selection 
bias) 
Unclear risk Published abstract only - allocation 
concealment not reported. 
Blinding participants Unclear risk N.B. RCT described as "double-
blind" by study authors but no 
further detail given. 
Blinding of participants - not 
reported (published abstract only): 
This may be difficult due to nature 
of treatments - larval therapy vs. 
hydrogel. 
Blinding personnel delivering 
intervention 
Unclear risk Blinding of personnel - not reported 
(published abstract only): This may 
be difficult due to nature of 
treatments - larval therapy vs. 
hydrogel. 
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Blinding outcome assessors Unclear Blinding of outcome assessors: not 
reported (published abstract only). 
Incomplete outcome data (attrition 
bias) 
Unclear risk Published abstract only - 
incomplete outcome data were not 
reported, if incomplete outcome 
data were present then assessment 
and how outcome data were 
addressed is not discernible. 
Selective outcome reporting 
(reporting bias) 
Unclear risk Published abstract only - selective 
reporting not discernible. 
Other Bias Unclear risk Published abstract only - other bias 
not discernible. 
Notes   
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19. Mazzone 1993   Methods RCT, Method of random 
sequence generation was not 
reported. 
 Participants 19 
A) 11 
B) 8 
No data on age, sex, or other 
patient specific demographics or 
characteristics were reported. 
 Interventions A) Polymeric membrane foam 
dressing 
B) Wet to Dry saline gauze 
mesh dressing 
 Outcomes Complete healing (no data on 
the time to this endpoint 
reported) 
A) 5/70 (7.1%) 
B) 2/70 (2.8%) 
(no report of whether this was a 
statistically significant 
difference was mentioned) 
 Notes Wound size reduction was 
reported as well. 
No other information on other 
risk factors such as diabetes 
type, duration, or disease 
severity was reported. No data 
reported on wound size or grade 
between treatment groups. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk The study reports randomization 
however method of random 
sequence generation was not 
specified. 
Allocation concealment 
(selection bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported 
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Incomplete outcome data 
(attrition bias) 
Unclear risk Not reported 
Selective outcome reporting 
(reporting bias) 
Unclear risk Not discernible; abstract only 
available. 
Other Bias High risk No data were reported on study 
participant characteristics 
between treatment groups, nor 
on other risk factors such as 
diabetes type, duration, or 
disease severity. No data 
reported on wound size or grade 
between treatment groups. 
Notes   
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20. Munter 2006   Methods Randomized controlled trial 
Duration = 4 weeks 
Reported that patients were 
assessed weekly at wound 
clinic as judged necessary. 
Study reports that 
participating clinics used 
same clinical guidelines and 
data-collection forms. 
 Participants 619 patients, Multi-etiology ulcers 
Mean age = 55.2 +/- 9.4 yrs., 
Duration of diabetes = 14.8 yrs. 
# Age Gender M/F (%), 
A) 326, 69.8 +/- 13.7 yrs., 38/62 
B) 293, 68.8 +/- 14.1 yrs., 39/61 
 Interventions A) Silver releasing hydrophilic 
polyurethane foam dressing 
Mean dressing changes = 3.1 days 
B) Local Best Practice (Study 
reports that this ranged from gauze, 
moist wound healing, wound 
healing products, to antimicrobial 
treatments) 
Mean dressing changes = 2.1 days 
Wound management included 
compression therapy. 
DFU's comprised 8% of Silver and 
8% Local best practice group 
 Outcomes The study conducted a 
subgroup analysis for diabetic 
foot ulcers. The study 
reported one of the outcomes 
of interest for this review, 
quality of life. The authors 
did not specify the results of 
this outcome for the subgroup 
of diabetic foot ulcers instead 
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it was reported that the results 
were comparable for all 
parameters between the two 
treatment groups, except for 
wound progress, exudate, and 
odor. 
 Notes The study reported other 
outcomes such as ulcer area 
reduction, slough, wound 
progress, maceration, 
exudate, leakage, ease of 
dressing use and time spent, 
malodor, pain, and cost 
effectiveness. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk The study reports open prospective 
parallel, block randomized 
evaluation. Specific method of 
sequence generation was a 
computer generated list. 
Allocation concealment (selection 
bias) 
Unclear risk The study reports that the computer 
generated sequence list was in 
sealed envelopes. 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported 
Incomplete outcome data (attrition 
bias) 
Low risk The study reports that in order to 
include patients in the analysis all 
missing data were addressed with 
last observation carried forward and 
obtained data were analyzed as 
intention to treat. 
Selective outcome reporting 
(reporting bias) 
Low risk There was no protocol available or 
reported in the study. The outcomes 
reported in the outcomes section 
were pre-specified in the methods 
section. 
Other Bias High risk The study reports private financial 
support. 
Notes   
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21. Ogce 2007   Methods Randomly assigned 
30 days’ study duration 
Weekly follow up with 4 
follow ups. Study reports that 
participating clinics used 
same clinical guidelines and 
data-collection forms. 
 Participants 60 patients, Gender = 36M/24F, 
mean age = 59.85, Hgba1c = 7.73, 
BMI = 25.06 24.47 
#, DM Type (1/2) Mean Age 
Hgba1c 
A) 30, 0.867/0.133 59.47 yrs., 
7.60%, 
B) 30, 0.733/0.267 60.23 yrs., 
7.86% 
 Interventions A) Hydrocolloid dressing 
(combined with paste for wound 
cavities, and powder for infection) 
B) Classic wound dressing 
Daily dressing changes 
 Outcomes The study reported that 
healing was much better and 
faster in the experimental 
group. 
 Notes The article was only available 
in Turkish and was translated 
through the use of Google 
translate as were all non-
English language publications 
that were retrieved through 
our search and accepted in 
this review. The translation 
was of higher quality for 
some languages and difficult 
in others. This study was 
among those that was 
difficult to translate. This 
posed a limitation in data 
extraction. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
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Random sequence generation 
(selection bias) 
Low risk Random assignment reported but 
method of sequence generation was 
not specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Unclear risk Not reported 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported 
Selective outcome reporting 
(reporting bias) 
High risk No protocol was available or 
reported in the study. The outcomes 
reported in the results were not 
explicitly pre-specified in the 
methods section. 
Other Bias Unclear risk Limited reporting. 
Notes   
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22. Piaggesi 2001 Methods Study duration = 8 weeks 
All subjects initial surgical 
debridement + postoperative 
pressure relieving shoes + 
crutches 
Weekly assessments: 
Photographed lesions traced 
on acetate film to measure 
maximal dimensions. 
Wound depth measured by 
probe and volume by gel. 
 Participants 24 identified, 20 enrolled, 4 
withdrawn 
A) 10, 61.3 +/- 7.5 years 
Duration of diabetes = 16.1 +/- 8.9 
years 
Hgba1c = 8.9 +/- 3.1% 
ABPI = 1.0 +/- 0.2 
B) 10, 63.1 +/- 4.6 years, 
Duration of diabetes = 14.8 +/- 6.2 
years 
Hgba1c = 8.1 +/- 2.7% 
ABPI = 1.1 +/- 0.3 
 Interventions A) Saline moistened gauze 
(renewed twice daily with saline to 
prevent drying) 
B) Sodium Carboxy-Methyl 
Cellulose Hydrofiber (Aquacel) 
changed every 2nd or 3rd day 
depending on extent of exudate 
produced by wound. 
Dressing changes by trained 
relative or visiting nurse. 
 Outcomes 1) Proportion healed 
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A) 10/10 = 1 
B) 9/10 = 0.90 
2) Healing Time 
A) 234 +/- 61 days 
B) 127 +/- 46 days 
Statistically significant 
difference 
3) Proportion with Infection 
A) 1/10 = 0.30 
B) 3/10 = 0.10 
4) Proportion amputations 
a) 1/10 
b) 0/10 
No statistically significant 
difference 
 Notes  
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Study reports random assignment 
but specific method of sequence 
generation was not reported. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
Blinding outcome assessors Low risk Reported that blindly evaluated by 
one of the authors. 
Incomplete outcome data (attrition 
bias) 
High risk 24 eligible patients, 20 enrolled and 
randomized. 2 refused consent, 1 
due to missed visits, 1 due to neuro-
osteoarthropathy. 
Selective outcome reporting 
(reporting bias) 
Low risk The study states a protocol was 
written and submitted to an ethics 
committee however this was 
unavailable, however the methods 
section reported the outcomes to be 
studied including: 1) rate of 
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reduction in lesion volume, 2) rate 
of granulation tissue, 3) infective 
complications, and 4) healing time. 
These outcomes are reported in the 
results section. Proportion requiring 
amputation was also reported that 
was not in methods section. 
Other Bias Unclear risk Reported that manufacturers not 
involved in any part of experiment. 
Amputations reported but difficult 
to determine if in same individuals 
or different individuals based on the 
report. Unclear if groups were 
balanced for other risk factors. 
Notes   
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23. Piaggesi 1998 Methods Randomized into 2 treatment 
groups 
Study period 1995. Follow up 
period was 24 weeks. Patients 
were followed twice a week. 
 Participants 42 patients with 46 ulcers 
A) 22 patients, (17 NIDDM / 3 
IDDM), 24 ulcers 
Mean age = 63.24 +/- 13.46 years 
Duration of diabetes = 18.2 +/- 8.41 
years 
Hgba1c = 9.5 +/- 3.8% 
B) 24 patients, (19 NIDDM / 2 
IDDM), 22 ulcers 
Mean age = 65.53 +/- 9.87 
Duration of diabetes = 16.84 +/- 
10.61 years 
Hgba1c = 8.9 +/- 2.2% 
No description of sex 
Baseline wound area measurement 
not reported. 
 Interventions A) Control - Non-surgical 
conventional treatment including 
pressure relief and regular dressing 
(type of dressing not reported. 
B) Treatment - Surgical 
debridement, removal of bone 
segments 
 Outcomes 1. Complete healing at 6 
months: Group A = complete 
re-epithelialization of lesions; 
Group B = formation of 
continuous scar 
A) 19/24 (79%) 
B) 21/22 (95%) 
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2. Healing time 
A) 48.7 +/- 36.99 days 
B) 130.38 +/- 90.49 days 
4. Recurrence rate 
A) 8/24 (33%) 
B) 3/22 (14%) 
5. Infective complications 
A) 3/24 (13%) 
B) 1/22 (5%) 
6) Amputations 
A) 1/24 = 0.04 
B) 0/22 = 0 
 Notes  
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Exact sequence generation not 
reported: "a table of 
randomization". 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Non-surgical debridement and 
pressure relief vs. surgical 
debridement. 
Blinding of participants difficult 
due to nature of treatments – 
nonsurgical control vs. surgical 
intervention. 
Blinding personnel delivering 
intervention 
Unclear risk Blinding of personnel: difficult due 
to nature of treatments - non-
surgical control vs. surgical 
intervention. 
Yes - Group A. Physicians and 
nurses treating Group A (control) 
patients were unaware of their 
patients' involvement in the trial: 
"the whole treatment course of 
group A patients from initial 
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debridement to follow-up visit was 
performed by physicians and nurses 
unaware of the participation of 
patients in the study, and did not 
differ from the standard protocol of 
treatment of non-complicated 
neuropathic ulcerations in our foot 
clinic". 
Unclear - Group B. It was not 
reported if personnel for the Group 
B (intervention) were aware of their 
patients' participation in the trial. 
Blinding outcome assessors Unclear risk Blinding of outcome assessors: 
unclear who conducted outcome 
assessment for both Groups (A and 
B). 
Incomplete outcome data (attrition 
bias) 
Unclear risk Patient numbers at follow-up were 
not reported. 
Selective outcome reporting 
(reporting bias) 
Low risk Four parameters were pre-specified 
as outcomes, all of which were 
reported. 
Other Bias High risk Group B given antibiotics 5 days 
after surgery: "general therapy for 
group B patients differed from 
group A in that systemic parenteral 
therapy with wide-spectrum 
antibiotics was given 5 days after 
surgery, according to the protocols 
of our hospital for the prophylaxis 
of nosocomial infection". 
Notes   
 
 
 
 
 
 
 
 
283 
 
24. Rhaiem 1998 Methods Randomization of subjects 
into 3 groups 
Study period was 1992 - 
1995, Follow-up period was 
40 +/- 13 days 
 Participants 80 patients, Gender 59M/21F, DM 
type 1/2 = 61/19, mean age = 56 +/- 
32 yrs. (26 - 89), diabetes duration 
= 13 +/-10.6 yrs. (1 - 26) yrs., 
peripheral neuropathy 74.6%, 
smokers 55%, Alcohol users 21%, 
infected wounds at baseline = 
51.7% 
G1: 16 patients 
G2: 24 patients 
G3: 40 patients 
 Interventions 3 treatment groups: 
A) G2: cleaning ulcers with 
hydrogen peroxide 3% + antibiotic-
therapy + local applied Jam sugar 
B) G3: cleaning ulcers with 
hydrogen peroxide 3% + antibiotic-
therapy (40 patients) 
C) G1: cleaning ulcers with 
hydrogen peroxide 3% + local 
applied Jam sugar 
 Outcomes ln groups 1 and 2 (using 
sugar): 47.5% of ulcers 
healed, compared with group 
3 in which 40% of ulcers 
healed with a mean delay 
respectively of 6 and 9 
weeks. 
Proportion healed 
A) G1 and G2 = 0.475 
B) G1 = 0.40 
Not a statistically significant 
difference. 
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 Notes This study was translated 
using Google translate from 
French into English. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk The study reports randomization, 
but does not specify the method of 
sequence generation. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
 
Blinding outcome assessors Unclear risk Not reported 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported. 
Selective outcome reporting 
(reporting bias) 
High risk The study does not report whether a 
protocol was pre-established. The 
methods section of the study does 
not pre-specify the outcomes 
reported in the results section. 
Other Bias High risk The study does not explicitly report 
whether the subjects received off-
loading. It is not mentioned in the 
study how the determination of 
ischemic wounds was established. 
The study does not clarify. The 
study reports the combined healing 
proportion for the G1 and G2 
groups, it does not report the 
proportion separately. The study 
reports that 51.7% of wounds were 
infected, no information was 
provided on whether infected or 
ischemic wounds were balanced 
between the 3 treatment groups. 
Notes   
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25. Roberts 2001   Methods RCT 
Dressing changed and wound 
assessment with tracings were 
reported to occur weekly. 
Study duration was 13 weeks 
 Participants 30 patients 23M/7F 
Type 1 DM 
Median Age = 59.5 years Range 
(37-77) 
Neuropathic ulcers of the plantar 
surfaces. 
Median wound size for sample was 
123 mm2, range (21 - 350 mm2) 
Median wound size for 
Hydrocellular foam was 114.5 mm2 
and 144.5 mm2 for saline soaked 
low adherent dressing. 
Median Wound duration 15.2 
weeks, range (1 week - 6 years) 
ABPI < 0.8 
A) 14 
B) 16 
 Interventions A) Allevyn hydrocellular foam 
dressing 
B) Saline soaked (low adherent) 
dressing and standard podiatric care 
 Outcomes 1) Proportion healed over 13 
weeks 
A) 6/14 = 43% 
B) 4/16 = 25% 
2) Time to healing - Not 
significantly different 
between both groups p = 
0.325 
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 Notes The study also reported the 
proportion of patients in each 
group that demonstrated a 
50% area reduction over 13 
weeks: 
A) 13/14 = 93% 
B) 12/16 = 75% 
The study reports that after 
adjusting for covariate risk 
factors: age, sex, ulcer size 
and duration, the 
hydrocellular dressing was 
associated with a significantly 
faster response (p=0.013), 
than saline soaked (low 
adherent) dressing. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Randomization was reported 
however method of sequence 
generation was not specified. 
Allocation concealment (selection 
bias) 
Unclear risk Published abstract only - allocation 
concealment not reported. 
Blinding participants Unclear risk Published abstract only - blinding 
not reported. 
Blinding personnel delivering 
intervention 
Unclear risk Published abstract only - blinding 
not reported. 
Blinding outcome assessors Unclear risk Published abstract only - blinding 
not reported. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Published abstract only - 
incomplete outcome data not 
reported. 
Selective outcome reporting 
(reporting bias) 
High risk Not clear that a protocol was 
available and methods did not pre-
specify outcomes reported. 
Other Bias High risk Published abstract only - other bias 
not discernible. 
Unclear if risk factors such as 
diabetes disease severity or others 
were balanced between the two 
intervention groups. Depth of 
wound between intervention groups 
was not reported. Study supported 
by an educational grant from 
manufacturer Smith & Nephew - 
Group Research Centre). 
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Notes   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
288 
 
26.  Shukrimi 2008 Methods Wagner grade II diabetic foot ulcers 
Wound assessments every other day 
by a surgeon blinded to the material 
of the dressing. 
 Participants 30 patients (31-51 yrs.), 15M/15F, 
mean age = 52.1 yrs. (31-65 yrs.), 
TcPO2 mean = 39 mmHg (36 - 42 
mmHg) 
 Interventions A) Honey dressing 
B) Standard dressing (Povidone 
Iodine/Normal saline, 1:10) 
All patients received antibiotics and 
ulcers debrided initially surgically 
(debridement specimens were sent 
for culture) 
Wound dressing started on first 
postoperative day by nurses and 
reported as daily dressing changes. 
 Outcomes The outcomes of interest for this 
review were not reported in this 
study. 
The study reported the cost to buy a 
bottle of commercial honey. The 
study reported that a bottle of honey 
could be used for the entire period 
of study. No other information on 
cost was provided on the standard 
dressing. 
 Notes Other outcomes reported include: 
Time to healing for surgical closure 
A) 14.4 days (7-26 days) 
B) 15.4 days (9-36 days) 
Statistically significant difference 
(p<0.005) 
The study reported all patients had 
less pain in the honey group. 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk The authors report randomization. 
Method of sequence generation not 
specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported. 
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Blinding participants Unclear risk Not reported. 
Blinding personnel delivering 
intervention 
Unclear risk Not reported. 
Blinding outcome assessors Low risk The study authors reported blinding 
of outcome assessor. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported. 
Selective outcome reporting 
(reporting bias) 
High risk No protocol was reported in the 
study. The outcomes reported in the 
results section including wound 
culture results and time to healing 
for surgical wound closure was 
reported in the methods section. 
Cost was reported in the results 
section but was not pre-specified in 
the methods section. 
Other Bias Unclear risk No information on diabetes disease 
severity such as Hgba1c or duration 
of diabetes was reported. 
Notes   
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27. Singh 2006 Methods Randomized clinical trial 
Ulcers x-ray to exclude 
Osteomyelitis 
Duration: two weeks 
First assessment at first day 
of debridement and again at 
day fourteen. 
 Participants 59 patients - 60 ulcers, 33M/27F, 
DM type 1/2 = 5/55, mean age = 
56.87 +/- 11.06 yrs. 
A) 33, 5/28 
B) 27 0/27 
 Interventions A) Non-contact Ultrasonic 
debridement (24 KHz) performed 
every other day 
B) Sharp/surgical debridement 
conducted every other day 
 Outcomes None of the outcomes of 
interest for this systematic 
review were reported in the 
study. 
 Notes  
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk The study reports the subjects were 
randomized into the two treatment 
groups. The specific method of 
sequence generation was not 
specified. 
Allocation concealment (selection 
bias) 
Unclear risk Not reported 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
 
Blinding outcome assessors Low risk The study reports that assessment 
was done by two independent 
observers who were blinded. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Not reported. 
Selective outcome reporting 
(reporting bias) 
Low risk No protocol was available or 
reported in the study. The outcomes 
reported in the results section were 
pre-specified in the methods 
section. 
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Other Bias Unclear risk The authors did not report other 
important risk factors for wound 
healing including disease severity 
and off-loading status. 
Notes   
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28. Tallis 2013   Methods Randomized controlled 
parallel group multicenter 
open-label study 
Duration 12 weeks, patients 
seen weekly. 
Wounds are measured with 
length of long axis times 
greatest width perpendicular 
to long axis. 
 Participants 48 patients, 32M/16F, 61 +/- 11.8 
yrs., 45 Caucasian 3 AA 
A) 24, 16M/8F, 58.5 +/- 13.3 yrs., 
22 Caucasian 2 AA 
B) 24 16M/8F, 63.5 +/- 9.8 yrs., 23 
Caucasian 1 AA 
No statistically significant 
difference in demographics, 
including race. 
 Interventions A) Clostridial Collagenase 
Ointment (CCO) 
B) Saline Moistened Gauze (SMG) 
+ Selective Sharp Debridement 
Randomized to both groups after 
baseline surgical debridement and 
6.9 mean debridement in total for 
the SMG group. 
 Outcomes 1) Direct mean costs per 
responder 
Physician office Wound 
clinic facility 
A) $832 $1607 
B) $1042 $1980 
Cost effectiveness analysis 
was used. 
 Notes . 
Risk of bias table   
Bias Authors' judgment Support for judgment 
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Random sequence generation 
(selection bias) 
Low risk The study reports a computer-
generated randomization sequence. 
Allocation concealment (selection 
bias) 
Low risk The study reports randomization 
was centralized and for or each 
qualified patient investigative sites 
contacted the central call center for 
the next sequential pre-determined 
treatment assignment. 
Blinding participants Unclear risk Not reported 
Blinding personnel delivering 
intervention 
Unclear risk Not reported 
 
Blinding outcome assessors Unclear risk Not reported 
Incomplete outcome data (attrition 
bias) 
Low risk The study reports that 8 patients 
discontinued the study. The authors 
reported that an Intention to treat 
analysis was used. Specifically, last 
observation carried forward was 
utilized for missing wound area 
measurements at any of the weeks 
resulting from wound healing, early 
discontinuations, or for any other 
reasons. 
Selective outcome reporting 
(reporting bias) 
Low risk No protocol was available for 
review or was reported in the study. 
The outcomes reported in the 
results section were pre-specified in 
the methods section. 
Other Bias High risk The study reports that a total of 23 
patients (28 in the CCO group, and 
33 in the SMG group) in the study 
experienced 61 treatment-emergent 
adverse events. The specific nature 
of the events was not specified 
other than the adverse events were 
reported to be similar in the 
treatment groups and unrelated to 
the treatment. 
Notes   
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29. Vandeputte 1997 Methods Pre-prepared randomization 
listing 
Study period was not 
reported. Follow up period 
was 12 weeks. Patients were 
followed up every 4 weeks. 
 Participants 29 patients with 30 wounds 
A) 15 patients (15 wounds) 
B) 14 patients (15 wounds) 
No description of age, sex or type 
of diabetes. 
Baseline wound area measurement 
not reported. 
 Interventions A) Hydrogel 
B) Dry gauze (control) includes 
moistened gauze with antiseptic. 
Other ancillary wound care 
measures not reported. 
 Outcomes Complete Healing at 3 
months 
A) 14/15 (93%) 
B) 7/14 (50%) 
Infective complications 
A) 1/15 (7%) 
B) 7/14 (50%) 
Amputations 
A) 1/15 
B) 5/14 
 Notes  
Other outcomes reported 
included: 
Peri-ulcer maceration 
A) 11.6% 
B 22.1% 
Low grade skin 
reactions/allergies reported 
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qualitatively in both groups, 
no numerical data provided. 
 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Specific sequence generation 
procedure was not reported: 
"patients were allocated to 
treatment groups according to a 
pre-prepared randomization 
listing". 
Allocation concealment (selection 
bias) 
Unclear risk Not reported. 
Blinding participants Unclear risk Blinding of participants was unclear 
in the report. 
Blinding personnel delivering 
intervention 
Unclear risk Blinding of personnel delivering 
intervention was unclear. 
Blinding outcome assessors High risk Blinding of outcome assessors: no - 
same nurses as personnel and 
outcome assessors. 
Incomplete outcome (attrition bias) Unclear risk Lack of clarity concerning 
patient deaths in control 
group. 
Methods and Results sections 
report control group as n=14. 
Results section states: "one 
patient of the control group 
died. One patient had a 
wound on both legs. The 
number of legs treated was 30 
(15 in each group)". 
Two deaths in the control 
group are reported in the 
'Overall healing time’ Table 5 
in the Results section: '2 - 
died during trial' in the 
control group, although the 
total participants remains 
stated as n=14. 
Selective outcome reporting 
(reporting bias) 
Low risk Nine parameters were pre-specified 
as outcomes, all of which were 
reported. 
Other Bias High risk Author had an affiliation with 
wound product manufacturer. 
Notes   
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30. Whalley 2001 Methods RCT Randomized into 2 
comparison groups 
Study period not reported, 
follow up period was 10 
weeks. 
 Participants 74 patients; (66 patients evaluated) 
no further data were available 
including how many patients 
allocated to each group. Age 55.2 
+/- 9.4 
 Interventions A) Purilon Hydrogel 
B) Intrasite Hydrogel using Biatain 
Non-adhesive dressing (Coloplast 
A/S) as a secondary dressing 
Dressings changed at least every 
second day 
 Outcomes 1. Complete healing at 10 
weeks 
A) 35% healed 
B) 19% healed 
No report of whether this was 
a statistically significant 
difference. 
2. Change in mean wound 
area 
A) 2.5 cm2 (SD 3.2) to 0.6 
cm2 (SD 1.1) 
B) 2.4 cm2 (SD 2.9) to 1.0 
cm2 (SD 1.8) 
 Notes Offloading reported in both 
groups. 
Abstract only; limited data 
Other outcomes reported 
included: 
Peri-ulcer maceration 
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A) 11.6% 
B 22.1% 
Low grade skin 
reactions/allergies reported 
qualitatively in both groups, 
no numerical data provided. 
 
Risk of bias table   
Bias Authors' judgment Support for judgment 
Random sequence generation 
(selection bias) 
Low risk Published abstract only - 
Randomization reported but method 
of sequence generation not 
reported. 
Allocation concealment (selection 
bias) 
Unclear risk Published abstract only - allocation 
concealment not reported. 
Blinding participants Unclear risk Published abstract only - allocation 
concealment not reported. 
Blinding personnel delivering 
intervention 
Unclear risk Published abstract only - allocation 
concealment not reported. 
Blinding outcome assessors Unclear risk Published abstract only - allocation 
concealment not reported. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Published abstract only - 
incomplete outcome data were 
reported but assessment and how 
outcome data were addressed is not 
discernible. "66 patients were 
evaluable" from the 74 patients 
recruited. 
Selective outcome reporting 
(reporting bias) 
Unclear risk Published abstract only - selective 
reporting not discernible. 
Other Bias Unclear risk Published abstract only - other bias 
not discernible. 
Notes   
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Characteristics of excluded studies   
Abbruzzese 2009   
Reason for exclusion Both groups received debridement. 
Abdelatif 2008   
Reason for exclusion Nonrandomized study 
Aceechurovai 2003   
Reason for exclusion Nonrandomized study 
Aftab 2010   
Reason for exclusion Soft tissue laser intervention in this study was not used 
as a form of debridement. 
Ahroni 1993   
Reason for exclusion Surgical debridement was reported as being carried out 
routinely throughout study on both treatment arms. 
Apelqvist 1994   
Reason for exclusion Varidase is used as a debriding agent but no separate 
data were available for this group of patients. If such 
data had been available, the size of the study (n=17) is 
unlikely to be sufficiently powered. 
 
Apelqvist 1996 
 
 
Reason for exclusion Authors report that both treatment groups received 
surgical debridement performed during the course of the 
study indicating that debridement was not the primary 
focus of this study. 
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Armstrong 2000   
Reason for exclusion Although all wounds were debrided the primary 
intervention measured was a foot compression system, 
there was no comparison or conclusions drawn regarding 
the debridement methods used. 
Ashry 1998 
Reason for exclusion Not an RCT on debrdement but a cost related archival 
analysis on amputations among in diabetic minority 
groups. 
Bahrami 2008 
Reason for exclusion Intervention was not a form of debridement but an oral 
herbal preparation. 
Berry 1996 
Reason for exclusion Randomized study on the debridement of cavity wounds 
not diabetic foot ulcers. 
Biliaieva 2009   
Reason for exclusion This was a non-randomized study investigating 
absorptive dressings. 
Bowling 2007   
Reason for exclusion This was a non-randomized study - case series 
investigating larval therapy. 
Brenes 2011 
Reason for exclusion This was a non-randomized study - case series on 
hyaluronate iodine. 
Caputo 2009 
Reason for exclusion The study does not report outcomes separately for 
diabetic and other wound types. 
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Cardinal 2009   
Reason for exclusion Non-randomized retrospective study of healing rates as 
predictors of complete wound closure. 
Chan 2007   
Reason for exclusion Systematic review of Maggot debridement therapy not 
RCT. 
Chiglashvili 2004   
Reason for exclusion Non-randomized study - case series not on debridement 
but IV infusion of complex medical regimen. 
Clavel 2008   
Reason for exclusion Narrative review article on preventing amputations in 
diabetics. 
Davydov 20111 
Reason for exclusion Narrative review article on Larval therapy. 
Dekhtiar 1995   
Reason for exclusion Non-randomized case series. 
Dereure 2012 
Reason for exclusion RCT on Venous leg ulcers and Mixed etiology ulcers 
using Hyaluronic acid. 
Ennis 2005   
Reason for exclusion Study utilized another form of debridement in both 
treatment arms. 
Freeman 2010   
Reason for exclusion Non-randomized study of bee honey. 
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Gelunenko 2000   
Reason for exclusion The intervention under study is an oral immune 
modulating agent not a form of debridement. 
Gottrup 2001   
Reason for exclusion This is a cost evaluation paper. Not an RCT. 
Gough 1997   
Reason for exclusion RCT which compares granulocyte stimulating factor, 
with a placebo. There is no debriding agent included in 
the trial. 
Graham 2014   
Reason for exclusion The study involved wounds of varying etiologies and 
was a non-randomized case series study on Oakin 
dressing. 
Grayson 1994   
Reason for exclusion RCT assessing the effectiveness of Imipenem / Cilastatin 
against ampicillin / Sulbactam in the treatment of pedal 
infections in diabetic. No debriding agent was 
considered. 
Holtzer 1998 
Reason for exclusion This study was not an RCT but an archival data analysis. 
Jan 2012 
Reason for exclusion This study was not an RCT but was reported as a quasi-
experimental study. 
Jude 2007   
Reason for exclusion Standardized surgical debridement was used regularly in 
both treatment arms concurrently as part of standard 
care. 
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Jude 2004   
Reason for exclusion RCT of 120 people that compares silver based fiber 
dressing with an alginate, alternate form of debridement 
confounded both arms. 
Kaviani 2011   
Reason for exclusion The laser therapy was not used here for debridement but 
to stimulate growth. Debridement was carried out 
separately. 
Khramilin 2011   
Reason for exclusion Narrative review article not an RCT. 
Krupski 1991   
Reason for exclusion RCT which compared platelet derived wound healing 
with a placebo. Although all wounds were extensively 
debrided initially, there were no debriding agents 
included in the trial. The trial sample was 'mixed ulcers' 
- with leg ulcers mainly identified. 
Krymets 2013   
Reason for exclusion Non-randomized study not an RCT. 
Kuo 2012   
Reason for exclusion Randomized study on the use of herbal botanical anti-
inflammatory creams. These herbal botanicals were not 
used as a form of debridement. 
Li 2006   
Reason for exclusion Growth factors as focus of RCT. (Debridement to aid 
growth factor only). 
Logachev 2001   
Reason for exclusion Nonrandomized study - Case series. 
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Macleod 1991   
Reason for exclusion Not an RCT. 
Martinez-de-Jesus 1997   
Reason for exclusion RCT where all foot ulcers underwent surgical 
debridement and were then treated with either topical 
Ketanserin or normal saline (placebo). Excluded as the 
topical treatment, although gel based was compounded 
by the fact that it contained Ketanserin gel. 
Metha 1999   
Reason for exclusion Review article on cost using claims data. 
Mohajeri 2014   
Reason for exclusion Though topical Kiwifruit possesses debridement 
properties both treatment arms of the study were 
subjected regularly to surgical debridement concurrently 
throughout the study. 
Moore 2011 
Reason for exclusion Systematic review on Silver dressings but in mixed 
etiology wounds, not restricted to diabetic foot ulcers. 
Moretti 2009   
Reason for exclusion Study on shock wave therapy which was not used for 
debridement but for angiogenesis. Debridement was 
conducted similarly in both groups. 
Motley 2014   
Reason for exclusion Serial sharp debridement was carried out on both 
treatment arms with and without enzymatic debridement. 
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Mulder 1994a   
Reason for exclusion RCT comparing lamin gel with standard care and 
vehicle gel. The lamin gel contains a peptide copper 
complex, which has been shown to be a chemoattractant 
for capillary endothelial cells and stimulates 
angiogenesis. It is therefore not a debriding agent. 
Mulder 2005 
Reason for exclusion RCT comparing lamin gel with standard care and 
vehicle gel. The lamin gel contains a peptide copper 
complex, which has been shown to be a chemoattractant 
for capillary endothelial cells and stimulates 
angiogenesis. It is therefore not a debriding agent. 
Naidu 2005   
Reason for exclusion Study did not pertain to debridement but on off-loading 
of callus. 
 
Nielsen 2012 
Reason for exclusion Nonrandomized study on surgical wounds and not 
specific to diabetic patients. 
Oluwatosin 2000 
Reason for exclusion Intervention was not a comparison between forms of 
debridement but included a comparison Phenytoin. 
 
Pettican 2012   
Reason for exclusion This study was not an RCT but a Non-randomized study 
on larval therapy, specifically a case series. 
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Pollak 1997   
Reason for exclusion RCT which assesses the effectiveness of human dermis 
replacement against conventional treatment. There is 
initially sharp debridement, but there is no debriding 
agent assessed in the trial. 
Ramsey 1999 
Reason for exclusion Nonrandomized study on healthcare costs of foot ulcers 
in diabetes. 
Razzak 1997   
Reason for exclusion RCT including 24 patients, dividing patients into 
treatment with either antibiotics or local insulin 
application. No debriding agent was assessed in this 
trial. 
Ricci 2010 
Reason for exclusion Nonrandomized study on unspecified leg wounds. 
Richard 2012 
Reason for exclusion Nonrandomized study on Immunomodulating NOSF 
dressing. 
Saap 2002   
Reason for exclusion Fulfills the inclusion criteria for RCT and diabetic foot 
ulcers. The paper, however, is concerned with measuring 
the standard of debridement and the effectiveness of a 
debridement scale rather than the effectiveness of 
debridement as a treatment. 
Saied 2011   
Reason for exclusion RCT of low intensity laser therapy as biostimulation not 
as a form of debridement. 
 
306 
 
Sanchez 2006   
Reason for exclusion This was a retrospective non-randomized study on 
collagen matrix. 
Santra 2012 
Reason for exclusion The comparison in the study was not form of 
debridement. 
Schindl 1998   
Reason for exclusion RCT of Low intensity laser therapy for use as 
biostimulation not a form of debridement. 
Schindl 2002   
Reason for exclusion An RCT of Low intensity laser therapy for use as 
biostimulation not a form of debridement. 
Sedlarik 1969   
Reason for exclusion This is a Non-randomized study - case series. 
Seidel 1994   
Reason for exclusion RCT which assess the use of short term retrograde 
transvenous leg perfusion. The trial is concerned with 
infection of foot ulcers; wound healing was not an 
outcome. 
Siavash 2015   
Reason for exclusion Though Royal Jelly could be considered a form of 
autolytic debridement both treatment arms received a 
regular form of debridement that was unspecified. 
Singh 2004   
Reason for exclusion Systematic review on using hydrocolloids in chronic 
wounds not strictly diabetic foot ulcers. 
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Solway 2011   
Reason for exclusion Non-randomized study. Sharp debridement was done on 
both groups. 
Soos 2003   
Reason for exclusion Narrative review article on diabetic foot ulcer 
management. 
Steed 1996   
Reason for exclusion RCT of 118 patients which compares treatment of 
human-derived growth factor against a placebo. The 
influence of debridement was evaluated by reviewing 
the records of the trial. This paper was used in the 
discussion section of this review. 
Steenvoorde 2007   
Reason for exclusion Non-randomized study - prospective case series on 
larval therapy. 
Tennvall 2000 
Reason for exclusion Non-randomized study on cost of care in diabetics with 
deep foot infections. 
Van Acker 2000   
Reason for exclusion Costs for prevention and treatment of foot lesions in 
diabetics in Belgium not on debridement. 
Van Houtum 1995   
Reason for exclusion The study investigates cost of amputations in the 
Netherlands not cost of debridement. 
Varma 2006   
Reason for exclusion RCT undertaken on people whose wounds had already 
been debrided, and the effectiveness of the post 
debridement dressing was the focus of the trial. 
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Wieman 1998   
Reason for exclusion RCT of 382 patients which assessed the efficacy and 
safety of topically applied recombinant human platelet 
derived growth factor at two strengths, either 
Becaplermin 30 mg or Becaplermin 100 mg. 
Wolff 2003   
Reason for exclusion Nonrandomized study - case series of larval therapy. 
Zgonis   
Reason for exclusion Expert opinion narrative review not RCT. 
Zimny 2008   
Reason for exclusion RCT of competing methods of off-loading including 
felted foam dressing versus pressure 
relief half-shoe. The debridement method was the same 
in both groups. 
Characteristics of studies awaiting classification    
Callaghan 1993   
Callaghan DP. Assessment of the effectiveness of Debrisan in healing ulceration on pressure 
areas of diabetic patients' feet. In: 2nd European Conference on Advances in Wound 
Management; 1992, 20-23 October; Harrogate, UK. 1993:82. 
Dolynchuk 2001   
Dolynchuk K. The use of collagenase in the debridement of diabetic foot ulcers: a double-blind 
prospective randomized study. In: 7th Annual Conference of the Canadian Association of 
Wound Care 1-3 November 2001 London, Ontario, Canada. 2001:56. 
Mulder 1994b   
Mulder GD, Jensen JL, Seeley JE, Peak Andrews K. A controlled randomized study of an 
amorphous hydrogel to expedite closure of diabetic ulcers. In: 4th European Tissue Repair 
Society Meeting; 1994, 25-28 August; Oxford, England. 1994:130 (Abstract 90). 
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Characteristics of ongoing studies  
         Michaeldis 2014 
Michailidis L, Williams CM, Bergin SM, Haines TP. Comparison of healing rate in diabetes-
related foot ulcers with low frequency ultrasonic debridement versus non-surgical sharps 
debridement: a randomized trial protocol. Journal of foot and ankle research. 2014;7(11):1 - 10. 
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Additional tables 
Table 1 of Descriptive Statistics 
Total number of 
studies 
30 
Total number of 
participants 
2564 
Sample size range 18 to 619 
Average sample size 
per study 
152 
Total Range of follow 
up 
10 days to 24 weeks 
Total Study period or 
duration 
1992 - 2012 
Studies reporting age 24/30 (70%) 
Mean age (range) 52.1 – 69.3 years 
Total number of 
studies reporting 
gender 
21/30 (70%) 
Range of number of 
males 
12 to 240 
Range of number of 
females 
1 to 88 
Number of studies 
reporting ethnicity 
5/30 (16.7%) 
Number of studies 
reporting 
socioeconomic status 
1/30 (3.3%) 
Geographic setting Europe and US (70%) 
Publication Language English 93% 
Healthcare setting Hospital 8/30 (26.7%) 
Outpatient 17/30 
(56.7%) 
Both 2/30 (6.7%) 
Studies reporting 
wound size (area) 
20/30 (67%) 
Studies reporting 
wound duration 
14/30 (70%) 
Studies reporting 
Hemoglobin a1c 
(Hgba1c) 
8/30 (26.7%) 
Hgba1c (range) 7.25% - 9.25% 
Studies reporting on 
duration of diabetes 
14/30 (70%) 
Duration of diabetes 
(range) 
13 to 21 years 
Studies reporting 
baseline peripheral 
arterial insufficiency 
9/30 (30%) 
Studies reporting BMI 5/30 (16.7%) 
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Table 2  IWGDF 2012 (Reproduced here with permission from the IWGDF) 
Costs of Treating Foot Ulcers and Amputations 
Reference Country Number 
of 
Patients 
Costs 
(year of 
costing) 
USD 2005 
equivalent 
Comments 
Ulcers not requiring amputation 
Apelqvist et al, 
1994 
Sweden 197 Sweden 
197 SEK 
51,000 
(1990) 
8,654 All ulcer types; total 
Harrington, et 
al, 2000 
USA 400,000 USA 
400,000 
USD 
3,999-6 
(1996) 
4,982-
7,821 
Inpatient and 
outpatient costs 
Holzer et al, 
1998 
USA 1846 c USD 
1,929 
(1992) 
2,695 Inpatient and 
outpatient costs, those 
>64 yr. excluded 
Metha et al, 
1999 
USA 5149 USA 
5149 
USD 
900-2,600 
(1995) 
1,150-
3,322 
Private insurance 
charges; mean age 51 
yr. 
Ragnarson 
Tennvall et al, 
2000 
Sweden 88 Sweden 
88 SEK 
136,600 
(1997) 
18,719 Deep foot infection; 
total direct costs 
Ramsey et al, 
1999 
USA 514 d USD 
27,987 
(1995) 
35,758 Including 2 yr. after 
diagnosis 
Van Acker et al 
2000 
Belgium 120 Belgium 
120 USD 
5,227 
(1993) 
7,039 Inpatient and 
outpatient costs 
Costs of lower extremity amputations 
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Apelqvist et al 
1994 
Sweden 27 Sweden 
27 SEK 
258,000 
(1990) 
43,778 All ulcer types; minor 
LEA; total direct 
costs 
Apelqvist et al 
1994 
Sweden 50 Sweden 
50 SEK 
390,000 
(1990) 
66,176 All ulcer types; major 
LEA; total direct 
Costs 
Ashry et al 1998 USA 5062 USA 
5062 
USD 
27,930 
(1991) 
39,891 Hospital charges 
Only 
Holzer et al, 
1998 
USA 504 c USD 
15,792 
(1992) 
22,062 Gangrene/amputation, 
those >64 yr. 
excluded 
van Houtum et 
al, 1995 
Netherlands 1575 e NLG 
28,433 
(1992) 
19,052 Hospital costs only 
Panayiotopoulos 
et al, 1997 
UK 20 UK 20 
GBP 
15,500 
(1994-95) 
33,587 Inpatient and 
prostheses costs 
(46% diabetics) 
Ragnarson 
Tennvall 
et al, 2000 
Sweden 77 Sweden 
77 SEK 
261,000 
(1997) 
35,767 Deep infection; 
minor LEA; total 
direct costs 
Ragnarson 
Tennvall 
et al, 2000 
Sweden 19 Sweden 
19 SEK 
234,500 
(1997) 
32,136 Deep infection; major 
LEA; total direct 
costs 
Van Acker et al, 
2000 
Belgium 7 Belgium 
7 USD 
18,515 
(1993) 
24,933 Inpatient and 
outpatient costs; 
minor LEA 
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Van Acker et al, 
2000 
Belgium 9 Belgium 
9 USD 
41,984 
(1993) 
56,538 Inpatient and 
outpatient costs; 
major LEA 
Footnotes 
For comparison of the results, costs were first adjusted for inflation to 2005 prices with the 
consumer price index f and then converted to USD with the appropriate currency exchange 
rate for 2005. 
NA = not applicable.  
LEA = Lower Extremity Amputation.  
Minor = amputation below the ankle; 
Major = amputation above the ankle. 
a Based on data from observational studies 
b Based on data from databases and other secondary sources 
c Number of episodes 
d Includes 80 amputations 
e Number of hospitalizations 
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Table 3 Wagner Wound Grade Classification System 
Grade 
0 1 2 3 4 5 
 
No ulcer in a 
high risk foot 
Wound 
involving full 
skin thickness 
Wound 
extending to 
ligament and 
muscle 
Wound with 
cellulitis or 
abscess 
Localized 
gangrene 
Extensive 
gangrene 
involving 
the whole 
foot 
 
Table 4 University of Texas Wound Classification System 
 Grade 
Stage 0 
Pre or Post 
ulcerative lesion 
completely 
epithelialized 
1 
Superficial 
wound not 
involving 
tendon, muscle, 
or bone 
2 
Wound 
penetrating to 
tendon or 
capsule 
3 
Wound 
penetrating to 
bone or joint 
 
A 
No Infection, or 
Ischemia 
0A 1A 2A 
 
3A 
B 
Infection but no 
ischemia 
0B 1B 2B 3B 
C 
Ischemia but no 
infection 
0C 1C 2C 3C 
D 
Infection and 
ischemia are 
present 
0D 1D 2D 3D 
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Table 5 Methods of debridement 
Debridement 
Method 
Explanation Advantages Disadvantages 
Mechanical    
Surgical 
(scalpel) 
The technique is considered a rapid means of 
debriding a wound, requiring the use of sterile 
scissors, a scalpel, or curette, it does require a 
certain amount of skill and may slightly 
enlarge the wound. 
Allows rapid 
removal of 
devitalized 
tissue. 
Can be complicated by infection, 
and bleeding. 
Expensive 
Wet-to dry The wound is soaked in saline to moisten the 
hardened wound material before the 
application of a moist gauze pad is placed over 
the affected area. As both the gauze and 
wound tissue dry, the wound tissue and gauze 
adhere to each other. When the dressing is 
removed it non-selectively pulls off the 
tissues. 
Allows rapid 
removal of 
hardened 
devitalized tissue 
Inexpensive 
It is not discriminating/non-
selective and may remove healing 
granulation tissue. It also may be 
painful for the patient. 
Aqueous High 
Pressure 
Lavage or 
Irrigation 
This involves a pressurized stream of aqueous 
solution such as saline to mechanically 
dislodge devitalized tissue from a wound. 
Whirlpool is also a form of lavage irrigation 
that is carried out with the affected wound 
immersed in the solution. 
Allows for rapid 
removal of 
devitalized 
tissue. 
It is non-selective and can dislodge 
healing granulation tissue. 
This procedure may be painful. 
Cross contamination and infection is 
possible. 
Low frequency 
Ultrasound 
This process uses sound waves through a 
contact or noncontact form of transducer to 
dislodge devitalized tissue. 
Permits a rapid 
removal of 
devitalized 
tissue. 
Nonselective and can remove 
healthy granulation tissue. 
Cost implication 
Aerosolizing pathogens 
Bio-Surgery 
Maggot 
Debridement 
therapy 
(larva, maggots) 
Sterile maggots of the green bottle fly Lucilia 
sericata are placed directly on to the wound 
(loose) and covered by a dressing, or held 
within a closed net dressing against the wound 
(bagged). The larvae have a ferocious appetite 
for necrotic material while actively avoiding 
newly formed healthy tissue. They also use 
enzymes to digest devitalized tissue and are 
believed to secrete antimicrobial and tissue-
growth promoting substances. Therefore, they 
are considered a complete system of wound 
care. 
 
They 
discriminate 
between the 
nonviable and 
the viable 
granulating 
tissue. 
There is at present no conclusive 
evidence of effectiveness in foot 
ulcers, there may also be a 
reluctance to use this treatment by 
patients and clinicians. There is a 
cost implication but other treatments 
discussed above may be costlier. 
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Debridement 
Method 
Explanation Advantages Disadvantages 
Non-Mechanical 
These treatments 
are easy to apply 
and have 
additional 
properties that may 
be beneficial for 
wound healing 
   
Enzyme 
Preparations 
The only formulation available in the 
UK contains Streptokinase and 
Streptodornase. This enzyme digests the 
proteins fibrin, collagen & elastin, which 
are commonly found in the necrotic 
exudate of a wound. This includes the 
enzymes Matrix Metalloproteinases 
contained within the wound and 
promoting auto-digestion or self-
digestion of the wound. Other enzymatic 
preparations include trypsin and 
collagenase, are licensed in other 
countries including the U.S. 
They can be applied 
directly onto the 
necrotic area. 
Nonpainful 
Streptokinase can be 
systemically 
absorbed and is 
therefore 
contraindicated in 
patients at risk of an 
MI. There is a cost 
implication. 
Non-Mechanical 
Primarily 
facilitating 
Autolytic 
Debridement 
   
Hydrogels These gels are biologically inert and 
have significant water content. They 
complement the body's natural debriding 
process by providing a moist 
environment, which promotes autolytic 
debridement, while still acting to 
preserve living healthy tissue. (Bradley 
1999) 
Can be applied to a 
wound at any stage, 
promotes moist wound 
healing and autolytic 
debridement. Minimal 
level of skill required. 
Promotes a slow 
process of 
debridement. 
If the surrounding 
skin is not masked 
properly they may 
macerate the 
surrounding tissue. 
Alginates These are absorbent, biodegradable 
dressings derived from seaweed. The 
high absorptivity is due to the 
hydrophilic gel formation that is formed 
when in contact with wounds. Alginate 
dressings are used for moderate to 
heavily exudating wounds 
Widely available in a 
wide variety of 
healthcare settings and 
can be applied to a 
wound at any stage, 
promotes moist wound 
healing and autolytic 
debridement. Minimal 
level of skill required. 
Not associated with pain 
as mechanical forms of 
debridement may be. 
Promotes a slow 
process of 
debridement. 
If the surrounding 
skin is not masked 
properly they may 
macerate the 
surrounding tissue. 
Cost factor. 
Hydrocolloids Hydrocolloids contain gel-forming 
substances, such as sodium 
carboxymethylcellulose (NaCMC) and 
gelatin. They can be combined with 
elastomers and adhesives and associated 
with a carrier such as polyurethane foam 
or film dressing. The result is an 
absorbent, self-adhesive, waterproof 
adherent dressing. When they contact 
wound exudate, hydrocolloids are 
hydrophilic and form a gel. 
Hydrocolloids are impermeable to water 
Can be applied to a 
wound at any stage, 
promotes moist wound 
healing and autolytic 
debridement. Minimal 
level of skill required. 
Not associated with pain 
as mechanical forms of 
debridement may be. 
Promotes a slow 
process of 
debridement. 
If the surrounding 
skin is not masked 
properly they may 
macerate the 
surrounding tissue. 
Cost Factor 
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vapor initially but subsequently become 
more permeable. 
Foam These are absorbent dressings made 
from a hydrophilic polyurethane foam. 
Foams can absorb exudate absorbing it 
from the wound and can decrease 
maceration to the surrounding tissue. 
The direct contact between the foam and 
the wound will maintain a moist wound 
environment. Used for exudative 
wounds. 
Can be applied to a 
wound at any stage, 
promotes moist wound 
healing and autolytic 
debridement. Minimal 
level of skill required. 
Not associated with pain 
as mechanical forms of 
debridement may be. 
Promotes a slow 
process of 
debridement. 
If the surrounding 
skin is not masked 
properly they may 
macerate the 
surrounding tissue. 
Cost factor 
Film Film dressings are made of thin 
polyurethane membrane coated with a 
layer of acrylic adhesive. They are 
flexible and allow direct visualization of 
the wound without always needing to 
remove the dressing. They do not absorb 
wound exudate. 
They are believed to 
limit friction and 
shearing forces that may 
be more common with 
other dressings. Film 
dressings should not be 
used for infected, deep, 
or significantly 
exudative wounds. 
Can be applied to a 
wound at any stage, 
promotes moist wound 
healing and autolytic 
debridement. Minimal 
level of skill required. 
Not associated with pain 
as mechanical forms of 
debridement may be. 
Promotes a slow 
process of 
debridement. 
If the surrounding 
skin is not masked 
properly they may 
macerate the 
surrounding tissue. 
Cost factor 
Honey Honey provides an osmotic hydrophilic 
environment that allows the rehydration 
of devitalized tissue, among other 
benefits. 
Can be applied to a 
wound at any stage, 
promotes moist wound 
healing and autolytic 
debridement. Minimal 
level of skill required. 
Not associated with pain 
as mechanical forms of 
debridement may be. 
Promotes a slow 
process of 
debridement. 
If the surrounding 
skin is not masked 
properly they may 
macerate the 
surrounding tissue. 
Cost factor 
Saline gauze Moist saline gauze is often widely 
utilized and can potentially serve as a 
control or standard form of debridement. 
Can be applied to a 
wound at any stage, 
promotes moist wound 
healing and autolytic 
debridement as long as 
it is kept from drying 
Minimal level of skill 
required. 
Promotes a slow 
process of 
debridement. 
If the surrounding 
skin is not masked 
properly they may 
macerate the 
surrounding tissue. 
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                    Table 7 Study year, sample sizes and study settings of included studies 
# [Study ID] Year 
[Total 
Sample 
Size] 
[Primary Intervention] 
(# patients preceding) 
[Comparator/Control] (# 
patients preceding) 
Study Setting Country 
1 Ali 2013 2013 70 
A) Cutimed Sorbact 
35 patients 
B) Standard Dressing 
(Saline cleansed 
povidone soaked gauze 
dressing) 
35 patients 
Hospital 
Saudi 
Arabia 
2 Amini 2013 2013 40 
A) Low frequency (20-
60kHz) ultrasound 
assisted wound therapy 
+ standard wound care 
20 patients 
B) Standard wound care 
alone 
20 patients 
Clinic Iran 
3 Apelqvist 1990 1990 44 
A) Hydrococolloid 
22 patients 
B) Adhesive Zinc Oxide 
tape 
22 Patients 
Outpatient Sweden 
4 Baker 1993 1993 19 
A) Allevyn 
Hydrocellular dressing 
? patients 
B) Sorbsan Calcium-
Alginate dressings 
? patients 
Clinic Unclear 
5 Belcaro 2010 2010 66 
A) Multivalent silver 
oxide Ag4O4 ointment 
+ elastic compression 
34 patients 
B) Control group 
(standard cleaning and 
elastic compression 
management methods 
without silver ointment) 
32 patients 
Unclear Italy 
6 Blackman 1994 1994 18 
A) Polymeric dressing 
11 patients 
B) Wet to dry saline 
dressing 
7 Patients 
Unclear US 
7 Bowling 2011 2011 20 
A) Jet lavage 
debridement with 
superoxide aqueous 
solution + hydrogel 
10 patients 
B) Jet lavage 
debridement with saline 
solution + hydrogel 
10 patients 
Hospital, 
Outpatient 
US, UK 
8 Clever 1995 1995 40 
A) Hydroactive 
polyurethane gel 
dressing Cutinova 
Hydro + standard 
therapy* 
20 patients 
B) Hydrophilic 
polyurethane foam 
dressing Allevyn + 
standard therapy* 
20 patients 
Outpatient Germany 
9 D'Hemeourt 1998 1998 138 
A) Good wound care + 
Sodium 
Carboxymethylcelluose 
Hydrogel 
70 patients 
B) Good wound care* 
alone 
68 patients 
Unclear USA 
10 Donaghue 1998 1998 75 
A) Collagen Alginate B) Saline gauze 
Outpatients USA 
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50 patients 25 patients 
11 
EhsanUrRehman 
2013 
2013 60 
A) Honey soaked 
dressing 
? patients 
B) Povidone-
iodine/normal saline 
dressing 
? patients 
Hospital, ED Pakistan 
12 Foster 1994 1994 30 
A) Hydrocellular 
polyurethane foam 
dressing Allevyn 
15 patients 
B) Calcium sodium 
alginate dressing 
15 patients 
Outpatient UK 
13 Goretti 2008 2008 40 
A) Super-oxidized 
solution (SOS) 
treatment 
20 patients 
B) Standard local 
treatment with povidone 
iodine 
20 patients 
Hospital Italy 
14 Hammouri 2004 2004 203 
A) Honey/Normal 
Saline, washed with 
normal saline post-
debridement 
100 patients 
B) Povidone 
Iodine/H2O2 (3:1) 
washed with same 
solution post-
debridement 
100 patients 
Hospital Jordan 
15 Jeffcoate 2009 2009 317 
A) Hydrofiber 
103 patients 
B) Iodine Gauze 
108 patients 
C) Gauze 
106 patients 
Multidisciplinary 
Outpatient 
9 centers 
UK 
16 Jensen 1998 1998 31 
A) Carrasyn hydrogel 
wound dressing 
(CHWD) cleansed with 
ULTRAKLENZ 
wound cleanser. 
14 patients 
B) Wet-to-moist saline 
gauze cleansed with 
ULTRAKLENZ wound 
cleanser 
17 patients 
Outpatient USA 
17 Lalau 2002 2002 77 
A) Calcium Alginate 
39 patients 
B) Vaseline Gauze 
38 patients 
Outpatients France 
18 Markevich 2000 1998 140 
A) Larval therapy 
(green bottle fly - 
Lucilia sericata 6-10 
larva per 1 cm2 of 
wound surface area) 
removed after 72 hours 
70 patients 
B) Hydrogel (no data on 
frequency of dressing 
change) 
70 patients 
Unclear Europe 
19 Mazzone 1993 1993 19 
A) Polymeric 
membrane foam 
dressing 
11 patients 
B) Wet to Dry saline 
gauze mesh dressing 
8 patients 
Outpatient USA 
20 Munter 2006 2006 619 
A) Silver releasing 
hydrophilic 
B) Local Best Practice 
(study reports that this 
ranged from gauze, 
moist wound healing, 
wound healing products, 
Outpatient 
Germany 
UK 
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polyurethane foam 
dressing 
326 patients 
to antimicrobial 
treatments) 
293 patients 
Denmark 
Italy 
Switzerland 
Belgium 
Slovenia 
Brazil 
Canada 
21 Ogce 2007 2007 60 
A) Hydrocolloid 
dressing (combined 
with paste for wound 
cavities, and powder 
for infection) 
30 patients 
B) Classic wound 
dressing 
30 patients 
Hospital Turkey 
22 Piaggesi 2001 2001 24 
A) Sodium Carboxy-
Methyl Cellulose 
Hydrofiber (Aquacel) 
changed every 2nd or 
3rd day depending on 
extent of exudate 
produced by wound. 
10 patients 
B) Saline moistened 
gauze (renewed twice 
daily with saline to 
prevent drying) 
10 patients 
Outpatient Italy 
23 Piaggesi 1998 1998 46 
A) Treatment - 
Surgical debridement 
22 patients 
B) Control - Non-
surgical conservative 
treatment and pressure 
relief 
24 patients 
Outpatient Italy 
24 Rhaiem 1998 1998 80 
A) G1: cleaning ulcers 
with hydrogen 
peroxide 3% + local 
applied Jam sugar 
16 patients 
B) G2: cleaning ulcers 
with hydrogen peroxide 
3% + antibiotic-therapy 
24 patients 
C) G3: cleaning ulcers 
with hydrogen peroxide 
3% + antibiotic-therapy 
40 patients 
Hospital Tunisia 
25 Roberts 2001 2001 30 
A) Allevyn 
hydrocellular foam 
dressing 
14 patients 
B) Saline soaked (low 
adherent) dressing and 
standard podiatric care 
16 patients 
Hospital UK 
26 Shukrimi 2008 2008 30 
A) Honey dressing 
? patients 
B) Standard dressing 
(Povidone 
Iodine/Normal saline, 
1:10) 
? patients 
Hospital Malaysia 
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27 Singh 2006 2006 60 
A) Non-contact 
Ultrasonic debridement 
(24 KHz) performed 
every other day 
33 patients 
B) Sharp/surgical 
debridement conducted 
every other day 
27 patients 
Hospital Malaysia 
28 Tallis 2013 2013 48 
A) Clostridial 
Collagenase Ointment 
(CCO) 
24 patients 
B) Saline Moistened 
Gauze (SMG) + 
Selective Sharp 
Debridement 
24 patients 
Outpatient USA 
29 Vandeputte 1997 1997 29 
A) Hydrogel 
15 patients 
B) Dry gauze (control) 
14 patients 
Outpatient Belgium 
30 Whalley 2001 2001 66 
A) Purilon Hydrogel 
? patients 
B) Intrasite Hydrogel 
using Biatain Non-
adhesive dressing 
(Coloplast A/S) as a 
secondary dressing 
Dressings changed at 
least every second day 
? patients 
Unclear Europe 
Footnotes: G1 = Group 1, G2 = Group 2 
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Table 8 Inclusion & exclusion criteria for included studies 
Trial Author Inclusion Criteria Exclusion Criteria 
1) Ali 2013 1) Texas 2nd grade diabetic foot ulcer Not reported. 
2) Amini 2013 1) Diabetes (type 1 and type 2) 
2) Diabetic foot ulcer 
3) Wagner Grade 3 chronic (>1 month) 
1) 0.6 </= ABI* </= 1.2 
(*Ankle Brachial Index) 
3) Apelqvist 1990 1) Previous diabetes mellitus 
2) Superficial skin ulcer below the ankle 
3) Systolic toe pressure > 45 mmHg or an 
absence of cutaneous erythema. 
4) Ulcers between 1 - 25 cm2 and > 50% 
covered by dry or wet necrotic tissue. 
5) Only one ulcer the largest was chosen for 
study in each patient. 
1) Patch test positive individuals. 
2) Clinical signs of cellulitis. 
3) Ulcers where application of intervention 
dressings would be inappropriate. 
4) Baker 1993 1) Patients with neuropathic foot ulcer in a 
diabetic foot center 
Type of DM unspecified 
Not reported 
5) Belcaro 2010 1) Patients who had ulcers resulting from 
chronic venous insufficiency or diabetes 
Not reported. 
6) Blackman 1994 1) Diabetes Type 1 or Type 2 
2) Partial or full thickness open wound or foot 
ulcer free; free of hard eschar 
1) Ulcers with Wagner stage 3 or higher 
2) Ulcers progressing to Wagner stage 3 or higher 
3) Subjects needing vascular surgery 
4) Ulcers from Charcot joints 
5) Ulcers of non-diabetic origin 
7) Bowling 2011 1) Type 1 or Type 2 DM 
2) Foot ulcer, full thickness, distal to malleoli 
2) Chronic > 4 weeks 
3) Non-clinically infected foot ulcers 
4) Necrotic tissue present and mechanical 
debridement indicated. 
5) One ulcer per patient included 
1) Ulcers larger than 25 cm2 
2) Texas Classification grade 3 
3) Osteomyelitis 
4) Peripheral arterial disease (ABI < 0.8/absent 
pulses. 
5) Prescription use of anticoagulants, 
immunosuppressive drug treatment 
6) Allergies to chlorine 
7) Clinically infected wounds excluded on 
grounds of antibiotic use. 
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8) Clever 1995 1) Age 18 - 80 years 
2) Pure neuropathic superficial ulcer 1-5 cm in 
diameter 
Diabetics with an ankle-brachial pressure 
index < 0.8 (measured using Doppler ultrasound) 
Clinical or radiological signs of osteomyelitis or 
tendon 
involvement. 
Large vessel disease 
Ulcers requiring additional topical treatment 
Known allergies to any product used 
9) D'Hemecourt 
(1998): written 
consent needed 
1) 19 years or older 
2) Type 1 or type 2 diabetes 
3) At least 1 full thickness ulcer (stage 3 or 4) 
chronic diabetic foot ulcer present for at least 
8 weeks. 
4) Target area (Length x Width) 1cm2-10cm2 
post debridement 5) Transcutaneous oximetry 
in the affected limb (TcpO2) >/= 30 mmHg 
1) Osteomyelitis affecting area of ulcer 
2) Target area < 1cm2 OR > 10 cm2 post-
debridement 
3) More than 3 ulcers present at baseline 
4) A cause of ulcer other than diabetes e.g. 
electrical, chemical or radiation 
5) Patients with cancer at time of enrollment 
6) Concomitant medication known to affect 
wound healing e.g. corticosteroids, chemotherapy, 
immunosuppressant’s 
7) Pregnant, nursing or of child bearing potential 
not using acceptable contraception. 
10) Donaghue 1998 1) At least 21 years of age 
2) Adequate nutritional intake (albumin > 2.5 
gms/dl) 
3) Adequate blood flow to lower extremity 
(palpable pulses, normal noninvasive tests) 
4) Foot ulceration at least 1 cm2 post-
debridement. 
1) Severe renal impairment (creatinine >) 
2) Severe liver impairment (liver function tests 
>/= 2 times normal levels. 
3) Serious medical disorder that can interfere with 
wound healing. 
4) Osteomyelitis (deep ulcer probing to bone, or 
radiographic evidence) 
5) Clinical signs of infection 
6) History of alcohol or drug abuse. 
11) EhsanUrRehman 
2013 
1) Diabetic patients of either gender 
2) All age groups 
3) Diabetic foot ulcers Wagner grade I & II 
1) Nonconsenting patients 
2) Systemic infection and other comorbidities 
12) Foster 1994 1) At least 18 years’ old 
2) A clean diabetic foot ulcer 
3) Willing and able to comply with study 
protocol 
1) Slough, necrotic, or infected ulcer 
324 
 
13) Goretti (2008) 1) Infected foot lesions post-surgical 
debridement 
2) surgical outcomes > 5 cm2 
3) ankle-brachial index > 0.9, 
4) presence of at least two arteries in the ankle 
documented by palpable pulses or Doppler 
CW 
Not reported 
14) Hammouri 2004 1) Diabetic foot ulcers Not reported 
15) Jeffcoate 2009 1) Type 1 and type 2 Diabetes 
2) Age > 18 yrs. 
3) Chronic (>/= 6 weeks) full thickness foot 
ulcer on or below malleoli 
4) Cross sectional area 25 mm2 - 2500 mm2 
5) Able and willing to give informed consent 
6) Reasonably accessible by car to the hospital 
1) Known allergy to treatment preparations 
2) Ulcer extending to tendon, periosteum, or bone 
3) Osteomyelitis 
4) Soft tissue infection requiring systemic 
antibiotics 
5) Ulcer on a limb being considered for 
revascularization 
6) Management with a non-removable cast 
without a dressing window. 
7) Gangrene on affected foot 
8) Eschar not removable by clinical debridement 
9) Sinus or deep track 
10) Hallux amputation preventing toe pressure 
measurement 
11) ABI < 0.7 or toe systolic pressure < 30 mmHg 
12) Ulceration by disease other than diabetes 
13) Any other serious disease likely to 
compromise outcome 
14) Cr > 300 µMol/L 
15) Immunosuppressant’s, systemic steroids other 
than inhalation, or any other preparation that could 
interfere with healing. 
16) Living > 10 miles from clinic 
17) Those withholding consent 
16) Jensen (1997): 
written consent needed 
1) Diabetic foot ulcer of at least 1cm diameter No exclusion criteria specified 
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2) No evidence of infection in ulcer or peri-
wound tissue 
3) Wagner grade 2 ulcer, full thickness into 
subcutaneous tissue, not involving tendon, 
joint capsule, or bone 
4) Documented blood supply consistent with 
the ability to heal (palpable pulses, non-
invasive vascular study) 
5) Willingness to comply with protocol. 
17) Lalau 2002 1) Age < 75 yrs. 
2) Diabetes either Type 1 or Type 2 
3) Foot lesion in the phase of cleansing 
(granulation tissue < 50% for wound area) 
4) Surface area between 1 - 50 cm2. 
Acute (< 2 months) and Chronic lesions 
2) Surface area of 1 - 50 cm2 
1) Hgba1c > 10% 
2) Presence of clinical infection (redness, 
swelling, warmth, periwound erythema) 
3) Osteomyelitis (on plain radiography, or probing 
of bone) 
4) Tunneled wound 
5) Severe hypo-vascularization (TcPO2 < 
30mmHg) 
18) Markevich (2000) Diabetic Neuropathic Foot wounds No exclusion criteria specified 
19) Mazzone 1993 1) Diabetic subjects with chronic foot ulcers 
Type of DM unspecified. 
No other inclusion criteria pre-specified. 
No exclusion criteria specified. 
20) Munter 1) 18 years or older 
2) Not pregnant or lactating 
3) Chronic wounds 
4) Mixed etiology wounds including: burns, 
donor sites, post-operative wounds, but most 
reported as leg ulcers, pressure ulcers, and 
Diabetic foot ulcers (Wagner grade 1 - 3) 
5) Ulcer depth < 0.5 cm 
Not reported 
21) Ogce 2007 1) Type 1 or Type 2 Diabetes 
2) Wagner grade 2 or grade 3 diabetic foot 
ulcers 
Not reported 
22) Piagessi 2001 1) All patients presenting to foot clinic in 
1998 
2) Age 18 - 75 
3) Type 1 or Type 2 diabetes > 5 years 
4) Ulcer deeper than 1 cm for 3 weeks 
1) Active infection: Local signs (purulent 
discharge, redness, swelling, tenderness or odor) 
OR systemic signs (fever, malaise, leukocytosis) + 
confirmed culture exams 
2) Plasma creatinine > 2 mg/dl 
3) Recent episode of ketoacidosis 
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5) Palpable peripheral pulses or ABPI > 0.9 
6) Ulcers due to diabetic neuropathy or 
surgical drainage of previous infection or 
both. 
4) Malignancies 
5) Any therapy of pathology that might interfere 
with healing process 
6) Candidates for a major amputation 
23) Piaggesi (1998) 1) All patients newly presenting to the 
diabetic foot clinic between January - 
December 1995 
2) One or more diabetic neuropathic ulcer 
3) Diabetes type 1, type 2, at least 5 years 
duration uncomplicated. 
1) Presence of symptomatic claudication OR 
absence of foot pulses 
2) Recent ketoacidosis 
3) Renal Failure Cr > 177 micromole/L 
4) Presence of Infection 
5) Congenital foot deformities or diabetic 
neuroarthropathy 
6) BMI > 30 
7) Clinical history of stroke, cardiac failure, 
cancer, HIV, Mental Illness 
8) ABPI < 0.9 
9) Osteomyelitis 
24) Rhaiem 1998 1) Diabetic hospitalized patients from 1992 - 
1995 
Not reported 
25) Roberts 2001 1) Type 1 diabetics with neuropathic foot 
ulcers of the plantar surface. 
No other inclusion criteria pre-specified. 
ABPI < 0.8 No exclusion criteria specified. 
26) Shukrimi 2008 1) All NIDDM patients with Wagner grade II 
ulcers admitted for surgery. 
2) Age 35 - 65 
3) TcPO2 > 30 mmHg 
4) Albumin > 35 g/dl 
1) Multiple medical comorbidity 
2) Steroid therapy 
3) Neutrophil count < 2000/mm3 
27) Singh 2006 1) Diabetic foot ulcers admitted to orthopedic 
wards. 
2) Wagner type 1 and type 2 
3) Known cases of DM Type 1 or Type 2 
treated medically 
4) Glycemic control during hospitalization 
with insulin. 
5) Sensate feet based on Modified 
Neuropathic Disability Score (NDS) 
1) Wagner grade 3 or grade 4 diabetic foot ulcers 
2) Ulcers covered with hard scab 
3) Peripheral neuropathy based on modified NDS 
4) Patients without at least one of the foot pulses 
palpable (dorsalis pedis or posterior tibial) 
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6) At least one of the foot pulses palpable 
(dorsalis pedis or posterior tibial arteries) 
28) Tallis 2013 1) 18 yrs. or older, any race, either sex 
2) Type 1 or Type 2 DM requiring diabetic 
medications. 
3) Full thickness neuropathic ulcers between 
0.5 cm2 - 10 cm2 
4) Ulcer duration 1 month 
5) Willing and able to perform daily dressing 
changes at home. 
6) Willing and able to use off-loading 
7) Adequate perfusion to target foot ulcer 
(TcPO2 > 40 mmHg, or toe pressure > 40 
mmHg or Doppler waveform consistent with 
adequate flow) 
8) Adequate nutrition (albumin >/= 2.0 g/dL 
and pre-albumin > 15 mg/dL) 
9) No active infection 
10) No target wound tunneling 
11) Target could not be on heel or over a 
Charcot deformity 
Not reported 
29) Vandeputte 
(1997): written 
consent needed 
Diabetic wound on foot Patient receiving systemic antibiotics 
30) Whalley (2001) 1) Diabetic neuropathic foot ulcer 
2) Type 1 and Type 2 Diabetics 
No exclusion criteria specified 
Foot notes 
TcPo2 – Transcutaneous oximetry in mmHg 
ABI – Ankle Brachial Index 
Hga1c = Hemoglobin a1c 
BMI – Body Mass Index 
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Table 9 Patient demographics for Included studies 
# [Study ID] [Mean Age yrs. +/- SD] [Gender M/F] 
1 Ali 2013 Not reported 48/22 
2 Amini 2013 55.2 +/- 9.4 24/16 
3 Apelqvist 1990 63 +/- 36 26/20 
4 Baker 1993 Not reported Not reported 
5 Belcaro 2010 55.9 +/- 3.8 29/37 
6 Blackman 1994 55.9 +/- 13.6 17/1 
7 Bowling 2011 53.1 +/- 12.6 12/8 
8 Clever 1995 56 +/- 13.13 32/8 
9 D'Hemeourt 1998 58.3 +/- 12.13 127/45 
10 Donaghue 1998 59.5 54/21 
11 EhsanUrRehman 2013 55.3 +/- 3.89 35/25 
12 Foster 1994 65.5 20/10 
13 Goretti 2008 Not reported Not reported 
14 HammouriJRMS2004 58 112/88 
15 Jeffcoate 2009 59.6 +/- 12.6 240/76 
16 Jensen 1998 Not reported Not reported 
17 Lalau 2002 62.2 +/- 11.75 45/32 
18 Markevich 2000 53.6 +/- 15.4 Not reported 
19 Mazzone 1993 Not reported Not reported 
20 Munter 2006 69.3 +/- 13.90 Not reported 
21 Ogce 2007 59.85 36/24 
22 Piaggesi 2001 62.2 +/- 6.05 Not reported 
23 Piaggesi 1998 64.39 +/- 11.67 Not reported 
24 Rhaiem 1998 56 +/- 32 59/21 
25 Roberts 2001 59.5 Median 23/7 
26 Shukrimi 2008 52.1 15/15 
27 Singh 2006 56.87 +/- 11/06 33/27 
28 Tallis 2013 61 +/- 11.8 32/16 
29 Vandeputte 1997 63.95 +/- 14.5 13/16 
30 Whalley 2001 Not reported Not reported 
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Table 10 Baseline wound size and duration characteristics of included studies 
Surface Area of 
wound ** 
** Expressed as 
means +/- SD unless 
otherwise noted 
Depth of wound 
** 
Wound Staging 
(Wagner Wound 
Grade 0 - 5 OR Texas 
classification 1 - 3, A, 
B, C, or D) 
(Staging indicates 
maximum stage or 
grade accepted for 
study.) 
Duration of ulcer 
** 
1) Ali 2013 
Reported as: 
< 4 cm2 4+ cm2  
A) 0 35 
B) 8 27 
Reported only as: 
< 3 cm 3+ cm 
A) 0 35 
B) 19 16 
Texas 1A -> 2D 
(Texas 2D) 
Total Sample 
Mean duration of 
foot ulcers = 9 
weeks (1 - 105) 
2) Amini 2013 
A) 6.8 +/- 6 cm2 
B) 9.9 +/- 7.6 cm2 
Not reported Wagner Grade 3 A) 3.4 +/- 3.5 
months 
(15.6 +/- 16.8 
weeks) 
B) 4.4 +/- 4.7 
months 
(17.6 +/- 18.8 
weeks) 
3) Apelqvist 1990 
A) median 2.2 cm2 (1 - 
10.5) 
B) median 2.2 cm2 (0.9 
- 20.4) 
Not reported Not reported Not reported 
4) Baker 1993 
No baseline data 
reported. 
Not reported Not reported Not reported 
5) Belcaro 2010 Not reported Not reported Not reported 
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Baseline at 4 weeks 
A) 2.22 cm2 0.24 cm2 
B) 2.18 cm2 1.66 cm2 
p<0.05 statistically 
significant difference 
6) Blackman 1994 
A) 2.67 +/- 1.20 cm2 
B) 1.81 +/- 0.75 cm2 
No statistically 
significant difference 
Not reported. Wagner Grade 1-2 
(Wagner 3) 
A) 25 +/- 7 weeks 
B) 28 +/- 6 weeks 
7) Bowling 2011 
A) 3.0 +/- 3.7 cm2 
B) 1.8 +/- 1.6 cm2 
Not reported Texas Grade 1-2 
(Texas 2) 
A) 13.7 +/- 12.0 
weeks 
B) 9.7 +/- 8.1 weeks 
8) Clever 1995 
Initial After 4 weeks 
A) 2.05 +/- 3.14 cm2 
A) 0.32 ± 0.54 cm2  
B) 2.08 +/- 2.72 cm2 
B) 0.34 ± 0.75 cm2 
(p > 0.2) Not 
statistically significant 
Not reported Not reported A) 162.37 +/- 
325.55 days 
(23.2 ± 46.5 weeks) 
B) 165.00 +/- 
318.68 days 
(23.6 ± 42.5 weeks) 
9) D'Hemecourt (1998) 
A) (Good Wound Care 
alone) 
3.5 +/- 3.53 cm2 
B) (Good Wound Care 
+ NaCMC) 
3.2 +/- 2.75 cm2 
A) 0.4 +/- 0.52 cm 
B) 0.4 +/- 0.20 cm 
Full thickness 
Stage 3 or 4 
Wagner Grade 3 - 4 
(Wagner 4) 
A) 42 +/- 42 weeks 
B) 52.8 +/- 60.92 
weeks 
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Target area 1 cm2 to 10 
cm2 post-debridement 
10) Donaghue 1998 
A) 2.6 +/- 0.50 cm2 
B) 2.99 +/- 0.62 cm2 
No statistically 
significant difference 
(p=0.6237) 
Not reported Wagner Grade 1 - 3 
(Wagner 3) 
A) 146 +/- 73 days 
(20.86 +/- 10.43 
weeks) 
B) 225 +/- 104 days 
(32.14 +/- 14.86 
weeks) 
No statistically 
significant 
difference 
(p=0.5369) 
11) EhsanUrRehman 
2013 
Not reported 
Not reported Wagner Grade 1 - 2 
(Wagner 2) 
Not reported 
12) Foster 1994 
A) 0.88 cm2 
B) 0.79 cm2 
Superficial Deep 
A) 12 3 
B) 13 2 
Not reported A) 107 days 
(15.3 weeks) 
B) 170 days 
(24.3 weeks) 
13) Goretti (2008) 
Surgical outcomes > 5 
cm2 
No other baseline data 
specified 
Not reported Not reported Not reported 
14) Hammouri 2004 
Not reported 
Not reported Not reported Not reported 
15) Jeffcoate 2009 
0.25-1 cm2 1.01- 0.25 
cm2 2.5-25 cm2 
A) 53 34 16 
Not reported Not reported Not reported 
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B) 48 36 24 
C) 50 34 22 
16) Jensen (1997) 
All ulcers at least 1 
cm2 
No other baseline data 
specified 
No other baseline 
data specified 
Wagner Grade 2 A) 8 months 
(32 weeks) 
B) 3 months 
(12 weeks) 
17) Lalau 2002 
A) 8.0 +/- 10.5 cm2 
B) 8.8 +/- 16.0 cm2 
Not reported Not reported A) 4.9 +/- 7.8 
months 
(19.6 +/- 31.2 
weeks) 
B) 9.1 +/- 13.1 
months 
(36.4 +/- 52.4 
weeks) 
18) Markevich (2000) 
A) 14.90 cm2 
B) 15.14 cm2 
Reported as 
comparable at 
baseline, but not 
otherwise specified 
Not reported Average duration 
reported for total 
sample as 15.8 +/- 
10.7 years. 
(821.6 +/- 556.4 
weeks) 
Not reported 
separately for each 
intervention group. 
19) Mazzone 1993 
Not reported 
Not reported Not reported Not reported 
20) Munter 2006 
A) 52.9 +/- 90 cm2 
B) 36.6 +/- 64.4 cm2 
Not reported Wagner Grade 1 - 3 
(Wagner grade 3) 
Not reported 
21) Ogce 
Not reported 
Not reported Not reported Not reported 
22) Piagessi 2001 A) 2.9 +/- 1.1 cm Not reported A) 5.9 +/- 1.3 weeks 
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A) 19.2 +/- 6.4 cm3 
B) 22.6 +/- 8.4 cm3 
No statistically 
significant difference 
B) 2.3 +/- 1.4 cm 
No statistically 
significant 
difference 
B) 6.8 +/- 2.6 weeks 
No statistically 
significant 
difference 
23) Piagessi 1998 
Not reported 
A) 1.58 +/- 2.20 cm 
B) 1.98 +/- 1.07 cm 
Wagner Grade 1 - 2 
(Wagner Grade 2) 
A) 32.74 +/- 19.25 
days 
(4.7 +/- 2.75 weeks) 
B) 39.43 +/- 18.92 
(5.6 +/- 2.7 weeks) 
24) Rhaiem 1998 
Not reported 
Not reported Not reported Not reported 
25) Roberts 2001 
Sample median 1.23 
cm2 
Sample median range 
(0.21 - 3.50 cm2) 
A) Median 1.1 cm2 
B) Median 1.45 cm2 
Not reported Not reported Sample 15.2 weeks 
Range (1 week - 6 
years) 
26) Shukrimi 2008 
Not reported 
Not reported Wagner Grade 2 Not reported 
27) Singh 2006 
Not reported 
Not reported Wagner Grade 1 - 2 
(Wagner Grade 2) 
Not reported 
28) Tallis 2013 
A) 3.0 +/- 2.1 cm2 
B) 2.4 +/- 2.1 cm2 
Not reported Not reported Not reported 
29) Vandeputte 1997 
Not reported 
Not reported Not reported Not reported 
30) Whalley 2001 
A) 2.5 +/- 3.2 cm2 
Not Reported Wagner Grade 1 - 2 
(Wagner grade 2) 
Not reported 
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B) 2.4 +/- 2.9 cm2 
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Table 11 Baseline participant complicating risk factors for delayed healing in the included studies 
[#] [Study ID] [Mean Hgba1c 
(%)] 
[Mean Duration of 
DM (yrs.)] 
[Proportion of sample 
with baseline 
PAD/PVD] 
 [Proportion of 
sample with baseline 
Infection] 
[Offloading] 
Reported Y/N 
 [Proportion with 
Baseline Immune-
suppression] 
[Nutritional status]  Proportion of sample 
Smoking 
Proportion of 
sample with 
Venous 
Insufficiency 
1 Ali 2013 Not reported Not 
reported 
Not reported 
 
Not reported Not reported Not 
reported 
Not 
reported 
0.214 Not 
reported 
2 Amini 2013 8.9 +/- 2.3 14.8 +/- 7.3 0.50 Not reported Yes Not 
reported 
Not 
reported 
0.075 Not 
reported 
3 Apelqvist 1990 8.2 +/- 1.75 20.5 +/- 13.5 Not reported Not reported Yes Not 
reported 
Not 
reported 
Not reported Not 
reported 
4 Baker 1993 Not 
Reported 
Not 
Reported 
Not 
Reported 
Not 
Reported 
Not Reported Not 
Reported 
Not 
Reported 
Not Reported Not Reported 
5 Belcaro 2010 Not 
Reported 
Not 
reported 
Not reported Not reported Not reported Not 
reported 
Not 
reported 
Not reported Not 
reported 
6 Blackman 1994 8.95 +/- 1 Not 
reported 
Not reported Not reported Yes Not 
reported 
Not 
reported 
Not reported Not 
reported 
7 Bowling 2011 8.7 +/- 1.8 19.35 +/- 8.1 0 0 Not reported Not 
reported 
Albumin 
40.1 +/- 4.5 
grams/Liter 
Not reported Not 
reported 
8 Clever 1995 Not reported Not 
reported 
Not reported 0.725 Yes Not 
reported 
Not reported 0.325 Not 
reported 
9 D'Hemeourt 1998 Not reported Not 
reported 
Not reported Not reported Yes Not 
reported 
Not reported Not reported Not 
reported 
10 Donaghue 1998 Not reported 18 
Range (30 - 81) 
Not reported 0 Yes Not 
reported 
Alb 
3.76 +/- 0.09 
Not reported Not 
reported 
11 EhsanUrRehman 2013 Not reported Not reported Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
12 Foster 1994 Not reported Not reported Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
13 Goretti 2008 Not reported Not reported 0 1 Not reported Not 
reported 
Not reported Not reported Not reported 
14 Hammouri 2004 Not reported Not reported Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
15 Jeffcoate 2009 Not reported 15.7 +/- 10.8 0.196 0 Yes 0 Not reported 0.170 Not reported 
16 Jensen 1998 Not reported Not reported 0 0 Yes Not 
reported 
Not reported Not reported Not reported 
17 Lalau 2002 7.75 +/- 1.75 18.05 +/- 10.35 0.22 Not reported Yes Not 
reported 
Not reported Not reported Not reported 
18 Markevich 2000 Not reported 15.8 +/- 10.7 Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
19 Mazzone 1993 Not reported Not reported Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
20 Munter 2006 Not reported Not reported Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
21 Ogce 2007 7.73 Not reported Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
22 Piaggesi 2001 8.5 +/- 2.9 15.45 +/- 7.55 0 0 Yes Not 
reported 
Not reported Not reported Not reported 
23 Piaggesi 1998 9.2 +/- 3.0 17.52 +/- 9.51 0 0 Yes 0 Not reported Not reported Not reported 
24 Rhaiem 1998 Not reported 13 +/- 10.6 Not reported 0.517 Not reported Not 
reported 
Not reported 0.55 Not reported 
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25 Roberts 2001 Not reported Not reported Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
26 Shukrimi 2008 Not reported Not reported Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
27 Singh 2006 Not reported Not reported Not reported Not reported Not reported Not 
reported 
Not reported Not reported Not reported 
28 Tallis 2013 Not reported Not reported 0 0 Yes Not 
reported 
Not reported Not reported Not reported 
29 Vandeputte 1997 Not reported Not reported Not reported 0.069 Not reported Not reported Not reported Not reported Not reported 
30 Whalley 2001 Not reported Not reported Not reported Not reported Yes Not 
reported 
Not reported Not reported Not reported 
Footnotes 
Study ID = Study Identification 
Hgba1c % = Hemoglobin A1c in percent 
Duration of DM = Duration of Diabetes in years 
PAD/PVD = Peripheral arterial disease/Peripheral vascular disease 
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Table 12 Table of industry supported included 
studies 
[#] [Study ID] [Industry support] 0 = No, 1 = Yes, 2 = Unclear 
1 Ali 2013 2 
2 Amini 2013 0 
3 Apelqvist 1990 1 
4 Baker 1993 1 
5 Belcaro 2010 2 
6 Blackman 1994 1 
7 Bowling 2011 1 
8 Clever 1995 1 
9 D'Hemeourt 
1998 
2 
10 Donaghue 1998 1 
11 EhsanUrRehman 
2013 
2 
12 Foster 1994 2 
13 Goretti 2008 1 
14 Hammouri 2004 2 
15 Jeffcoate 2009 2 
16 Jensen 1998 1 
17 Lalau 2002 1 
18 Markevich 2000 2 
19 Mazzone 1993 1 
20 Munter 2006 1 
21 Ogce 2007 2 
22 Piaggesi 2001 0 
23 Piaggesi 1998 2 
24 Rhaiem 1998 2 
25 Roberts 2001 1 
26 Shukrimi 2008 2 
27 Singh 2006 2 
28 Tallis 2013 1 
29 Vandeputte 
1997 
2 
30 Whalley 2001 2 
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Table 13 Table of study debridement types 
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Table 14 Summary of Results, Overall Effect Sizes, and Heterogeneity 
             RR (95% CI) **MD (95% CI) Heterogeneity of Outcome Effects Summary 
Statisticsb 
Intervention 
comparison 
Outcome k Fixed-Effects Random-Effects τ2 χ2 I2 (%) p-value 
Hydrogel vs. 
Gauze 
Proportion of 
Amputations 
2 0.26 (0.05, 1.37) 0.26 (0.05, 1.40) 0.00 0.11 0 0.74 
 Proportion of 
Infections 
3 0.87 (0.54, 1.40) 0.74 (0.18, 2.99) 0.91 4.89 59 0.09 
 Proportion of 
Ulcers Healing 
3 1.68 (1.14, 2.49) 1.71 (1.16, 2.52) 0.00 0.95 0 0.62 
Foam vs. Wet to 
Dry 
Proportion of 
Ulcers Healing          
2 studies 
2 4.35 (1.33, 14.29) 3.56 (0.93, 13.66) 0.18 1.15 13 0.28 
Hydrofiber vs. 
Gauze 
Proportion of 
Amputations 2 
studies 
2 1.31 (0.33, 5.16) 1.34 (0.29, 6.10) 0.05 1.03 3 0.31 
 Proportion of 
Infections      2 
studies 
2 1.11 (0.84, 1.46) 0.96 (0.40, 2.31) 0.21 1.37 27 0.24 
 Proportion of 
Ulcers Healing          
2 studies 
2 0.06 (0.06, 0.19) 0.07 (0.05, 0.19) 0.00 0.09 0 0.76 
 Mean Time to 
Complete Healing          
2 studies 
2 **-13.87 (-27.91, 0.16) **-53.37 (-153.29, 
46.56) 
4892.23 16.29 94 < 0.0001 
Any debridement 
vs. Gauze 
Proportion of 
Amputations 5 
studies (n=6) 
5 0.49 (0.19, 1.27) 0.48 (0.17, 1.37) 0.00 2.67 0 0.75 
 Proportion of 
Infections      7 
studies (n=8) 
7 1.10 (0.89, 1.36) 1.07 (0.76, 1.52) 0.07 10.82 35 0.15 
 Quality of Life                
1 study (n=2) 
1 -0.01 (-0.04, 0.01) -0.01 (-0.04, 0.01) 0.00 0.00 0 0.95 
 Proportion of 
Ulcers Healing        
10 studies (n=11) 
3 1.17 (1.00, 1.36)        
 
1.22 (1.04, 1.44) 
 
0.02 13.89 28 0.18 
 Proportion of 
Ulcers Healing        
(two studies 
available only as 
abstracts) 
10 1.12 (0.95, 1.32)]  1.18 (0.99, 1.41) 0.02 12.26 35 0.14 
 Proportion of Ulcer 
Recurrence   2 
studies (n=3) 
2 0.77 (0.34, 1.71) 0.81 (0.25, 2.58) 0.42 3.29 39 0.19 
 Mean Time to 
Complete Healing          
4 studies (n=5) 
4 2.54 (1.20, 3.87) -27.88 (-52.53, -3.23) 614.40 39.33 90 < 0.00001 
Note: 
** indicates a significant effect; k represents the number of interventions for each outcome included in the analysis; Q represents Cochran’s Q indicating 
significance of heterogeneity; I2 represents the magnitude of heterogeneity; p-value represents the significance of heterogeneity. 
 
 
 
b) Relative risk (RR) was the effect estimate for proportion of amputations, proportion of infections, and proportion of ulcers healed, and proportion of 
recurrence. Mean difference (MD) was the effect estimate for the outcomes Quality of life, and Time to complete healing.  
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                                        Table 15 Tests for Publication Bias 
Intervention Outcome Egger’s Begg’s 
Any debridement as 
compared with gauze 
Proportion of Ulcers 
Healing 
*p = 0.8958 **p = 0.5858 
Footnote                                                                                                                                                    
*2 tailed p-value                                                                                                                                        
* Beggs performed without continuity correction, 2 tailed p-value.                                              
Beggs and Eggers test for publication bias performed on outcomes and interventions that 
included 10 or more studies. 
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Table 16 with scatterplot. Model for outcome 
Proportion of complicating infections using 
Age as a moderator. Any debridement vs 
Moistened gauze. 
 
    Model  Goodness of fit 
Outcome Moderator Coeff Standard 
error 
Q p-value R2 Tau2 Q I2(%) p-value 
Proportion of 
Complicating 
Infections 
Age(yrs.) -0.2132 0.1156 3.40 0.0651 0.00 0.0014 6.94 13.57 0.3263 
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                        Age (years)  
                   Coeff = -0.2132, CI = (-0.4397, 0.0133), R2 = 0.00 
 
 
 
 
 
 
 
 
Regression of Log risk ratio on age 
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Table 17 with scatterplot. Model for outcome 
proportion of ulcers healed using age as a 
moderator. Any debridement vs Moistened 
gauze. 
 
 
    Model  Goodness of fit 
Outcome Moderator Coeff Standard 
error 
Q p-
value 
R2 Tau2 Q I2(%) p-
value 
Proportion of 
ulcers healed 
Age (yrs.) -
0.0130 
0.0322 0.16 0.6873 0.00 0.00 1.68 0.00 0.8917 
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                                                                            Age (years) 
                                           Coeff = -0.0130, CI = (-0.0760, 0.0501), R2 = 0.00 
 
 
 
 
 
Regression of Log risk ratio on age
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Table 18 with scatterplot. Model for outcome 
Proportion of complicating infections using 
Peripheral Arterial Disease (PAD) as a 
moderator. Any debridement vs Moistened 
gauze. 
 
    Model  Goodness of fit 
Outcome Moderator Coeff Standard 
error 
Q p-value R2 Tau2 Q I2(%) p-value 
Proportion of 
Complicating 
Infections 
Proportion 
with 
peripheral 
arterial 
disease 
3.3706 3.2676 1.06 0.3023 0.00 0.00 4.44 9.82 0.3502 
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                        Proportion of sample with Peripheral arterial disease 
                            Coeff = 3.3706, CI = (-3.0338, 9.7750), R2 = 0.00 
 
 
 
 
 
Regression of Log risk ratio on proportion of baseline PAD 
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Table 19 with scatterplot. Model for outcome 
ulcers healed using Peripheral Arterial 
Disease (PAD) as a moderator. Any 
debridement vs Moistened gauze. 
 
    Model  Goodness of fit 
Outcome Moderator Coeff Standard 
error 
Q p-
value 
R2 Tau2 Q I2(%) p-
value 
Proportion 
of ulcers 
healed 
Proportion 
of baseline 
with 
peripheral 
arterial 
disease 
-
0.4095 
0.8237 0.25 0.6191 0.00 0.00 3.89 0.00 0.4206 
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                            Proportion of sample with peripheral arterial disease 
                                  Coeff = -0.4095, CI = (-2.0240, 1.2050), R2 = 0.00 
 
 
 
Regression of Log risk ratio on Proportion with baseline PAD 
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Table 20 with scatterplot. Model for outcome 
proportion of complicating infections using 
diabetes duration as a moderator. Any 
debridement vs Moistened gauze. 
 
 
 
 
Outcome Moderator Coeff Standard 
error 
Q p-value R2 Tau2 Q I2(%) p-value 
Proportion of 
Complicating  
Infections 
Duration of diabetes 
(years) 
-0.1528 0.2530 0.36 0.5460 0.00 0.00 5.11 21.68 0.2764 
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                     Duration of Diabetes (years) 
                          Coeff = -0.1528, CI = (-0.6487, 0.3432), R2 = 0.00 
 
 
 
 
 
Regression of Log risk ratio on Duration of Diabetes 
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Table 21 with scatterplot. Model for outcome 
number of ulcers healed using duration of 
diabetes as a moderator. Any debridement vs 
Moistened gauze. 
 
    Model  Goodness of fit 
Outcome Moderator Coeff Standard 
error 
Q p-
value 
R2 Tau2 Q I2(%) p-
value 
Proportion 
of ulcers 
healed 
Diabetes 
duration 
(years) 
0.0419 0.0723 0.34 0.5625 0.00 0.00 0.09 0.00 0.9930 
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                    Diabetes Duration (years) 
                     Coeff = 0.0419, CI = (-0.0999, 0.11836), R2 = 0.00 
 
 
 
Regression of Log risk ratio on Duration of Diabetes 
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Table 22 with scatterplot. Model for outcome 
proportion of complicating infections using 
proportion of females as a moderator. Any 
debridement vs Moistened gauze. 
 
 
    Model  Goodness of fit 
Outcome Moderator Coeff Standard 
error 
Q p-
value 
R2 Tau2 Q I2(%) p-
value 
Proportion 
of 
Complicating 
Infections 
Proportion 
of females 
-
6.1651 
2.7765 4.93 0.0264 0.00 0.00 2.76 0.00 0.5995 
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                                           Proportion of sample with females 
                                 Coeff = -6.1651, CI = (-11.6070, -07232), R2 = 0.00 
 
 
 
Regression of Log risk ratio on Proportion of Females 
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Table 23 with scatterplot. Model for outcome 
number of ulcers healed using proportion of 
females as a moderator. Any debridement vs 
Moistened gauze. 
 
Outcome Moderator Coefficient Standard 
error 
Q p-
value 
R2 Tau2 Q I2(%) p-value 
Proportion of 
ulcers healed 
Proportion of 
females 
0.2486 1.4998 0.03 0.8683 0.00 0.00 1.62 0.00 0.8053 
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                                         Proportion of sample with females 
                               Coeff = 0.2486, CI = (-2.6909, 3.1882), R2 = 0.00 
 
 
 
Regression of Log risk ratio on Proportion of Females 
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Table 24 with scatterplot. Model for outcome 
proportion of complicating infections using 
data collection year as moderator. Any 
debridement vs Moistened gauze. 
 
    Model  Goodness of fit 
Outcome Moderator Coeff Standard 
error 
Q p-
value 
R2 Tau2 Q I2(%) p-
value 
Proportion 
of 
Complicating 
Infections 
Data 
collection 
year 
0.0246 0.0286 0.74 0.3890 0.00 0.00 3.98 0.00 0.5526 
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                                                    Data Collection year 
                               Coeff = 0.0246, CI = (-0.0314, 0.0806), R2 = 0.00 
 
 
 
 
 
 
Regression of Log risk ratio on Data Collection Year 
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Table 25 with scatterplot. Model for outcome 
number of ulcers healed using data collection 
year as a moderator. Any debridement vs 
Moistened gauze. 
 
Outcome Moderator Coefficient Standard 
error 
Q p-
value 
R2 Tau2 Q I2(%) p-value 
Proportion of 
ulcers healed 
Data collection 
year 
0.0013 
 
0.0137 0.01 0.9274 0.00 0.00 5.55 0.00 0.6972 
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                                                      Data collection Year 
                                  Coeff = 0.0013, CI = (-0.0256, 0.0281), R2 = 0.00 
 
 
 
 
 
 
Regression of Log risk ratio on Data Collection Year 
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Table 26 with scatterplot. Model for outcome 
proportion of complicating infections using 
duration of follow up as moderator. Any 
debridement vs Moistened gauze. 
 
 
    Model  Goodness of fit 
Outcome Moderator Coeff Standard 
error 
Q p-
value 
R2 Tau2 Q I2(%) p-
value 
Proportion 
of 
Complicating 
Infections 
Duration 
of follow 
up 
0.0482 0.0365 1.75 0.1857 0.00 0.00 4.35 0.00 0.6294 
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                                                 Follow up period (days) 
                             Coeff = 0.0482, CI = (-0.0232, 0.1197), R2 = 0.00 
 
 
 
 
 
 
Regression of Log risk ratio on Duration of Follow up 
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Table 27 with scatterplot. Model for outcome 
number of ulcers healed using duration of 
follow up as a moderator. Any debridement 
vs Moistened gauze. 
 
Outcome Moderator Coefficient Standard 
error 
Q p-
value 
R2 Tau2 Q I2(%) p-value 
Proportion of 
ulcers healed 
Duration of 
follow up 
0.0048 0.0093 0.27 0.6043 0.00 0.00 5.29 0.00 0.6252 
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                                                             Follow up period (days) 
                                      Coeff = 3.3706, CI = (-3.0338, 9.7750), R2 = 0.00 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regression of Log risk ratio on Duration of Follow up 
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Table 28 Moderators of effect size magnitude for the “Any debridement vs. gauzea” 
comparison. 
Outcome(s) Moderator(s)Characteristic(s)/Level(s) RR (95% 
CI) 
Kb Coefficient p-value 
 Participant-specific demographic 
characteristics 
 
Proportion of 
infections 
Age 1.07 (0.76, 
1.52) 
7 -0.2132 0.0651 
 Risk-specific characteristics  
Proportion of 
infections 
PADc 1.07 (0.76, 
1.52) 
7 3.3706 0.3023 
Proportion of 
infections 
Duration of diabetes (yrs.) 1.07 (0.76, 
1.52) 
7 -0.1528 0.5460 
Proportion of 
infections 
Proportion of females 1.07 (0.76, 
1.52) 
7 -6.1651 0.0264 
 Study-specific characteristics  
Proportion of 
infections 
Data collection year 1.07 (0.76, 
1.52) 
7 0.0246 0.3890 
Proportion of 
infections 
Duration of follow up 1.07 (0.76, 
1.52) 
7 0.0482 0.1857 
Proportion of 
Ulcers healed 
Age 1.17 (1.00, 
1.36) 
10 -0.0130 0.6873 
Proportion of 
Ulcers healed 
PAD(c) 1.17 (1.00, 
1.36) 
10 -0.4095 0.6191 
Proportion of 
Ulcers healed 
Duration of diabetes (yrs.) 1.17 (1.00, 
1.36) 
10 0.0419 0.5626 
Proportion of 
Ulcers healed 
Proportion of females 1.17 (1.00, 
1.36) 
10 0.2486 0.8683 
 Study-specific characteristics  
Proportion of 
Ulcers healed 
Data collection year 1.17 (1.00, 
1.36) 
10 0.0013 0.9247 
Proportion of 
Ulcers healed 
Duration of follow up 1.17 (1.00, 
1.36) 
10 0.0048 0.6043 
a. Each moderator listed is evaluated individually without controlling for the other listed moderators. Effect sizes 
are based on random effects assumptions for the comparison and respective outcome listed in two columns. In this 
analysis there was 1 comparison (“any debridement” as compared with gauze) and 2 outcomes (proportion of 
infections, and Proportion of ulcers healed) that approximated a sufficient (number of studies): moderator ratio in 
order to facilitate moderator analysis. 
b. k = number of studies 
c. PAD = proportion with initial baseline peripheral arterial disease. 
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Table 29 Non-Significant Moderators 
Non-Significant Moderators 
All the following moderators assessed were non-significant. 
Age 
PAD (Peripheral arterial disease) 
Duration of diabetes 
Data collection year 
Duration of follow up 
 
Table 30 Moderators that were Unable to be analyzed due to lack of Reported Information 
235 coded variables on our data extraction form 
138 of these were non-effect size related variables.  
These were thoroughly reviewed as candidate variables for regression analysis and most were unable to 
be analyzed due to lack of reported information as either none of the studies reported certain outcomes 
or only very few did. Many had as few as 1 or no study reporting information. See Data extraction form 
Appendix 2. 
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32 Summary of Finding Tables (SoF) 
Hydrogel compared to Gauze/Good wound care (gwc) for 
Diabetic foot ulcers (DFU) 
Hydrogel compared to Gauze/Good wound care (gwc) alone for Diabetic foot ulcer 
Patient or population: patients with Diabetic foot ulcer 
Settings: Outpatient 
Intervention: Hydrogel 
Comparison: Gauze/Good wound care (gwc) alone 
Outcomes Illustrative comparative risks* (95% CI) Relative effect 
(95% CI) 
No of Participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Comments 
Assumed risk Corresponding risk 
 
Gauze/Good wound care (gwc) 
alone 
Hydrogel 
    
Number of amputations 
reported 
Follow-up: 20 weeks 
Study population RR 0.26  
(0.05 to 1.4) 
60 
(2 studies) 
⊕⊕⊝⊝ 
low1,2,3 
 
19 per 100 5 per 100 
(1 to 26) 
Moderate 
20 per 100 5 per 100 
(1 to 27) 
Number of Infections reported 
Follow-up: 12 - 20 weeks 
Study population RR 0.74  
(0.18 to 2.99) 
198 
(3 studies) 
⊕⊝⊝⊝ 
very low1,2,4,5,6 
 
27 per 100 20 per 100 
(5 to 82) 
Moderate 
28 per 100 21 per 100 
(5 to 83) 
Number of ulcers completely 
healed 
Follow-up: 12 - 20 weeks 
Study population RR 1.71  
(1.16 to 2.52) 
198 
(3 studies) 
⊕⊕⊝⊝ 
low1,7 
 
26 per 100 45 per 100 
(30 to 66) 
Moderate 
35 per 100 60 per 100 
(41 to 89) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio;  
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  
Very low quality: We are very uncertain about the estimate. 
1 Many of the risk of bias characteristics were either unclear or high. 
2 The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit.  
3 2/3 did not mention whether industry support was sought and the studies yet all had negative findings. 
4 No explanation was provided 
5 Point estimates are far apart and confidence intervals do not overlap. 
6 The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable harm. 
7 The total (cumulative) sample size is lower than the calculated OIS.  
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Table 33 Summary of Findings Table 
Foam dressing compared with Wet to Dry Saline for DFU 
Foam dressing compared to Wet to Dry Saline for Diabetic foot ulcer 
Patient or population: patients with Diabetic foot ulcer 
Settings:  
Intervention: Foam dressing 
Comparison: Wet to Dry Saline 
Outcomes Illustrative comparative risks* (95% 
CI) 
Relative 
effect 
(95% CI) 
No of Participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Comments 
Assumed risk Corresponding risk 
 
Wet to Dry 
Saline 
Foam dressing 
    
Number of ulcers 
completely healed 
Follow-up: 8 to 24 weeks 
Study population RR 3.56  
(0.93 to 
13.66) 
37 
(2 studies) 
⊕⊕⊝⊝ 
low1,2,3 
 
13 per 100 47 per 100 
(12 to 100) 
Moderate 
12 per 100 44 per 100 
(12 to 100) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 
95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio;  
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the 
estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the 
estimate. 
Very low quality: We are very uncertain about the estimate. 
1 Many of the risk of bias characteristics were either unclear or high. 
2 The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) 
appreciable benefit. 
3 The total (cumulative) sample size is lower than the calculated Optimal Information Size OIS and/or total number of events is less than 300 (a 
threshold rule-of-thumb value) (based on: Mueller et al. Ann Intern Med. 2007;146:878  
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Table 34 Summary of Findings Table 
Hydrofiber compared to Gauze dressing for DFU 
Hydrofiber compared to Gauze dressing for Diabetic foot ulcers 
Patient or population: patients with Diabetic foot ulcers 
Settings: Outpatient 
Intervention: Hydrofiber 
Comparison: Gauze dressing 
Outcomes Illustrative comparative risks* (95% CI) Relative 
effect 
(95% CI) 
No of 
Participants 
(studies) 
Quality of the 
evidence 
(GRADE) 
Comments 
Assumed risk Corresponding risk 
 Gauze dressing Hydrofiber     
Number of amputations 
reported 
Study population RR 1.34  
(0.29 to 6.1) 
229 
(2 studies) 
⊕⊕⊝⊝ 
low1,2,3 
 
3 per 100 3 per 100 
(1 to 16) 
Moderate 
6 per 100 8 per 100 
(2 to 36) 
Number of Infections 
reported 
Follow-up: 8 - 24 weeks 
Study population RR 0.96  
(0.4 to 2.31) 
229 
(2 studies) 
⊕⊕⊝⊝ 
low1,2,3 
 
44 per 100 42 per 100 
(18 to 100) 
Moderate 
38 per 100 36 per 100 
(15 to 87) 
Number of ulcers 
completely healed 
Follow-up: 8 - 24 weeks 
Study population RR 1.13  
(0.92 to 1.38) 
229 
(2 studies) 
⊕⊕⊝⊝ 
low1,2,4 
 
43 per 100 49 per 100 
(40 to 59) 
Moderate 
64 per 100 73 per 100 
(59 to 89) 
Time to complete healing 
(days) 
Scale from: 0 to 295. 
Follow-up: 8 to 24 weeks 
The mean time to complete healing (days) 
ranged across control groups from  
78.3 to 295 days 
The mean time to complete healing (days) in 
the intervention groups was 
53.37 lower 
(153.29 lower to 46.56 higher) 
 229 
(2 studies) 
⊕⊝⊝⊝ 
very low1,5,6,7 
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed 
risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio;  
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1 Many of the risk of bias characteristics were either unclear or high. 
2 The total (cumulative) sample size is lower than the calculated optimal information size OIS) and total number of events is less than 300 (a threshold rule-of-thumb value) (based on: Mueller et 
al. Ann Intern Med. 2007;146:878-881.  
3 The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit and appreciable harm. 
GRADE suggests that the threshold for "appreciable benefit" or "appreciable harm" that should be considered for downgrading is a relative risk reduction (RRR) or relative risk increase (RRI) 
greater than 25%.  
4 The 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit. GRADE suggests that the 
threshold for "appreciable benefit" or "appreciable harm" that should be considered for downgrading is a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%. 
5 There exists widely differing estimates of the treatment effect (i.e. heterogeneity or variability in results) across studies suggesting true differences in underlying treatment effect.  
6 The total (cumulative) sample size is lower than the calculated Optimal Information Size (OIS) and/or total population size is less than 400 (a threshold rule-of-thumb value; using the usual α 
and β, and an effect size of 0.2 SD, representing a small effect. 
7 The 95% confidence interval includes no effect and the upper or lower confidence limit crosses the minimal important difference (MID), either for benefit of harm (Note: if the MID is not 
known or the use of different outcomes measures required calculation of an (ES), we suggest downgrading if the upper or lower confidence limit crosses an effect size of 0.5 in either direction).  
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35 Any debridement compared to Gauze control for Diabetic 
Foot Ulcers  
Any debridement compared to Saline gauze for Diabetic Foot Ulcers 
Patient or population: patients with Diabetic Foot Ulcers 
Settings:  
Intervention: Any debridement 
Comparison: Saline gauze 
Outcomes Illustrative comparative risks* (95% CI) Relative effect 
(95% CI) 
No of Participants 
(studies) 
Quality of the evidence 
(GRADE) 
Comments 
Assumed risk Corresponding risk 
 Saline gauze Any debridement  
   
Number of amputations reported 
Follow-up: 8 to 24 weeks 
Study population RR 0.48  
(0.17 to 1.37) 
443 
(5 studies) 
⊕⊕⊝⊝ 
low1,2 
 
6 per 100 3 per 100 
(1 to 8) 
Moderate 
5 per 100 2 per 100 
(1 to 7) 
Number of Infections reported 
Follow-up: 4 to 24 weeks 
Study population RR 1.07  
(0.76 to 1.52) 
659 
(7 studies) 
⊕⊕⊝⊝ 
low1,2 
 
30 per 100 32 per 100 
(23 to 46) 
Moderate 
29 per 100 31 per 100 
(22 to 44) 
Number of ulcers completely healed 
Follow-up: 4 to 24 weeks 
Study population RR 1.22  
(1.04 to 1.44) 
798 
(10 studies) 
⊕⊝⊝⊝ 
very low1,2,3 
 
40 per 100 49 per 100 
(41 to 57) 
Moderate 
40 per 100 48 per 100 
(41 to 57) 
Number of ulcers completely healed - Any Debridement vs 
Saline Gauze 
Follow-up: 4 to 24 weeks 
Study population RR 1.18  
(0.99 to 1.41) 
728 
(8 studies) 
⊕⊕⊝⊝ 
low2 
 
40 per 100 47 per 100 
(39 to 56) 
Moderate 
40 per 100 47 per 100 
(39 to 56) 
Number of ulcers completely healed - SA w/o Abstracts 
Follow-up: 13 to 24 weeks 
Study population RR 1.57  
(1.05 to 2.35) 
70 
(2 studies) 
⊕⊕⊝⊝ 
low1,2 
 
42 per 100 65 per 100 
(44 to 98) 
Moderate 
40 per 100 63 per 100 
(42 to 94) 
Quality of life 
Scale from: 0 to 100. 
Follow-up: 13 to 24 weeks 
 The mean quality of life in the intervention groups was 
0.01 lower 
(0.04 lower to 0.01 higher) 
 317 
(1 study) 
⊕⊕⊝⊝ 
low1,4 
 
Time to complete healing (days) 
Follow-up: 8 to 24 weeks 
 The mean time to complete healing (days) in the intervention 
groups was 
27.88 lower 
(52.53 to 3.23 lower) 
 458 
(4 studies) 
⊕⊕⊝⊝ 
low1,5 
 
Recurrence rates Study population RR 0.81  
(0.25 to 2.58) 
357 
(2 studies) 
⊕⊕⊝⊝ 
low1,2 
 
88 per 1000 71 per 1000 
(22 to 227) 
Moderate 
38 per 1000 31 per 1000 
(9 to 98) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the 
relative effect of the intervention (and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio;  
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect.  
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1 Downgraded as substantial risk of bias characteristics were either unclear or high. 
2 Downgraded due to the 95% confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both 1) no effect and 2) appreciable benefit or appreciable harm. GRADE suggests that the 
threshold for "appreciable benefit" or "appreciable harm" that should be considered for downgrading is a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%. 
3 Downgraded for asymmetric funnel plot distribution around the null value is observed favoring a positive effect that includes studies with smaller sample sizes. 
4 Downgraded due to total (cumulative) sample size is lower than the calculated optimal information size (OIS) and/or total population size is less than 400 (a threshold rule-of-thumb value; using the usual α and β, and an effect size 
of less than 0.2 SD, representing a small effect). 95% confidence interval includes no effect and the upper or lower confidence limit crosses the minimal important difference (MID), either for benefit of harm.  
5 Downgraded due to widely differing estimates of the treatment effect (i.e. heterogeneity or variability in results) across studies suggest true differences in underlying treatment effect.  
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Figures   
Figure 1 Serial images depicting measurements of wound progress 
over the course of sequential combined forms of debridement lasting 
12 weeks including sharp, enzymatic, and autolytic. 
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Figure 2 Study selection Prisma flow diagram. 
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Figure 3 Methodological quality graph across all studies 
 
Methodological quality graph: review authors' judgements about each methodological quality 
item presented as percentages across all included studies. 
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Figure 4 Methodological quality summary review of risk of 
bias tables across all studies.  
 
Methodological quality summary: 
review authors' judgements about 
each methodological risk of bias 
quality item for each included 
study. 
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Figure 23 (Analysis 6.1)   
 
Forest plot of comparison: 6 Hydrogel compared with gauze or good wound care (gwc), 
outcome: 6.1 Number of amputations reported. 
Figure 24 (Analysis 6.2)   
 
Forest plot of comparison: 6 Hydrogel compared with gauze or good wound care (gwc), 
outcome: 6.2 Number of Infections reported. 
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Figure 25 (Analysis 6.3)   
 
Forest plot of comparison: 6 Hydrogel compared with gauze or good wound care (gwc), 
outcome: 6.3 Number of ulcers completely healed. 
Figure 26 (Analysis 10.1)   
 
Forest plot of comparison: 10 Foam dressing compared with Wet to Dry Saline, outcome: 10.1 
Number of ulcers completely healed. 
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Figure 27 (Analysis 13.1)   
 
Forest plot of comparison: 13 Hydrofiber compared with gauze dressing, outcome: 13.1 Number 
of amputations reported. 
Figure 28 (Analysis 13.2)   
 
Forest plot of comparison: 13 Hydrofiber compared with gauze dressing, outcome: 13.2 Number 
of Infections reported. 
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Figure 29 (Analysis 13.4)   
 
Forest plot of comparison: 13 Hydrofiber compared with gauze dressing, outcome: 13.4 Number 
of ulcers completely healed. 
Figure 30 (Analysis 13.5)   
 
Forest plot of comparison: 13 Hydrofiber compared with gauze dressing, outcome: 13.5 Time to 
complete healing (days). 
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Figure 31 (Analysis 19.1)   
 
Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome: 
19.1 Number of amputations reported. 
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Figure 32 (Analysis 19.2)   
 
Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome: 
19.2 Number of Infections reported. 
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Figure 33 (Analysis 19.3)   
 
Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome: 
19.3 Number of ulcers completely healed. 
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Figure 34 (Analysis 19.4)   
 
Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome: 
19.4 Quality of life. 
Figure 35 (Analysis 19.5)   
 
Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome: 
19.5 Time to complete healing (days). 
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Figure 36 (Analysis 19.6)   
 
Forest plot of comparison: 19 Any debridement compared with saline gauze control, outcome: 
19.6 Recurrence rates. 
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Figure 37 (Analysis 19.3)  
 
Funnel plot of comparison: 19 Any debridement compared with Saline Gauze, outcome: 19.3 
Number of ulcers completely healed. Note: Funnel plot to assess for publication bias was 
performed on outcomes and interventions that included 10 or more studies. This included the 
outcome Number of ulcers healed for the intervention Any debridement vs. Saline gauze. 
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Sources of support   
Internal sources   
 No sources of support provided 
External sources   
 No sources of support provided 
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Appendix – Search Strategies 
1 Search strategy for the fourth update and expansion of the 
existing review 2014   
There were three separate and independent searches conducted. The first search was carried out 
by the Cochrane Review Group - Wounds through the trials search coordinator. The second 
search was conducted as an institutional search by the authors independent of Cochrane Review 
Group - Wounds. The reason for this was that this systematic review was not strictly an update of 
an existing review but a significant expansion on the outcomes of interest in order to include 
additional public health related and clinical outcomes beyond the outcomes covered in the earlier 
reviews. This entailed expanding on the existing search provided through the trials search 
coordinator at CRG-wounds. It included new search terms with expanded dates and not restricted 
to the dates used by CRG-wounds. The search involved the same databases previously searched 
with the addition of the Web of Science database that is included. The third search was 
conducted by CRG-wounds to include any recent literature that might have been published since 
the last search provided by CRG-wounds through April 2015. All search strategies are described 
in detail below. 
2 Ovid MEDLINE, PubMed search strategy   
The trials search coordinator with the Cochrane Review Group - Wound searched the database 
Ovid Medline utilizing the following search strategy and dates: 
Database: Ovid MEDLINE(R) without Revisions <1996 to March Week 4 2013> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1 exp Debridement/ (7831) 
2 (debrid$ or slough$ or deslough$).ti,ab. (12051) 
3 exp Larva/ (24406) 
4 (larva$ or maggot$ or biosurgery or bio-surgery).ti,ab. (38005) 
5 (wound$ adj (irrigat$ or cleanse$)).ti,ab. (161) 
6 whirlpool.ti,ab. (149) 
7 (collagenase$ or fibrinolytic$ or proteolytic$ or trypsin or streptokinase or streptodornase or 
varidase).ti,ab. (58063) 
8 exp Papain/ (1033) 
9 papain.ti,ab. (2276) 
10 (hypochlorite or hydrogen peroxide).ti,ab. (25102) 
11 (malic acid or benzoid acid or salicylic acid or propylene glycol).ti,ab. (6877) 
12 dakin solution.ti,ab. (1) 
13 (dextranomer$ or cadexomer or xerogel or eusol or debrisan).ti,ab. (451) 
14 (polysaccharide adj (bead$ or paste$)).ti,ab. (7) 
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15 (iodoflex or iodosorb).ti,ab. (8) 
16 (((gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam or hydrofibre 
or hydrofiber) adj dressing$) or saline gauze or hydrocolloid$ or granuflex or tegasorb or aquacel 
or hydrocoll or combiderm or duoderm).ti,ab. (1122) 
17 "wet-to-dry dressings".ti,ab. (18) 
18 exp Honey/ (1503) 
19 honey$.ti,ab. (7264) 
20 exp Hydrogel/ (2336) 
21 (hydrogel$ or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or 
vigilon).ti,ab. (9889) 
22 exp Zinc Oxide/ (2378) 
23 zinc oxide.ti,ab. (1273) 
24 or/1-23 (170471) 
25 exp Foot Ulcer/ (5689) 
26 exp Diabetic Foot/ (4929) 
27 (diabet$ adj3 ulcer$).ti,ab. (1975) 
28 (diabet$ adj3 (foot or feet)).ti,ab. (3663) 
29 (diabet$ adj3 wound$).ti,ab. (1091) 
30 or/25-29 (7198) 
31 24 and 30 (800) 
32 randomized controlled trial.pt. (245491) 
33 controlled clinical trial.pt. (39951) 
34 randomized.ab. (200013) 
35 placebo.ab. (93002) 
36 clinical trials as topic.sh. (80489) 
37 randomly.ab. (137654) 
38 trial.ti. (74410) 
39 or/32-38 (554321) 
40 (animals not (humans and animals)).sh. (1639102) 
41 39 not 40 (504319) 
42 31 and 41 (111) 
43 (2009* or 2010* or 2011* or 2012* or 2013*).ed. (3070501) 
44 42 and 43 (50) 
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The authors conducted a search in conjunction with our library search coordinator at the 
University of Connecticut. The database Medline was searched utilizing the following search 
strategy and search dates: 
PubMed 
Dates Searched: 1940’s to present 
Results: 811 
(diabetes OR diabetic* OR "Diabetes Mellitus"[Mesh]) AND (wound* OR ulcer* OR callus* 
OR "Diabetic Foot"[Mesh] OR "diabetic foot" OR "diabetic feet") AND ("Toes"[Mesh] OR toe 
OR toes OR phalange* OR "Lower Extremity"[Mesh] OR "Leg"[Mesh] OR leg OR legs OR 
extremity OR "Foot"[Mesh] OR foot OR feet) AND ("Debridement"[Mesh] OR debrid* OR 
slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR "bio-surgery" OR 
surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR enzyme* OR 
mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* OR irrigation 
OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* OR trypsin OR 
streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR "hydrogen 
peroxide" OR acid OR acids OR "propylene glycol" OR "dakin solution" OR dextranomer* OR 
cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex OR iodosorb OR 
gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR hydrofibre* OR 
hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR hydrocolloid* OR 
granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR duoderm OR sterigel* 
OR granugel* OR nugel OR purilon OR vigilon OR "zinc oxide" OR phenytoin) AND 
(("clinical"[tiab] AND "trial"[tiab]) OR "clinical trials as topic"[mesh] OR "clinical trial"[pt] OR 
random*[tiab] OR "random allocation"[mesh] OR "therapeutic use"[sh]) AND "humans"[mesh] 
NOT ("Cross-Sectional Studies"[MeSH Terms] OR "Case Reports"[pt] OR Comment[pt] OR 
Editorial[pt] OR Letter[pt] OR Review[pt] OR "case control"[ti] OR "case report"[ti] OR "case 
study"[ti] OR "case series"[ti] OR "Case-Control Studies"[Mesh] OR "Follow-Up 
Studies"[Mesh] OR "observational study"[ti] OR "prospective cohort"[ti] OR "cohort studies" 
[Mesh:NoExp] OR "cohort study"[ti] OR "Longitudinal Studies" [Mesh:NoExp] OR "Follow-Up 
Studies"[mesh] OR "Retrospective Studies"[mesh] OR "non-randomized"[ti] OR "follow up 
study"[ti] OR rat[ti] OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR cats[ti]) 
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PubMed Supplemental Search 1: systematic reviews & meta-analysis 
Dates Searched: 1940’s to present 
Results: 237 
(diabetes OR diabetic* OR "Diabetes Mellitus"[Mesh]) AND (wound* OR ulcer* OR callus* 
OR “Diabetic Foot”[Mesh] OR “diabetic foot” OR “diabetic feet”) AND ("Toes"[Mesh] OR toe 
OR toes OR phalange* OR "Lower Extremity"[Mesh] OR "Leg"[Mesh] OR leg OR legs OR 
extremity OR "Foot"[Mesh] OR foot OR feet) AND ("Debridement"[Mesh] OR debrid* OR 
slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-surgery OR 
surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR enzyme* OR 
mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* OR irrigation 
OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* OR trypsin OR 
streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR “hydrogen 
peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR dextranomer* OR 
cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex OR iodosorb OR 
gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR hydrofibre* OR 
hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR hydrocolloid* OR 
granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR duoderm OR sterigel* 
OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR phenytoin) AND 
systematic [sb] NOT (rat[ti] OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR 
cats[ti]) 
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PubMed Supplemental Search 2: pre-indexed citations 
Dates Searched: 2014 to present 
Results: 89 
(diabetes OR diabetic* OR "Diabetes Mellitus"[Mesh]) AND (wound* OR ulcer* OR callus* 
OR “Diabetic Foot”[Mesh] OR “diabetic foot” OR “diabetic feet”) AND ("Toes"[Mesh] OR toe 
OR toes OR phalange* OR "Lower Extremity"[Mesh] OR "Leg"[Mesh] OR leg OR legs OR 
extremity OR "Foot"[Mesh] OR foot OR feet) AND ("Debridement"[Mesh] OR debrid* OR 
slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-surgery OR 
surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR enzyme* OR 
mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* OR irrigation 
OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* OR trypsin OR 
streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR “hydrogen 
peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR dextranomer* OR 
cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex OR iodosorb OR 
gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR hydrofibre* OR 
hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR hydrocolloid* OR 
granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR duoderm OR sterigel* 
OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR phenytoin) NOT ("Cross-
Sectional Studies"[MeSH Terms] OR “Case Reports”[pt] OR Comment[pt] OR Editorial[pt] OR 
Letter[pt] OR Review[pt] OR "case control"[ti] OR "case report"[ti] OR "case study"[ti] OR 
“case series”[ti] OR "Case-Control Studies"[Mesh] OR "Follow-Up Studies"[Mesh] OR 
“observational study”[ti] OR “prospective cohort”[ti] OR “cohort studies” [Mesh:NoExp] OR 
“cohort study”[ti] OR “Longitudinal Studies” [Mesh:NoExp] OR “Follow-Up Studies”[mesh] 
OR “Retrospective Studies”[mesh] OR “non-randomized”[ti] OR “follow up study”[ti] OR rat[ti] 
OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR cats[ti]) 
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3 Ovid EMBASE, Embase via Scopus search strategy   
The trials search coordinator with the Cochrane Review Group - Wound searched the database 
Embase utilizing the following search strategy and dates: 
Database: Embase <1996 to 2013 Week 13> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1 exp Decubitus/ (9327) 
2 (pressure adj (ulcer$ or sore$)).ti,ab. (5772) 
3 (decubitus adj (ulcer$ or sore$)).ti,ab. (801) 
4 (bedsore$ or (bed adj sore$)).ti,ab. (417) 
5 or/1-4 (10522) 
6 exp Nutrition/ (910056) 
7 nutrition$.ti,ab. (142489) 
8 diet$.ti,ab. (282256) 
9 (tube adj (fed or feed or feeding)).ti,ab. (2344) 
10 or/6-9 (1017934) 
11 5 and 10 (1232) 
12 exp Clinical trial/ (798274) 
13 Randomized controlled trial/ (288746) 
14 Randomization/ (50983) 
15 Single blind procedure/ (15731) 
16 Double blind procedure/ (86635) 
17 Crossover procedure/ (32192) 
18 Placebo/ (167856) 
19 Randomi?ed controlled trial$.tw. (81720) 
20 RCT.tw. (10802) 
21 Random allocation.tw. (919) 
22 Randomly allocated.tw. (14440) 
23 Allocated randomly.tw. (1221) 
24 (allocated adj2 random).tw. (265) 
25 Single blind$.tw. (9774) 
26 Double blind$.tw. (91413) 
27 ((treble or triple) adj blind$).tw. (244) 
28 Placebo$.tw. (139064) 
29 Prospective study/ (203909) 
30 or/12-29 (1099022) 
31 Case study/ (16391) 
32 Case report.tw. (169255) 
33 Abstract report/ or letter/ (515715) 
34 or/31-33 (697032) 
35 30 not 34 (1070653) 
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36 animal/ (727929) 
37 human/ (8737685) 
38 36 not 37 (486914) 
39 35 not 38 (1048222) 
40 11 and 39 (227) 
41 (2011* or 2012* or 2013*).em. (2630697) 
42 40 and 41 (47) 
The authors conducted an independent search in conjunction with our library search coordinator 
at the University of Connecticut. The database EMBASE via Scopus was searched utilizing the 
following search strategy and search dates: 
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EMBASE via Scopus 
Dates Searched: 1960 to present 
Limiters: Exclude Publication Types: Review, Editorial, Letter 
Results: 893 
1 diabet* 
2 (wound* OR ulcer* OR callus* OR “diabetic foot” OR “diabetic feet”) 
3 (toe OR toes OR phalange* OR "lower extremity" OR leg OR legs OR extremity OR foot OR 
feet) 
4 (debrid* OR slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-
surgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR 
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* 
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* 
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR 
“hydrogen peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR 
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex 
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR 
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR 
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR 
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR 
phenytoin) 
5 (in article title) clinical OR trial 
6 (in abstract) clinical OR trial 
7 (in article title) random* 
8 (in abstract) random* 
9 “clinical trial” 
10 #5 AND #6 
11 #10 OR #7 OR #8 OR #9 
12 #1 AND #2 AND #3 AND #4 AND #11 
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13 (in article title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "cross-
sectional study" OR “case report” OR comment OR editorial OR letter OR "case control" OR 
"case study" OR “case series” OR "follow-up study” OR “observational study” OR “prospective 
cohort” OR “cohort study” OR “longitudinal study” OR “retrospective study” OR “non-
randomized” OR review 
14 #12 AND NOT #13 
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EMBASE Supplemental Search: systematic reviews & meta-analysis 
Dates Searched: 1960 to present 
Limiters: Exclude Publication Types: Editorial, Letter 
Results: 189 
1 diabet* 
2 (wound* OR ulcer* OR callus* OR “diabetic foot” OR “diabetic feet”) 
3 (toe OR toes OR phalange* OR "lower extremity" OR leg OR legs OR extremity OR foot OR 
feet) 
4 (debrid* OR slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-
surgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR 
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* 
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* 
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR 
“hydrogen peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR 
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex 
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR 
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR 
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR 
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR 
phenytoin) 
5 “systematic review” OR “systematic literature review” OR “meta-analysis” OR “meta-
synthesis” 
6 #1 AND #2 AND #3 AND #4 AND #5 
7 (in article title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats 
8 #6 AND NOT #7 
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4 EBSCO CINAHL search strategy   
The trials search coordinator with the Cochrane Review Group - Wound searched the database 
EBSCO CINAHL utilizing the following search strategy and dates: 
S30S23 and S29 
S29S24 or S25 or S26 or S27 or S28 
S28TI diabet* N3 wound* or AB diabet* N3 wound* 
S27TI (diabet* N3 foot or diabet* N3 feet) or AB (diabet* N3 foot or diabet* N3 feet) 
S26TI diabet* N3 ulcer* or AB diabet* N3 ulcer* 
S25(MH "Foot Ulcer+") 
S24(MH "Diabetic Foot") 
S23S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or 
S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 
S22TI zinc oxide or AB zinc oxide 
S21(MH "Zinc Oxide") 
S20TI (hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or 
vigilon) or AB (hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon 
or vigilon) 
S19(MH "Hydrogel Dressings") 
S18TI honey or AB honey 
S17(MH "Honey") 
S16TI wet-to-dry dressings or AB wet-to-dry dressings 
S15TI (dressing* or gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam 
or hydrofibre or hydrofiber or hydrocolloid* or granuflex or tegasorb or aquacel or hydrocoll* or 
combiderm or duoderm)or AB (dressing* or gauze or adherent or absorbent or tulle or 
polysaccaride or alginate or foam or hydrofibre or hydrofiber or hydrocolloid* or granuflex or 
tegasorb or aquacel or hydrocoll* or combiderm or duoderm) 
S14TI ( iodoflex or iodosorb ) or AB ( iodoflex or iodosorb ) 
S13TI (polysaccharide bead* or polysaccharide paste) or AB (polysaccharide bead* or 
polysaccharide paste) 
S12TI (dextranomer* or cadexomer or xerogel or eusol or debrisan) or AB (dextranomer* or 
cadexomer or xerogel or eusol or debrisan) 
S11TI dakin solution or AB dakin solution 
S10TI (malic acid or benzoid acid or salicylic acid or propylene glycol) or AB (malic acid or 
benzoid acid or salicylic acid or propylene glycol) 
S9TI (hypochlorite or hydrogen peroxide) or AB (hypochlorite or hydrogen peroxide) 
S8TI whirlpool or AB whirlpool 
S7TI (wound irrigat* or wound cleans*) or AB (wound irrigat* or wound cleans*) 
S6TI papain or AB papain 
S5TI (collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or streptodornase 
or varidase) or AB (collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or 
streptodornase or varidase) 
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S4TI (larva* or maggot* or biosurgery or bio-surgery) or AB (larva* or maggot* or biosurgery 
or bio-surgery) 
S3(MH "Larval Therapy") 
S2TI (debrid* or slough* or deslough*) or AB (debrid* or slough* or deslough*) 
S1(MH "Debridement") 
The authors conducted an independent search in conjunction with our library search coordinator 
at the University of Connecticut. The database EBSCO CINAHL was searched utilizing the 
following search strategy and search dates: 
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CINAHL 
Dates Searched: 1981 to present 
Limiters: Exclude MEDLINE records; Human 
Results: 57 
S1 (MH "Diabetes Mellitus+") 
S2 diabet* 
S3 (MH "Diabetic Foot") 
S4 wound* OR ulcer* OR callus* OR “diabetic feet” OR “diabetic foot” 
S5 (MH "Toes") 
S6 (MH "Lower Extremity+") 
S7 (MH "Leg") 
S8 (MH "Foot+") 
S9 toe OR toes OR phalange* OR leg OR legs OR extremity OR foot OR feet 
S10 (MH "Debridement+") 
S11 debrid* or slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-
surgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR 
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* 
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* 
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR 
"hydrogen peroxide" OR acid OR acids OR "propylene glycol" OR "dakin solution" OR 
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex 
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate* OR foam* OR 
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR 
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR 
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR "zinc oxide" OR 
phenytoin 
S12 TI (clinical OR trial) AND AB (clinical OR trial) 
S13 (MH "Clinical Trials+") 
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S14 TI random* OR AB random* 
S15 S1 OR S2 
S16 S3 OR S4 
S17 S5 OR S6 OR S7 OR S8 OR S9 
S18 S10 OR S11 
S19 S12 OR S13 OR S14 
S20 S15 AND S16 AND S17 AND S18 AND S19 
S21 (in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "cross-sectional 
study" OR “case report” OR comment OR editorial OR letter OR "case control" OR "case study" 
OR “case series” OR "follow-up study” OR “observational study” OR “prospective cohort” OR 
“cohort study” OR “longitudinal study” OR “retrospective study” OR “non-randomized” OR 
review 
S22 S20 NOT S21 
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CINAHL Supplemental Search: systematic reviews & meta-analysis 
Dates Searched: 1981 to present 
Limiters: Exclude MEDLINE records; Human; Publication Type: Meta Analysis, Meta 
Synthesis, Systematic Review 
Results: 18 
S1 (MH "Diabetes Mellitus+") 
S2 diabet* 
S3 (MH "Diabetic Foot") 
S4 wound* OR ulcer* OR callus* OR “diabetic feet” OR “diabetic foot” 
S5 (MH "Toes") 
S6 (MH "Lower Extremity+") 
S7 (MH "Leg") 
S8 (MH "Foot+") 
S9 toe OR toes OR phalange* OR leg OR legs OR extremity OR foot OR feet 
S10 (MH "Debridement+") 
S11 debrid* or slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-
surgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR 
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* 
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* 
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR 
"hydrogen peroxide" OR acid OR acids OR "propylene glycol" OR "dakin solution" OR 
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex 
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate* OR foam* OR 
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR 
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR 
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR "zinc oxide" OR 
phenytoin 
S12 S1 OR S2 
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S13 S3 OR S4 
S14 S5 OR S6 OR S7 OR S8 OR S9 
S15 S10 OR S11 
S16 S12 AND S13 AND S14 AND S15 
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5 Web of Science search strategy   
The authors conducted an independent search in conjunction with our library search coordinator 
at the University of Connecticut. The database Web of Science was searched utilizing the 
following search strategy and search dates: 
Web of Science 
Dates Searched: 1974 to present 
Results: 522 
1 diabet* 
2 (wound* OR ulcer* OR callus* OR “diabetic foot” OR “diabetic feet”) 
3 (toe OR toes OR phalange* OR "lower extremity" OR leg OR legs OR extremity OR foot OR 
feet) 
4 (debrid* OR slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-
surgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR 
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* 
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* 
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR 
“hydrogen peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR 
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex 
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR 
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR 
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR 
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR 
phenytoin) 
5 clinical AND trial 
6 random* 
8 #5 OR #6 
11 #1 AND #2 AND #3 AND #4 AND #8 
12 Title=(rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "cross-sectional study" 
OR “case report” OR comment OR editorial OR letter OR "case control" OR "case study" OR 
“case series” OR "follow-up study” OR “observational study” OR “prospective cohort” OR 
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“cohort study” OR “longitudinal study” OR “retrospective study” OR “non-randomized” OR 
review) 
13 #11 NOT #12 
Web of Science Supplemental Search: systematic reviews & meta-analysis 
Dates Searched: 1974 to present 
Results: 70 
1 diabet* 
2 (wound* OR ulcer* OR callus* OR “diabetic foot” OR “diabetic feet”) 
3 (toe OR toes OR phalange* OR "lower extremity" OR leg OR legs OR extremity OR foot OR 
feet) 
4 (debrid* OR slough* OR deslough* OR larva* OR maggot* OR MDT OR biosurgery OR bio-
surgery OR surgery OR surgical OR scalpel* OR hydrogel* OR "moist wound healing" OR 
enzyme* OR mechanical OR autolytic OR ultrasound OR laser OR lasers OR sharp OR irrigate* 
OR irrigation OR cleanse* OR whirlpool* OR collagenase* OR fibrinolytic* OR proteolytic* 
OR trypsin OR streptokinase OR streptodornase OR varidase OR papain OR hypochlorite OR 
“hydrogen peroxide” OR acid OR acids OR “propylene glycol” OR “dakin solution” OR 
dextranomer* OR cadexomer* OR xerogel* OR eusol* OR debrisan* OR paste* OR iodoflex 
OR iodosorb OR gauze* OR tulle OR polysaccharide* OR bead OR alginate*OR foam* OR 
hydrofibre* OR hydrofiber* OR dressing* OR saline OR honey* OR gel OR gels OR 
hydrocolloid* OR granuflex OR tegasorb OR aquacel OR hydrocoll* OR combiderm OR 
duoderm OR sterigel* OR granugel* OR nugel OR purilon OR vigilon OR “zinc oxide” OR 
phenytoin) 
5 ("systematic review" OR "systematic literature review" OR "meta-analysis" OR "meta-
synthesis") 
6 #1 AND #2 AND #3 AND #4 AND #5 
7 Title=(rat OR rats OR mice OR mouse OR dog OR dogs OR cats ) 
8 #6 NOT #7 
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6 The Cochrane Library search strategy   
The authors conducted an independent search in conjunction with our library search coordinator 
at the University of Connecticut. The database Web of Science was searched utilizing the 
following search strategy and search dates: 
The Cochrane Library 
Dates searched: 1898 to present 
Results: 103 Central Register of Controlled Trials (CENTRAL) 
3 Database of Abstracts of Reviews of Effect (DARE) 
Title, Abstract, Keywords= debrid* 
AND 
Title, Abstract, Keywords= diabet* 
NOT 
Record Title=(rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "cross-sectional 
study" OR “case report” OR comment OR editorial OR letter OR "case control" OR "case study" 
OR “case series” OR "follow-up study” OR “observational study” OR “prospective cohort” OR 
“cohort study” OR “longitudinal study” OR “retrospective study” OR “non-randomized”) 
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7 Cochrane Wounds Group Specialized Register (Searched 
15/04/15)   
Cochrane Wounds Group Specialized Register (Searched 15/04/15) 
The Cochrane Central Register of Controlled Trials (CENTRAL) - The Cochrane Library 2015, 
Issue 3 
Ovid MEDLINE & Ovid MEDLINE - In-Process & Other Non-Indexed Citations 2013 to April 
14 2015 
Ovid EMBASE - 2013 to April 14 2015 
EBSCO CINAHL - 2013 to April 15 2015 
Cinahl Search Strategy 
S43 S30 and S42 
S42 S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 
S41 MH "Quantitative Studies" 
S40 TI placebo* or AB placebo* 
S39 MH "Placebos" 
S38 TI random* allocat* or AB random* allocat* 
S37 MH "Random Assignment" 
S36 TI randomi?ed control* trial* or AB randomi?ed control* trial* 
S35 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* ) 
S34 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* ) 
S33 TI clinic* N1 trial* or AB clinic* N1 trial* 
S32 PT Clinical trial 
S31 MH "Clinical Trials+" 
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S30 S23 and S29 
S29 S24 or S25 or S26 or S27 or S28 
S28 TI diabet* N3 wound* or AB diabet* N3 wound* 
S27 TI (diabet* N3 foot or diabet* N3 feet) or AB (diabet* N3 foot or diabet* N3 feet) 
S26 TI diabet* N3 ulcer* or AB diabet* N3 ulcer* 
S25 (MH "Foot Ulcer+") 
S24 (MH "Diabetic Foot") 
S23 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or 
S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 
S22 TI zinc oxide or AB zinc oxide 
S21 (MH "Zinc Oxide") 
S20 TI ( hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or 
vigilon ) or AB ( hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or 
purilon or vigilon ) 
S19 (MH "Hydrogel Dressings") 
S18 TI honey or AB honey 
S17 (MH "Honey") 
S16 TI wet-to-dry dressings or AB wet-to-dry dressings 
S15 TI ( dressing* or gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam 
or hydrofibre or hydrofiber or hydrocolloid* or granuflex or tegasorb or aquacel or hydrocoll* or 
combiderm or duoderm ) or AB ( dressing* or gauze or adherent or absorbent or tulle or 
polysaccaride or alginate or foam or hydrofibre or hydrofiber or hydrocolloid* or granuflex or 
tegasorb or aquacel or hydrocoll* or combiderm or duoderm ) 
S14 TI ( iodoflex or iodosorb ) or AB ( iodoflex or iodosorb ) 
S13 TI ( polysaccharide bead* or polysaccharide paste ) or AB ( polysaccharide bead* or 
polysaccharide paste ) 
S12 TI ( dextranomer* or cadexomer or xerogel or eusol or debrisan ) or AB ( dextranomer* or 
cadexomer or xerogel or eusol or debrisan ) 
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S11 TI dakin solution or AB dakin solution 
S10 TI ( malic acid or benzoid acid or salicylic acid or propylene glycol ) or AB ( malic acid or 
benzoid acid or salicylic acid or propylene glycol ) 
S9 TI ( hypochlorite or hydrogen peroxide ) or AB ( hypochlorite or hydrogen peroxide ) 
S8 TI whirlpool or AB whirlpool 
S7 TI ( wound irrigat* or wound cleans* ) or AB ( wound irrigat* or wound cleans* ) 
S6 TI papain or AB papain 
S5 TI ( collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or streptodornase 
or varidase ) or AB ( collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or 
streptodornase or varidase ) 
S4 TI ( larva* or maggot* or biosurgery or bio-surgery ) or AB ( larva* or maggot* or 
biosurgery or bio-surgery ) 
S3 (MH "Larval Therapy") 
S2 TI ( debrid* or slough* or deslough* ) or AB ( debrid* or slough* or deslough* ) 
S1 (MH "Debridement") 
Search Name: 42 Smith Debridement for DFU_Issue 3 2015 
Date Run: 17/06/15 08:33:47.466 
Description: Re-ran searches over all issues (Issue 3 2015) [Revised SS Issue 2 2009] 
ID Search Hits 
#1 MeSH descriptor: [Debridement] explode all trees 
#2 (debrid* or slough* or deslough*):ti,ab,kw 
#3 MeSH descriptor: [Larva] explode all trees 
#4 (larva* or maggot* or biosurgery or bio-surgery):ti,ab,kw 
#5 (wound* next (irrigat* or cleanse*)):ti,ab,kw 
#6 whirlpool:ti,ab,kw 
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#7 (collagenase* or fibrinolytic* or proteolytic* or trypsin or streptokinase or streptodornase or 
varidase):ti,ab,kw 
#8 MeSH descriptor: [Papain] explode all trees 
#9 papain:ti,ab,kw 
#10 (hypochlorite or hydrogen peroxide):ti,ab,kw 
#11 (malic acid or benzoid acid or salicylic acid or propylene glycol):ti,ab,kw 
#12 "dakin solution":ti,ab,kw 
#13 (dextranomer* or cadexomer or xerogel or eusol or debrisan):ti,ab,kw 
#14 (polysaccharide next (bead* or paste*)):ti,ab,kw 
#15 (iodoflex or iodosorb):ti,ab,kw 
#16 (((gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam or hydrofibre 
or hydrofiber) next dressing*) or saline gauze or hydrocolloid* or granuflex or tegasorb or 
aquacel or hydrocoll* or combiderm or duoderm):ti,ab,kw 
#17 "wet-to-dry dressings":ti,ab,kw 
#18 MeSH descriptor: [Honey] explode all trees 
#19 honey:ti,ab,kw 302 
#20 MeSH descriptor: [Hydrogel] explode all trees 
#21 (hydrogel* or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or 
vigilon):ti,ab,kw 
#22 MeSH descriptor: [Zinc Oxide] explode all trees 
#23 "zinc oxide":ti,ab,kw 
#24 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 
or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 
#25 MeSH descriptor: [Foot Ulcer] explode all trees 
#26 MeSH descriptor: [Diabetic Foot] explode all trees 
#27 diabet* near/3 ulcer*:ti,ab,kw 
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#28 diabet* near/3 (foot or feet):ti,ab,kw 
#29 diabet* near/3 wound*:ti,ab,kw 
#30 #25 or #26 or #27 or #28 or #29 
#31 #24 and #30 
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Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
MEDLINE(R) <1946 to Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1 exp Debridement/ 
2 (debrid$ or slough$ or deslough$).ti,ab. 
3 exp Larva/ 
4 (larva$ or maggot$ or biosurgery or bio-surgery).ti,ab. 
5 (wound$ adj (irrigat$ or cleanse$)).ti,ab. 
6 whirlpool.ti,ab. 
7 (collagenase$ or fibrinolytic$ or proteolytic$ or trypsin or streptokinase or streptodornase or 
varidase).ti,ab. 
8 exp Papain/ 
9 papain.ti,ab. 
10 (hypochlorite or hydrogen peroxide).ti,ab. 
11 (malic acid or benzoid acid or salicylic acid or propylene glycol).ti,ab. 
12 dakin solution.ti,ab. 
13 (dextranomer$ or cadexomer or xerogel or eusol or debrisan).ti,ab. 
14 (polysaccharide adj (bead$ or paste$)).ti,ab. 
15 (iodoflex or iodosorb).ti,ab. 
16 (((gauze or adherent or absorbent or tulle or polysaccaride or alginate or foam or hydrofibre 
or hydrofiber) adj dressing$) or saline gauze or hydrocolloid$ or granuflex or tegasorb or aquacel 
or hydrocoll or combiderm or duoderm).ti,ab. 
17 "wet-to-dry dressings".ti,ab. 
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18 exp Honey/ 
19 honey$.ti,ab. 
20 exp Hydrogel/ 
21 (hydrogel$ or intrasite gel or intrasitgel or sterigel or granugel or nugel or purilon or 
vigilon).ti,ab. 
22 exp Zinc Oxide/ 
23 zinc oxide.ti,ab. 
24 or/1-23 
25 exp Foot Ulcer/ 
26 exp Diabetic Foot/ 
27 (diabet$ adj3 ulcer$).ti,ab. 
28 (diabet$ adj3 (foot or feet)).ti,ab. 
29 (diabet$ adj3 wound$).ti,ab. 
30 or/25-29 
31 24 and 30 
32 randomized controlled trial.pt. 
33 controlled clinical trial.pt. 
34 randomized.ab. 
35 placebo.ab. 
36 clinical trials as topic.sh. 
37 randomly.ab. 
38 trial.ti. 
39 or/32-38 
40 (animals not (humans and animals)).sh. 
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41 39 not 40 
42 31 and 41 
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Database: Embase <1974 to 2015 June 16> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1 exp Decubitus/ 
2 (pressure adj (ulcer$ or sore$)).ti,ab. 
3 (decubitus adj (ulcer$ or sore$)).ti,ab. 
4 (bedsore$ or (bed adj sore$)).ti,ab. 
5 or/1-4 
6 exp Nutrition/ 
7 nutrition$.ti,ab. 
8 diet$.ti,ab. 
9 (tube adj (fed or feed or feeding)).ti,ab. 
10 or/6-9 
11 5 and 10 
12 exp Clinical trial/ 
13 Randomized controlled trial/ 
14 Randomization/ 
15 Single blind procedure/ 
16 Double blind procedure/ 
17 Crossover procedure/ 
18 Placebo/ 
19 Randomi?ed controlled trial$.tw. 
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20 RCT.tw. 
21 Random allocation.tw. 
22 Randomly allocated.tw. 
23 Allocated randomly.tw. 
24 (allocated adj2 random).tw. 
25 Single blind$.tw. 
26 Double blind$.tw. 
27 ((treble or triple) adj blind$).tw. 
28 Placebo$.tw. 
29 Prospective study/ 
30 or/12-29 
31 Case study/ 
32 Case report.tw. 
33 Abstract report/ or letter/ 
34 or/31-33 
35 30 not 34 
36 animal/ 
37 human/ 
38 36 not 37 
39 35 not 38 
40 11 and 39 
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Appendix 2 
 
DATA EXTRACTION CODING FORM 
DEBRIDEMENT OF DIABETIC FOOT ULCERS 
SYSTEMATIC REVIEW, META-ANALYSIS, AND META_REGRESSION 
Developed July 2013 
 
For any missing or unreported data, indicate with “blank” 
 
Study Information 
 
(V1) coder  ________   Coder (Dayya = 1, Huedo-Medina = 2, O’Neill = 3, Habib = 4, Other = 5) 
 
(V2)  study_id               ________   Study ID # Study Citation (e.g. 1stAuthorJournalYear, i.e. SmithJAMA2014 ):                             
  
(V3)    pub_yr  ________   Publication Year (e.g. 2014) (consider this missing if unpublished) 
  
(V4) data_yr                ________   Estimated year of data collection (e.g. 2014) (earliest date for data collection or 
                                                        manuscript submission/publication; if  unpublished and date unknown, use year 
                                                        manuscript was acquired; for 
                                                      dissertation or thesis, use year)  
 
(V5) lang  ________   Language of publication 
    0=English       
    1=Spanish 
    2=French 
                                  3=German 
    4=Other, specify: __________________________ 
 
(V6) source  ________: 
    0= journal      
    1= book      
    2= thesis/dissertation      
    3= conference proceedings    
    4= unpublished document/abstract 
                                  5= other, specify:______________________            
 
(V7)    finance                   __________Financial Support 
                                           0= None 
                                           1= Public; agency:____________________ 
                                           2= Private; company:_______________________ 
                                           3= Unclear 
 
(V8)     score              ________ Impact Score of the Journal (use ISI Web of Knowledge journal citation reports) 
   
(V9)     debride                 ________Method of Debridement Intervention 
                                       0= Autolytic 
                                       1= Sharp/Surgical Debridement 
                                       2= Biosurgery or Maggot debridement Therapy 
                                       3= Mechanical Debridement 
                                         4= Enzymatic Debridement 
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                                       5= Ultrasound 
                                       6= Laser 
Sample Characteristics (proportion: 0.0- 1.0) 
 
(V7)    eth  ________   Ethnicity reported?    0 = no; 1 = yes   
(V8)    prop_wh               ________   Proportion Caucasian (e.g. 0.50 for 50%); if whole number available:______ 
(V9)    prop_blk               ________   Proportion African American; if whole number: ______ 
(V10) prop_hisp             ________   Proportion Latino/Hispanic; if whole number: ______ 
(V11) prop_asian ________   Proportion Asian; if whole number: ______ 
(V12) prop_min    ________   Proportion Minority/other; if whole number: ______ 
 
(V13) educ  ________   Education reported? 0 = no; 1 = yes 
(V14) prop_hs      ________   Proportion high school; if whole number available: ______  
(V15) prop_coll   ________   Proportion college; if whole number available: ______  
(V16) prop_grad ________   Proportion graduate school; if whole number available:______ 
 
(V17) ses  ________   SES reported? 0 = no; 1 = yes 
(V18) prop_low              ________   Proportion of low SES Low (< 25k) 
(V19) prop_mid  ________   Proportion of Middle SES (25k-100k) 
(V20) prop_high ________   Proportion of high SES (>100k)  
 
(V21) #female               ________   Number of Females in Sample as a whole number? 
(V22) prop_fem             ________   Proportion of females in sample (e.g. 0.50 for 50%) 
 
(V23) region  ________   of sample 
 1=American city: __________________ 
 2=Other U.S. general region (city not specified):  __________________ 
 3=Canada (city: _______________________) 
 4=Europe (city: _______________________) 
 5=South or Central America, Mexico, Caribbean (city: _______________________) 
 6=Africa (city: _______________________) 
 7=Asia (city: _______________________) 
 8=Australia (city: _______________________) 
 
(V24) us_zip  ________   Zip Code (US Only) _____________  
 
(V25) pop_type   ________   Population 
  0= Not reported 
 1= Outpatient Office 
  2= Specialized Center source (e.g., wound clinic/center, hyperbaric center) 
________________________________________________________ 
  3=Hospitalized; specify source (e.g. inpatient, hospital): 
 ________________________________________________________ 
  
________ Notes on sample characteristics relevant to coding  
_______________________________________________________________________________ 
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Risk Characteristics (if SEM, change to SD; SD= SEM *√𝑛; use DSTAT to pool variances if applicable) 
 
(V26) age  ________   Mean age of total sample (years)  
(V27) age_sd  ________   SD for age (years) 
 
(V28) ht  ________   Mean height of total sample (cm)  
(V29) ht_sd  ________   SD of height (cm) 
 
(V30) wt  ________   Mean weight of total sample (kg) 
(V31) wt_sd  ________   SD of weight (kg) 
 
(V32) waist  ________   Mean waist circumference of total sample (cm) 
(V33) waist_sd    ________   SD of waist circumference (cm) 
 
(V34) w-h  ________   Mean Waist-to-Hip Ratio of total sample 
(V35) w-h_sd  ________   SD of Waist-to-Hip Ratio 
 
(V36) bmi  ________   Mean Body Mass Index of total sample (BMI, kg•m-2) (if calculating, use 
                                                    NHLBI equation) 
(V37) bmi_sd  ________   SD of mean BMI for total sample. 
(V38) bmi_norm ________   Proportion normal weight (18.5-24.9) 
(V39) bmi_over              ________   Proportion overweight (25.0-29.9) 
(V40) bmi_obese1 ________   Proportion obese, Class I (30.0-34.9)  
(V41) bmi_obese2 ________   Proportion obese, Class II (35.0-39.9)  
(V42) bmi_obese3 ________   Proportion obese, Class III (≥ 40.0)  
 
(V43) bf%  ________   Mean value of body fat composition of total sample (Body Fat %) 
(V44) bf%_sd  ________   SD of Body Fat % 
(V45) bf%_assess ________   Method of Body Fat % Assessment 
                       1= Skinfold thickness  
                       2= Hydrostatic weighing 
                       3= Bioelectrical impedance, specify:_________________ 
                       4= Air displacement plethysmography, specify:_________________ 
                       5= Dual energy x-ray absorptiometry (DEXA), 
                                                          specify:_________________ 
                       6= Other, specify:__________________ 
 
(V46)  prop_pad              ________ Proportion of total sample with peripheral arterial vascular disease; if 
                                                       whole number available__ 
 
(V47)  tcpo2                      ________ Mean peri-wound tissue oxygenation levels (mmHg) for total sample. 
 
(V48) hgba1c                  ________ Mean Hgba1c (% glycosylated Hgb) for total sample. 
 
(V49) prop_immune      ________ Proportion of total sample with immunosuppression including: HIV 
                                                              status, chemotherapy, steroids, immunosuppressants; If whole number 
                                                              available__ 
 
(V50)  prop_hd     ________  Proportion of total sample with history of coronary heart disease; if 
                                                     whole number available ______  
 
(V51)  prop_ htn ________   Proportion of total sample with hypertension;  
                       if whole number available ______  
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(V52) prop_thyroid        ________  Proportion of total sample with Thyroid disease; if whole number 
                                                             available _____ 
                                                        (If mean TSH level available for total sample enter this value instead and 
                                                         Notate accordingly in coding form) 
 
(V53) prop_neurop       _________ Proportion of total sample with peripheral Neuropathy; if whole 
                                                      number available _____ 
 
(V54) prop_venous       _________ Proportion of total sample with Venous Insufficiency; if whole number 
                                                      available ______ 
 
(V55) prop_rf                _________ Proportion of total sample w/ Renal Failure/Dialysis; if whole number 
                                                      available ______ 
                                                             (If mean creatinine level for total sample is available enter this value 
                                                             instead and notate accordingly in coding form) 
 
 
(V56) prop_anemia       _________ Proportion of total sample with Anemia; if whole number available 
                                                       ______(If mean hemoglobin level for total sample is available enter this 
                                                       value instead and notate accordingly in coding form) 
 
(V57) prop_copd           _________ Proportion of total sample with Chronic Obstructive Pulmonary 
                                                      Disease; if whole number available________ OR if available report 
                                                       mean oxygen hemoglobin saturation for sample in mmHg. Notate 
                                                       accordingly here in coding form which is to be used. 
 
(V58) chf  ________   Enter proportion of total sample with congestive heart failure 
 
(V59) heartfunc                ________ If available enter the functional classification of CHF/Heart Disease for 
                                                              the sample according to New York Heart Association NYHA criteria. 
                                                              0= Not Reported 
                       1= Class I,  2= Class II,  3= Class III, 4= Class IV 
    
(V60) prop_sed   ________   Proportion of sample that is sedentary (≤ 2d/ wk of regular physical 
                                                     activity); if whole number available ______ 
 
(V61) antithromb_med ________   Proportion of the patients on antithrombotic medications (includes 
                                                     anticoagulants, antiplatelet agents aspirin/Nsaids, etc.) 
 
(V62) prop_ocp_use _________Proportion of total sample using oral contraceptives. 
 
(V63) caffeine_use         ________   Mean number of days per week of caffeine consumption for total sample 
 
(V64) caffeine_day ________   Mean number of caffeinated beverages per day for total sample 
 
(V65) caffeine_wk ________   Mean number of caffeinated beverages per week for total sample 
 
(V66) prop_caffeine ________   Proportion of sample with regular caffeine consumption; if whole 
                                    number available ______ 
 
(V67) etoh_use               ________   Mean number of days per week of alcohol consumption for total sample 
 
(V68) etoh_day               ________   Mean number of alcoholic drinks per day for total sample 
 
(V69) etoh_wk   ________   Mean number of alcoholic drinks per week for total sample 
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(V70) prop_etoh ________   Proportion of sample reporting regular alcohol consumptions. Those 
                                                               drinking at home and more often than restricting to social occasions; if 
                                                               whole number available ______ 
 
(V71) smoking    ________  Proportion of total sample currently smoking, or smoked within last 6 
                                                     months. 
 
(V72) smoking_yrs ________   Mean number of years smoking for total sample 
 
(V73) smoke_pack ________   Mean number of packs per day for total sample 
 
(V74) smoke_pack_yrs    ________  (Pack years calculated in pack/day*yrs for total sample) 
 
(V75) diabetes_duration ________  Enter the mean duration of diabetes in years for total sample. 
 
 
Notes on risk characteristics relevant to coding  
 
_____________________________________________________________________________________ 
Co-Interventions (Associated Standard of Care Measures in Diabetic Foot Ulcers) 
 
(V76) offload            _________0= No, 1= Yes (includes orthotics, Inserts, crutches, wheelchairs, Partial weight-bearing, 
                                              Non weight bearing etc.), 2= Unclear 
 
(V77) pt                    _________0= No, 1= Yes, 2= Unclear If so number of sessions__________ 
 
(V78) nutcons          _________0= No, 1= Yes, 2= Unclear If so number of sessions__________ 
 
(V79) vascsurg         _________0= No, 1= Yes (Includes percutaneous interventions such as angioplasty, stenting, or 
                                                     thrombectomy, bypass procedures), 2= Unclear If so number of procedures__________ 
 
(V80) hbot                _________0= No, 1= Yes, 2= Unclear If so number of sessions__________ 
 
(V81) antibiotic         _________0= No, 1= Yes (Includes topical or systemic treatment), 2= Unclear If so number of 
                                                     sessions__________ 
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Methods & Design 
 
DESIGN & MEASUREMENT 
 
(V82) design_typ   ______Type of Design 
                           1= Quasi-experimental 
                           2= Matched with Randomization 
                           3= Randomized controlled trial 
                           4= Other:_______________________ 
 
(V83) unit_assign ______Unit of Assignment 
                           1= Community (e.g., city) 
                           2= Group (hospital, clinic, etc.) 
                           3= Individual 
                           4= Other: _______________________ 
 
(V84) recruit_meth _____Recruitment Method 
                                     1= Self-selected from community (e.g. via flyers, community centers, etc.) 
                                     2= Recruited on the internet 
                                     3= Recruited though chart review  
                                     4= Recruited through clinical contact (hospital, primary care, clinic, hyperbaric center, 
wound center, 
                                     other consultant etc) 
                                     5= Experimental credit or equivalent in class (i.e. subject pool) 
                              6= Other, specify:   ___________________________________________ 
                              7= Unclear 
 
(V85) accept_rate   _____Acceptance rate (if reported: percent successfully recruited = # who agreed to 
participate / # 
                              targeted) 
 
(V86) incent           ______Specific incentives offered/facilitators: 
                            1. Free Medical Care  5.  Transportation provided 
                            2. Monetary               6.  No apparent 
                            3. Food               7.  Other, specify:_______________________________ 
                            4. Childcare               8.  Multiple, specify:____________________________ 
      
(V87) #f/u              ______Number of follow-ups: ______________________________  
                                   (e.g 1= acute/post intervention only, 2= pre and postintervention, 3, 4, 5 follow ups) 
 
(V88) f/u_int         ______Interval of follow-ups: ______________________________  
                           (0= acute, 1= every 3 days, 1= weekly, 2= biweekly, 3= monthly)  
 
(V89) short_f/u    ______Short-term follow-up period for the entire study in weeks (if less than 1 year, specify 
                                      time(s):_____________________________) 
 
(V90) long_f/u     ______Long-term follow-up period for the entire study in years (if greater than 1 year or 
more, specify 
                                              time(s):______________________________) 
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CONTROL/COMPARISON CONDITION: 
 
**Label given by author and description of control condition (if more than one, use the control condition with 
the least 
        contact such as an assessment only condition): 
________________________________________________ 
  
(V91) cont                 _________Control condition: 
                                 0= No control/comparison group used. 
                                        1= Yes control/comparison group used. 
                                        2= Unclear 
 
(V92)    cont_grp          _________Type of control group used 
                                       0= non-random assignment of individuals to conditions (i.e. intervention or control group) 
                                       1= random assignment of individuals to conditions (i.e. intervention or control group) 
                                       2= other, specify: _____________________________________________________  
 
(V93) cont_comp         _________Composition of comparison condition 
                                   0= Targeted to group, other specify: 
________________________________________________ 
                                   1= Individual (e.g. targeted to one person) 
                                   2= Unclear 
 
(V94) cont_meth        _________Method of control/comparison delivery was followed according to generally 
                                                   accepted standards. 
                                 0= No 
                                 1= Yes 
                                 2= Unclear 
 
(V95) #cont                   _________Total number of participants in control/comparison group (Men: ______; 
                                                      Women: ______) 
 
(V96) #part_beg_cont  _________Number of participants at study beginning in the control/comparison group. 
 
(V97) #part_end_cont  _________Number of participants at study completion in the control/comparison group. 
 
(V98) #part_lost_cont  _________Number of participants lost during study in the control/comparison group 
 
(V99) %adhere_cont   _________Percent Participant adherence in the control group (V97/V96) x 100 or 
                                                            (
𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠
𝑡𝑜𝑡𝑎𝑙 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠
)x100 
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EXPERIMENTAL/INTERVENTION CONDITION: 
 
(V100) #exp_cond    _________Number of experimental conditions for which effect sizes will be calculated 
                                               (complete pages separately if needed, using variables for each experimental 
condition) 
 
(V101) exp_cond      _________Specify intervention/experimental condition 
                                                    0= Autolytic 
                                                    1= Sharp/Surgical Debridement 
                                                    2= Biosurgery or Maggot debridement Therapy 
                                                    3= Mechanical Debridement 
                                                      4= Enzymatic Debridement 
                                                    5= Ultrasound 
                                                    6= Laser 
 
(V102) del_meth      _________Method of delivery: 
                                               0= Delivered by a primary care provider 
                                               1= Delivered by non-surgeon wound care physician 
                                               2= Delivered by a surgeon 
                                               3= Multiple/Other, specify: 
______________________________________________________ 
                                               4= Unclear  
 
(V103) exp_meth       ________Method of intervention delivery according to generally accepted standards. 
                                               0= No 
                                               1= Yes 
                                               2= Unclear 
 
(V104) #part_beg_exp  ______Number of participants at beginning of intervention in the experimental group 
 
(V105) #part_end_exp  ______Number of participants at study completion in the experimental group 
 
(V106) #part_lost_exp  ______Number of participants lost during study in the experimental group (V104-V105) 
 
(V107) %adhere_exp   ______ Percent participant adherence in the experimental group (V105/V104) x 100  
                                                            or (
𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠
𝑡𝑜𝑡𝑎𝑙 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠
)x100 
 
(V108) #sess_exp         _______Number of sessions in experimental group 
 
(V109) #fac/exp           _______Number of facilitators/experimenters in the study. (blank if no contact/wait 
                                                      list)_____ 
 
(V110) rand_assign    _______Random assignment 
                                                     0= Violated randomization and/or nonequivalence of comparison group was not 
addressed 
                                                     1= Quasi-experimental design; group assignment, arbitrary assignment; 
sequential; how: 
                                                     _____________________ 
                                                     2= Matching individuals on some variable or strata (e.g., SES, age), then random 
assignment 
                                                     3= Random assignment of individuals 
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(V111) qual_cont       _______Quality control 
                                             0 = No standardization of treatment is specified 
                                             1 = Treatment standardized by manual, specific training, content coding, sessions 
                                             monitored for fidelity. 
                                             2= Unclear 
 
(V112) pretest_eval   _______Pretest evaluation of intervention conducted. (0 = No, 1 = Yes, 2= Unclear) 
 
(V113) f/u_rate          _______Follow-up rate (i.e., largest follow-up rate at any delayed post-test) 
                                             2 = 85-100% completed, 1 = 70 – 84% completed, 0 = <70% completed 
 
(V114) f/u_length      _______Follow-up length of the study. (i.e. final assessment interval) ____________ 
                                             2 = 6 months or longer, 1 = 3 to 5 months, 0 = less than 3 months 
(V115) obj_meas  __________Used objective measures to define the intervention.. 
                                0 = No objective measure used or unspecified 
                         1 = Objective measures (e.g., laboratory testing) used in more than 50% of the cases 
                         2= Unclear 
 
(V116) with_drop __________Withdrawal/Drop-outs and/or attrition  
                                 0 = Not reported or all non-completers were excluded from analyses 
                          1 = Enumerated  
                          2 = Compared with completed cases (e.g., intent-to-treat; baseline differences, imputing 
                          missing values) 
 
(V117) %loss_f/u  __________Loss to follow up?  
                                              (e.g 10%, 20%, 50%)   % Dropouts______;If whole number available_______ 
 
 
         _____Notes on methods & study design relevant to coding  
 
         ______________________________________________________________________________________ 
 
 
(V118)  exper   _________Experimental condition(s) 
 
                   Independent (unrelated/unpaired) groups 
                   1= autolytic debridement control/comparison + one experimental group 
                   2= autolytic debridement control/ comparison + two experimental groups 
               3= autolytic debridement control/ comparison + three experimental groups 
                   4= autolytic debridement control/ comparison + three experimental groups 
                   5= autolytic debridement control/ comparison + four experimental groups 
                   6= autolytic debridement control/ comparison + five experimental groups 
                        7= autolytic debridement control/comparison + six experimental groups 
 
               Non-Independent (related/paired) groups 
                   6= autolytic debridement control/comparison + one experimental group 
                7= autolytic debridement control/ comparison + two experimental groups 
                    8= autolytic debridement control/ comparison + three experimental groups 
                         9= autolytic debridement control/ comparison + three experimental groups 
                       10= autolytic debridement control/ comparison + four experimental groups 
                       11= autolytic debridement control/ comparison + five experimental groups 
                  12= autolytic debridement control/comparison + six experimental groups 
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(V119) exp_setting _______Setting of Experiment/ Intervention 
      1= private office 
      2= wound clinic/center 
                         3= hospital setting 
      4= Other, specify:_____________________________ 
      5= multiple, specify:___________________________ 
     
(V120) inter_lvl  ________  Dose of level of intervention used in the study 
1= 1-3      debridement sessions required 
2= 4-6      debridement sessions required 
3= 7-9      debridement sessions required 
4= 10-12  debridement sessions required 
5= multiply, specify number of debridement sessions required:______________________ 
 
 
(V121) sub_group (i.e. female, male, hypertensive, normotensive, white, black, etc.), specify:________________ 
                           (0= No, 1= Yes, 2=Unclear) 
 
 
STUDY QUALITY 
 
Cochrane Risk of Bias Table 
 
(V122) asg               ___________Adequate sequence generation 
                          (0= No, 1=Yes, 2= Unclear) 
 
(V123) asc                ___________Allocation sequence concealment 
                          (0= No, 1=Yes, 2= Unclear) 
 
(V124) blind             ___________Blinding (single, double, triple) 
                          (0=No, 1= single, double, or triple blinding, 4= Unclear) Specify what level of 
blinding:________ 
 
(V125) inc_out_data __________Incomplete outcome data addressed 
                           (0= No, 1= Yes 2= Unclear) 
                           (If so how ITT, Bayesian methods, impution, Last Observation Carried Forward 
(LOCF), dropped 
                           Missing data)______________ 
 
(V126) fsr                  __________Free of selective reporting 
                           (0= No, 1= Yes,  2= Unclear) 
 
(V127) fob                 __________Free of other bias 
                           (0= No, 1= Yes, 2= Unclear) 
 
(V128) fs                   __________Financial support 
                          (0= No, 1= Yes, 2= Unclear) 
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Other Study Quality Considerations 
 
(V129) #hypoth_test __________Number of hypothesis tests performed_________ 
 
(V130) alpha             __________Alpha cutoff value used 
 
(V131) typ1_error   __________Type 1 error probability reported if positive study________ 
 
(V132) power           __________Power Reported 
 
(V133) typ2_error   __________Type 2 error probability reported if negative study 
 
(V134) stat_anal      __________ Hypothesis test used for statistical Analyses 
                                                         0= No statistical analysis; inappropriate, or unspecified 
                                                         1= Appropriate statistical analyses of group differences (e.g., comparing two 
groups using at least 
                                                         more than one t or F test but did not control for baseline and/or other 
characteristics) 
                                                         2= Controlled for baseline and/or other characteristics in appropriate statistical 
analyses of group 
                                                         differences (e.g. compared two groups using at least a t or F test) 
 
(V135) sampl_bal    __________Samples Balanced for Confounders/Effect Modifiers between Sample and 
Control 
                                                        (0 = No, 1= Yes, 2= Unclear) 
 
(V136) sampl_bias   __________Sampling Bias Probable 
                                                        (0 = No, 1= Yes, 2= Unclear) 
 
(V137) sel_bias        __________Selection Bias Probable 
                                                (0 = No, 1 = Yes, 2 = Unclear) 
 
(V138) info_bias      __________Information Bias Probable 
                                                (0 = No, 1 = Yes, 2 = Unclear) 
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EFFECT SIZES 
 
VARIABLE 
 
Initial and Post Debridement 
Wound Assessments 
(V139) total#part_beg  
       # of participants at beginning of 
intervention 
 
(V140) total#part_end 
       # of participants at study completion  
 
(V141) total#part_lost 
       # of participants lost during study 
 
(V142) meanadherence 
  Mean participant adherence 
(
𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠
𝑡𝑜𝑡𝑎𝑙 𝑠𝑒𝑠𝑠𝑖𝑜𝑛𝑠
) x 100 
 
(V143) wound_assess 
       Wound Measurement Type 
       1= Length, width, depth 
       2= Surface area 
       3= Volume 
       4= multiple, specify #s__________ 
 
(V144) wound_size_init_cont 
       Initial Mean Wound Measurement 
       control/comparison 
       [size (cm), surface area (cm2)] 
 
(V145) wound_size_initial_cont_sd 
       SD of Initial Mean Wound Size 
       control/comparison 
 
(V146) wound_size_post_cont 
       Post Intervention Mean Wound 
Measurement 
       control/comparison. 
              [size (cm), surface area (cm2)] 
 
(V147) wound_size_post_cont_sd 
       SD of Post Intervention Mean Wound 
Size 
       control/comparison 
       (size, surface area) 
 
(V148) wound_size_init_exp 
       Initial Mean Wound Measurement 
experimental 
       group [size (cm), surface area (cm2)] 
 
(V149) wound_size_initial_exp_sd 
       SD of Initial Mean Wound Size 
experimental 
       group (size, surface area) 
 
(V150) wound_size_post_exp 
       Post Intervention Mean Wound 
Measurement 
       experimental group (size, surface area) 
 
(V151) wound_size_post_exp_sd 
       SD of Post intervention Mean Wound 
Size 
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       experimental group (size, surface area?) 
(V152) wound_size_cont_absΔ 
       Absolute change in mean wound size in 
              control/comparison group. 
       if not calculated, leave blank (calculate 
in 
       spreadsheet) 
 
(V153) wound_size_cont_absΔ_sd 
       SD of Absolute change in mean wound 
size in 
       control group. 
 
(V154) wound_size_exp_absΔ 
       Absolute change in mean wound size 
        experimental group. if not calculated, 
leave 
       blank (calculate in spreadsheet) 
 
(V155) wound_size_exp_absΔ_sd 
       SD of mean absolute change in wound 
size in 
       experimental group. 
 
(V156) time_to_heal_cont 
       Time to complete healing for 
control/comparison 
       group. 
 
(V157) time_to_heal_cont_sd 
       SD for time to complete healing for 
      control/comparison group. 
 
(V158) time_to_heal_exp 
              Time to complete healing for 
experimental 
              group. 
 
(V159) time_to_heal_exp_sd 
       SD for time to complete healing for 
       experimental group. 
 
(V160) time_to_heal_cont_absΔ 
       Absolute change in time to complete 
healing in 
       control/comparison group. 
       if not calculated, leave blank (calculate 
in 
       spreadsheet) 
 
(V161) time_to_heal_cont_absΔ_sd 
       SD of Absolute change time to 
complete 
       healing in control/comparison group. 
 
(V162) time_to_heal_exp_absΔ 
       Absolute change in time to complete 
healing in 
       experimental group. 
       if not calculated, leave blank (calculate 
in 
       spreadsheet) 
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(V163) time_to_heal_exp_absΔ_sd 
       SD of Absolute change time to 
complete 
       healing in experimental group. 
 
(V164) prop_indiv_heal_cont 
       Proportion of individuals w/ complete 
healing 
       control/comparison group. 
 
(V165) prop_indiv_heal_cont_sd 
       SD for proportion of individuals w/ 
complete 
       healing control/comparison group. 
 
(V166) prop_indiv_heal_exp 
       Proportion of individuals w/ complete 
healing 
       experimental group. 
 
(V167) prop_indiv_heal_exp_sd 
       SD for proportion of individuals w/ 
complete 
       healing in the experimental group. 
 
(V168) prop_indiv_heal_cont_absΔ 
       Absolute change in proportion of 
individuals w/ 
       complete healing in control/comparison 
group. 
       if not calculated, leave blank (calculate 
in 
      spreadsheet) 
 
(V169) prop_indiv_heal_cont_absΔ_sd 
       SD of absolute change in proportion of 
       individuals w/ complete healing in 
       control/comparison group. 
 
(V170) prop_indiv_heal_exp_absΔ 
       Absolute change in proportion of 
individuals w/ 
       complete healing in experimental 
group. 
       if not calculated, leave blank (calculate 
in 
       spreadsheet) 
 
(V171) prop_indiv_heal_exp_absΔ_sd 
       SD of absolute change in proportion of 
       individuals w/ complete healing in 
experimental 
       group. 
 
(V172) prop_ulcers_recur_cont 
       Proportion of individuals w/ ulcer 
recurrence in 
       control/comparison group. 
 
(V173) prop_ulcers_recur_cont_sd 
       SD for proportion of individuals w/ 
ulcer 
              recurrence in control/comparison 
group. 
 
(V174) prop_ulcers_recur_exp  
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       Proportion of individuals w/ ulcer 
recurrence in 
       experimental group. 
(V175) prop_ulcers_recur_exp_sd 
       SD for Proportion of individuals w/ 
ulcer 
       recurrence in experimental group. 
 
(V176) prop_ulcers_recur_cont_absΔ 
       Absolute change in proportion of 
individuals w/ 
       ulcer recurrence in control/comparison 
group. 
      if not calculated, leave blank (calculate 
in 
      spreadsheet) 
 
(V177) prop_ulcers_recur_cont_absΔ_sd 
       SD of Absolute change in proportion of 
       individuals w/ ulcer recurrence in 
       control/comparison group. 
 
(V178) prop_ulcers_recur_exp_absΔ 
       Absolute change in proportion of 
individuals w/ 
       ulcer recurrence in experimental group. 
       if not calculated, leave blank (calculate 
in 
               spreadsheet) 
 
(V179) prop_ulcers_recur_exp_absΔ_sd 
       SD of Absolute change in proportion of 
       individuals w/ ulcer recurrence in 
       experimental group. 
 
(V180) amp_freq_cont or 
       amp_prop_cont 
       # of amputations/proportion of 
amputations in 
       control/comparison group. 
 
(V181) amp_freq_cont_sd or 
       amp_prop_cont_sd 
       SD of # of amputations/proportion of 
       amputations in control/comparison 
group 
 
(V182) amp_freq_exp or amp_prop_exp 
       # of amputations/proportion of 
amputations in 
       experimental group. 
 
(V183) amp_freq_exp_sd or 
       amp_prop_exp_sd 
      SD of # of Amputations/proportion of 
      Amputations in experimental group. 
 
(V184) amp_freq_cont_absΔ or 
       amp_prop_cont_absΔ 
       Absolute change in amputation 
frequeny or 
       proportion of individuals requiring 
amputation in 
       control/comparison condition 
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       if not calculated, leave blank (calculate 
in 
      spreadsheet) 
(V185) amp_freq_cont_absΔ_sd or 
       amp_prop_cont_absΔ_sd 
        SD of Absolute change AMP_FREQ 
or 
        PROP_AMP in control/comparison 
condition. 
 
(V186) amp_freq_exp_absΔ or 
       amp_prop_exp_absΔ 
       Absolute change in amputation 
frequeny or 
       proportion of individuals requiring 
amputation in 
       experimental condition 
       if not calculated, leave blank (calculate 
in 
       spreadsheet) 
 
(V187) amp_freq_exp_ absΔ_sd or 
       amp_prop_exp_absΔ_sd 
        SD of Absolute change AMP_FREQ 
or 
        PROP_AMP in experimental 
condition. 
 
(V188) inf_freq_cont or 
       inf_prop_cont 
       # of Infections/Proportion of Infections 
of 
       control/comparison group 
 
(V189) inf_freq_cont_sd or 
       inf_prop_cont_sd 
       SD of # of Infections/Proportion of 
Infections of 
       control/comparison group 
 
(V190) inf_freq_exp or inf_prop_exp 
       # of Infections/Proportion of Infections 
in 
       experimental group. 
 
(V191) inf_freq_exp_sd or 
       inf_prop_exp_sd 
       SD of # of Infections/proportion of 
amputations 
       in experimental group. 
 
(V192) inf_freq_cont_absΔ or 
inf_prop_cont_absΔ 
       Absolute change INF_FREQ or 
INF_PROP in 
       control/comparison group. 
       if not calculated, leave blank (calculate 
in 
      spreadsheet) 
 
(V193) inf_freq_cont absΔ_sd  or 
       inf_prop_cont_absΔ_sd 
       SD of Absolute change INF_FREQ or 
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       INF_PROP in control/comparison 
condition. 
(V194) inf_freq_exp_absΔ or 
inf_prop_exp_absΔ 
       Absolute change INF_FREQ or 
INF_PROP in 
       experimental group. 
       If not calculated, leave blank (calculate 
in 
       spreadsheet) 
 
(V195) inf_freq_exp_ absΔ_sd or 
       inf_prop_exp_absΔ_sd 
       SD of Absolute change INF_FREQ or 
       INF_PROP in control/comparison 
condition. 
 
(V196) cost_cont 
       Mean treatment cost for the 
control/comparison 
       group. 
 
(V197) cost_cont_sd  
       Standard Deviation for mean treatment 
cost for 
       the control/comparison group. 
 
(V198) cost_exp 
       Mean treatment cost for the 
experimental group. 
 
(V199) cost_exp_sd 
       Standard Deviation for mean treatment 
cost for 
       the experimental group. 
 
(V200) cost_cont_absΔ 
       Absolute change mean COST in the 
control 
      /comparison group. 
       if not calculated, leave blank (calculate 
in 
       spreadsheet) 
 
(V201) cost_cont_absΔ_sd  standard deviation  
of 
       Absolute change in mean COST for the 
       control/comparison group. 
 
(V202) cost_exp_absΔ 
       Absolute change mean COST in the 
       experimental group. 
       if not calculated, leave blank (calculate 
in 
       spreadsheet) 
 
(V203) cost_exp_absΔ_sd  standard deviation  
of 
       Absolute change in mean COST for the 
       experimental group. 
 
(V204) qol_indices_cont 
       Mean quality of life indices for the 
       control/comparison group. 
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(V205) qol_indices_cont_sd  
       Standard Deviation for quality of life 
indices for 
       the control/comparison group. 
 
(V206) qol_indices_exp 
       Mean quality of life indices for the 
experimental 
       group. 
 
(V207) qol_indices_exp_sd 
       Standard Deviation for mean quality of 
life 
       indices for the experimental group. 
 
(V208) qol_indices_cont_absΔ 
       Absolute change QOL_INDICES for 
the 
       control/comparison condition. 
       if not calculated, leave blank (calculate 
in 
       spreadsheet) 
 
(V209) qol_indices_cont_absΔ_sd 
       SD of Absolute change 
QOL_INDICES  for the 
       control/comparison condition.                                                                                                                          
 
(V210) qol_indices_exp_absΔ 
       Absolute change QOL_INDICES for 
the 
       experimental condition. 
       if not calculated, leave blank (calculate 
in 
       spreadsheet) 
 
(V211) qol_indices_exp_absΔ_sd 
       SD of Absolute change 
QOL_INDICES  for the 
       experimental condition.                                                                                                                          
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Statistical Analyses 
 
Statistical Variable 
 
Cont
rol 
Auto
lytic 
Sharp 
(specify
:___) 
Operativ
e 
(specify:
____) 
 
 
 
 
 
 
 
Biosur
gery 
 
 
 
 
 
 
 
Mecha
nical 
 
 
 
 
 
 
 
Enzy
matic 
 
 
 
 
 
 
 
Ultras
ound 
 
 
 
 
 
 
 
La
ser 
(V212)  
wound_size_pval 
 P-Value 
(0= if not calculated) 
        
(V213) time_to_heal_
pval 
 P-Value 
(0= if not calculated) 
        
(V214) prop_indiv_he
al_pval 
P-Value 
(0= if not calculated) 
        
(V215) prop_ulcers_r
ecur_pval 
P-Value 
(0= if not calculated) 
        
(V216) amp_freq_pva
l or amp_prop_pval 
P-Value 
(0= if not calculated) 
        
(V217) inf_freq_pval 
or inf_prop_pval 
P-Value 
(0= if not calculated) 
        
(V218) cost_pval 
P-Value 
(0= if not calculated) 
        
(V219) qol_indices_pv
al 
P-Value 
(0= if not calculated) 
        
(V220)  
wound_size_test_stat 
 Test Statistic 
(0= if not calculated) 
        
(V221) time_to_heal_t
est_stat 
 Test Statistic 
(0= if not calculated) 
        
(V222) prop_indiv_he
al_test_stat 
Test Statistic 
(0= if not calculated) 
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(V223) prop_ulcers_r
ecur_test_stat 
Test Statistic 
(0= if not calculated) 
        
(V224) amp_freq_test
_stat or 
amp_prop_test_stat 
Test Statistic 
(0= if not calculated) 
        
(V225) inf_freq_pval 
or inf_prop_test_stat 
Test Statistic 
(0= if not calculated) 
        
(V226) cost_test_stat 
Test Statistic 
(0= if not calculated) 
        
(V227) qol_indices_tes
t_stat 
Test Statistic 
(0= if not calculated) 
        
(V228)  
wound_size_ci 
 Confidence Interval 
(0= if not calculated) 
        
(V229) time_to_heal_c
i 
 Confidence Interval 
(0= if not calculated) 
        
(V230) prop_indiv_he
al_ci 
Confidence Interval 
(0= if not calculated) 
        
(V231) prop_ulcers_r
ecur_ci 
Confidence Interval 
(0= if not calculated) 
        
(V232) amp_freq_ci or 
amp_prop_ci 
Confidence Interval 
(0= if not calculated) 
        
(V233) inf_freq_pval 
or inf_prop_ci 
Confidence Interval 
(0= if not calculated) 
        
(V234) cost_ci 
Confidence Interval 
(0= if not calculated) 
        
(V235) qol_indices_ci 
Confidence Interval 
(0= if not calculated) 
        
 
________ Notes on statistical analyses relevant to coding  
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